Cues Guiding Leukocyte Transendothelial Migration across the Blood-Brain Barrier in Neuroinflammation: Endothelial Heterogeneity, Chemokines, and Extracellular Vesicles by Paul, Debayon
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
8-17-2015
Cues Guiding Leukocyte Transendothelial
Migration across the Blood-Brain Barrier in
Neuroinflammation: Endothelial Heterogeneity,
Chemokines, and Extracellular Vesicles
Debayon Paul
University of Connecticut - Storrs, paul@uchc.edu
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Paul, Debayon, "Cues Guiding Leukocyte Transendothelial Migration across the Blood-Brain Barrier in Neuroinflammation:
Endothelial Heterogeneity, Chemokines, and Extracellular Vesicles" (2015). Doctoral Dissertations. 900.
https://opencommons.uconn.edu/dissertations/900
Cues Guiding Leukocyte Transendothelial Migration across the Blood-Brain Barrier in 
Neuroinflammation: Endothelial Heterogeneity, Chemokines, and Extracellular Vesicles  
 
Debayon Paul 
University of Connecticut, 2015 
 
 
Leukocyte infiltration into the central nervous system (CNS) underlies the pathology in a wide 
spectrum of neuroinflammatory and neurodegenerative diseases like multiple sclerosis (MS), 
stroke, meningitis, and neuroAIDS. While the steps that mediate the initial adhesion of activated 
leukocytes to the endothelial wall has been well-characterized, not much is known about their 
subsequent transendothelial migration (TEM) across the blood-brain barrier (BBB), a highly 
restrictive paracellular barrier established by the specialized CNS endothelial cells, thus severely 
limiting the treatment options.  
 In Multiple Sclerosis (MS) ‘focal’ leukocyte infiltration into the CNS parenchyma early in 
disease is thought to be critical for the inflammatory response, and eventual neurodegeneration. 
Therefore, to explore the cues that regulate leukocyte TEM across the BBB in a 
neuroinflmmatory milieu, in this dissertation, we evaluated the role of three factors- endothelial 
heterogeneity, chemokine CCL2 from CNS sources, and extracellular vesicles (EVs) from 
endothelial cells containing a major tight-junction (TJ) protein, Claudin-5 (CLN-5), in CNS 
leukocyte infiltration, in an animal model of MS called Experimental Autoimmune 
Encephalomyelitis (EAE). 
 
Using a novel high-resolution three-dimensional confocal image analysis approach, existence of 
a functional heterogeneity in microvascular response was found during neuroinflammation in 
EAE. Specifically BBB damage and leukocyte extravasation in EAE was restricted to venules 
only. Furthermore, Chemokine CCL2, which only surges in a neuroinflammatory milieu to 
detectable levels and released predominantly from endothelium and astrocytes in the CNS, was 
shown to uniquely guide leukocytes across the 'respective' (endothelial and astrocyte) basement 
membranes. Interestingly, leukocytes invading the CNS early in EAE were found to be coated 
with TJ protein CLN-5. Brain microvascular endothelial cells (BMECs) were seen to release 
extracellular vesicles (EVs) in neuroinflammation that contained CLN-5, and could bind to the 
adherent leukocytes possibly for conveying the TJ protein cargo. These CLN-5+ leukocytes were 
found to transmigrate more efficiently across cultured BMECs. The obtained results from these 
studies have shed significant light on previously uncharacterized cues and mechanisms that 
guide circulating leukocytes across the BBB in disease, and holds the key for novel therapeutic 
strategies to treat a myriad of neurologic disorders and vasculopathies that display immune 
infiltration in the CNS.  
Debayon Paul, University of Connecticut, 2015 
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CHAPTER I 
INTRODUCTION 
1.1 The CNS: A castle protected by specialized barriers 
The Central Nervous System (CNS) is the regulatory center of the body- consisting of two main 
parts, namely, the Brain, and the Spinal Cord. It controls our vital bodily functions, including 
awareness, movements, sensations, thoughts, speech, memory, and also influences our 
behavior; both conscious and unconscious. Though, contributing to only 2% of the total body 
mass, the brain demands a constant supply of nutrients and consumes 20% of the body’s 
energy. As the name suggests, CNS is the ‘control tower’ where sensory information from the 
peripheral nervous system is fed, carefully integrated and interpreted, yielding intricate 
cognitive processing, regulation of motor functions, or emotional responsiveness (Purves et al., 
2001). Precisely controlled gradients for ions such as Na+, K+, Cl-, and Ca2+ is indispensable in 
the CNS for eliciting action potentials. Therefore, a tight regulation of CNS homeostasis is 
required to avoid disturbances in function. Although, CNS is considered an immune-privileged 
environment, innate and adaptive immune defense mechanisms are operational at this site, as 
the immune cells can resolve certain viral, bacterial, fungal, and parasitic infections that affect 
the brain. However, these responses are not always beneficial. Owing to the presence of the 
rigid bone casing of the brain, i.e., the skull, classic features of an inflammatory response, such 
as swelling and expansion, can have detrimental consequences. Other pathologies, like the 
 
 
2 
ones underlying meningitis and encephalitis, might reduce neuronal function or induce their 
apoptosis (Wilson et al., 2010). Inflammation in the brain can thus contribute to the 
pathogenesis of a multitude of neurodegenerative diseases, including Multiple Sclerosis (MS), 
Parkinson disease and Alzheimer’s disease. Therefore, specialized structural and functional 
barriers, mainly, the blood-brain barrier, have evolved to protect it, and to maintain a precisely 
regulated milieu for reliable CNS activity while keeping the immune cells at bay. 
1.2 The Blood-Brain Barrier (BBB) 
The CNS vasculature is equipped to actively supply the brain with essential nutrients and 
oxygen through specific transport mechanisms. Interestingly, these endothelial cells that line 
the lumen of the CNS vessels also establish an intricately regulated and specialized barrier to 
protect the central nervous system (CNS) from unwanted molecules, cytotoxic compounds and 
immune cells in the systemic circulation, called the Blood-Brain Barrier (BBB). In effect, the 
BBB is not a rigid barrier, but rather a dynamic structure that receives continuous input from the 
resident CNS cells it protects, e.g., endothelial cells, astrocytes, pericytes, and neurons. This 
intricate communication allows for a thorough response to the local demands for oxygen, 
nutrients, and buffering, which is crucial for the maintenance of CNS homeostasis that favors 
optimal neuronal function (Mizee et al., 2014). All areas of the brain possess a BBB excluding 
the ones in direct contact with the ventricular system, termed circumventricular organs, which 
are protected via the blood-cerebrospinal fluid barrier (BCSFB) instead. 
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1.3 The History of BBB 
The concept of BBB has been recognized for its physiological existence for over a century. The 
earliest evidence of “blood-brain barrier” dates back to the work of Paul Ehrlich (1885, 1906) 
and his student, Edwin Goldman (1909, 1913), who found that water soluble dyes injected into 
the peripheral circulation were excluded from the brain and cerebrospinal fluid (CSF); however 
the choroid plexus showed heavy staining. This concept of a BBB was further bolstered 
through subsequent experiments, whereby, injection of dyes into the brain through 
subarachnoid space showed staining in CSF but not in the peripheral tissues. In 1950, Tschirgi 
showed through a series of experiments that these dyes can bind to albumin, a plasma protein 
widely employed as an indicator of BBB permeability in in vitro models.  
 The existence of BBB in cerebral blood vessels was confirmed by Biedl and Kraus (1898). 
They observed intravenously injected sodium ferrocyanide or cholic acids had no effects on the 
central nervous system (CNS) pharmacologically. However, intraventricular administration of 
the same agent produced neurological symptoms post injection. It was not until 1900 that 
Lewandowsky first introduced the term “blood-brain barrier”. Later, a series of additional 
experiments carried out by Goldman in 1909 and 1913 with the Trypan blue injection in animals 
further proved the existence of BBB. 
 Later on, Friedemann (1942) found that lipid soluble dye could permeate across the CNS 
microvessels and stain the brain. In 1941, Broman introduced his findings of two barrier 
systems in the brain- one at the choroid plexus, called BCSFB, and the other at the cerebral 
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microvasculature, called BBB. BBB constitutes the largest barrier in the brain, featuring a 
continuous layer of specialized endothelial cells connected by tight junctions, such as the lining 
of capillaries (Figure 1). BCSFB exists at the choroid plexus epithelium and at the avascular 
arachnoid epithelium under the dura mater that completely encases the brain. The barrier 
function of BCSFB is provided by the junctions between epithelial cells, which are slightly more 
permeable than those of the brain endothelial cells that form the BBB. These barriers within the 
CNS serve multiple protective functions for the brain. 
 Broman (1941) argued that the capillary endothelial cells and not the astrocytic endfeet 
confers the blood-brain barrier function. Through the development of high resolution electron 
microscopy, as well as sensitive tracer methods; the BBB was structurally shown to exist at the 
astrocytic and endothelial level in 1967.  It was revealed by Reese and Karnovsky 
ultrastructurally using electron-dense tracer horseradish peroxidase (HRP), a 39.8 KDa 
glycoprotein, that endothelial cells in mouse cerebral capillaries form a structural barrier to HRP. 
They found that HRP could travel through the first luminal inter-endothelial tight junctions. The 
tight junctions between the adjacent endothelial cells at the BBB appeared to be continuous; 
pinocytotic vesicles could hardly be found and were not engaged in the transport. Other 
experiments with smaller protein tracers such as microperoxidase and ionic lanthanum were 
tested through intravenous injection by Feder in 1971, and Brightman and Reese in 1969, 
respectively. All these experiments demonstrated the contribution of tight junctions in BBB’s 
ability to actively keep out specific substances from entering the brain interstitial fluid.  
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1.4 The building blocks  
It has been shown that the microvascular endothelium, astrocytes, pericytes, neurons, and 
extracellular matrix exist as an intricately regulated structural and functional network, to 
constitute the “neurovascular unit” (NVU). Therefore, a knowledge of the structural and 
functional regulation of the NVU is critical for undertstanding the development and physiology 
of the BBB (Cohen et al., 1996; Neuwelt, 2004; Wang et al., 2004). The concept of the NVU 
establishes a framework for an integrative approach to understanding how the CNS responds 
in vasculopathies or inflammation (Lo et al., 2004), while providing a basis to understand the 
intricate pathways by might alter the microvascular permeability in disease. 
1.4.1 Component Cells- The Neurovascular Unit 
The BBB is an integral component of the neurovascular unit (NVU). The NVU is comprised of 
CNS microvessels in close proximity to the astrocytic end feet, pericytes, and neuronal 
processes (Figure 1). Complex intercellular signaling among the NVU components regulates 
proper neuronal activity. The endothelium separates blood and the brain parenchyma and 
selectively allows vital nutrients to reach the brain while restricting the passage of neurotoxic 
substances or circulating immune cells. The endothelial cells that line the CNS microvessels 
and house the BBB establish a thin basement membrane (i.e. basal lamina) supporting the 
abluminal surface of the endothelium. This basement membrane surrounds the endothelial 
cells and the juxtaposed pericytes; the region between which is known as the perivascular 
space. Astrocytes are closely apposed to the endothelium, with astrocytic end feet comprising 
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a second basement membrane, termed the glia limtans. The vascular contractility is partially 
contributed by the pericytes, that contain contractile proteins as well as a number of vasoactive 
mediators (Hamilton et al., 2010).  
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Figure 1. The neurovascular unit (NVU). Schematic cross-sectional representation of a CNS capillary. The capillary lumen is 
surrounded by a single endothelial cell (EC). TJs exist at the interface of the two apposing endothelial membranes. Pericytes are 
juxtaposed on the abluminal surface of the endothelial cell, and these two cell types are ensheathed by a common endothelial 
basement membrane. The endothelial basement membrane is closely juxtaposed by the astrocyte basement membrane or glia 
limitans at the astrocyte end-feet and the interneurons. The BBB is a highly restrictive yet dynamic barrier between the blood and 
the CNS tissue, intricately regulated both structurally and functionally by these components of the NVU. 
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Astrocytes 
It has long been thought that astrocytes are critical in the development of BBB characteristics 
(Davson and Oldendorf, 1967) and regulate endothelial cell proliferation, survival, migration, 
differentiation, and vascular branching (Hellstrom et al., 2001). The contribution of astrocytes in 
the establishment of the BBB was demonstrated through the injection of purified neonatal 
astrocytes into the anterior chamber of the eye. These Injected astrocytes formed aggregates 
that were rapidly vascularized. Interestingly, intravenous injection of Evans blue showed that 
these newly formed microvessels excluded the dye from the neighboring astrocytes; similar to 
that observed in the brain (Janzer and Raff, 1987). Similarly, coculture of brain endothelial cells 
(BMECs) with astrocytes (Tao-Cheng et al., 1987; Neuhaus et al., 1991) or with the conditoned 
media from astrocytes (Maxwell et al., 1987) has been shown to strengthen the BBB properties 
in vitro. It is believed that astrocytes can act as intermediaries acting in concert with neurons to 
regulate CNS microvascular permeability (Ballabh et al., 2004), particularly through a dynamic 
Ca2+ signaling between astrocytes and the BMECs via gap junctions and purinergic 
transmission (Braet et al., 2001; Zonta et al., 2003). 
Pericytes 
Pericytes are flat, undifferentiated, contractile connective tissue cells, which develop closely 
apposed to the capillary wall. They maintain a close physical association with the endothelium 
and are ensheathed by a common basement membrane or the basal lamina. Pericytes are 
thought to influence the brain endothelium, through their specialized junctions, e.g., gap 
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junctions, tight junctions, and adherens junctions. Pericytes extend cellular processes, which 
penetrate the basal lamina and cover approximately 20-30% of the microvascular 
circumference (Frank et al., 1987). Although the molecular mechanism by which pericytes 
regulate vascular integrity isn’t well understood, perivascular pericytes have been reported to 
release growth factors and angiogenic molecules might regulate microvascular permeability 
and angiogenesis. Lack of pericytes can lead to endothelial hyperplasia and irregular vascular 
morphology (Hellstrom et al., 2001). It is believed that pericytes of the BBB might derive from 
microglia, since they can phagocytose exogenous proteins in the CNS (Coomber and Stewart, 
1985). Additional evidence shows that pericytes are able to mimic astrocyte ability to enhance 
"tightness" of the BBB (Minakawa et al., 1991). The blood flow in CNS capillaries has been 
shown to be partly regulated by pericytes via rhythimic contractions and relaxtions (Yemisci et 
al., 2009). 
Neurons 
The high metabolic demand of neurons and the dynamic pattern of their activity require a tight 
regulation of the CNS microcirculation to supply essential nutrients and drain out the waste. 
The coupling of brain activity and CNS blood flow is therefore indispensable for normal 
neuronal function (Mizee and de Vries, 2013). An intricate crosstalk between the components 
of the NVU is thus required for the regulation of CNS blood flow by neurons; the vascular 
contractility however, is partly contributed by the pericytes (Hamilton et al., 2010). In addition, 
neurons can also directly innervate brain endothelium or juxtaposed astrocytes for mediating 
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the neuronal-endothelial coupling. Therefore, neuronal damage is often found to be associated 
with the disruption of BBB integrity underlying pathological changes in CNS blood flow. In 
support, noradrenergic, serotonergic, cholinergic, and GABA-ergic neurons have been found to 
directly contact the microvascular endothelium. Although, the exact mechanism is unknown, 
neurons innervating the NVU are believed to contribute to BBB permeability. For instance, the 
loss of cholinergic innervation of the CNS microvasculature causes impaired cerebrovascular 
functioning in Alzheimer’s disease. In summary, neurons in the NVU not only regulate the CNS 
blood flow, but also directly influence BBB permeability, by innervating the microvascular 
endothelium. 
1.4.2 The Anchor- The Extracellular Matrix (ECM) 
Besides the astrocytes, pericytes, and neurons, the ECM of the basal lamina also interacts with 
the CNS microvascular endothelium for establishment of the BBB (Hawkins and Davis, 2005). 
Pathological ECM damage correlates with increased BBB permeability (Rosenberg et al., 1993; 
Rascher et al., 2002). The ECM serves as an anchor or scaffold for the specialized CNS 
endothelial cells via interaction of laminin and other matrix proteins with the endothelial integrin 
receptors (Hynes, 1992). Such cell-matrix interactions trigger many intracellular signaling 
pathways (Tilling et al., 2002), and regulate the expression and localization of endothelial TJ 
proteins (Tilling et al., 1998; Savettieri et al., 2000). This suggests, endothelial-ECM 
interactions are required for maintenance of the TJs that pose an impediment to paracellular 
diffusion of soluble substances and immune cells into the CNS. 
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1.4.3 The Glue- Junctional proteins 
The interendothelial regions of cerebral microvasculature houses junctional complexes that 
includes adherens junctions (AJ) (Schulze and Firth, 1993), tight junctions (TJ) (Kniesel and 
Wolburg, 2000; Wolburg and Lippoldt, 2002; Vorbrodt and Dobrogowska, 2003), and perhaps 
gap junctions as well (Tao-Cheng et al., 1987; Braet et al., 2001; Kojima et al., 2003; Simard et 
al., 2003). The AJ and TJ serve to restrict the paracellular passage of soluble molecules and 
immune cells entering the brain parenchyma (Bazzoni and Dejana, 2004). 
Tight Junctions (Claudin, Occludin and ZO proteins) 
TJs are comprised of three integral membrane protein families (claudins, occludin, and junction 
adhesion molecules) and several accessory or adaptor proteins including zona occludens 
(ZO-1, ZO-2, ZO-3), cingulin, paracingulin, and others (Kniesel et al., 2000; Gumbiner et al., 
1991; Haskins et al., 1998). Claudins are 22-kDa phosphoproteins that are major components 
of the tight junctions (Furuse et al., 1999). Over 20 members of the claudin family have been 
identified so far (Morita et al., 1999). Claudins mostly interact with other claudins on adjacent 
endothelial cells homotypically and establish the primary seal of the tight junction (Furuse et al., 
1999). The carboxy terminus of the claudins interacts with cytoplasmic adapter proteins, like 
ZO-1, ZO-2, and ZO-3 (Furuse et al., 1999). The ZO proteins together with cingulin and many 
others are cytoplasmic proteins involved in tight junction formation (Citi et al., 1988; Stevenson 
et al., 1989). ZO-1 and ZO-2 bridge the integral TJ proteins to the actin cytoskeleton at their 
carboxy terminus (Furuse et al., 1999). This critical link serves for structural stability of the BBB 
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and is an important means of regulating paracellular permeability (Hawkins et al., 2005). 
Occludin is a 65-kDa phosphoprotein with four transmembrane domains, a long 
carboxy-terminal cytoplasmic domain, and a short amino-terminal cytoplasmic domain (Ueno et 
al., 2007; Furuse et al., 1993; Ando-Akatsuka et al., 1996). Two extracellular loops of occludin 
and claudin from neighboring cells can also establish a paracellular barrier at the tight junctions 
(Ueno et al., 2007). Occludin is also linked to the ZO proteins and regulates permeability 
through their association with the actin cytoskeleton (Mitic et al., 2000). Junctional adhesion 
molecules (JAMs) are 40-kDa membrane proteins that also bind ZO-1 (Ebnet et al., 2000). Of 
the three JAM molecules identified, only JAM-1 and JAM-3, but not JAM-2, are expressed in 
brain endothelium (Aurrand-Lions at al., 2001). JAM-1 localizes with actin and is involved in 
cell-to-cell adhesion (Aurrand-Lions at al., 2001). 
Adherens junctions (VE-cadherin, JAMs) 
AJ establish adhesive contacts between cells and consist of the membrane protein cadherin 
that connects to the actin cytoskeleton via intermediary proteins, called catenins (Ueno et al., 
2007; Watabe et al., 1994). AJs form homophilic interactions between the exposed extracellular 
domains of cadherins on the surface of connected cells (Lampugnani et al., 1995). The 
cytoplasmic domains of cadherins bind to β- or γ-catenin, which are in turn linked to the 
cytoskeleton via α-catenin (Lampugnani et al., 1995). AJs interact with TJs via ZO-1 and 
catenins to influence TJ assembly (Matter and Balda, 2003). 
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1.4.4 The delivery guys- Transporters 
Although the BBB freely allows passage to oxygen, carbon dioxide, and small lipophilic 
substances, it actively regulates the entry of hydrophilic molecules such as glucose, amino 
acids, and other nutrients essential to life (Zlokovic, 2008). Thus, a major physiological function 
of the BBB is the stringent regulation of transport of nutrients and other molecules into and out 
of the brain tissue. In addition, BBB transporters are also involved in inactivation and reuptake 
of neurotransmitters (Zlokovic, 2008; Ueno et al., 2007). The TJs at the BBB maintain high 
electrical-resistance and only allow small lipid-soluble molecules (<400 Da) to enter the brain 
(Pardridge, 2007). All other substances requires specific transporters on either the apical or 
basolateral endothelial membrane to cross the BBB (Zlokovic, 2008; Ueno et al., 2007). 
Specialized carrier-mediated transport systems facilitate transport of nutrients such as glucose 
and galactose, amino acids, nucleosides, purines, amines, and vitamins down their 
concentration gradient from the blood to the brain (Zlokovic, 2008; Ueno et al., 2007). Transport 
of these nutrients is generally regulated by metabolic demand of the brain and the 
concentration of these substrates in the plasma. Receptor-mediated transport systems are 
present for aiding the transport of proteins and peptides, e.g., neuroactive peptides, 
chemokines, and cytokines, into the brain (Rennels et al., 1975; Ueno et al., 2007). Specific 
receptor-mediated transport systems are also present to allow larger proteins like transferrin, 
low-density lipoprotein (LDL), leptin, insulin, and insulin-like growth factor into the brain (Jones 
and Shusta, 2007). Active efflux transporters located on both apical and basolateral endothelial 
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membranes serve to flush neurotoxic substances from the brain back into the circulation. Many 
active efflux transporters have been identified, most belonging to the ATP-binding cassette 
(ABC) transporter superfamily (Zlokovic, 2008; Ueno et al., 2007). ABC transporters use 
ATP-bound energy for the transport of molecules across the cell membrane and include the 
multidrug resistance (MDR) transporter P-glycoprotein (P-gp) that mediates removal of toxic 
lipophilic metabolites and cationic drugs, multidrug resistance-associated proteins (MRP), the 
breast cancer resistance protein (BCRP), and others (Zlokovic, 2008; Ueno et al., 2007). 
1.5 Crossing the line- Leukocyte transendothelial migration across the BBB in 
neuroinflammation 
Leukocyte trafficking is critical for immune surveillance in the central nervous system (CNS). 
However, in several diseases the entry of leukocytes into the CNS is heightened, which can 
disrupt the blood-brain barrier (BBB) and trigger neuroinflammation. These pathologic 
processes result in BBB permeability, gliosis, and neuronal damage and/or demyelination, 
which contribute to neuroinflammation. The resulting neuronal damage and death are 
characteristic of many neuroinflammatory conditions including Alzheimer disease, multiple 
sclerosis, HIV-1 encephalopathy, sepsis, ischemia and reperfusion, and CNS tumors.  
1.5.1 Routes of transendothelial migration 
Leukocyte migration across the endothelium in an inflammatory milieu is an active process for 
the migrating leukocytes as well as the endothelial cells, and this entry of leukocytes into the 
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target tissues is tightly regulated. With increasing literature about the mechanisms controlling 
the endothelial cell-cell adhesion and barrier properties, this transmigration is predominantly 
believed to take place at the endothelial junctions, with the leukocyte squeezing through the 
adjacent endothelial cells –termed the ‘paracellular route’. This passage reportedly occurs in 
a zipper-like fashion, whereby the traversing leukocyte transiently replaces the homophilic 
interactions of transmembrane proteins localized at the endothelial junctions. However, this 
paradigm of leukocyte transmigration across the endothelium is challenged by a number of 
elaborate in vivo studies that provide evidence for an alternate exit pathway whereby 
leukocytes migrate through the endothelial cells – the ‘transcellular route’ (Engelhardt and 
Wolburg, 2004). It has been shown that transendothelial leukocyte migration (TEM) can occur 
through specialized membrane compartments either attached to the cell surface or proximal to 
the cell borders called lateral border recycling compartment (LBRC). For instance, TEM of 
monocytes and neutrophils across human endothelial cells involves trafficking of the LBRC to 
the site of transcellular diapedesis. In addition to PECAM, the LBRC is known to contain CD99 
and JAM-A, but not vascular endothelial cell–specific cadherin (VE-cadherin; cadherin 5, 
CD144) (Mamdouh et al., 2009). Notably, based on the LBRC hypothesis, since, both 
paracellular and transcellular TEM happens close to the endothelial cell-cell junctions, it difficult 
to ascertain the exact route of exit undertaken by the pathogenic leukocytes in vivo. Moreover, 
the extent of inflammation, type of microvessels involved, and the immune cell subtype might 
further dictate one route preferentially over the other.  
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1.6 Exploring the unknown- Cues and routes for leukocyte transmigration across BBB 
While the cascade of events that initiate leukocyte adhesion and diapedesis across the 
peripheral vascular beds has been well characterized (Rossi et al., 2011; Sallusto et al., 2012), 
we lack an appreciable understanding of the cues required for transendothelial migration (TEM) 
of leukocytes across the BBB in CNS. A knowledge of cues governing the exit of immune cells 
across the BBB in neuroinflammation, holds key to novel therapeutic strategies for treating a 
wide spectrum of diseases like Parkinson disease, Alzheimer disease and Multiple Sclerosis 
(Mae et al., 2001; Pander et al., 2002; Wiendl, 2002; Weber et al., 2012).  
1.6.1 Knowledge of permissible sites- Endothelial Heterogeneity 
Although the special attributes of endothelial cells that confer the BBB phenotype, has been 
nearly exclusively described in the capillaries, the terms “capillaries” and “microvessels” are 
often used interchangeably. Such a practice is inappropriate and dismissive of the fact that the 
microvasculature is constituted of morphologically and functionally unique vascular segments. 
The CNS microvasculature is comprised of arterioles (10–100 µm diameter), capillaries (4–10 
µm diameter), and venules (10–100 µm diameter), each branch with its own distinguishing 
features (Simionescu and Simionescu, 1977). Though the unique properties of these distinct 
segments arise in part from the contributions of adventitial cells (e.g., pericytes and smooth 
muscle cells) associated with the microvascular wall, functional differences also originate from 
the heterogeneous nature of the endothelial cells themselves. Such endothelial heterogeneity 
raises a possibility that the BBB, as well as other aspects of vascular function in the CNS, is 
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restricted to specific microvessel subtypes. Considering the role of BBB in maintaining 
neuronal homeostasis, loss or permeability of this barrier can cause cerebral microvascular 
dysfunction as reflected in a multitude of neuroinfectious, neuroinflammatory, and 
neurodegenerative diseases (Floyd, 1999; Farkas and Luiten, 2001; Dietrich, 2002). Therefore, 
understanding the diversity along the CNS microvessels is required for effectively treating a 
myriad of neurologic disorders that involve vasculopathies. Thus, while the microvascular 
endothelium remains the undisputed source of the BBB, it is imperative to ask- Which specific 
branch or branches harbor the actual BBB properties and how does such heterogeneity affect 
microvascular response in physiology and pathophysiology? If endothelial heterogeneity 
reflects functional diversity, this will underline a division of labor along the brain microvascular 
endothelium, which might warrant differential response among the CNS microvasculature 
tributaries in disease. Thus, we believe that BBB properties might be endowed within specific 
microvascular segments. Alternatively, it is possible that is that select aspects of the BBB are 
differentially expressed by specific microvascular segments; with no one segment representing 
the BBB in its entirety (Ge et al., 2005). 
1.6.2 The negotiation- Leukocyte-Endothelial Crosstalk 
Leukocytes devise several tacks to breach the endothelium to enter the perivascular space, 
and subsequently find a way through the glia limitans, into the brain parenchyma (Sixt et al., 
2001; Wu et al., 2009). The classic steps of capture-rolling-tethering, activation, arrest-crawling 
and transmigration/diapedesis have been well established in the peripheral vasculature and 
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extensively studied in the CNS microvessels as well. These steps require leukocyte-endothelial 
interactions via expression of cell adhesion molecules (CAMs) by the endothelial cells, such as 
intercellular CAM-1 (ICAM-1) and vascular CAM-1 (VCAM-1), as well as their cognate ligands 
on the leukocytes, e.g., leukocyte functional antigen-1 (LFA-1), and very Late Antigen-4 
(VLA-4). Of further importance, is the contribution of extracellular matrix (ECM) components in 
leukocyte TEM across the BBB, as the laminin composition of the vascular and parenchymal 
BMs might determine accessibility to the CNS (Wu et al., 2009). Since, the integrins on the 
surface of resting leukocytes are not constitutively active, they have a limited ability to breach 
the BBB. However, freshly activated T cells can migrate into the CNS irrespective of their 
antigen specificity (Ludowyk et al., 1992; Hickey et al., 2001). The TEM of initial leukocytes 
through the BBB can cause barrier damage, favoring further leukocyte infiltration. Thus, the 
initial entry of pro-inflammatory leukocytes into the CNS in neuroinflammation might trigger 
other events, e.g., expression of inflammatory cytokines, reactive oxygen species (ROS) and 
matrix-metallo proteinases (MMPs), by these leukocytes, inducing further BBB disruption, 
allowing continued infiltration of pathogenic leukocytes (Larochelle et al., 2011). 
1.6.3 Inflammatory chemokines at the BBB 
An inflammatory response in the peripheral and central nervous system often begins when the 
injured cells release inflammatory mediators called cytokines and chemokines, into the 
immediate microenvironment that act to alter the function of neighboring cells or to attract 
immune cells into the affected region for repair (Chavarria and Alcocer-Varela, 2004; Ramesh 
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et al., 2013). Unlike in peripheral tissues, the expression and regulation of lymphoid and 
inflammatory chemokines within the brain microvasculature has not been explored extensively. 
Several chemokines are known to be expressed by the CNS microvasculature, including CCL2, 
CCL4, CCL5, CCL19, CCL21, and CXCL12. These molecules bind chemokine receptors 
expressed by activated mononuclear cells (Holman et al., 2010).  
 The chemokine CCL2 (formerly termed Monocyte Chemoattractant Protein-1, MCP-1) has 
long been established as a crucial mediator of inflammation within and outside the central 
nervous system (CNS). It can mediate the extravasation of mononuclear leukocytes into CNS 
and peripheral tissues (Leonard et al., 1991; Mantovani et al., 1993; Bennett et al., 2003; 
Toft-Hansen et al., 2006; Yadav et al., 2010). Elevated expression of CCL2 in the CNS has 
been a consistent observation in MS, and its animal correlate experimental autoimmune 
encephalomyelitis (EAE) (Izikson et al., 2002; Mahad and Ransohoff, 2003; Conductier et al., 
2010). This chemokine’s singular importance in EAE progression was demonstrated by global 
CCL2 knockout (KO) mice (CCL2-/-), which showed diminished severity and delay in onset of 
disease. Using,  adoptive transfer EAE experiments, this study further revealed, effector T 
cells from CCL2-/- mice could cause EAE in wild-type (WT) recipients but not vice versa (Huang 
et al., 2001). In another set of elegant bone marrow chimera studies, EAE induction was shown 
to be markedly diminished when bone marrow from WT mice was engrafted into lethally 
irradiated CCL2 mice, but not when bone marrow from CCL2-/- mice was delivered to the WT 
recipients (Dogan et al., 2008). Collectively, these findings underscore the role of CCL2 from 
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CNS sources in mediating EAE, perhaps for driving the circulating myelin-specific 
encephalitogenic leukocytes into the CNS tissue. However, the specific CCL2 sources in the 
CNS that significantly contribute to neuroinflammation, and the mechanism of their pathogenic 
action, still remains unclear, hindering its therapeutic targeting.  
1.6.4 Reading the message in a package- Endothelial extracellular vesicles (EVs) 
Recently, a heterogeneous group of nano-sized extracellular vesicles (EVs) shed by multiple 
cell types, including endothelial cells, into the plasma and other bodily fluids, have emerged as 
a means of complex intercellular communication that conveys a broad spectrum of bioactive 
molecules (including protein, mRNA, miRNA, and DNA) over long and short distances (Turturici 
et al., 2014; Raposo and Stoorvogel, 2013; Ludwig and Giebel, 2012; Camussi et al., 2010; 
Simons and Raposo, 2009). These EVs can be broadly categorized into exosomes (30nm to < 
100nm in diameter) and microvesicles (100nm to 1μm in diameter). The cargo carried by EVs 
uniquely reflects the identity of the parent cell. Intercellular communication can be 
accomplished by bioactive molecules on the EV surface (e.g., an adhesion protein or receptor) 
or ones contained in the intravesicular lumen (e.g., mRNA, miRNA, DNA).  Importantly, 
inflammation in and outside the CNS is known to trigger the release of EVs from the activated 
endothelial cells (Horstman et al., 2007; Meziani et al., 2008; Chironi et al., 2009; Leroyer et al., 
2010; Dignat-George and Boulanger, 2011; Yuana et al., 2013). EVs are also recognized for 
their immunomodulatory capacity (Chaput et al., 2004; Thery et al., 2009; Chaput and Thery, 
2011; Robbins et al., 2014). They can modulate leukocyte activation (Muturi et al., 2013), 
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and/or adhesion (Liu et al., 2012), and exhibit strong association with several autoimmune 
conditions including MS. This has led to EVs being characterized as a critical component in the 
nexus between inflammation and immunity (Morel at al., 2011). As such, EVs are considered 
critical biomarkers of inflammatory disease in general, and perhaps neuroinflammatory disease 
in particular (Liu et al., 2012; Colombo et al., 2012; Barteneva  et al., 2013; Gupta and Pulliam, 
2014; Saenz-Cuesta et al., 2014). EVs can also play a causative role in inflammatory 
processes. For example, Rautou et al. (2011) reported EVs isolated from atherosclerotic 
plaques promote monocyte adhesion and TEM across cultured human umbilical vein 
endothelial cells. Furthermore underscoring the correlation of EVs and CNS leukocyte 
extravasation in neuroinflammation is the reported elevation in plasma endothelial EVs in MS 
(Mandel et al., 2012). These EVs can bind and activate monocytes (Jy et al., 2004), and when 
isolated from plasma of MS patients in exacerbation – but not in remission – forge 
monocyte-EV complexes with enhanced capacity for TEM across cultured BMEC (Jimenez et 
al., 2005) Shedding of junction protein+-EVs from cultured human BMEC (Haqqani et al., 2013), 
lung microvascular endothelial cells and aortic endothelial cells (Takahashi et al., 2013) further 
focuses attention on endothelial cells as promising key players in the EV:TJ protein+-leukocyte 
relationship. Conceivably, EVs from the endothelium may transfer TJ protein and/or mRNA to 
leukocytes, possible aiding their TEM at the permissive microvascular locales in the CNS. 
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CHAPTER II 
Novel 3D analysis of Claudin-5 reveals significant endothelial heterogeneity 
among CNS microvessels1 
1. Abstract 
Tight junctions (TJs) feature critically in maintaining the integrity of the blood-brain barrier 
(BBB), and undergo significant disruption during neuroinflammatory diseases. Accordingly, the 
expression and distribution of Claudin-5 (CLN-5), a prominent TJ protein in central nervous 
system (CNS) microvessels and BBB determinant, has been shown to parallel physiological 
and pathophysiological changes in microvascular function. Therefore, it is critical to quantify the 
expression and/or distribution of predominant TJ proteins, like, CLN-5 along the various CNS 
microvessel subtypes under physiological and pathological conditions, for understanding which 
microvessels serve as an actual seat for the BBB, and explore whether the BBB damage in 
neuroinflammatory diseases is restricted to specific subsets of CNS microvessels only. 
However, efforts to quantify CLN-5 within the CNS microvasculature in situ, by using 
conventional two-dimensional immunohistochemical analysis of thin sections, are encumbered 
by the tortuosity of capillaries and distorted diameters of inflamed venules. Herein, we describe 
a novel contour-based 3D image visualization and quantification method, employing 
high-resolution confocal z-stacks from thick immunofluorescently-stained thoraco-lumbar 
                                                             
1
 This work was published in Paul, D, Cowan, AE, Ge, S, Pachter, JS. Novel 3D analysis of Claudin-5 reveals significant endothelial 
heterogeneity among CNS microvessels. Microvascular Res. 2013;86:1-10. 
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spinal cord cryosections, to analyze CLN-5 along the junctional regions of different-sized CNS 
microvascular segments. Analysis was performed on spinal cords of both healthy mice, and 
mice experiencing experimental autoimmune encephalomyelitis (EAE), an animal model of the 
neuroinflammatory disease multiple sclerosis.  Results indicated that, under normal conditions, 
the density of CLN-5 staining (CLN-5 intensity/ endothelial surface area) was greatest in the 
capillaries and smaller venules, and least in the larger venules. This heterogeneity in junctional 
CLN-5 staining was exacerbated during EAE, as spinal venules revealed a significant loss of 
junctional CLN-5 staining that was associated with focal leukocyte extravasation, while 
adjacent capillaries exhibited neither CLN-5 loss nor infiltrating leukocytes.  However, despite 
only venules displaying these behaviors, both capillaries and venules evidenced leakage of IgG 
during disease, further underscoring the heterogeneity of the inflammatory response in CNS 
microvessels. This method should be readily adaptable to analyzing other junctional proteins of 
the CNS and peripheral microvasculature, and serve to highlight their role(s) in health and 
disease. 
2. Introduction 
 Significant restriction of paracellular movement of soluble substances between the central 
nervous system (CNS) parenchyma and systemic circulation is one of the properties conferred 
by the blood-brain barrier (BBB). Such limitation is generally considered to derive from an 
intricate circumferential network of specialized membrane contacts, tight-junctions (TJs), which 
exist between CNS microvascular endothelial cells (Furuse, 2010; Blasig and Haseloff, 2011; 
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Coisne and Engelhardt, 2011). 
 The integrity of the BBB has been reported to be compromised during neuroinflammatory 
and neurodegenerative diseases, with disruption of TJs widely thought to contribute 
significantly to pathology (Petty and Lo, 2002; Hawkins and Davis, 2005; Carvey et al., 2009; 
Coisne and Engelhardt, 2011; Grammas et al., 2011). Some reports have noted that 
dysregulated expression, dephosphorylation and/or redistribution of TJ proteins at the BBB 
precede signs of clinical disease (Morgan et al., 2007; Argaw et al., 2009; Bennett et al., 2010). 
Such findings have been interpreted that alterations in TJs play a causative role in the 
inflammatory process. In this regard, disruption of TJs might facilitate leukocyte diapedesis 
through weakened inter-endothelial contact points (Garrido-Urbani et al., 2008), and/or support 
extravasation of serum proteins to which leukocytes must attach to invade the CNS 
parenchyma (Pober and Sessa, 2007). Additional reports have pointed to TJ disruption and 
associated BBB damage as being a consequence of the leukocyte diapedesis process itself  
-– particularly through the actions of leukocyte-derived matrix metalloproteinases and reactive 
oxygen species (Gidday et al., 2005; Pun et al., 2009; Moxon-Emre and Schlichter, 2011). And 
still others have found intermediate ground by linking opening of TJs to initial intimate contact 
between activated/infected leukocytes and the brain microvascular endothelium (Haorah et al., 
2005; Suidan et al., 2008; Ivey et al., 2009). These interpretations are not mutually exclusive, 
and one mechanism may foster the others leading to protractive BBB dysfunction, TJ disruption, 
and a degenerative sequence of neurologic sequelae (Carvey et al., 2009). 
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 TJs in the CNS are mainly comprised of three distinct families of integral membrane 
proteins, namely, occludin, junctional adhesion molecules A, B and C, and claudins (CLNs) – of 
which there are now more than 20 recognized isoforms in various endothelial and epithelial 
beds (Liebner et al., 2011; Paolinelli et al., 2011). In turn, these integral proteins are linked to 
the actin cytoskeleton through several scaffolding proteins, including zonula occludens (ZO) 
proteins 1, 2 and 3 (Hawkins and Davis, 2005; Abbott et al., 2006), which assist in regulating TJ 
performance and BBB phenotype through a variety of signal transduction cascades (Ishizaki et 
al., 2003; Fischer et al., 2005; Haorah et al., 2005; Zhong et al., 2008; Jalali et al., 2010; 
Morin-Brureau et al., 2011; Ma et al., 2012). 
 CLN-5 has been localized to endothelial cell junctions of CNS microvessels in situ (Morita 
et al., 1999; Wolburg et al., 2003; Dobrogowska and Vorbrodt, 2004; Sheikov et al., 2008) and 
ex vivo (Bake et al., 2009), as well in culture (Song and Pachter, 2003; Calabria et al., 2006; 
Nakagawa et al., 2009; Gesuete et al., 2011; Luissint et al., 2012).   A critical role for CLN-5 in 
BBB function has further been established. Specifically, overexpression of CLN-5 in cultured 
brain microvascular endothelial cells was shown to heighten barrier properties (Ohtsuki et al., 
2007), while its deficiency imparted size-selective loosening of the BBB in vivo (Nitta et al., 
2003).  In order to correlate altered status of TJs with BBB dysfunction and disease processes, 
it is thus imperative to be able to accurately assess expression and distribution of TJs proteins 
such as CLN-5 at the BBB in situ.   
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 While two-dimensional (2D) assessment of immunofluorescent confocal images obtained 
from thin sections of CNS tissue has revealed apparent changes in the amount and distribution 
of TJ proteins with neuroinflammatory disease (Persidsky et al., 2006; Alvarez and Teale, 2007; 
Argaw et al., 2009), this approach is limited in scope as it is restricted to visualization of only a 
minor fraction of any given vessel segment. Because of the severe tortuosity of CNS 
microvessels, 2D analysis of thin sections is largely confined to vessels of larger diameter, e.g., 
venules or arterioles, cut in cross-sectional profile (Janacek et al., 2011). Longitudinal profiles 
are not acquired to any significant extent by this tack and, therefore, much of the intercellular 
TJ network embedded within the long axis of the vascular wall is excluded from quantitative 
morphometric assessment.  The information thus acquired may fail to capture highly focal 
changes in TJ expression/distribution. Moreover, cross-sections of the smaller diameter, but far 
more numerous, capillaries cannot accurately be evaluated for TJ expression as their 
circumference contains but only one to two cells. As endothelial heterogeneity may dictate that 
arterioles, capillaries, post-capillary venules and venules, differentially contribute to the BBB 
and inflammatory processes (Vorbrodt et al., 1986; Ge et al., 2005; Bechmann et al., 2007; 
Macdonald et al., 2010; Saubamea et al., 2012), it is possible that TJ responses and their 
physiological consequences are highly segment-dependent.  Thus, it is important to be able to 
assay TJ expression qualitatively and quantitatively within all segment types along the CNS 
microvascular tree. It would further be advantageous to sample thicker tissue sections and 
access as much of the vascular surface as possible so as not to miss events that might be 
spatially restricted or polarized, and correlate TJ effects with those occurring in the perivascular 
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spaces during inflammation such as step-wise penetration of leukocytes from lumen into the 
CNS parenchyma (Sixt et al., 2001; van Horssen et al., 2005). 
 With these considerations in mind, and using CLN-5 as an example, herein we describe a 
protocol aimed at providing more accurate focal information, greater resolution and enhanced 
spatial perspective regarding junctional TJ proteins during CNS inflammation. Specifically, 
expression of CLN-5 was analyzed by subjecting microvessels in thick sections to 3D rendering, 
yielding both qualitative and quantitative information about the status of BBB integrity, and its 
relationship to inflammatory disease. Using this protocol to analyze CNS tissue from mice 
inflicted with experimental autoimmune encephalomyelitis (EAE), an animal model for multiple 
sclerosis (Mix et al., 2010; Batoulis et al., 2011), examples are presented to show alterations in 
the amount and distribution of CLN-5 at inter-endothelial junctions of spinal cord microvessels, 
and how these changes correlate with other vascular manifestations of inflammation. 
3. Materials and methods 
3.1 EAE induction 
Female C57BL/6J mice (Charles River Laboratories), age 8–10 weeks, were used throughout. 
All animal protocols were in compliance with Animal Care and Use Guidelines of the University 
of Connecticut Health Center (Animal Welfare Assurance #A3471-01). Active EAE was induced 
as recently described (Murugesan et al., 2012), following a modification of the procedure of 
Suen et al. (1997). Subcutaneous flank injection of 300μg MOG35-55 peptide 
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(MEVGWYRSPFSRVVHLYRNGK; synthesized by the Keck Biotechnology Resource Center at 
Yale University) in complete Freund's adjuvant (Difco) containing 300 μg M. tuberculosis was 
performed on day 0 (d0), and supplemented by intraperitoneal injections of 500 ng pertussis 
toxin (List Biological) on d0 and d2. The typical disease that results from this protocol is 
monophasic, with acute symptoms beginning ~ d10–d12, and peak clinical disease appearing 
by ~ d15–d20, associated with ascending paralysis. Chronic disease then continues with 
disability achieving a plateau or diminishing somewhat by d25. The mice were scored on a 
scale of 0 to 5 with gradations of 0.5 for intermediate scores: 0, no clinical signs; 1, loss of tail 
tone; 2, wobbly gait; 3, hind limb paralysis; 4, hind and fore limb paralysis; and 5, moribund. 
3.2 Tissue preparation 
At designated times post-EAE induction, mice were anesthetized with ketamine (80 mg/kg, i.p.) 
and xylazine (10 mg/kg, ip) in phosphate buffered saline, pH 7.4 (PBS). Following exposure of 
the heart by left anterolateral thoracotomy, the mouse was transcardially perfused (via the left 
ventricle) first with Heparin-PBS (10 usp/ml), to flush out the blood, and then with fixation buffer 
(4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4), using an “in-house” constructed 
gravity perfusion apparatus. 
Laminectomy was performed for harvesting the spinal cord. Briefly, the entire spinal column 
containing the spinal cord was removed and, after clearing the overlying ligaments and muscle, 
was incubated in fixation buffer for 2 hours at room temperature. The lamina was then 
ectomized by opening the spinal canal from the C1 to L5 vertebra, breaking one at a time using 
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a pair of fine laminectomy forceps. The dissected spinal cords were post-fixed again in fixation 
buffer for 30 min, and then cryoprotected in 30% sucrose in 0.1 M phosphate buffer, pH 7.4, 
overnight at 4 °C prior to freeze-embedding in cryomatrix. Subsequently, 12 × 60 μm 
cryosections were obtained from the thoraco-lumbar region, approximately between the T10 
and L3 vertebrae (Figure 2c), using a Thermo Fisher Scientific microtome (maintained at − 
25 °C), and adhered to poly-l-lysine coated slides. 
3.3 Immunostaining 
Sections were permeabilized with 1% Triton X-100 in PBS for 30 min, and non-specific binding 
blocked by incubation with Powerblock® in UltraPure™ (GIBCO) distilled water for 10 min. The 
microvascular endothelium was stained by rat anti-mouse CD31 (BD Pharmingen; 1:100 
dilution) followed by incubation with goat anti-rat Alexa® 555 (Life Technologies; 1:200). The 
basement membranes were labeled with rabbit anti-mouse Laminin 1 (Cedarlane; 1:100) and 
goat anti-rabbit Alexa® 555 (Life Technologies; 1:200). Anti-mouse Claudin5-Alexa® 488 (Life 
Technologies; 1:150) was employed to highlight the TJs at the interendothelial borders. 
Anti-mouse IgG-Alexa® 488 or IgG-Alexa® 555 Fab’ fragment (Life Technologies; 1:200) was 
utilized to detect the leaked endogenous serum IgG from inflamed CNS microvessels. 
Anti-mouse CD4-Alexa® 488 antibody (generously provided by Dr. H. E. de Vries, VU medical 
center, Netherlands) was used to immunolabel the perivascular leukocytes associated with 
inflamed microvessels. Additionally, nuclear stain DRAQ5 (Biostatus Ltd., Leicestershire, UK) 
was utilized to reveal the perivascular cellularity surrounding inflamed CNS microvessels due 
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to leukocyte extravasation. Sections were mounted in Mowiol® 4-88 (Sigma-Aldrich, Missouri, 
USA). 
3.4 Image acquisition 
Spinal cord microvessels (capillaries and venules) from the dorsolateral white matter (between 
T10 and L3) were imaged and categorized into appropriate segments based on their average 
diameter (Figs. 2.1a–c). This region, just underneath the meninges, was intentionally selected 
for analysis as it sustains the earliest inflammation in the spinal cord parenchyma in the 
MOG35-55 EAE model (Brown and Sawchenko, 2007). Confocal z-stacks were acquired (at 1 
μm increments between z-slices) following a multitrack scan, using a Zeiss LSM 510 Meta 
confocal microscope equipped with a 40 × Zeiss Fluar (NA 1.3, determining voxels of 0.62 × 
0.62 × 1 μm3) and a 63 × Plan-neofluar (NA 1.25, determining voxels of 0.39 × 0.39 × 0.51 μm3) 
oil immersion objective lens. Stitching of z-stacks from overlapping regions (in x, y plane) of the 
same vessel was performed by XuV stitch v1.8 software (Free Software Foundation Inc., 
Boston, USA). 
3.5 3D quantification of microvascular CLN-5 density 
To quantify relative CLN-5 protein expression within select microvessels, confocal z-stacks 
were imported into Imaris® suite version 7.1 × 64 software (Bitplane Inc., South Windsor, CT). 
Fluorescence intensities above a background value were assigned for each color channel in 
the volume rendered image (i.e., 3D reconstruction) and kept constant for all the acquired 
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z-stacks. For quantification in 3D, manual contour tracing was first performed by cursoring out 
the vessel of interest in each confocal z-slice and the individual contours merged into a 3D 
contour surface. Surface area of the generated 3D contour was used as an estimate of the 
“microvascular surface area” defined by the endothelial layer. This 3D contour surface was 
subsequently used as a mask to isolate only the microvessel of interest from rest of the dataset 
by setting all voxel intensities “outside” the 3D contour surface to zero. The CLN-5 channel was 
isosurface rendered using surface creation wizard and the density of CLN-5 calculated as 
follows: 
    Total CLN-5 intensity = Mean CLN-5 intensity x # of voxels 
           CLN-5 intensity per unit area (i.e., CLN-5 density) =  Total CLN-5 intensity 
                                                   Microvascular surface area 
In effect, this method allowed the surface area of the microvascular endothelium to be spread 
out in 3D space (x, y, z axes) for quantification of CLN-5 density per unit area ( Figs. 2.1d–e), 
while excluding the luminal volume (Figure S1a–b). 
3.6 Re-slicing isosurface-rendered images 
The Clipping Plane module on Imaris® was employed to optically “re-slice” 3D isosurface 
rendered microvessels along a desired oblique plane, in a manner perpendicular to axis of the 
microvessel, so as to uncover hidden views and resolve the interior versus exterior or luminal 
versus abluminal vascular compartments. This tool further allowed resolution of the 
microvascular basement membrane into its endothelial and parenchymal counterparts, which 
split apart during neuroinflammation to accommodate the CNS invading leukocytes 
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( Engelhardt and Sorokin, 2009). 
 To introduce the clipping plane tool into the 3D dataset, its icon in the object list was 
selected and the clipping plane first placed along a desired orthogonal plane (xy, yz or xz) with 
the manipulator (Figure S1). To further orient the clipping plane in an oblique plane, and align it 
perpendicular to axis of the microvessel for a cross-sectional view, the manipulator was 
selected and rotated as required. Finally, to alter the location of the clipping plane along the 
same axis, and thereby obtain different depths within the vessel, the manipulator was 
re-positioned accordingly. 
3.7 2D quantification of CLN-5 immunostaining 
Background subtracted volume rendered confocal z-stacks of venules from thoraco-lumbar 
spinal cord were exported from Imaris® as tiff images for ImageJ (NIH, Maryland, USA) based 
2D quantification of mean CLN-5 pixel intensities along the interendothelial junctions. Relative 
intensity values corresponding to the level of CLN-5 immunostaining were measured over 30–
50 ROIs, each defining 10 × 10 pixels, traced in a non-overlapping manner along the 
intercellular borders in each venule, as previously described ( Song and Pachter, 2004). For 
inflamed venules from EAE mice, ROIs were sampled from regions with visible reduction in 
CLN-5 immunoreactivity, and displaying dense perivascular cellularity. For venules from naïve 
mice, ROIs were randomly selected along the microvessel profile. Mean pixel values were then 
obtained by averaging the intensity values of all ROIs. 
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3.8 Statistical analysis 
All statistical analyses were performed employing GraphPad Prism 5 software (La Jolla, CA, 
USA). Microvascular CLN-5 density values obtained from Imaris® 3D image analysis were 
expressed as mean ± standard error of the mean (SEM). One-way analysis of variance 
(ANOVA) was employed to assess statistically significant differences in junctional CLN-5 
density between microvascular segments from naïve and d24 EAE mice, followed by 
Bonferroni's multiple comparison post-hoc analysis. For assessing the relationship between 
CLN-5 density and microvessel diameter, a Pearson product–moment correlation coefficient 
was determined. Comparison of CLN-5 mean pixel intensity values from 2D images of venules 
from naïve versus d24 EAE mice was performed by one-tailed unpaired Student's t-test. 
Results were considered significant at a p ≤ 0.05. 
4. Results 
4.1 Segmental heterogeneity of CLN-5 density in naïve spinal cord microvessels 
To initially determine if normal spinal cord microvessels demonstrate segmental heterogeneity 
with respect to CLN-5 density at endothelial junctions, spinal cord sections from naive mice 
were immunostained for CLN-5. Isosurface rendering of high-resolution confocal z-stacks 
obtained from the different-sized microvascular segments were subjected to 3D quantification 
of endothelial CLN-5 density. Microvascular segments were classified as larger venules (> 20 
μm in diameter); smaller, possibly ‘postcapillary’ venules (10–20 μm in diameter); and 
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capillaries (< 10 μm in diameter). This classification was based primarily on a consensus of 
established size criteria (Fawcett, 1994, Leeson et al., 1988, Ross and Pawlina, 2006 and 
Simionescu and Simionescu, 1977), as there is no widely recognized marker that distinguishes 
postcapillary venules (Owens et al., 2008). The smaller venules were often seen connecting 
capillaries to larger venules, lending support to the smaller venules being postcapillary in 
nature. To further verify venule identity, 3D isosurface rendered datasets were re-sliced along a 
desired plane using the clipping plane module in Imaris® to analyze microvessels in cross 
section (Figure S1c). The presence of a smooth, non-puckered lumen lent to microvessels (> 
20 μm in diameter) being classified as venules rather than arterioles (Macdonald et al., 2010). 
 Isosurface rendered z-stacks of venules and capillaries revealed appreciable 
heterogeneity in endothelial CLN-5 density (CLN-5 staining intensity/μm2 microvascular 
surface) in naïve mice (Figs. 2.2a–f). Specifically, 3D quantification of CLN-5 density in larger 
venules yielded a significantly lower mean value than that found in smaller, venules (19.95 ± 
1.65 vs. 48.89 ± 2.97, respectively). CLN-5 density in larger venules was also significantly 
lower (2-fold) than that in naïve capillaries (19.95 ± 1.65 vs. 39.77 ± 2.54, respectively). 
However, junctional density of CLN-5 was not statistically different between capillaries and the 
smaller diameter venules. These results suggest that, under normal conditions, the density of 
CLN-5 at endothelial junctions within CNS microvessels tends to vary inversely with 
microvessel diameter, being greatest in the capillaries and smaller venules, and least in the 
larger venules (Figure S3). Specifically, a significant negative linear correlation coefficient was 
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established with a Pearson's correlation coefficient (r) = − 0.73. 
4.2 Reduction of CLN-5 density in spinal cord venules during MOG-induced EAE 
As MOG-induced EAE has been reported to result in diffuse TJ breakdown and relocalization of 
the TJ scaffolding protein ZO-1 in CNS microvessels (Bennett et al., 2010), we evaluated if 
EAE affects junctional CLN-5 density equally in various microvascular segments (capillaries vs. 
venules) at the peak of disease. 
 Isosurface rendering of spinal cord venules at d24 EAE revealed significant disruption of 
CLN-5 distribution at sites of dense perivascular cellularity (Figure 4a and b). These sites 
largely coincided with CD4+ leukocyte infiltrates (Figure S2) and thus corroborated the vessels 
as inflamed. Moreover, there was considerable heterogeneity in junctional CLN-5 loss among 
venules — possibly reflecting a range in inflammatory status and/or vulnerability within this 
vessel population. The venules analyzed varied in diameter from ~ 20 to 50 μm — a range 
shown to become inflamed in this and similar EAE paradigms (Bergman, 2012 and Pfeiffer et 
al., 2011) — and thus could have included initially smaller, postcapillary venules that had 
distended in size due to disease. In keeping with the prior description that relocalization of the 
TJ scaffolding protein ZO-1 correlates with sites of inflammatory cell accumulation (Bennett et 
al., 2010), venules qualitatively showing near complete breakdown of CLN-5 staining pattern 
and displaying a CLN-5 density of < 10 were considered to be severely inflamed. By contrast, 
those venules showing small punctate regions of CLN-5 loss and having a CLN-5 density of ≥ 
10 were considered moderately inflamed. Capillaries in regions with even severely inflamed 
 
 
36 
venules appeared refractory to CLN-5 loss (Figure 4c). Specifically, quantification of junctional 
CLN-5 density revealed a 5-fold difference in severely inflamed venules compared to capillaries 
(4.79 ± 0.78 vs. 24.0 ± 5.85, respectively), while moderately inflamed venules and capillaries 
did not significantly differ in this measure (12.95 ± 0.49 vs. 24.0 ± 5.85, respectively). As the 
moderately inflamed venules displayed only small punctate regions of CLN-5 loss, it was 
unclear if they had yet to suffer diffuse extensive disruption, were less susceptible to disruption, 
or in stages of repair. As all size vessels analyzed in naïve mice clearly showed continuous 
CLN-5 staining along interendothelial borders in a 60μm section (Figure 3), it is unlikely that the 
significant reduction in venular CLN-5 junctional density in EAE mice was due to obstacles to 
antibody penetration. Instead, it probably reflected a differential response in this vessel 
population. 
4.3 Comparison of junctional CLN-5 density in inflamed venules from EAE mice and 
normal venules from naïve mice 
Having first established the heterogeneity of CLN-5 density at endothelial junctions within the 
normal spinal microvasculature, and then within the diseased microvasculature during EAE, we 
next directly compared capillaries and venules from naïve and EAE mice. Results reveal that 
d24 EAE venules had significantly lower (~ 3.9 fold) CLN-5 density compared to both naïve 
venules (8.87 ± 1.31 vs. 34.42 ± 6.65, respectively) and naïve capillaries (8.87 ± 1.31 vs. 34.74 
± 3.70, respectively) (Figure 5i). Additionally, there was no statistically significant alteration in 
CLN-5 density between the naïve and d24 EAE capillaries, or evidence of perivascular 
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cellularity associated with capillaries during disease. These findings highlight that venules are 
the primary sites of neuroinflammation-associated junctional CLN-5 staining loss and possibly 
TJ breakdown, while capillaries appear to maintain their pattern of junctional CLN-5 
immunoreactivity during EAE. 
To confirm that our 3D analysis of CLN-5 density reflected diminished expression of the TJ 
protein at interendothelial junctions in venules during EAE, and not just redistribution of CLN-5 
over a dilated, wider surface area, conventional 2D analysis of mean pixel intensity was 
performed along the intercellular junctional regions. Figure S4 shows that CLN-5 staining in 
inflamed venules from d24 EAE mice had significantly lower mean pixel intensity than that in 
venules of naive subjects (~ 4.2-fold). The higher variability of CLN-5 staining during EAE, as 
indicated by both increased standard deviation and standard error of mean pixel intensity 
measure, were consistent with the more fragmented, irregular appearance of TJ staining 
associated with neuroinflammatory disease. 
4.4 Heterogeneity of CLN-5 density in contiguous spinal cord microvessels during EAE 
Though diverse inflammatory responses of closely located microvessels have provided strong 
evidence of segmental endothelial heterogeneity (Thurston et al., 2000 and Xu et al., 2005), it 
is not clear if venules and capillaries directly attached to each other show such disparity within 
the inflamed CNS. Therefore, a contiguous venule/capillary pair from a d24 EAE spinal cord 
section was subjected to 3D reconstruction and isosurface rendering for CLN-5 (Figs. 2.5a–b), 
to visualize segmental changes in CLN-5 density at the endothelial junctions. In what amounts 
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to yet another clear display of segmental endothelial heterogeneity, a capillary emanating from 
a severely inflamed venule had intact junctional CLN-5 staining similar to that seen in 
capillaries of naïve mice. However, the immediately adjacent venule demonstrated near 
obliteration of CLN-5 junctional organization, along with separation of endothelial and 
parenchymal basement membranes and increased perivascular cellularity (Figure 6a, insets). 
This finding reinforces the view that loss of junctional CLN-5 protein during neuroinflammation 
reflects an inherent susceptibility of CNS venules — a property not shared even by the most 
closely juxtaposed capillaries (Figure 6c). 
4.5 Heightened microvascular permeability to endogenous serum IgG occurs in both 
capillaries and venules during EAE 
Given the disparate CLN-5 response between venules and capillaries during EAE, we next 
sought to determine if both microvessel types evidenced inflammation-associated leakage of 
serum IgGs. Thick spinal cord cryosections from both d6 (early stage) and d24 (late stage) 
EAE animals were stained for endogenous IgG and the basement membrane protein laminin-1 
(Lam-1), followed by 3D reconstruction and isosurface rendering of the z-stacked confocal 
dataset (Figs. 2.6a–d). IgG leakage was detected as focal deposits around both venules and 
capillaries at d6. Despite evidence of IgG extravasation at this early time, no loss of junctional 
CLN-5 was apparent (Figure S5). By d24, extravasation of IgG was so pronounced and diffuse 
that it obscured boundaries between the microvessel segments, though increased perivascular 
cellularity was associated with inflamed venules only (Figure 7). 
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5. Discussion 
 Given the importance of TJs in neuroinflammatory disease, and increasing awareness of 
endothelial heterogeneity, this report described a novel microvascular contour-based 3D 
quantification method of acquiring and analyzing expression of the TJ protein CLN-5, a critical 
BBB determinant, along different type microvessel segments of the spinal cord during EAE. 
Venules were shown to display significant loss of CLN-5 at intercellular junctions during EAE, 
which was accompanied by severe extravasation of leukocytes and disruption of basement 
membrane integrity. In stark contrast, capillaries showed none of these responses. 
 This 3D approach also allowed for capture and analysis of small diameter capillaries lying in 
close proximity to venular structures. Due to their small caliber and tortuosity, such capillaries are 
typically precluded from conventional 2D analysis of TJs in thin-sectioned material. However, in 
the current protocol capillaries and venules directly attached to each other could be readily 
contrasted, allowing for a clearer picture of their diverse phenotypes in physiology and 
pathophysiology to emerge. In this regard, the density of CLN-5 expression under normal 
conditions was observed to vary inversely with microvessel diameter, being greatest in the 
capillaries and smaller venules, and least in the larger venules. That the correlation coefficient 
was − 0.73, and not closer to − 1.0, might reflect that CLN-5 density reaches asymptotes at the 
extreme diameters of the microvascular tree, and/or the 3D quantification approaches its limits of 
accuracy at these extremes. Nevertheless, this inverse relationship of CLN-5 density with 
diameter size was significant. This discrepancy in CLN-5 density between capillaries and 
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venules was further exaggerated during EAE, as loss of CLN-5 expression appeared restricted 
to venular structures. Loss of junctional CLN-5 might render the venular endothelium more 
amenable to leukocyte extravasation via the paracellular pathway (Garrido-Urbani et al., 2008). 
Alternatively, it could be the result of a sustained transendothelial leukocyte migration specifically 
at venular domains (Xu et al., 2005). 
 Despite the most significant CLN-5 loss being reserved for venules, IgG leakage was 
nevertheless detected around all size microvessels during early and late EAE. As capillaries did 
not sustain significant CLN-5 loss even as late as d24 EAE, this might reflect that 
inflammation-associated IgG leakage at these sites occurred primarily through transcytosis 
(Claudio et al., 1989 and Proulx et al., 2012) — a process that, presumably, would not have 
required TJ breakdown (Kreuter, 2013). Venules, on the other hand, might have similarly 
employed IgG transcytosis early during EAE, but also engaged in paracellular leakage later 
following the extensive CLN-5 loss. 
 Xu et al. (2005) described similar breakdown of TJs and loss of CLN-1/3 and occludin at 
inter-endothelial contacts within retinal venules during a related condition, experimental 
autoimmune uveoretinitis. And in a further parallel with our results, they similarly reported retinal 
capillaries were apparently spared disruption of these TJ proteins — again highlighting 
endothelial heterogeneity and the differential endothelial response to inflammation. Using 
confocal microscopy of retinal whole mounts, this group has most recently elaborated a means to 
portray relative fluorescent intensity values of microvessel-associated CLN-1/3 in a 3D heat map 
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(Xu and Liversidge, 2011). Our work extends these studies by employing 3D isosurface 
renderings of individual microvessels, thereby allowing a holistic perspective of TJ protein 
distribution within the microvascular network, in addition to enabling relative quantification. 
Furthermore, the acquisition of high-resolution confocal z-stacks from 60μm thick sections 
supported analysis of local effects, which in thinner sections or 2D analysis might well have been 
missed. 
 The d24 time-point of EAE was selected for analysis as it is soon after the apex of clinical 
disease in this particular paradigm (Suen et al., 1997), and into the chronic phase when 
inflammatory histopathology is at or near maximum (Pachner, 2011). Thereafter, clinical 
presentation either plateaus or abates somewhat. The spinal cord region between T10 and L3 
vertebrae was the area of focus as disease commences at the lumbo-sacral level and 
progresses in the caudal-to-rostral direction (Gruppe et al., 2012). We thus reasoned that by the 
d24 time-point, maximal CLN-5 disorganization would be achieved at the spinal level analyzed. It 
is significant that IgG leakage was apparent from both capillaries and venules during early (d6) 
and late (d24) EAE, though no reduction in CLN-5 density was apparent in capillaries at either of 
these time-points. This scenario underscores a differential responsiveness between CNS 
capillaries and venules vis-à-vis neuroinflammation-associated changes in CLN-5 density at 
endothelial junctions. That C57BL/6 mice display a similar overall CNS microvascular 
architecture and BBB transcriptome from mouse-to-mouse (Macdonald et al., 2010 and Ward et 
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al., 1990) perhaps contributed to the low variance in CLN-5 density within each group of 
microvessels analyzed, and aided in highlighting this heterogeneity. 
 Owing to the fact that microvascular density is greatly reduced in white matter compared to 
gray matter (Cavaglia et al., 2001), and venules constitute only a small percentage of the 
microvascular surface area (Berne and Levy, 1988), we were limited in the venule population to 
sample from the dorsolateral region. A further constraint was trying to capture venules with 
juxtaposed capillaries, so as to compare both basal and reactive CLN-5 expression by the two 
types of microvessel segments within the same or similar microenvironment. Nonetheless, 
sampling of 12 × 60μm sections between T10 and L13 vertebrae enabled sufficient acquisition of 
venules/capillaries for statistical comparisons, while minimizing differences in endothelial 
phenotype due exclusively to regional heterogeneity within the CNS (Ge et al., 2005). 
 In contrasting TJ protein during health and disease, and between different microvessel 
subtypes, we chose to express the density of CLN-5 expression in relation to microvessel 
surface area rather than microvessel volume, as volume (πr2h) increases with the square of the 
radius of a cylinder. As the lumen — which is ‘dead space’ — disproportionately contributes 
more to the vascular volume of bigger segments, reporting TJ protein density per unit volume 
would yield artifactually lower values in larger diameter vessels even if the number of TJ proteins 
per unit area of endothelial membrane were unaltered from vessel to vessel. This is important 
not only for comparing different vessel subtypes in healthy subjects, but also when evaluating 
changes in any one vessel subtype during disease, as vessel caliber may swell along with the 
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separation of basement membranes. We recognize, however, individual endothelial cells of 
larger diameter vessels may also be bigger than in the smallest capillaries, and that this could 
also lend toward a skewing of TJ protein density data being highest in the smaller vessels. It is 
nevertheless significant that Nagy et al. (1984) reported that the ‘complexity’ of brain TJ protein 
particles; i.e., the degree to which they comprise long, uninterrupted strands when viewed in 
freeze-fracture faces, is highest at the capillary end of the vascular tree and much less so at the 
venular end. Thus, our method of analysis yielded results consistent with the freeze-fracture 
technique, which displayed the en face vista of the interior of the cell membrane and focused 
exclusively at the intercellular junctions. That the reduced CLN-5 density in venules during EAE 
reflects diminished protein expression and not just dilation-associated distortion in endothelial 
cell size, is reinforced by our observations of reduced mean pixel intensity of CLN-5 
immunostaining along the venular endothelial junctions during EAE, and the recent report 
describing loss of CLN-5 protein in EAE brain (Errede et al., 2012), as evidenced by Western 
blotting and quantitative optical densitometry. The current method should thus have broad 
applications in efforts to link changes in the expression and/or distribution of TJ proteins with 
focal microvascular incidents in the CNS and peripheral tissues. 
 
 
 
 
 
 
44 
 
 
Figure 2. 3D Contour-based quantification of junctional CLN-5 in spinal cord microvessels. (a) CNS venule from a naïve 
mouse detailing CLN-5 (Green) staining at intercellular junctions. The image shows microvascular tributaries (e.g. capillaries, 
post-capillary venules) emerging from a venule, whose lumen has been “optically” cut open to reveal the inner vessel wall.  
Endothelial cells are highlighted with CD31 (Red). (b,c) To gauge endothelial heterogeneity with respect to CLN-5, spinal cord 
microvessels (capillaries and venules) obtained in confocal z-stacks from the dorsolateral white matter (between T10 and L3 
vertebrae) were imaged and categorized into appropriate segments based on their average diameter. (d) Schematic indicating this 
method effectively allows the surface area of the microvascular endothelium to be spread out in 3D space (x, y, z axes) for 
quantification of CLN-5 density per unit area, while excluding the luminal volume. (e) To quantify CLN-5 staining associated with a 
microvessel in 3D, an individual contour for each confocal z-slice was created by cursoring out the vessel of interest, and the 
individual z-slice contours then merged into a 3D contour surface. This contour surface was utilized to isolate the microvessel of 
interest from the rest of the dataset (masking), and its area was used as an estimate of the “microvascular surface area” defined by 
the endothelial layer. An isosurface for the CLN-5 channel was then created from the selected vessel for statistical analysis. Scale 
bar = 50µm. 
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Figure 3. Heterogeneity in CLN-5 density distribution among different-sized microvessels in naïve spinal cord. Isosurface 
rendering of the CLN-5 channel was performed in confocal z-stacks of different-sized spinal cord microvessels in tissue sections 
from naïve mice: (a,b) larger venules; (c,d) smaller venules; (e,f) capillaries. Top row, shows CLN-5 (Green) and nuclei/DRAQ5 
(Blue). Bottom row, shows CLN-5 only, to emphasize the disparity in junctional CLN-5 immunostaining between the smaller and 
larger microvessels. (g,h) 3D contour-based quantification of CLN-5 density (intensity per unit surface area of the endothelium) 
within naïve spinal cord microvessels. Junctional CLN-5 density was greatest in the capillaries and smaller venules, and least in the 
larger venules. A total of 5 microvessels were analyzed in each group sampled from 3 mice. *p < 0.001. Scale bar = 15µm. 
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Figure 4. CLN-5 density in spinal cord microvessels during EAE. Isosurface rendering of the CLN-5 channel was performed in 
confocal z-stacks of spinal cord microvessels at d24 EAE. Top row, shows CLN-5 (Green) and nuclei/DRAQ5 (Blue) to highlight the 
close association of altered CLN-5 with dense perivascular cellularity. Bottom row, shows staining of only CLN-5 to emphasize 
significant TJ protein disruption. Inflamed venules demonstrated heterogeneity in CLN-5 loss: (a,b) severely inflamed venules 
displayed diffuse and extensive disruption of CLN-5; (c,d) moderately inflamed venules showed small punctate regions of CLN-5 
loss; and (e,f) capillaries adjacent to severely inflamed venules appeared refractory to CLN-5 loss.  3D quantification of 
intercellular CLN-5 staining showed a significant reduction in intensity of CLN-5 staining per unit area of the endothelium in the 
severely inflamed venules compared to the capillaries (g,h). The boundaries of inflamed venules are marked with dashed white 
lines. A total of 6 microvessels were analyzed in each group sampled from 3 mice. *p < 0.0001. Scale bar = 20µm.  
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Figure 5. CLN-5 density in spinal cord microvessels from naïve vs. EAE mice. Isosurface rendering of z-stacked images of 
spinal cord sections from naïve mice and mice at d24 EAE. Top row, shows staining of CLN-5 (Green) and DRAQ5 (Blue) to 
highlight the close association of altered CLN-5 with dense perivascular cellularity (reflective of leukocyte infiltrates) during EAE. 
Bottom row, shows staining of only CLN-5 to emphasize significant TJ protein disruption that accompanies disease. (a,b) Venules 
from naïve mice; (c,d) Venules from d24 EAE mice; (e,f) Capillaries from naïve mice; and (g,h) Capillaries from d24 EAE mice. (i,j) 
3D quantification of CLN-5 microvascular staining showed a significant reduction in CLN-5 density in inflamed venules compared to 
the naïve venules and naïve capillaries. The boundary of inflamed venule is marked with dashed white line. A total of 6 
microvessels were analyzed in each group sampled from 3 mice. *p < 0.0001. Scale bar = 15µm. 
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Figure 6. Heterogeneity in CLN-5 density in a contiguous venule/capillary pair during EAE. (a) Isosurface rendered 3D 
reconstruction of a contiguous venule and capillary in spinal cord section from d24 EAE mouse, highlighting basement 
membrane/Lam1 (Red), CLN-5 (Green), and nuclei/DRAQ-5 (Blue). (b) Isosurface rendered CLN-5 channel only, with boundary of 
the inflamed venule marked with dashed white line.  The venule shows severe loss and fragmentation of junctional CLN-5, while 
the attached capillary displays intact junctional CLN-5 staining. The insets reveal cross sections through the inflamed venule, 
optically cut using clipping plane module in Imaris
®
, demonstrating association of venular CLN-5 loss with seminal signs of 
inflammation: (top) separation of endothelial and astrocyte basement membranes (BM); and (bottom) increased perivascular 
cellularity. (c) Schematic representation showing, qualitatively, heterogeneity in CLN-5 density distribution in a contiguous 
venule/capillary pair at d24 EAE. 
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Figure 7. Endogenous serum IgG leakage from spinal cord microvessels during EAE. (a,c,e) Shows volume rendered 
images of confocal z-stacks from microvascular segments obtained from naïve mice, and mice at d6 and d24 EAE. (b,d,f) Shows 
the corresponding isosurface rendered images for purpose of enhanced spatial perspective. Staining of IgG (Green) and basement 
membrane/LAM 1 (Red) highlights vascular permeability around venules and capillaries. (a,b) Microvessels from naïve mice reveal 
no visible IgG immunostaining associated with venules or capillaries. (c,d) Microvessels at d6 EAE – prior to evidence of clinical 
disease – display focal IgG immunoreactivity around both venules and capillaries. (e,f) Microvessels at d24 EAE show pronounced 
and diffuse IgG immunoreactivity – reflecting endogenous serum protein extravasation – which obscured boundaries between the 
microvessel segments. Increased perivascular cellularity, indicative of leukocyte infiltration (inset), is highlighted by DRAQ5 
staining (Blue). Scale bar = 20µm. 
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CHAPTER III 
Cell-selective knockout and 3D confocal image analysis reveals separate roles 
for astrocyte- and endothelial-derived CCL2 in neuroinflammation2 
1. Abstract 
Although, the tight junctions (TJs) at the blood-brain barrier (BBB) pose an impediment to entry 
of the circulating leukocytes into the central nervous system (CNS) under normal conditions, 
upregulated expression of pathogenic chemokines, like CCL2, by the resident CNS cells in 
neuroinflammation can mediate the transendothelial migration of pathogenic leukocytes across 
the BBB. Expression of chemokine CCL2 in the normal central nervous system (CNS) is nearly 
undetectable, but is significantly upregulated and drives neuroinflammation during experimental 
autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, and considered a 
contributing factor in the human disease. As astrocytes and brain microvascular endothelial cells 
(BMEC) forming the blood-brain barrier (BBB) are sources of CCL2 in EAE and other 
neuroinflammatory conditions, it is unclear if one or both CCL2 pools are critical to disease and 
by what mechanism(s). Mice with selective CCL2 gene knockout (KO) in astrocytes (Astro KO) 
or endothelial cells (Endo KO) were used to evaluate the respective contributions of these 
sources to neuroinflammation, i.e., clinical disease progression, BBB damage and parenchymal 
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leukocyte invasion in myelin oligodendrocyte glycoprotein peptide (MOG35-55)-induced EAE 
model. High-resolution 3-dimensional (3D) immunofluorescence confocal microscopy and 
colloidal gold immuno-electron microscopy were employed to confirm sites of CCL2 expression, 
and 3D immunofluorescence confocal microscopy utilized to assess inflammatory responses 
along the CNS microvasculature. Cell-selective loss of CCL2 immunoreactivity was 
demonstrated in the respective KO mice. Compared to wild-type (WT) mice, Astro KO mice 
showed reduced EAE severity but similar onset, while Endo KO mice displayed near normal 
severity but significantly delayed onset. Neither KOs showed deficits in T cell proliferation, or 
IL-17 and IFN-g production, following MOG35-55 exposure in vitro, or altered MOG MHC Class II 
tetramer binding.  3D confocal imaging further revealed distinct actions of the two CCL2 pools in 
the CNS. Astro KOs lacked the CNS leukocyte penetration and disrupted immunostaining of tight 
junction protein claudin-5 at the BBB seen during early EAE in WT mice, while Endo KOs 
uniquely displayed leukocytes stalled in the microvascular lumen. These results point to 
astrocyte and endothelial pools of CCL2 each regulating different stages of neuroinflammation in 
EAE, and carry implications for drug delivery in neuroinflammatory disease. 
2. Introduction  
The chemokine CCL2 (formerly called Monocyte Chemoattractant Protein-1, MCP-1) has long 
been established as a critical mediator of inflammation within and outside the central nervous 
system (CNS), and stimulates extravasation of mononuclear leukocytes into CNS and peripheral 
tissue beds (Leonard et al., 1991; Mantovani et al., 1993; Bennett et al., 2003; Toft-Hansen et al., 
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2006; Yadav et al, 2010). Our laboratory (Song et al., 2004) and others (Stamatovic et al., 2003; 
Yao et al., 2011) have also revealed a role of CCL2 in the disruption, redistribution, or reduced 
expression of tight junction (TJ) proteins in cultured BMEC, which might contribute in part to 
allow the passage of leukocytes across the BBB in vivo. Elevated CNS expression of CCL2 has 
been a consistent observation among the different paradigms of experimental autoimmune 
encephalomyelitis (EAE) (Izikson et al., 2002; Mahad et al., 2003; Conductier et al., 2010), a 
CNS demyelinating inflammatory disease that serves as a model for multiple sclerosis. This 
chemokine’s singular importance in driving EAE was demonstrated by global CCL2 knockout 
(KO) mice (CCL2-/-), which showed diminished severity and delay in onset of disease in C57BL/6 
mice actively immunized with myelin oligodendrocyte glycoprotein35-55 (MOG35-55) (Huang et 
al., 2001). Adoptive transfer EAE experiments also revealed effector T cells from 
MOG-immunized CCL2-/- mice could transfer EAE to naïve wild-type (WT) recipients, while 
encephalitogenic T cells from WT donors were unable to induce EAE in CCL2-/- mice (Huang et 
al., 2001). Bone marrow chimera studies further showed active immunization EAE was markedly 
reduced when bone marrow from WT mice was engrafted into lethally irradiated CCL2-/- mice, 
but not when bone marrow from CCL2-/- mice was transferred into WT recipients (Dogan et al., 
2008). Collectively, these findings of induced CNS expression of CCL2 during EAE, together with 
the adoptive transfer and bone marrow chimera studies, are consistent with a prominent role for 
CNS CCL2 in mediating EAE and diminish or negate the pathogenic impact of CCL2 from the 
peripheral leukocyte compartment. 
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 What remains unclear, however, is which specific sources of CCL2 significantly contribute to 
disease, whether any reside locally in the CNS, their pathogenic mechanisms, and how they 
might be targeted therapeutically. Astrocytes are a major CNS source of CCL2 in both EAE and 
multiple sclerosis (MS) (Mahad et al., 2003; Conductier et al., 2010; Giraud et al., 2010). By 
projecting their endfeet toward the abluminal surface of brain microvascular endothelial cells 
(BMEC) that form the blood–brain barrier (BBB), astrocytes are ideally situated to intimately 
modulate BBB function and CNS leukocyte extravasation (Hermann et al., 2012). Our laboratory 
(Song et al., 2004) and others (Stamatovic et al., 2003; Yao et al., 2011) have demonstrated that 
CCL2 can disrupt integrity of cultured BMEC along with causing redistribution and reduction in 
expression of tight junction (TJ) proteins. A priori, CCL2 released from astrocyte endfeet may be 
partly responsible for the loss of BBB properties that accompanies both EAE (Bennett Jet al., 
2010) and MS (Meinl et al., 2008), assisting development of a chemotactic gradient across the 
microvascular wall to drive the migration of adhered leukocytes past the endothelium, and/or 
further guiding extravasated leukocytes into the CNS parenchyma (Carrillo-de Sauvage et al., 
2012). In addition to astrocytes, BMECs have also been shown to express CCL2 during EAE 
(Berman et al., 1996) and MS (Subileau et al., 2009). The observations that anti-CCL2 antibody 
prohibits firm attachment of leukocytes in vivo to CNS pial venules of mice immunized for EAE 
(dos Santos et al., 2005), and inhibits monocyte transendothelial migration (TEM) across 
cultured BMEC(Seguin et al., 2003), support the concept that CCL2 presented on the luminal 
endothelial surface aids in arresting leukocytes prior to their extravasation. The recent 
description that TEM of lymphocytes is mediated, in part, by intraendothelial vesicle stores of 
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CCL2 (Shulman et al., 2012), further accents a novel role for the endothelium as a critical source 
of this chemokine.  
To resolve the respective contributions of astrocyte and endothelial cell CCL2 to 
neuroinflammation, we developed cell-conditional chemokine KO mice, in which the CCL2 gene 
was selectively eliminated in each of these cell types (Ge et al., 2009). Here we report for the first 
time that targeted CCL2 gene deletion from either astrocytes or endothelial cells abates EAE 
pathogenesis, while differentially affecting separate aspects of CNS leukocyte extravasation and 
clinical disease course. 
3. Materials and Methods 
3.1  Animals  
Astrocyte- and endothelial cell-specific CCL2 KO mice were generated by intercrossing mice 
containing a floxed CCL2 allele with transgenic mice of GFAP-Cre or Tie2-background, 
respectively, and previously characterized in detail (Ge et al., 2009).  Astrocyte-specific 
knockout mice are referred to as Astro KO, and endothelial specific knockout mice as Endo KO 
mice throughout this study. KO mice and their wild-type (WT) littermate controls were housed in 
specific pathogen-free conditions. All procedures involving animals were performed in 
accordance with the Animal Care and Use Guidelines of the University of Connecticut Health 
Center.  
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3.2  EAE induction  
EAE was induced by active immunization with MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK; W. M. Keck Biotechnology Resource Center, Yale 
University), as described (Murugesan et al., 2012). Briefly, on day 0 (d0), female mice 8 - 10 
weeks of age were injected subcutaneously into the right and left flanks with a total of 300 mg 
of MOG peptide in complete Freund’s adjuvant containing 300 mg Mycobacterium tuberculosis 
(DIFCO). Mice were also injected intraperitoneally with 500 ng pertussis toxin (List Laboratories) 
in phosphate buffered saline (PBS, Gibco/BRL) on d0 and d2 post-immunization (p.i.). 
3.3  Clinical assessment of EAE   
Mice were scored daily for clinical disease severity according to the following scale: 0 = normal; 1 
= tail limpness; 2 = limp tail and weakness of hind legs; 3 = limp tail and complete paralysis of 
hind legs; 4 = limp tail, complete hind leg and partial front leg paralysis; and 5 = death. Several 
disease parameters were calculated as described (Suen et al., 1997). The Mean Day of Onset 
was calculated by averaging the time when clinical symptoms; i.e., a clinical score of > 1, were 
first observed for two consecutive days in each mouse. The Mean Maximum Clinical Score was 
calculated by averaging the highest score for each mouse. The Disease Index was calculated by 
adding the daily average clinical scores in each group, dividing by the mean day of onset, and 
multiplying by 100. If an animal showed no disease, the day of onset was arbitrarily counted as 
one day after the last day of the experiment. Disease Incidence was the fraction of mice 
experiencing EAE. 
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3.4 Cell culture and Cytokine assay  
MOG MOG35-55-immunized mice were sacrificed and draining lymph nodes were dissected on 
d12. Mashed lymph nodes were pressed through a 70 μm mesh into cold RPMI. Cells were 
pelleted at 450g at 4°C for 5 min and resuspended in red blood cell lysing buffer (Sigma) on ice 
for 5 min. After three washes with cold PBS, cells were stained with 0.4% Trypan Blue (Sigma 
Aldrich) and counted with the Countess® Automated Cell Counter (Invitrogen) to permit 
discrimination of dead cells.   
     Single cell suspensions of lymph node cells (LNCs) were prepared and cultured in  
24-well plates (Corning) at 1 × 106 viable cells/ml in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), 1.25% HEPES buffer,1% sodium pyruvate, 1% penicillin-streptomycin, 1% 
glutamine, 1% non-essential amino acids, 0.01% 0.05M- 2 mercaptoethanol (2-ME) (Sigma 
Aldrich). LNCs were restimulated with a combination of 10 mg/ml MOG35-55 and 0.5 
ng/mL interleukin-12 (IL-12) (R&D Systems). Cytokines present in the cell culture supernatants 
of LNC were quantified using the multiplex ELISA kit (R&D Systems). 
3.5 Proliferation assay 
LNCs were prepared as for the cytokine assay. Cells were pulse-labeled with 2µΜ 
carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes) in RPMI for 5 min at room 
temperature (RT). After extensive washing with PBS, the CFSE-labeled cells were suspended 
and cultured in complete medium as above in 24-well plates (2 x 106/well) for 72h. Cell viability 
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was assessed by trypan blue exclusion. The LNC samples were washed in FACS buffer (1% 
FCS and 0.1% sodium azide in PBS). After blocking with Fc Block (BD Biosciences) at 4°C for 
20 min in dark, the cells were washed and stained with fluorochrome-labeled antibodies 
against murine CD3, CD4, and CD11a (BD Biosciences) at 4°C for 30 min. After the cells were 
washed, the fluorescence intensities were measured by a FACS LSRII flow cytometer (BD 
Biosciences) and the data analyzed using FlowJo software (Treestar). 
3.6 MOG38-49 MHC Class II tetramer binding assay  
The procedure was based on that of Cravens et al. (2011). LNCs from MOG35-55-immunized 
mice were prepared and cultured as for cytokine and proliferation assays for 72 h. Thereafter, 
LNCs were washed with FACS buffer, and blocked with Fc Block in FACS buffer at 4°C for 20 
min in dark.  LNCs were washed again, and MOG38-49 MHC class II tetramer-PE or MHC class 
II control tetramer-PE hCLIP103-117-PE (obtained from the NIH Tetramer Core Facility) were 
added and incubated at 37°C for 1 hour in the dark. After the incubation, the cells were directly 
stained with fluorochrome-labeled antibodies against murine CD4, CD11a and CD44 at 4°C for 
30 min. LNCs were washed and resuspended in FACS buffer. Samples were acquired on a 
FACS LSRII flow cytometer (BD Biosciences) and the data analyzed using FlowJo software 
(Treestar). Cells were gated as single live CD4+ T lymphocytes and examined for CD11a, CD44, 
and tetramer reactivity. Cells that were MOG tetramer-positive and CD11a+ were considered 
MOG-specific and previously activated. 
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3.7 Immunofluorescence and 3D analysis of confocal z-stack images   
Tissue was prepared as described by Paul et al. (2013). In brief, following transcardiac 
perfusion/fixation of mice, spinal cords were removed by laminectomy and freeze-embedded in 
cryomatrix. Subsequently, 12×60μm cryosections from the thoraco-lumbar region, approximately 
between the T10 and L3 vertebrae were adhered to poly-L-lysine coated slides. Following 
staining, sections were mounted in Mowiol® prior to microscopic analysis.  
 For immunodetection of CCL2, affinity-purified rabbit anti-mouse CCL2 (Peprotech) was 
utilized with a corresponding anti-rabbit Alexa® 555-conjugated antibody (Life Technologies). 
Sections were subsequently double-immunostained with either rat anti-mouse CD31 (BD 
Pharmingen) followed by secondary incubation with anti-rat Alexa® 488 (Life Technologies) to 
highlight the endothelium, or Alexa® 488-conjugated anti-mouse GFAP (Life Technologies) to 
identify astrocytes. To specifically enhance detection of CCL2 – which shows dispersed punctate 
immunoreactivity – confocal z-stacks were first deconvolved using AutoQuant X3 (Media 
Cybernetics) software, to correct for z-axis distortion. This significantly improved z-resolution and 
the resulting high-resolution images were exported into Imaris® (Bitplane Inc.). Representative 
z-slices, showing the co-localization of CCL2 with endothelial CD31 or astrocyte marker GFAP 
were then obtained.  
 For 3D quantification of microvascular CLN-5 density, the protocol recently detailed by Paul 
et al. (2013) was used. The microvascular basement membrane (BM), a fusion of the respective 
endothelial and parenchymal BMs (Owens et al., 2008), was labeled with rabbit anti-mouse 
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Laminin 1 (Cedarlane) and anti-rabbit Alexa® 555 (Life Technologies). Anti-mouse 
Claudin5-Alexa® 488 (Biolegend) was employed to highlight TJs. Additionally, nuclear stain 
DRAQ5 (Biostatus Ltd.) was utilized to reveal the perivascular cellularity surrounding inflamed 
CNS microvessels, identified as venules (Paul et al., 2013), due to leukocyte extravasation.  
 Spinal cord venules from comparable regions of the dorsolateral white matter were imaged. 
Confocal z-stacks were acquired, at 1µm increments between z-slices, following a multitrack 
scan, using a Zeiss LSM 510 Meta confocal microscope equipped with a 40X Fluar (NA 1.3) and 
a 63X Plan-neofluar (NA 1.25) oil immersion lens.  Confocal z-stacks were imported into Imaris® 
(version 7.6) software (Bitplane Inc.) and the venule of interest was segmented out from rest of 
the 3D dataset by manually tracing the vessel contour in each confocal z-slice, followed by 
merging the z-slice contours into a 3D contour surface. Surface area of the generated 3D 
contour was used as an estimate of the microvascular “surface area” defined by the endothelial 
layer. The CLN-5 channel was isosurface rendered (within the 3D contour surface) and the 
density of CLN-5 staining calculated as Total CLN-5 intensity/Microvascular surface area. CLN-5 
density values were expressed as mean ± standard error of the mean (SEM). 
 To optically isolate (3D segmentation) and resolve the DRAQ5+ cellularity associated with 
leukocyte accumulation (Paul et al., 2013) in the luminal or perivascular compartments of an 
inflamed venule, confocal z-stacks of venules revealing a cross-sectional view were acquired 
and imported into Imaris®. The venule of interest was then isolated from rest of the 3D dataset by 
creating a 3D contour surface, defining the parenchymal BM. This effectively eliminated the 
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parenchymal cellularity (i.e., extravascular infiltrates). Additionally, the lumen was segmented out 
in a similar manner, by creating another 3D surface, approximating the contour of the endothelial 
BM. Spatial location of the observed cellularity between the BMs was considered perivascular. 
 To graphically resolve the distribution of DRAQ5+ luminal and perivascular cells along 
microvascular x, y and z axes with respect to the endothelial and parenchymal BMs, a 3D 
volume was first constructed from the acquired confocal z-stack, followed by 3D segmentation 
of the luminal and perivascular compartments as described above.  Imaris® spot creation 
wizard was then employed to represent each of the DRAQ+ nuclei as a “spot object” in 3D 
space. Only DRAQ5+ nuclei >3 µm in diameter were considered. The 3D profiles of the created 
spot objects, representing the position of luminal and perivascular leukocytes, were then 
plotted on a 3D Imaris® Vantage plot (Figure 14) for revealing its spatial location. 
3.8 Immuno-electron microscopy (Immuno-EM) 
Colloidal gold detection of CNS microvascular CCL2 immunoreactivity by immuno-EM was 
performed as described previously (Li et al., 2010). WT mice at d16 EAE were anesthetized as 
described above, and subjected to transcardiac perfusion/fixation with Ringer’s solution, pH 6.9, 
followed by 4% paraformaldehyde, 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB), pH 7.4.  
Vibratome sections of spinal cord (300-500 μm thick) were cryoprotected with 2M sucrose in 
PB and plunge-frozen in liquid propane cooled by liquid nitrogen (-186oC). Sections were 
stained en bloc with 1.5% uranyl acetate in anhydrous methanol at -90oC for 30 hours and 
infiltrated with Lowicryl HM20 resin (Polysciences), followed by polymerization with UV light for 
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72 hours in a freeze-substitution instrument (Leica AFS) in a temperature gradient (-45oC to 
0oC). Sections (70-80 nm thick) were cut and collected onto 400-mesh gold-gilded nickel grids 
coated with a Coat-Quick “G” pen (Daido).  Tissue sections were incubated with anti-mouse 
CCL2 antibody (Peprotech), followed by incubation with goat anti-mouse IgG labeled with 
colloidal gold particles of 12 nm diameter (Jackson ImmunoResearch). After immunoreaction, 
tissue sections were counterstained with 2% uranyl acetate and then with 2% lead citrate.  
Primary antibody was omitted in immunoreaction as a control, and yielded no detectable gold 
labeling.  
3.9 Statistical analysis  
For analysis of cell-specific KO on clinical EAE parameters, a chi-square (χ2) test was used for 
comparisons of disease incidence; a Mann-Whitney U-test was used for comparisons of 
disease severity; and ANOVA, followed by Bonferroni's multiple comparison post-hoc analysis, 
was used for comparison of disease onset (Ge et al., 2012).  ANOVA/Bonferroni post-hoc test 
was also employed to assess differences in CLN-5 density values (Paul et al., 2013). To 
contrast the rate of rise of clinical EAE progression among the different mouse groups, linear 
regression was performed on data points beginning at the onset of disease through attainment 
of the plateau or highest score. Statistical analyses were performed employing Prism 5 
software (GraphPad), and results were considered significant at a p ≤ 0.05. 
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4. Results  
4.1 Astro KO and Endo KO mice show cell-selective loss of CCL2 
Immunofluorescent staining of CCL2 in spinal cord during EAE in Astro KO, Endo KO, and WT 
mice is shown in high-resolution z-stack confocal images in Figure 8. Using identical image 
acquisition parameters, no CCL2 staining was detected either in naïve mice, or EAE mice in 
the absence of primary antibody (Figure S6), thus highlighting specific immunoreactivity to 
inflamed CNS tissue. In WT mice at d16 post-EAE induction, CCL2 staining was 
vessel-associated as well as within the perivascular space (Figure 8a). Notably, CCL2 staining 
appeared aligned with inter-endothelial junctions (CD31), and showed a punctate distribution 
rather than a diffuse appearance throughout the cytoplasm. This could reflect containment of 
CCL2 within vesicles, as recently described by Shulman et al. (2012) for cultured human 
umbilical vein endothelial cells (HUVECs). A representative z-slice further revealed intense 
double staining (CCL2 and CD31) of the endothelial layer. Parenchymal CCL2 staining (Figure 
8b) was largely observed in association with GFAP+ astrocytes. Localization within astrocytes 
was confirmed in a representative z-slice. Some large deposits of CCL2 could also be seen just 
outside the astrocytes, which may indicate secreted chemokine. Both endothelial and astrocyte 
immunoreactivity in WT mice with EAE were confirmed by immuno-electron microscopy (Fig 
8.1c–f). Notably, CCL2 immunoreactivity was detected within the inter-endothelial junctions 
(Figure 8c), and could also be seen in association with endothelial vesicular-like structures 
(Figure 8d). There was also abundant immunoreactivity within cellular processes at the 
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abluminal side of the endothelium, possibly representing CCL2 destined for or contained within 
astrocyte endfeet (Figure 8e–f).  
 The CCL2 staining patterns with both KO mice were markedly different (Figure 9). Astro KO 
mice at d16 (Figure 9a) showed vessel-associated CCL2 staining but greatly diminished 
staining in the perivascular space. Conversely, Endo KO mice (Figure 9b) exhibited a near 
absence of vessel-associated CCL2 staining, while robust CCL2+ astrocytes were still clearly 
evident. These staining patterns are consistent with previous results from this laboratory 
showing CCL2 RNA expression by both microvessel and parenchymal fractions of brain and 
spinal cord from WT mice with EAE (Ge et al., 2012), and argue that CCL2 protein is produced 
by astrocytes and BMECs, and not merely taken up at these sites. That some vessels in Astro 
KO mice and some astrocytes in Endo KO mice appeared devoid of CCL2 staining possibly 
reflects that not all of the respective endothelial cell and astrocyte populations became similarly 
inflamed, a prospect supported by only a subset of vessels/vessel segments being associated 
with leukocyte infiltrates (data not shown). It may further be that CCL2 from endothelial cells or 
astrocytes exerts some positive control over CCL2 expression by the other cell type (Ge et al.,  
2008; 2009). 
4.2 Astro KO and Endo KO mice are both resistant to EAE, but show different clinical 
phenotypes 
Figure 10a,b shows that targeted CCL2 gene eliminations in astrocytes and endothelial cells, 
respectively, prominently affected development of EAE, consistent with earlier reports of the 
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effects of global CCL2 knockout (Huang et al., 2001; Dogan et al., 2008). While the incidence 
of disease was largely unaffected in both KO mice compared to WT, there was clear evidence 
of altered disease progression in the two cell-selective CCL2 KO groups. Astro KO mice 
exhibited significantly reduced disease severity (clinical score) compared with WT littermates 
throughout the time frame observed, along with just a slight, insignificant delay in disease onset. 
In sharp contrast and nearly mirror image effect, Endo KO mice showed only mild reduction in 
disease severity, but a significantly protracted delay in the onset of disease. It was further 
observed that the rate of rise of clinical disease, as reflected by the slope of the linear, 
ascending region of the disease score graphs, was different between Astro KO and Endo KO 
mice. Astro KO mice showed a lesser rate of rise of clinical disease than both WT and Endo KO 
mice, while the latter two mouse groups showed similar rates of disease rise. Thus, it appears 
that while disease was significantly delayed in Endo KO mice, once disease commenced it 
proceeded on a normal time course (for the period evaluated). Comparisons of Disease 
Incidence, Mean Day of Onset, Mean Maximum Clinical Score, and Disease Index in Astro KO, 
Endo KO, and WT mice are tabulated in Figure 10c.  
4.3 Astro KO and Endo KO mice do not show different MOG-specific T cell responses 
Endo KO mice have the CCL2 gene eliminated from all endothelial cells, central and peripheral. 
This could mean that observed alterations in EAE disease progression in Endo KO mice might 
stem from a defect in the afferent immune arm, such as attenuated T cell priming. Indeed, this 
possibility is prompted by findings that CCL2 is expressed and presented by high endothelial 
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venules in lymph nodes (Palframan et al., 2001), instrumental in dendritic cell maturation 
(Jimenez et al., 2010), and released by dendritic cells to attract antigen-specific T cells (Secco 
et al., 2009). Hence, several T cell proliferation parameters – % Divided, Division Index, 
Proliferation Index, Expansion Index, and Replication Index – were assayed in CSFE 
pulse-labeled LNC cultures from MOG-immunized Astro KO, Endo KO, and WT mice (Figure 
11a). Following restimulation with MOG, no significant differences were detected among cells 
from the three types of mice for any of these parameters. This is in agreement with previous 
findings that indicated no difference in T cell proliferation between LNC cultures from WT and 
global CCL2-/- mice (Huang et al., 2001). 
 We also assayed the ability of cultured LNCs from each of these mice to produce IFN-γ or 
IL-17, which are cytokines considered instrumental in autoimmunity and EAE (Damsker et al, 
2010), in response to restimulation with MOG. Figure 11b shows that MOG-stimulated 
expression of neither cytokine was significantly altered in Astro KO or Endo KO mice compared 
to their WT cohorts. Earlier, Huang et al. (2001) had described diminished production of IFN-γ 
in LNCs from CCL2-/- mice, which might reflect the effects of having depleted a peripheral CCL2 
pool distinct from that of endothelial cells. Figure 11c further reveals that, following MOG 
immunization, the percentage of MOG38-49 MHC class II tetramer positive CD4 T cells was in 
line with another report (Cravens et al., 2011) and similar in LNCs from Astro KO, Endo KO, or 
WT mice, indicating that the frequency of MOG-specific T cells was comparable among these 
groups. Hence, our results argue against either astrocyte- or endothelial cell-targeted CCL2 
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gene deletion having significantly impaired peripheral T cell behavior and immune 
responsiveness to MOG peptide. These findings are further in accord with reports that 
MOG-specific, encephalitogenic T cells can be generated in mice with global knockout of CCL2 
(Huang et al., 2001). 
4.4 Astro KO and Endo KO mice display altered inflammatory responses along the CNS 
microvasculature during EAE 
Given the different clinical EAE phenotypes of Astro KO and Endo KO mice with apparent 
absence of overt impact on T cell priming, we next sought to determine effects of cell selective 
CCL2 loss on inflammatory events along the CNS microvasculature. 3D perspective projection 
views of confocal reconstructions were generated using Imaris® to provide a more realistic 3D 
representation of the z-stack dataset. Notable differences in staining of CLN-5, a prominent TJ 
protein in CNS microvessels and BBB determinant (Nitta et al., 2003), were found among WT, 
Astro KO, and Endo KO mice during EAE (Fig 3.5), while naïve mice of all groups showed no 
evidence of disparities (data not shown). At d9, prior to evidence of clinical disease, WT mice 
showed focal fragmentation of the CLN-5 staining pattern. This discontinuous appearance of 
CLN-5 staining in regions of increased perivascular cellularity was not a result of CLN-5 
staining being distributed in z-planes not captured during acquisition, as the confocal 
reconstructions shown represent 3D images generated from 60 × 1-μm thick z-slices. Rather, 
the areas lacking immunostaining reflected actual sites of CLN-5 disruption associated with 
extravasating leukocytes. This picture differed significantly from that seen with naïve mice, 
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where CLN-5 immunostaining appeared continuous, without obvious interruptions, and 
perivascular cellularity was absent (Figure S7). Hence, for the purpose of highlighting the 
pathologic role(s) of CCL2 released from astrocyte and endothelial sources in 
neuroinflammation, statistical comparisons for CLN-5 density were only made between WT, 
Astro KO, and Endo KO mice during evolving EAE. The significantly altered CLN-5 pattern 
observed in WT mice during EAE corresponded with a sharp decrease of approximately 60% in 
the density of CLN-5 staining. In stark comparison, Astro KO mice demonstrated little if any 
change in CLN-5 staining, while Endo KO mice displayed a somewhat intermediate response 
at this time-point. By d16- following disease onset- WT mice showed further disruption and loss 
of CLN-5 staining, down approximately 80% from that demonstrated by naïve mice. Astro KO 
mice at this later time showed a precipitous loss of CLN-5 staining, declining by approximately 
60% (compared to naïve and d9 mice), while Endo KO mice at d16 showed only a moderate, 
non-significant CLN-5 decrease of approximately 19% (compared to d9).   
 Differences in leukocyte infiltration patterns were also obvious among the various strains of 
mice when vessels were viewed in longitudinal- and cross-section (Figure 13). During 
neuroinflammation, the BM splits into its respective endothelial and parenchymal components 
(Owens et al., 2008), highlighting two spaces: the subendothelial space (between the 
endothelium and endothelial BM) and the perivascular space (between the endothelial BM and 
the parenchymal BM). Both these spaces swell with leukocytes that have recently extravasated 
across the BMECs, but as the BM becomes extensively fragmented during this process, 
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demarcation between the spaces is blurred in longitudinal sections. Thus, in referring to 
leukocyte distribution, the term “perivascular” is used herein to describe all extravasated 
leukocytes that are vessel-associated. At d16, dense perivascular infiltrates were seen to be 
associated with venules in WT mice, with cells apparently penetrating the parenchymal BM to 
enter the parenchyma (Figure 13a,d). Astro KO mice showed similar type clusters of 
perivascular cells, but no clear evidence of leukocytes in the act of rupturing the parenchymal 
BM (Figure 13b,e). Venules of both WT (Figure 13d) and Astro KO (Figure 13e) further 
exhibited lumens within which no cells were detectable. By contrast, Endo KO mice alone 
displayed aggregated cells apparently stalled in the lumen, as well as a seemingly lesser extent 
of perivascular cells (Figure 13c,f–h). To further resolve the aggregated cells throughout the 
microvascular lumen of an entire 60μm section from Endo KO mice, and graphically distinguish 
this pattern from that in WT and Astro KO mice, the distribution profiles of cells associated with 
the lumen and perivascular space, respectively, were mapped in 3D (Figure 14). Intra-luminal 
cells could only be detected in Endo KO mice (Figure 14c). As the actual number of spinal 
vessels showing any evidence of inflammation was extremely low in Endo KO mice at this time, 
the few examples detected showed this common appearance of hindered leukocyte migration. 
Moreover, since tissue was perfusion-fixed, these luminal cells are not likely to have resulted 
from blood stasis but, instead, suggest a possible deficit in extravasation from CNS 
microvessels in Endo KO mice. 
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5. Discussion 
While the critical role of CCL2 in EAE has been revealed in global CCL2 knockout studies 
(Huang et al., 2001), and the chemokine sources mediating this effect are suggested to reside 
in the CNS (Dogan et al., 2008), the identities of the sources responsible for specific 
neuroinflammatory events, e.g., effects at the BBB and leukocyte penetration into the CNS, 
have not been resolved. In the present study, we used mice with targeted CCL2 gene deletion 
in astrocytes or endothelial cells, along with 3D confocal imaging, to establish - for the first time 
– that CCL2 from each of these sources regulates different aspects of neuroinflammation and 
EAE course. Astro KO mice exhibited a similar onset but reduced severity of disease compared 
to WT, while Endo KO mice displayed nearly the opposite clinical pattern. However, neither of 
these KO mice showed any significant changes in MOG-specific T cell responses in LNC 
cultures, consistent with the observed effects of CCL2 gene deletion being limited to the CNS. 
Further reflecting CNS action, Astro KO mice failed to show the parenchymal leukocyte 
infiltration and clear disruption of CLN-5 that accompanied WT EAE, while Endo KO mice 
revealed leukocytes apparently stalled in the lumen of spinal cord microvessels. Significantly, 
the combined effect of separate astrocyte and endothelial CCL2 elimination on clinical disease 
closely mirrors the phenotype reported when CCL2 gene ablation was confined to the “central 
compartment” by adoptive transfer of WT T cells (Huang et al., 2001) or transplantation of WT 
bone marrow (Dogan et al., 2008) into global CCL2 KO mice; i.e., reduced disease severity 
along with delayed disease onset. This reinforces the notion that CCL2 from astrocytes and 
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endothelial cells each contribute to EAE disease in a major, yet different way. The differences in 
EAE noted between Astro KO and Endo KO mice may reflect direct consequences of 
cell-specific CCL2 release on the CNS microvascular endothelium, leukocyte migration, or both. 
Possible actions of CCL2 released by CNS endothelial cells or astrocytes are schematized in 
Figure 14.  
5.1 Astrocyte-derived CCL2 regulates BBB integrity and leukocyte penetration into the 
CNS parenchyma, while endothelial-derived CCL2 impacts leukocyte transendothelial 
migration 
The failure of only Astro KO mice to show clear disruption of CLN-5 staining at d9 EAE 
supports the interpretation that CCL2 released from astrocytes figures prominently in 
destabilizing endothelial TJs at the abluminal microvascular surface early during the 
neuroinflammatory process (Song et al., 2004). Later loss of CLN-5 in these mice by d16 may, 
instead, reflect disruption of TJs by extravasating leukocytes. Astrocyte-derived CCL2 may 
additionally serve to recruit extravasated leukocytes into the parenchyma, as Astro KO mice 
revealed leukocytes congregated in the perivascular space. This latter role is supported by 
Carrillo-de Sauvage et al. (2012), who described contact of CNS infiltrating T cells with 
CCL2-expressing perivascular astrocytes during neuroinflammatory disease. 
 The disruption of CLN-5-containing TJs during EAE and its prominent control by 
astrocyte-derived CCL2, is consistent with numerous reports on the action of CCL2 on TJs and 
BBB properties in cultured BMECs (Song et al., 2004; Stamatovic et al., 2003; Yao et al., 2011; 
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Dhillon et al., 2008), CNS microvessels in vitro (Song et al., 2004), and CNS microvessels in 
vivo in other neurological settings (Stamatovic et al., 2005; Dimitrijevic et al., 2006; Strecker et 
al., 2013). Notably, however, a recent report describing the effect of pertussis toxin injection in 
mice constitutively overexpressing CCL2 selectively in oligodendrocytes under direction of the 
myelin basic protein (MBP) promoter, found no evidence of a disrupted CLN-5 pattern 
accompanying leukocyte extravasation into brain (Schellenberg et al., 2012). This apparent 
contradiction may be due, in part, to the high level of chronic over-expression of CCL2 
(<100,000 times normal values) having caused down-modulation of CCR2, the cognate 
receptor for CCL2, on BMECs (Dzenko et al., 2001), as well as inappropriate or inadequate 
access of oligodendrocyte-derived CCL2 – normally not found in health or disease – to the 
CNS microvasculature. The present study thus underscores the unique relationship between 
endogenous, astrocyte-derived CCL2, TJs, and BBB permeability in neuroinflammatory 
disease (Yao and Tsirka, 2014). 
 Endothelial-derived CCL2, on the other hand, may facilitate a ‘post-adhesion’ stage of 
leukocyte extravasation, as the absence of this chemokine pool was uniquely associated with 
the appearance of leukocytes stalled within the microvascular lumen. In support of this 
hypothesis, Shulman et al. (2012) recently showed that an intraendothelial vesicle pool of 
CCL2 within cultured HUVECs is a critical regulator of TEM of adherent effector T cells. Our 
data, showing both apparently stalled leukocytes in the microvascular lumen of Endo KO mice 
and punctate CCL2 immunostaining in BMECs of WT mice, may thus represent an extension of 
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the results of Shulman et al. (2012) to an in vivo scenario and advance a critical role for a CNS 
endothelial pool of CCL2, possibly vesicle bound, in mediating leukocyte TEM during 
neuroinflammatory disease. While this differs from the finding that CCL2 facilitates adhesion of 
leukocytes to pial microvessels (dos Santos et al., 2005.), this distinction may represent the 
considerable endothelial heterogeneity along the CNS microvasculature (Ge et al., 2005). 
The smaller but significant loss of CLN-5 staining noted in Endo KO mice from d9 to d16 may 
chiefly represent the action of astrocyte-derived CCL2, as lesser extravasation was observed in 
these mice during this period. Conceivably, the astrocyte CCL2 pool could also have guided the 
lesser amount of extravasated cells into the parenchyma, resulting in the delayed disease 
noted. 
5.2 Cell-selective CCL2 knockout highlights CNS actions of CCL2 in neuroinflammatory 
disease 
Our collective findings reinforce critical and non-redundant roles of CNS CCL2 in mediating 
EAE, as previously implicated in adoptive transfer and bone marrow chimera EAE studies with 
global CCL2 knockout mice (Huang et al., 2001; Dogan et al., 2008). Of further importance, the 
use of Astro KO and Endo KO mice together with high-resolution 3D confocal imaging in this 
study was able to resolve apparently unique contributions of astrocyte and endothelial CCL2 
pools to EAE pathogenesis. That both types of mice might share some effects of conditional 
CCL2 deletion is in accord with reports that BMECs can deposit CCL2 abluminally (Chui et al., 
2010), and CCL2 can be transcytosed from the abluminal to luminal BMEC surface (Ge et al., 
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2008). Because all endothelial cells in the Endo KO mice are deficient in CCL2 expression, at 
this time it cannot be concluded that CCL2 from CNS endothelial cells, as opposed to 
peripheral endothelial cells, affected the disease process. However, given the failure of LNCs 
from these mice to show any deficits in MOG-stimulated proliferation, IFN-γ or IL-17 production, 
or MOG MHC class II tetramer staining, it is doubtful that the absence of CCL2 from peripheral 
endothelial cells was a major factor in the aberrant EAE patterns noted. Diminished CLN-5 
disruption and heightened presence of luminal leukocytes in Endo KO mice further point to the 
CNS endothelial pool of CCL2 as featuring critically in EAE. 
 Though only EAE was analyzed in this study, astrocytes and BMECs have been suspected 
as critical sources of CCL2 during other neuroinflammatory conditions investigating three 
different CNS inflammatory scenarios (human glioma, striatal injection of LPS in mice, and 
adenovirally injected monkeys) reporting that extravasation of lymphocytes is mediated by 
CCL2-expressing astrocytes independent of the inflammatory situation and species (Carrillo-de 
Sauvage et al., 2012). Further, Tei et al. (2013) most recently argued that CCL2 expression by 
both astrocytes and BMECs may contribute to the invasion and parenchymal migration of brain 
Iba1+/NG2+ cells, descendants of subpopulations of circulating monocytes, following cerebral 
ischemia. Thus, expression of CCL2 by astrocytes and/or BMECs may be considered a 
widespread phenomenon associated with neuroinflammation. The seminal importance 
attributed to these particular sources of CCL2 does not preclude contributions by other 
CCL2-expressing cell types, e.g., microglia (Dogan et al., 2008; Starossom et al., 2012), which 
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may further modulate neuroinflammatory disease in their unique ways. 
 It has nevertheless been firmly established through elegant adoptive T cell transfer (Huang 
et al, 2001) and bone marrow chimera (Dogan et al., 2008) studies, that CCL2 derived from the 
peripheral leukocyte compartment is not critical to the development of EAE. Hence, even 
though Tie-2-driven Cre expression has been reported in cells of the hematopoietic lineage 
(Tang et al., 2010), any potential loss of CCL2 from this population would not detract from our 
interpretation that CCL2 elimination from BMEC, rather than leukocytes, predominantly altered 
EAE disease. The delay of disease phenotype in Endo KO mice, in fact, is consistent with the 
lack of CCL2 immunostaining in BMEC and apparent stalling of adherent leukocytes observed 
in these animals.  
5.3 Therapeutic targeting of CNS CCL2 
Lastly, as the BBB has generally been recognized as the major impediment to drug delivery to 
the CNS (Pardridge et al., 2005), these results have significant implications for targeting CCL2 
in the treatment of neuroinflammatory disease. It is thus notable to point out that injection of a 
CCL2-neutralizing antibody directly into the brain was effective at suppressing lymphocyte 
infiltration following striatal lipopolysaccharide injection (Carrillo-de Sauvage et al., 2012), a 
situation in which astrocytes were observed to be the major CCL2-expressing cell type. 
Arguably, therapeutic inhibition of endothelial CCL2 would not require circumventing or 
penetrating the BBB, in contrast to suppressing astrocyte production of this chemokine. 
However, as our and the recent results of Shulman et al. (2012) point out, merely targeting 
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CCL2 with antibodies or receptor antagonists may not be effective against vesicle-bound 
endothelial CCL2 depots. The recent demonstration that the anti-inflammatory compound 
bindarit, a synthetic indazolic derivative (MWr 324 Daltons) that preferentially inhibits 
transcription of the monocyte chemoattractant subfamily of CC chemokines (MCP-1/CCL2, 
MCP-2/CCL8, and MCP-3/CCL7), delayed and suppressed EAE in concert with diminishing 
CNS microvascular CCL2 expression (Ge et al., 2012), suggests that interfering with 
intra-endothelial CCL2 might be of high therapeutic value. However, as BBB disruption often 
accompanies neuroinflammatory disease (Paul et al., 2013; Ge Set al., 2005), drugs that inhibit 
CCL2 synthesis could potentially have opportunity to strike at both endothelial cells and 
astrocytes, even if only with limited efficiency at the latter, and thus offer better therapeutic 
prospects than antibodies or antagonists. Recent descriptions of CCL2 involvement in 
post-ischemic disruption of the BBB (Strecker et al., 2013), beta-amyloid neurotoxicity (Severini 
et al., 2014), and traumatic brain injury (Ho et al., 2012), further underscore that modulating 
CNS CCL2 synthesis at the vascular and/or parenchymal level may offer a novel therapeutic 
option for a wide range of neuropathologies. 
6. Conclusions 
In light of our results, it is determined that CCL2 from either astrocytes or BMECs separately 
impacts clinical EAE and associated neuroinflammatory processes in distinct ways and through 
different mechanisms depending on the source cell type. CCL2 from astrocytes regulates 
severity of clinical EAE disease, while controlling penetration of leukocytes into the CNS 
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parenchyma and disrupting CLN-5 staining pattern along the CNS microvasculature. In 
contrast, CCL2 from BMECs appears to more so determine disease onset, and effect 
post-adhesion leukocyte transendothelial migration (Figure 15). Therapeutic targeting of CCL2 
expression or action at the parenchymal or vascular levels may thus offer promise in treating 
neuroinflammatory disease. 
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Figure 8. CCL2 expression in spinal cord of WT mice during EAE. (a–b) z-stack confocal images from spinal cord cryosections of 
WT mice at d16 EAE are shown, revealing staining of CCL2 (red), and CD31 or GFAP (green) to delineate the endothelial cells and 
astrocytes, respectively. CCL2 staining was isosurface rendered for enhanced spatial perspective. (a) WT mice express CCL2 both 
along the CD31
+
 microvascular endothelium, where staining appears aligned along the endothelial junctions, and within the 
perivascular space (left). (b) CCL2 staining is also associated with GFAP
+
 astrocytes (right). Insets show co-localization of CCL2 with 
CD31 or GFAP (yellow) in a single z-slice from the respective regions marked by the hatched white boxes, or CCL2 (red) channel 
alone. (c–f) Colloidal gold immuno-EM localization of CCL2 localization along microvessels in sections of spinal cord from mice at 
d16 EAE. (c) CCL2 immunoreactivity is localized within the inter-endothelial junction (arrow) and scattered throughout the endothelial 
cytoplasm. (d) A cluster of CCL2 immunoreactivity (arrow) is shown in close apposition to an endothelial vesicular structure that is 
near the plasma membrane. (e) Low magnification showing cross-section of a microvessel (possibly a postcapillary venule or small 
venule) and punctate distribution of CCL2 immunoreactivity in the perivascular space (arrows). (f) Higher magnification, revealing a 
high density of CCL2 immunoreactivity in and around what may represent astrocyte endfeet (arrows). Results are representative of 
5–7 sections sampled from three mice in each group and two independent experiments. Scale bars are noted on the respective 
images.  
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Figure 9. CCL2 expression in spinal cord of Astro KO and Endo KO during EAE. Representative z-stack confocal images 
from spinal cord cryosections of KO mice at d16 EAE are depicted. Cell-specific CCL2-KO mice display loss of CCL2 staining in 
respective targeted cell types. (a) Astro KO mice show venule-associated CCL2 staining, but lack staining in the parenchymal 
astrocytes (left). (b) In contrast, Endo KO mice are deficient in vessel-associated CCL2 staining, but maintain astrocyte staining 
(right). The endothelial boundary is marked with yellow lines. Insets show co-localization of CCL2 with CD31 or GFAP (yellow) in a 
single z-slice from the respective regions marked by the hatched white boxes, or CCL2 (red) channel alone. Results are 
representative of 5–7 sections sampled from three mice in each group and two independent experiments. 
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Figure 10. Astro KO and Endo KO mice show different patterns of clinical EAE. EAE was induced in WT, Astro KO, and Endo 
KO mice by MOG35-55 immunization; all mice were observed daily and scored for clinical disease for 30 days. Each group consisted 
of 5–6 mice, and analysis was performed in triplicate. Graphs represent mean data points from all three analyses ± standard error. 
(a) Mean clinical EAE scores. Astro KO mice do not attain as severe disease as WT during the evaluation period, while Endo KO 
mice approach WT disease severity but do so only after significantly delayed onset. The rate of rise of clinical disease, as reflected 
by the slope of each regression line (hatched lines) through the respective ascending disease scores for the different mice, is 
similar in both WT and Endo KO mice, but notably less in Astro KO mice. (b) Disease incidence. All mice show a similar incidence 
of disease but, compared to WT mice, Astro KO mice show only a mild delay while Endo KO mice show a prolonged delay in 
disease onset. (c) Summary of various clinical disease parameters among the three mouse groups. 
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Figure 11. LNCs from MOG35-55-immunized WT, Astro KO, and Endo KO mice show similar responses to MOG35-55 
restimulation in vitro. LNCs were prepared from MOG35-55-immunized mice on d12, and restimulated with MOG35-55 for 72 h in 
culture, after which time different responses were measured. (a) T cell proliferation. LNC were pulse-labeled with 2 μΜ CFSE for 5 
min at the beginning of culture and analyzed after 72 h by FACS, gating on CD3, CD4, CD11a. (b) Cytokine production. The 
concentrations of IL-17 and IFN-γ were determined in supernatants of LNC after 72 h in culture. (c) Binding of MOG38-49 MHC class 
II tetramer-PE. Binding was determined after 72 h in culture, and hCLIP103-117 tetramer-PE served as a control for non-specific 
binding. Plots were gated on CD4
+
 T lymphocytes. The frequency of MOG38-49 I-Ab tetramer
+
 CD4
+
 T cells is similar among WT, 
Astro KO, and Endo KO groups, while hCLIP103-117 I-Ab tetramer does not bind cultured T cells. The data shown are 
representative of at least two independent experiments; data in (a) and (b) reflect mean value ± standard error. 
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Figure 12. Astro KO and Endo KO mice show differential loss of CLN-5 staining in spinal venules during EAE. (a) 
Isosurface-rendered images were generated from confocal z-stacks of 60 μm thick thoraco-lumbar spinal cord cryosections at d9 
and d16 EAE, as described in Materials and Methods. Staining of CLN-5 (green isosurface) and nuclei/DRAQ5 (blue) is shown. 
Larger images displaying 3D perspective projection views of confocal reconstructions show CLN-5 channel only, to emphasize the 
fragmented pattern of TJ protein staining. Inserts depict both CLN-5 and nuclei, highlighting the close association of altered CLN-5 
staining with dense perivascular cellularity representing infiltrating leukocytes. Arrows demark overt gaps in CLN-5 staining, where 
the TJ pattern is clearly disrupted. Notably, CLN-5 staining pattern during EAE appears most intact in Astro KO mice, least so in 
WT mice, and intermediate in Endo KO mice. (b) Quantification of CLN-5 staining as intensity per unit surface area of the 
endothelium. CLN-5 density in naïve WT mice is included as a reference for the normal state, wherein the pattern of CLN-5 
junctional staining is continuous [30]. Statistical comparisons are between groups and within days. (c) Summary of CLN-5 changes. 
Statistical comparisons are within groups and between days. A total of 12 venules were analyzed in each group sampled from 
three mice. Data reflect mean value ± standard error. Scale = 20 μm. 
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Figure 13. Astro KO and Endo KO mice display differences in perivascular cellularity associated with spinal venules during 
EAE. Isosurface-rendered images were generated from confocal z-stacks of 60 μm cryosections at d16 EAE. Staining of BM Lam 1 
(red), CLN-5 (green), and nuclei/DRAQ5 (blue) is shown. (a, b, c) Longitudinal sections reveal the extent of vessel-associated 
leukocytes. CLN-5 staining is presented to highlight the endothelial boundary. Insets represent enlarged view of areas highlighted in 
white hatched boxes, while double-headed arrows denote the space between the endothelial and parenchymal BMs. All extravasated 
leukocytes within this space are considered “perivascular”. In WT mice, a dense accumulation of DRAQ5+ perivascular cells 
(representing leukocytes) is seen, a few apparently penetrating the fragmented parenchymal BM (arrowhead). In Astro KO mice, a 
similar dense perivascular cellularity is observed, with visibly intact parenchymal BM and lack of parenchymal leukocyte migration. In 
Endo KO mice, the BM is also apparently intact, with minimal perivascular cellularity. Scale = 20 μm. (d, e, f) Cross-sections highlight 
the spatial distribution of vessel-associated leukocytes. In WT mice, the vessel lumen (demarked by white dashes) appears empty 
and cells are seen in the perivascular space. A few cells are visibly penetrating the parenchymal BM (arrowheads), alongwith dense 
parenchymal cellularity (brackets). In Astro KO mice, the lumen again appears empty; congregated cells are evident in the 
perivascular space, with a few parenchymal clusters. In Endo KO mice, cells are clearly present in the lumen, with apparently fewer 
cells in the perivascular space as compared to WT and Astro KO mice. Parenchymal clustering is seemingly absent. The diffuse 
DRAQ5+ cells are likely parenchymal neural cells. (g-h) The red arrow designates the same Endo KO image subject to 
contour-based 3D segmentation (see Materials and Methods) to further resolve luminal (blue) from perivascular (turquoise) cells. 
Results are representative of 5–6 microvessels sampled from three mice in each group and two independent experiments. Scale = 10 
μm.  
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Figure 14. Astro KO and Endo KO mice display differences in 3D distribution profiles of luminal and perivascular cells. 
Isosurface-rendered images were generated from confocal z-stacks of 60-μm thick cryosections from WT, Astro KO, and Endo KO 
mice at d16 EAE. The BM is highlighted by staining of Lam1 (red). (Top row) DRAQ5
+
 nuclei in luminal and perivascular 
compartments were optically isolated using 3D contour based segmentation (as described in Materials and Methods), and 
pseudo-colored blue (luminal) and turquoise (perivascular), respectively. Using Imaris
®
 spot creation module, each of these nuclei 
is shown in the 3D dataset (volume) as a “spot object,” designating its luminal or perivascular location. Scale = 10 μm. (Bottom row) 
Imaris
®
 vantage plots showing the 3D distributions of luminal and perivascular cells along microvascular x, y, and z-axes in the 
corresponding vessels from the top row. Scale = 20 μm. (a) Representative WT vessel showing an empty lumen (*). (b) The lumen 
in the Astro KO vessel also appears empty (*) but partially collapsed, possibly owing to accumulation of perivascular cells that are 
missing guidance cues from deleted astrocyte-derived CCL2. (c) In contrast, Endo KO vessel shows evidence of congregation of 
cells in the lumen (blue), possibly reflecting stalled leukocyte transmigration in absence of endothelial-derived CCL2. 
Box-and-whisker plots are shown indicating the maximum and minimum spread from the median, in μm, of luminal or perivascular 
nuclei along the x, y, and z-axes. 
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Figure 15. Differential actions of astrocyte-derived and endothelial cell-derived CCL2 at CNS venules. Based on 
observations with Astro KO and Endo KO mice during EAE, the schematic depicts endothelial-derived CCL2 facilitating migration 
across the endothelium (1), a step post-adhesion. Astrocyte-derived CCL2 is shown promoting both breakdown of endothelial tight 
junctions (2), and penetration of leukocytes across the parenchymal BM into the CNS parenchyma (3).   
 
 
 
 
 
 
 
 
85 
CHAPTER IV 
Endothelial extracellular vesicles transfer tight junction protein Claudin-5 
to circulating leukocytes in neuroinflammation3  
1. Abstract 
Leukocyte transendothelial migration (TEM) across the blood-brain barrier (BBB) is a hallmark of 
neuroinflammatory disease like multiple sclerosis (MS), and its animal model, experimental 
autoimmune encephalomyelitis (EAE). The neurodegeneration underlying MS stems from focal 
infiltration of myelin-reactive leukocytes into the central nervous system (CNS) parenchyma, 
which in turn correlates to BBB dysfunction. While the mechanism(s) of TEM remains unclear, 
the presence of tight junctions (TJs) at the BBB is generally considered an impediment to 
leukocyte extravasation in the central nervous system (CNS). Paracellular TEM across the intact 
BBB must therefore require leukocytes to negotiate the endothelial TJs. To address this, 
high-resolution 3D confocal imaging was used to highlight disposition of the TJ protein claudin-5 
(CLN-5), a major BBB determinant, during experimental autoimmune encephalomyelitis (EAE) – 
a model of multiple sclerosis (MS). Strikingly, a sub-population of leukocytes immunoreactive for 
CLN-5 on their surface was seen to infiltrate the CNS of mice early during EAE, in close 
apposition to inflamed vessels.  Confocal imaging and Western blotting confirmed the presence 
of CLN-5+ leukocytes in plasma from EAE mice.  As circulating CLN-5+ leukocytes have been 
                                                             
3
 The abstract of this work was published in Paul, D, Ge, S, Jellison, ER, Agalliu, D, Pachter, JS. Extracellular vesicles as possible 
conveyors of tight junction protein to leukocytes in neuroinflammation. Journal of Extracellular Vesicles 2015;4: 27783. 
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described in MS patients, and extracellular vesicles (EVs) from cultured brain microvascular 
endothelial cells (BMEC) of the BBB reported to express a variety of adhesion molecules and 
stimulate leukocyte TEM in vitro, we investigated if BMEC-derived EVs have CLN-5 cargo and 
bind to leukocytes. Western blotting showed BMEC-derived EVs, corresponding in size to both 
exosomes and microvesicles, expressed CLN-5. Confocal imaging and flow cytometry further 
showed EVs from TNFα-stimulated BMECs can bind leukocytes. Additional imaging of inflamed 
vessels from endothelial targeted, Tie-2-eGFP-CLN-5 transgenic mice showed labeled 
leukocytes in the CNS during early EAE, consistent with the transfer of CLN-5 from endothelial 
cells to leukocytes in vivo. eGFP-EVs were also detected by flow cytometry in culture 
supernatants from both BMEC and plasma of Tie-2-eGFP-CLN-5 mice, and observed by 
confocal imaging to bind leukocytes. Lastly, serial scanning electron microscopy and 3D 
contour-based surface rendering revealed a close association of membrane-bound structures 
resembling EVs between the marginating leukocytes and BMECs in vivo during EAE. Results 
indicate CLN-5+ EVs released from BMEC can bind to leukocytes and thereby transfer CLN-5 
protein. This action may be a prelude to facilitate TEM through the formation of TJ protein 
bridges between these two cell types.  
2. Introduction 
Cells require constant communication with neighbors for their normal physiological function or 
during a pathological insult. Burgeoning evidence further implicates a role of 
membrane-enclosed sacs shed from the surface of cells, collectively termed extracellular 
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vesicles (EVs), as vehicles for such communication (Ratajczak et al., 2006b; Mause and Weber 
2010). EVs of sizes ranging from 30 to 1000 nm can be of endosomal or plasma membrane 
origin, and termed exosomes or microvesicles, respectively (Shifrin et al., 2013). Both EV 
subtypes relay cell-specific repertoires of proteins, lipids, and genetic material to their targets. 
Owing to their small size and membrane-bound nature, EVs can be rapidly mobilized throughout 
the circulation, while protecting their cargo from degradation in bloodstream.  
 In the central nervous system (CNS), neurons, microglia, astrocytes, oligodendrocytes and 
endothelial cells have been reported to secrete microvesicles and/or exosomes into the 
extracellular environment. Though their molecular cargo awaits rigorous evaluation, EVs from 
CNS-resident cells are thought critical for CNS function in health and disease (Verderio et al., 
2012; van der Vos et al., 2011). For instance, EVs derived from oligodendrocytes can regulate 
myelination (Bakhti et al., 2011; Frühbeis et al., 2012), while those released by neurons may aid 
clearance of pathogenic agents or degenerative proteins like beta-amyloid (Yuyama  et al., 
2015). These findings imply EVs perform functions necessary for CNS homeostasis. 
 However, EVs can also act as pathogenic effectors in the CNS, as they have been 
implicated in the dispersal of toxic proteins in a number of neurodegenerative diseases, e.g., 
Multiple Sclerosis (MS), transmissible spongiform encephalopathies, Alzheimer’s disease, 
Parkinson’s disease, tauopathies, and amyotrophic lateral sclerosis (Horstman et al., 2007; 
Jimenez et al., 2005; Vingtdeux et al.,2007; Vella et al.,2008; Guest et al.,2011; Frühbeis et al., 
2013). Microglia-derived EVs contain inflammatory cytokines, such as interleukin (IL) 1β, and 
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can influence neuronal activity (Turola et al., 2012). MVs of myeloid origin have also been 
detected in the cerebrospinal fluid (CSF) of humans and rodents, and reported to increase in 
concentration upon brain inflammation, possibly implicating their role as pathogenic effectors 
and/or biomarkers of disease activity (Verderio et al., 2012). It is of further high significance that 
EVs can potentially travel long distances for horizontal transfer of the contained bioactive 
molecules to these distal sites. 
 Apart from contributing to the dispersal of toxic bioactive molecules, EVs have also been 
reported to contribute to immune pathologies in the periphery by modulating multiple facets of 
leukocyte biology, e.g., their activation, migration, or adhesion (Zech et al., 2012; Jimenez et al., 
2005; Lee et al., 2010). For instance, exosomes released by cancer cells can create an 
immune-privileged environment by inducing apoptosis of activated tumor-specific T cells (Kim et 
al., 2005). A study on rheumatoid arthritis patients further demonstrated TNFα–containing 
exosomes from synovial fluid fibroblasts can potentiate the disease by delaying the 
activation-induced death of infiltrating T cells (Zhang et al., 2006). Additionally, exosomes from 
bronchial epithelial cells of asthmatic patients have been reported to induce the proliferation and 
chemotaxis of monocytes (Kulshreshtha et al., 2013). 
In accord with their immunomodulatory role in the periphery, EVs have also been been 
recently called into question as possible players in leukocyte entry into the CNS in 
neuroinflammatory disease like MS (Jy et al., 2004; Jimenez et al., 2005; Horstman et al, 2007) 
and in stroke (Simak et al., 2006; Jung et al., 2009). Leukocyte infiltration into CNS tissue is often 
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reported to be associated with a transient focal loss in the endothelial TJs, suggesting that 
invading leukocytes somehow negotiate the physical obstacle of BBB (Paul et al., 2013; Cosetti 
et al., 2012). For instance, Xu et al. (2005) used intravital scanning laser ophthalmoscopy to 
demonstrate activated T cells in mice inflicted with experimental autoimmune uveoretinitis 
interact with the endothelium, upregulate ICAM-1, and induce transient breakdown of the 
blood-retinal barrier. In a subsequent study (Xu et al., 2005b), these authors also reported that 
sites of leukocyte extravasation in retinal venules correlated with areas of TJ protein loss in vivo. 
Accompanying this TJ protein loss, was the redistribution or loss of ensheathing astrocyte 
processes at venular sites, but not at adjacent capillaries or arterioles. Plumb et al., (2002) used 
enhanced MRI to reveal in vivo breakdown of BBB and subtle elevation of microvascular 
permeability in expanding inflammatory lesions in relapsing-remitting and chronic progressive 
MS. Analysis of microvascular TJ abnormalities using fluorescence confocal imaging further 
highlighted beading, discontinuity, absence or diffuse cytoplasmic localization of TJs, suggestive 
of BBB damage, in forty percent of vessels inside the lesions (Plumb et al., 2002). These findings 
were also mimicked in EAE, an animal model of MS, where brain and spinal cord microvessels 
showed a selective loss of claudin-3 immunostaining in venules surrounded by inflammatory 
cuffs (Wolburg et al, 2003). Such loss of endothelial TJs can also be seen in other human 
disease like glioblastoma multiforme, where selective loss of claudin-3 immunostaining was 
reported in altered cerebral microvessels (Wolburg et al, 2003). Using an in vitro model and 
human brain tissues with HIV-1 encephalitis, Persidsky et al. (2006), showed that monocyte 
migration across brain microvascular endothelial cells requires dislocation of membrane 
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recruited TJ protein occludin from the cell junctions.  
Interestingly, these TJ abnormalities or increased microvascular permeability in the CNS, 
suggestive of BBB damage in neuroinflammation, is often associated with a concomitant 
increase in circulating endothelial EVs (Marcos-Ramiro et al., 2014; Cosetti et al., 2012). A 
recent study has thus, offered EVs as a possible link between leukocytes and TJ damage.  
Mandel et al. (2012), reported expression of TJ protein Claudin-1 and Claudin-5 in peripheral 
blood leukocytes (PBLs), predominantly in B and T lymphocytes and monocytes in multiple 
sclerosis (MS) patients in relapse. Strikingly, RNA levels for these TJ proteins decreased in these 
cells following glucocorticoid treatment of patients, which suppress immune activation and 
inflammation. The study concluded increased TJ proteins on leukocytes were associated with 
immune activation and overall MS disease activity, implicating leukocyte TJ proteins as 
significant elements of autoimmunity. However, it is unclear if the leukocytes endogenously 
express these TJ proteins or acquire it through TJ protein+ EVs released into the circulation by 
endothelial cells. It is also unclear how leukocyte-associated TJ proteins contribute to TEM 
across the BBB, a critical feature of a multitude of neuroinflammatory diseases. It is possible that 
TJ protein+ leukocytes define a small subset of the total leukocyte population, that contribute to 
the initial opening of the BBB in neuroinflammatory disease, paving a route for the trailing 
pathogenic leukocytes to extravasate along. Therefore, addressing the role, source, and mode of 
acquisition of these TJ proteins on the circulating leukocytes, might be critical for understanding 
how they breach the BBB during the onset and/or progression of neuroinflammation. 
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3. Materials and Methods 
3.1 High resolution 3D imaging of leukocyte transendothelial migration in vivo 
Processing of thoraco-lumbar spinal cord tissue, immunofluorescent staining of 60µm thick 
cryosections and analysis of confocal z-stack images were performed as described previously 
(Paul et al., 2013; 2014). 
3.2 Isolation of EVs from brain endothelial cell line (bEND3) and primary brain 
microvascular endothelial cells (BMEC) 
Brain endothelial cells (bEND3) (ATCC) were cultured in DMEM media supplemented with 10% 
Debayon, FBS till 90% confluence. The cells were switched to DMEM supplemented with 2% 
exosome free FBS, and grown for additional 12 hours with 10ng/ml TNFα in the media. The 
bEND3 supernatant was spun at 300×g for 10 min at 4°C, 2000×g for 10min at 4°C, and finally 
8000×g for 30 minutes at 4°C to remove the debris and cell fragments. The clear supernatant 
was spun first at 20,000×g and 60,000×g for 30 mins for isolating the larger and smaller 
MVs-sized vesicles respectively, and then at 100,000g for 60 mins to isolate the exosomes-sized 
vesicles. 
 Brain microvascular endothelial cells were isolated from mice in a fashion described earlier 
(Ge et al., 2007). Briefly, after removal of the brain from 4-6 week old mice, the meninges and big 
vessels were discarded and the cortex homogenized with a 7 mL Dounce tissue grinder 
(Kimble/Kontes) in Dulbecco’s modified Eagle medium (DMEM; Gibco BRL) supplemented with 
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antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). The homogenates were 
suspended in 18% dextran (v/v, molecular weight 60,000–90,000; USB Corporation) and 
centrifuged at 10,000 × g for 15 min. The pellet was resuspended in Ca2+ and Mg2+- free Hank’s 
balanced salt solution (HBSS) (Gibco BRL), and filtered through a 40 μm cell strainer (Becton 
Dickinson Labware). The microvessels trapped on the filter were digested with 0.1% 
collagenase-dispase (Roche) in HBSS containing 20 U/mL deoxyribonuclease-I, and 0.147 
μg/mL of the protease inhibitor tosyllysine chloromethyl ketone at 37°C for 40–60 min. Digestion 
was continued with occasional agitation, until endothelial cells were seen popping out from most 
of the microvessel fragments. These microvessels were pelleted at 1000×g for 5 min, and 
washed once with phosphate-buffered saline (PBS) containing 1% bovine serum albumin. The 
pelleted vessels purified with anti-murine PECAM-1-coated Dynabeads M-450 (Dynal) at 4°C for 
60 min with gentle mixing, and then subjected to immunomagnetic purification (Song et al., 2003, 
2004). The bead-purified vessel fragments resuspended in complete culture medium (DMEM 
containing 10% fetal bovine serum, 10% horse serum, 100 μg/mL penicillin and 100 μg/mL 
streptomycin, 100 μg/mL heparin, and 100 μg/mL endothelial cell growth factor supplement), and 
plated onto tissue culture dishes coated with murine collagen IV (BD Biosciences). After 48 h, 
cultures the cells were resuspended in fresh media after washing off the free magnetic beads. 
Cultures were allowed to reach about 90 percent confluence prior to their subculture. At that time, 
purity was gauged to be ≥ 98% BMEC, according to diI-acetylated LDL uptake (Song and 
Pachter 2003). 
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BMECs were isolated and cultured from eGFP-CLN-5 transgenic mice in the same way. EVs 
were isolated from TNFα-treated wild-type and eGFP-CLN-5 transgenic BMECs as described for 
the bEND3 cells. 
3.3 Isolation of leukocytes and EVs from blood  
Naïve and EAE mice (n=10) were anesthetized with anesthetized with ketamine (80 mg/kg, ip) 
and xylazine (10 mg/kg, ip) in PBS, pH 7.4. A 3ml syringe with 25 gauge needle was briefly 
flushed with 0.109M 3.2% Sodium Citrate (BD) and blood was slowly acquired using 
transcardiac puncture. 3ml of fresh anticoagulant treated blood was diluted 1:1 with HBSS at 
25°C by gently inverting the tube and slowly layered on 3ml of Ficoll-Paque PLUS in a 15ml 
Falcon tube. Samples were spun at 400×g for 40 min at 25°C in a swing-bucket centrifuge 
(Eppendorf 5804R) without acceleration or brakes.  
 The “buffy” lymphocyte layer from the Ficoll-Paque PLUS gradient was carefully aspirated 
using a 1ml pipette, washed in 3 volumes of HBSS and spun at 100×g for 10 min. After, 
discarding the supernatant, 1 ml of RBC lysis buffer was added in each tube to remove left over 
RBC contamination and incubated for 5 min at 25°C. The sample was neutralized with three 
volumes of HBSS (Gibco) and spun at 100×g for 10 min. The pellet was resuspended in HBSS 
and the yield was calculated by Trypan blue exclusion technique with a hemocytometer. 
 The upper layer containing plasma was slowly drawn using a sterile Pasteur pipette and 
used for microvesicle and exosome isolation. The plasma was spun at 300g for 10min at 25°C, 
 
 
94 
2000g for 10min at 25°C, and finally 8000g for 30 minutes at 4°C to remove the debris and cell 
fragments. The clear supernatant was then spun first at 20,000×g and 60,000×g for 30 mins for 
isolating the larger and smaller MVs and then at 100,000g for 60 mins to isolate the exosomes. 
 Enrichment of microvesicle and exosome – sized vesicles in these fractions was validated 
by nanoparticle tracking analysis (NTA) (Figure S9). 
3.4 EAE induction and scoring in wild-type and eGFP-CLN-5 mice 
EAE was induced, and the disease score analysis was done as published before (Paul et al., 
2013, 2014) 
3.5 Western blotting  
Protein level was assayed by the Micro BCA protein assay kit (Pierce). Leukocytes were 
analyzed for CLN-5 protein using mouse monoclonal anti-CLN-5 (Life Technologies) as 
previously detailed (Paul et al, 2013, 2014). Blots were developed using the chemiluminescent 
HRP substrate kit (SuperSignal West FemtoMaximum Sensitivity; Pierce) and signal detected 
using a G:Box XX6 digital gel imager (Syngene). Images were acquired by GeneSys software 
(Syngene) and automated densitometric analysis performed using GeneTools software 
(Syngene). 
3.6 Binding of total EVs to leukocytes 
Exosome and microvesicle- sized EVs were labeled with the fluorescent membrane dye PKH67 
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(green), while isolated PBMCs were labeled with another fluorescent membrane dye, PKH26 
(red). PKH67-labeled EVs were incubated with PKH26-labeled leukocytes in Ca2+/Mg2+-free 
HBSS supplemented with 2% exosome-free serum (System Biosciences) at 4oC overnight on 
poly-L-lysine-coated 8-well chamber slides (Nunc). Following washing in HBSS, the 
leukocyte-EV complex was spun down at 200×g and fixed in 4% PFA. High-resolution images 
were acquired using a Zeiss LSM 510 Meta confocal microscope equipped with a 100X 
plan-apochromatic oil immersion lens, 1.3NA, as described above for 3D imaging of CLN-5+ 
leukocytes. While leukocytes might need to be activated to bind EVs, circulating leukocytes from 
EAE mice might already be saturated with EVs bound in vivo prior to our isolation. Also, EVs 
released into the blood during neuroinflammation might differ in binding capacity from those 
present in the normal state. Thus, for our in situ experiments EVs purified from EAE mice plasma 
were incubated with leukocytes from naïve mice. 
3.7 Isolation of CLN-5 leukocytes from eGFP-CLN-5 mice  
Transgenic C57BL/6 mice expressing reporter eGFP fused to CLN-5 protein, under the 
endothelial Tie-2/Tek-1 promoter/enhancer, in all endothelial cells, underwent EAE induction and 
CLN-5 expression in the CNS microvessels evaluated by high-resolution 3D fluorescence 
imaging as described earlier (Paul et al., 2013, 2014), and the eGFP-CLN-5 leukocytes studied 
in situ in mice inflicted with EAE in a similar fashion. eGFP-CLN-5 leukocytes were isolated from 
blood and CNS tissue as described in previous section, and further purified via FACS. 
Co-localization with anti-CLN-5 staining (Red) and the transgenic eGFP (Green) was performed 
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to validate epitope specificity of the immunostaining (data not shown).  
3.8 Serial scanning electron microscopy (serial EM) and 3D contour surface creation 
using Imaris® 
Serial EM was performed as described before (Terasaki et al., 2013). Mice were anesthetized 
with Ketamine/Xylazine and transcardially perfused first with PBS to wash off the blood, and then 
with 2.5% glutaraldehyde and 2.0% paraformaldehyde in 0.1M cacodylate buffer through the left 
ventricle of the heart. The spinal cords were isolated by laminectomy and fixed for an additional 
3-4 hours in the same fixative, then rinsed and stored in 0.1 M cacodylate buffer at 4°C. The 
lumbar section of the spinal cord was cut with a razorblade into ~1mm thick slices and rinsed in 
0.1M cacodylate buffer several times. The samples were processed using the ROTO protocol 
(Tapia et al., 2012), they were dehydrated in grade ethanol solutions and embedded in epoxy 
resin (Polybed, Polysciences; Warrington, PA).  
 After the samples were polymerized, the face of each block was shaped to a ~2 x 3 mm 
rectangle using a diamond trimming knife. Thin sections, 60nm thick, were cut using a microtome 
(Leica EM UC7, Buffalo Grove, IL) and a diamond knife. Serial sections were collected on kapton 
tape (glow-discharged to minimize wrinkling of sections) using the ATUM tape collector 
(Hayworth et al., 2006), the tape with sections was cut into strips and mounted on 4-inch silicon 
wafers (University Wafers, South Boston, MA), and then carbon coated for electron grounding 
(Denton 502B, Moorestown, NJ). 
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 The sections were imaged using a field emission scanning EM (Zeiss Sigma FE-SEM; 
Peabody, MA) in backscatter mode (10 keV electrons, ~5 nA beam current). A high-precision 
map of the sections on the wafer (± 4 μm) was generated, then the Atlas Large Area Imaging 
software (Fibics Inc.; Ottawa, Ontario, Canada) was used to automatically image a ~65 μm × 65 
μm field of the serial sections at 5-7 nm/pixel resolution (12,288 × 12,288 pixels). The images 
were aligned using the Linear Alignment with SIFT algorithm (FIJI, Image J), and reconstructed 
using Imaris®. 
 To visualize the endothelium and EVs at the site of leukocyte adhesion in 3D, the serial EM 
slices were first imported into Imaris for volume rendering. Manual contour tracing was then 
performed by cursoring out the endothelium, EVs and the ‘adherent’ leukocyte of interest in each 
serial EM z-slice and the individual contours merged into a 3D contour surface, as detailed 
previously (Paul et al., 2013; Bohórquez et al, 2014). 
3.9 Transendothelial migration (TEM) of leukocytes across BMEC 
TEM of leukocytes across a mouse BBB model was performed as previously described (Ge at al., 
2008). bEND3, brain microvascular endothelial cells (BMEC) (ATCC), were cultured on Transwell 
inserts (24-well format, 8.0 um pore) till confluent.  Leukocytes were isolated from the blood of 
Tie-2-eGFP-CLN-5 transgenic mice at day 9 post EAE induction and separated based on 
presence or absence of eGFP-CLN-5 using a flow cytometer (BD FACSAria™ II). 1×105 
leukocytes were placed on the upper chamber, and chemokine CCL2 (10 nM; Biolegend) added to 
the lower chamber. After different times (2h, 6hr, and 18hr) at 37oC, transmigrated leukocytes in 
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the lower chamber were removed and counted by flow cytometry (MACSQuant® Analyzer 10, 
Miltenyi Biotech).  
4. Results 
4.1 TEM of CLN-5+ leukocytes during preclinical EAE 
To determine the status of blood-brain barrier integrity, with respect to endothelial CLN-5 
immunostaining, during the earliest leukocyte TEM events,  spinal cord sections from mice at 
D9 post EAE induction (preclinical phase) were immunostained for TJ protein CLN-5, endothelial 
marker CD31, and nuclear stain DRAQ5. 3D reconstruction and Isosurface rendering of 
microvessels in high-resolution confocal z-stacks were performed as detailed previously (Paul et. 
al, 2014). Loss of TJ protein CLN-5 has been previously reported to be restricted to venules and 
post-capillary venules in EAE (Paul et al., 2013). Venular CLN-5 staining seemed to largely 
localize with the CD31 staining at this time-point. However, a population of leukocytes 
transmigrating across inflamed thoraco-lumbar spinal cord venules (meningeal and parenchymal) 
at this time point was immunostained for CLN-5+ (Figure 16a; Figure S8). Such, leukocytes were 
mostly visible along the meningeal microvessels or the infiltrating parenchymal vessels at this 
early time point (Figure S8). Notably, the TEM of CLN-5+ leukocytes appeared to happen in 
regions proximal to focal discontinuities in CLN-5 immunoreactivity, indicative of BBB damage. 
The CLN-5 staining on these abluminal leukocytes was apparently distributed all around the 
leukocyte surface in a discreetly punctate pattern (Figure 16b inset). This could suggest that 
these leukocytes acquire endothelial CLN-5 either prior to or during the process of TEM by a yet 
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uncharacterized mechanism, which might be critical for these leukocytes to negotiate their 
passage across the BBB. These CLN-5+ leukocytes might in effect be the first ones to focally 
open the BBB, for the others to follow. Using identical staining and image acquisition parameters 
no evidence of CLN-5+ leukocytes was detected in spinal cord venules from naïve mice (data not 
shown). 
4.2 Expression of CLN-5 on leukocytes in EAE 
High resolution 3D reconstruction of confocal images of leukocytes isolated from plasma of mice 
inflicted with EAE (d7 post induction) revealed punctate CLN-5 immunostaining distributed 
around the leukocyte surface, similar to the CLN-5+ extravasating leukocytes observed in vivo. 
The CLN-5 staining could be localized on leukocyte surface under both permeabilizing and 
non-permeant conditions, suggesting surface binding of the CLN-5 antibody (Figure 17a). FACS 
analysis of leukocytes from d7 EAE mice immunostained with the same antibody further 
validated the CLN-5 staining under both permeabilizing and non-permeant conditions, although, 
permeabilization yielded marginally higher staining intensity compared to the non-permeabilized 
group, suggesting better accessibility of the antibody epitope when permeabilized (Figure 17b). 
Specificity of the CLN-5 antibody was further confirmed by using the same antibody clone in 
immunoblot analysis of lysates obtained from plasma leukocytes at D7 p.i. Immunoblot analysis 
yielded a band of 23KDa, consistent with the reported molecular weight of CLN-5 protein (Figure 
17c). These results could reflect the presence of CLN-5 on extravasating leukocytes prior to their 
TEM across CNS microvessels.  
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4.3 Endothelial origin of CLN-5 on leukocytes 
Given the reported loss of endothelial CLN-5 in the CNS microvessels during neuroinflammation 
in EAE (Paul et al., 2013, 2014), to explore if the CLN-5 on these CNS infiltrating leukocytes in 
EAE is endothelial in origin, transgenic mice expressing eGFP-CLN-5 in endothelial cells, 
Tie-2-eGFP-CLN, were employed (Knowland et al., 2014). Figure 18a shows CLN-5 staining 
along inter-endothelial locales in various microvessel subtypes- venules, post-capillary venules 
and capillaries in spinal cord from naïve eGFP-CLN-5 mice. This picture differed in eGFP-CLN-5 
mice inflicted with EAE at D9 p.i., as an emergence of CLN-5+ extravasating leukocytes were 
clearly seen in inflamed venules at this time (Figure 18b), suggesting a predominantly 
endothelial origin of the CLN-5 on leukocytes undergoing TEM. 
4.4 Expression of CLN-5 on EVs isolated in vitro and in vivo 
Since, two main categories of extracellular vesicles (EVs), namely exosomes (50nm -100nm in 
diameter) and microvesicles (100nm -2µm in diameter), have been reported to bind leukocytes 
(Lee at al., 2010), mediate their immune responses (Muturi et al., 2013; Zech et al., 2012; 
Raposo and Stoorvogel, 2013) and adhesion to endothelium (Lee at al., 2010), we investigated if 
EVs released from brain microvascular endothelial cells (BMECs) both in vitro and in vivo contain 
CLN-5 protein. 
 Figure 19a, shows the expected 23 KDa band for CLN-5 in total EV lysates obtained 
following a 100,000×g spin from BMEC cultures treated with proinflammatory cytokine TNFα. To 
 
 
101 
further dissect the specific EV subtypes released from TNFα-treated BMECs that might contain 
CLN-5, three EV fractions were isolated using differential ultracentrifugation at 20,000×g, 
60,000×g, and 100,000×g. All the obtained EV fractions displayed the expected 23KDa band, 
suggesting the presence of CLN-5 in EVs from BMECs in vitro (Figure 19b).  
 We next assayed the presence of CLN-5 in EVs released during EAE from BMECs in vivo 
using mice expressing eGFP-CLN-5 in endothelial cells (Tie-2-eGFP-CLN-5) (Figure 19c). FACS 
analysis of plasma EVs isolated from eGFP-CLN-5 mice at D9 p.i. and co-stained with PKH-26 
dye showed evidence of the transgenic eGFP labeled endothelial CLN-5 on EVs at this time 
point, although, eGFP-CLN-5 EVs comprised only 0.4% of the total PKH-26 labeled EV 
population (Figure 19d). 
4.5 Binding of BMEC-derived EVs to naïve leukocytes  
Having shown the presence of endothelial-specific CLN-5 on circulating leukocytes in EAE, and 
that BMECs-released EVs, we next addressed if BMEC-derived EVs can bind naïve leukocytes 
in vitro and in vivo. For, in vitro analysis EVs were isolated from TNFα-stimulated bEND3 cultures 
and separated by differential ultracentrifugation into sizes corresponding to exosomes and 
microvesicles followed by validation with nanoparticle tracking analysis (NTA) (Figure S9). Figure 
20a shows, these exosome and microvesicle –sized vesicles from bEND3 cells labeled with 
PKH-67 dye, could bind to naïve PKH-26 stained leukocytes. This binding was further confirmed 
as PKH-67+ PKH-26+ (double-positive) events in FACS analysis (Figure 20b), which revealed 7.1% 
co-localized events. However, this could have included the possibility of multiple EVs binding to 
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one leukocyte. Notably, the binding of PKH-67+ EVs to PKH-26+ naïve leukocytes was saturable, 
and could be competed out with a thousand-fold excess of unlabeled EVs, under identical 
binding conditions. 
 To explore if CLN-5+ EVs released from ‘inflamed’ BMECs in vitro and in vivo can also bind 
naïve leukocytes, Tie-2-eGFP-CLN-5 mice was used for obtaining the transgenic reporter (eGFP) 
labeled CLN-5+ EVs. CLN-5+ EVs isolated from TNFα-treated primary BMECs (data not shown) 
or the serum of Tie-2-eGFP-CLN-5 mice at d9 post-EAE induction, showed apparent binding to 
the naïve CD45+ leukocytes (Figure 20d).  
4.6 EVs are present in vivo between the endothelium and site of leukocyte attachment 
Till date, it is not known if EVs can be released locally by endothelial cells in vivo to aid leukocyte 
attachment or TEM, an event post attachment. Capturing such an event would require electron 
microscopic (EM) resolution; although, the likelihood of imaging an adherent or transmigrating 
leukocyte in its entirety along the microvascular endothelium in vivo at this resolution is very thin. 
Therefore, 3D serial scanning EM (serial EM) acquiring 300-350 slices each being 60 nm thick, 
i.e., equivalent of a 20 µm thick section, and sampling of several spinal cord tissue blocks 
encompassing multiple thoraco-lumbar regions obtained from the spinal cord of a mouse at d13 
EAE, were undertaken to visualize the leukocytes adhered to inflamed microvascular 
endothelium (Figure 21a). Furthermore, using a novel Imaris® based 3D contour tracing 
approach, which allowed us to trace contours of the endothelium, adherent leukocytes, and 
vesicular structures in these EM stacks, we found EV-like structures at the leukocyte-endothelial 
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interface. These EV-like multilamellar structures appeared to be partially embedded in the 
endothelium proximal to site of leukocyte-endothelial attachment (Figure 21c-e), suggesting 
endothelial EVs are released in vivo during EAE close to the leukocyte attachment site, perhaps 
for aiding TEM of the adherent leukocytes.  
4.7 CLN-5+ leukocytes are more efficient in TEM in vitro 
To gauge the role of endothelial CLN-5 on leukocytes in EAE, CLN-5+ leukocytes were FACS 
sorted from the blood of endothelial-specific Tie-2-EGFP-CLN-5 mice at d9 EAE (Figure 22a) 
and their TEM efficiency across a bEND3 endothelial cell monolayer was compared to CLN-5- 
leukocytes isolated from the same animals. TEM efficiency of CLN-5+ leukocytes seemed to be 
1.9, 2, and 2.68 fold higher at 2 hours, 6 hours and 18 hours respectively, compared to the 
CLN-5- controls (Figure 22b).  
5. Discussion 
The TEM of leukocytes across the blood-brain barrier (BBB) has been known to underlie the 
histopathology in a multitude of neurodegenerative conditions, like Multiple Sclerosis (Al-Omaishi 
et al., 1999; Larochelle et al., 2011). While the mechanism(s) of leukocyte-endothelial adhesion 
and the molecules involved in the extravasation of circulating leukocytes across the endothelial 
wall in peripheral microvessels is well understood (Muller, 2011), the TEM of leukocytes across 
the highly restrictive blood-brain barrier (BBB) remains largely unclear. Several intravital imaging 
studies have shed some light on the differences in TEM across the CNS microvessels compared 
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to that in the periphery, e.g., leukocytes have been reported to crawl preferentially against blood 
flow before their diapedesis across the vascular wall in the CNS (Engelhardt, 2010; Greenwood 
et al., 2011) under the influence of adhesion molecules (Engelhardt, 2006), and chemokines like 
CCL2 (Paul et al., 2014; Huang et al., 2001; Dogan et al., 2008). Since, the presence of tight 
junctions (TJs) at the BBB is generally considered an impediment to leukocyte extravasation in 
the CNS (Larochelle et al., 2011); the initial leukocytes crossing the almost intact BBB are 
believed to negotiate these TJ to access the CNS tissue by a yet uncharacterized mechanism. 
 In this study, we present the first report of a sub-population of leukocytes infiltrating the CNS 
of mice early in EAE (d9), an animal model of MS, being immunoreactive for TJ protein CLN-5, a 
BBB determinant, in close apposition to the inflamed microvessels. These CLN-5+ cells appeared 
in microvascular regions displaying dense perivascular cellularity, suggestive of an inflamed 
status (Paul et al., 2013; 2014). Such, leukocytes were visible only along the meningeal 
microvessels or the infiltrating parenchymal vessels at this early time point which are known to 
display higher expression of adhesion molecules (Kivisäkk et al., 2009; Owens et al., 2008) and 
get inflamed earlier in MS (Choi et al., 2012) and its animal correlate, EAE (Christy et al., 2013).  
 Using high-resolution 3D confocal imaging, the CLN-5 immunostaining appeared to localize 
on the surface of these transmigrating leukocytes in a discreetly punctate pattern, and close to 
inflamed microvessels displaying focal beading, discontinuity, or diffuse pattern of CLN-5 staining, 
suggestive of BBB damage (Plumb et al., 2002). Leukocyte entry into the CNS tissue has been 
reported to be associated with a transient focal loss of TJ proteins in both animal models of 
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neuroinflammation (Xu et al., 2005; Wolburg et al., 2003) as well as in human CNS diseases, like, 
MS (Plumb et al., 2002), glioblastoma multiforme (Wolburg et al., 2003), and HIV-1 encephalitis 
(Persidsky et al., 2006).  
 Interestingly, a recent report described the expression of TJ protein Claudin-1 and Claudin-5 
in peripheral blood leukocytes (PBLs), predominantly in B cells, T cells and monocytes in MS 
patients in relapse (Mandel et al., 2012). Furthermore, following glucocorticoid treatment in these 
patients, which confers both anti-inflammatory and immunosuppressive properties, RNA levels of 
these TJ proteins in PBLs decreased. The study reinforced the notion that increased number 
and/or expression CLN5+ leukocytes is correlated with immune activation, and overall MS 
disease activity, suggesting a potential role of leukocyte TJ proteins in physiological states, and 
autoimmunity. However, the emergence of leukocytes having TJ proteins across the inflamed 
microvessels, their TEM efficiency, and possible role in BBB damage has never been reported 
before. These TJ positive leukocytes could define a small subset of the total leukocyte population, 
that contribute to the initial opening of the BBB in disease, paving a route for the trailing 
pathogenic leukocytes to extravasate along. 
 3D confocal z-stack images of isolated leukocytes from mice with EAE at d7 post-induction 
revealed a similar distinct CLN-5 immunostaining all around the leukocyte surface as seen in 
vivo. It was noteworthy that the intensity of CLN-5 immunostaining on the isolated leukocytes 
was weak, either suggesting they are not bonafide CLN-5 expressing cells, or they acquire it 
from other sources. Western Blot analysis on leukocyte lysates obtained d7 EAE mice using the 
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same antibody clone used on immunohistochemistry yielded the expected 23KDa molecular 
weight band, consistent with the molecular weight of CLN-5.  
 Since, CLN-5 on CNS endothelial cells has been shown to be a BBB determinant (Nitta et al., 
2003), and leukocytes breaching the BBB were likely to acquire in from the endothelium, 
high-resolution confocal imaging was used to capture the transmigrating leukocytes across the 
inflamed microvessels in EAE using a transgenic mice expressing eGFP-CLN-5 predominantly in 
endothelial cells (Tie-2-eGFP-CLN-5). Leukocytes undergoing TEM across the inflamed 
microvessels at d9 EAE displayed a similar pattern of CLN-5 labeled with eGFP as seen in the 
WT mice with EAE, which was absent in the naïve Tie-2-eGFP-CLN-5 mice, indicative of this 
TEM of CLN-5+ leukocytes being related to the onset and/or progression of the disease. 
 Since Mandel et al., (2012) reported the presence of CLN-5+ leukocytes in the blood of MS 
patients, and accumulating evidence indicates that EVs released by resident CNS cells, like,  
neurons, microglia, astrocytes, oligodendrocytes and endothelial cells can aid in dispersal of 
pathogenic bioactive effectors (proteins, DNA, or RNA) into the blood in neurodegenerative 
diseases, e.g., transmissible spongiform encephalopathies, Alzheimer’s disease, Parkinson’s 
disease, tauopathies, and amyotrophic lateral sclerosis (Vingtdeux et al.,2007; Vella et al.,2008; 
Guest et al.,2011; Frühbeis et al., 2013) which in turn can modulate the activation, adhesion and 
migration of the circulating immune cells (Lee et al., 2010), we looked for the presence of CLN-5 
in EVs derived from BMECs in vitro and in vivo. Owing to the fact that 80% of the EVs present in 
blood have been reported to be derived from platelets (György et al., 2011), we first looked into 
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presence of CLN-5 in EVs obtained from TNFα-stimulated bEND3 cells. Surprisingly, despite the 
EVs being known to originate from different subcellular locales (i.e., MVs from cell membrane, 
and the exosomes from endosomal compartment), the EV fractions isolated by differential 
centrifugation and characterized according to size using nanoparticle tracking analysis, 
contained TJ protein CLN-5. Endothelial-specific EVs isolated from the plasma of mice 
expressing eGFP-CLN-5 (Tie-2-eGFP-CLN-5) at D9 p.i., showed only about 0.4% EVs positive 
for CLN-5 among the total PKH-26 labeled EV population, as expected considering a major 
contribution of plasma EVs from the platelets. As, FACS couldn’t resolve vesicles lower than 
300nm -400nm in diameter, based on calibration with florescent nano-beads (data not shown), 
exosomes and smaller MVs could have been excluded from our FACS based EV analysis. 
 PKH-67 labeled EVs from bEND3 cells following differential centrifugation and categorized 
into exosomes and MVs based on size, clearly appeared to bind PKH-26 stained naïve 
leukocytes. Total EV population isolated from plasma of WT mice or endothelial-EVs isolated 
from Tie-2-eGFP-CLN-5 mice with EAE could also bind naïve leukocytes in a similar fashion. 
Since, incubation of naïve PKH-26+ leukocytes with a 1000 fold excess of unlabeled EVs could 
almost compete out the binding of PKH-67+ EVs, the binding sites for EVs on the leukocytes 
could possibly be discreet. 
 However, in vitro binding analysis of EVs to leukocytes can’t accurately model the events 
happening in vivo in a neuroinflammatory milieu. In additional, the nano-sized EVs can’t be 
visualized at high-resolution in vivo by using conventional epifluorescence or confocal 
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microscopy. Therefore, using a 3D serial scanning electron microscopy (serial EM) followed by a 
novel Imaris based 3D contour tracing  approach, we provide the first evidence of EV-like 
structures being released in vivo during EAE proximal to site of leukocyte-endothelial attachment 
site, perhaps aiding TEM of the adherent leukocytes. These EV-like structures seemed to display 
multilamellar appearance. Since, the likelihood of capturing an adherent or transmigrating 
leukocyte in its entirety along the microvascular endothelium in vivo at EM resolution is very thin, 
serial EM of 300-350 slices each being 60 nm thick, and sampling of several spinal cord tissue 
blocks enabled us to capture the docked leukocytes. 
 Finally, using the endothelial specific Tie-2-EGFP-CLN-5 mice, the TEM efficiency of CLN-5+ 
leukocytes migrating across a bEND3 monolayer was consistently found 2-3 fold higher with time 
(at 2h, 6h and 18h) compared to the CLN-5- controls isolated from the same mice. Notably, based 
on the scatter property analysis, the population transmigrated cells lacked monocytes.   
 In summary, based on the scattered literature on presence of TJ proteins on leukocytes and 
a role of EVs in immunomodulation, while unifying the two observations, we report for the first 
time that CLN-5 transmigrating leukocytes can be seen on the abluminal side of inflamed 
microvessels in EAE and endothelial EVs can transfer CLN-5 to the circulating leukocytes for 
their efficient TEM in neuroinflammation. An understanding of the contribution of these TJ 
proteins on leukocytes in TEM across the BBB, a step critical for pathogenesis underlying many 
inflammatory diseases like MS, might be critical for therapeutic targeting of these pathogenic 
leukocytes for the treatment of central and/or peripheral inflammation.  
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Figure 16. TEM of CLN-5
+
 leukocytes in early EAE. z-stack confocal images acquired from thoraco-lumbar spinal cord 
cryosections of WT mice at d9 EAE are shown, revealing staining of TJ protein CLN-5 (green), and CD31 (red) to delineate the 
endothelial cells, respectively. DRAQ5 staining reveals the cellularity associated with TEM of CNS infiltrating leukocytes. a, b and c 
demonstrate a population of leukocytes undergoing TEM being immunostained for CLN-5 in a punctate fashion, around the leukocyte 
surface. Arrows (yellow) point toward discontinuity in microvascular CLN-5 immunostaining, suggestive of BBB damage. 
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Figure 17. Expression of CLN-5 on circulating leukocytes in EAE. (a) Representative z-stack confocal images of leukocytes 
isolated from blood of WT mice at day 7 (d7) post EAE induction and immunostained with CLN-5 in presence or absence of Triton-X 
100 detergent, underscoring the presence of CLN-5 binding epitope on the leukocyte surface. (b) FACS analysis of leukocytes from 
d7 EAE mice immunostained with the same antibody shows CLN-5 staining under both permeabilizing and non-permeant conditions, 
although, permeabilization with Triton X-100 yields marginally higher staining intensity (along the x-axis) compared to the 
non-permeabilized group, suggesting better accessibility of the antibody epitope when permeabilized. Leukocytes stained with an 
isotype antibody were used as control. (c) Western blot analysis of lysates from the same batch of leukocytes and same antibody 
clone used in (a) and (b) showing a 23 KDa molecular weight band, consistent with the molecular weight of CLN-5.   
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Figure 18. Transmigrating leukocytes have CLN-5 of endothelial origin. z-stack confocal images acquired from thoraco-lumbar 
spinal cord cryosections from Tie-2-eGFP-CLN-5 mice showing (a) distribution of eGFP-CLN-5 in naïve microvessels, (b) TEM of 
eGFP-CLN-5
+
 leukocytes at day 9 (d9) EAE, suggesting the predominantly endothelial origin of the observed eGFP-CLN-5 on the 
extravasating leukocytes. Inset shows DRAQ staining for nuclei in these leukocytes. 
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Figure 19. CLN-5
+
 expression in BMEC derived EVs. Western blot analysis of CLN-5 in EVs from supernatants of TNFα-treated 
bEND3 cultures. (a) Total EV population pelleted following a 100,000×g and (b) EV pellets obtained following differential 
ultracentrifugation at  20,000×g, 60,000×g and a 100,000×g spin, showing the expected 23 KDa molecular weight band. (c) 
Schematic representation of endothelial specific EV isolation strategy from endothelial-specific Tie-2-eGFP-CLN-5 mice. (d) FACS 
analysis of EVs isolated from Tie-2-eGFP-CLN-5 mice, showing eGFP EVs alone (left), or eGFP EVs co-stained with PKH-67 dye. 
Ultrapure distilled water (below), and nano-fluorescent size standard beads (now shown) were used for setting the gates. 
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Figure 20. EVs from ‘inflamed’ BMECs bind naïve leukocytes in vitro. (a) z-stack confocal images showing PKH-26 labeled EVs, 
enriched for exosome- and microvesicle- sized particles by differential ultracentrifugation, isolated from TNFα-treated bEND3 cells 
can bind PKH-26 labeled naive leukocytes. Insets further highlight the co-localization on single leukocytes. (b) FACS analysis of 
PKH-67 labeled Total EVs, isolated following a 100,000×g spin, binding to naïve PKH-26 labeled leukocytes, analyzed as 
double-positive events. (c) Shows the binding of PKH-67
+
 EVs to naïve leukocytes is ‘saturable’ and can be competed out by adding 
a 1000-fold excess of unlabeled EVs. (d) Endothelial-specific Tie-2-eGFP-CLN-5
+
 EVs FACS purified from plasma of mice at d9 post 
EAE induction, as described in Figure 18, can bind naïve leukocytes in culture. 
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Figure 21. Endothelial EVs are released in vivo at sites proximal to leukocyte adhesion. Serial scanning EM images from 
thoraco-lumbar spinal cord sections of perfusion-fixed d13 EAE mice. (a) 3D reconstruction from 130 serial slices showing 
cross-section on an inflamed venule highlighting adherent leukocytes, some apparently undergoing TEM. Insets highlight EV like 
membrane-bound structures at the leukocyte-endothelial interface in single serial slices. (b) Representative 3D reconstruction of a 
single adherent-leukocyte. (c) Contour surface reconstruction from the ‘traced’ leukocyte, EVs and endothelium in all serial slices, 
providing 3D view of released endothelial EVs proximal to the site of leukocyte docking. Inset shows the site of leukocyte attachment 
on the endothelium and the site of EV release. (c, d) Serial EM images containing the 3D surface reconstruction of the same 
leukocyte in (c) and representative single serial slices highlighting various patterns of released endothelial EVs, close to the sites of 
leukocyte binding.  
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Figure 22. CLN-5
+
 leukocytes undergo efficient TEM. (a) FACS sorting of CLN-5
+
 leukocytes isolated from blood of 
Tie-2-eGFP-CLN-5 mice at d9 post-EAE induction (right). Control leukocytes from naïve mice were used to set up the gate (left). (b) 
FACS analysis of TEM efficiency, represented as fold increase in the number of transmigrated CLN-5
+
 leukocytes over time (in hours) 
compared to control leukocytes isolated from the same mice, across bEND3 brain endothelial cell monolayer plated on transwell 
chambers. Each group consisted of leukocytes obtained from 10 mice, and analysis was performed in triplicate. Graphs represent 
mean ± standard error. p values depicted were obtained from two-way ANOVA analysis followed by Bonferroni post hoc test. *p≤0.01 
and ** p≤0.001. 
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CHAPTER V 
Concluding remarks & future directions 
Leukocyte extravasation into the central nervous system (CNS) features critically in the 
pathogenesis of neuroinflammatory and neurodegenerative disease (Zlokovic, 2008; Glass et al., 
2010; Qian et al., 2010; Holman et al., 2011; de Vries et al., 2012; van Noort et al., 2012). Hence, 
an understanding of the cues governing the exit of circulating immune cells, and thereby, 
breaching the BBB, holds key to novel therapeutic strategies for treating a wide spectrum of 
diseases like Parkinson disease, Alzheimer disease and Multiple Sclerosis (Mae et al., 2001; 
Pander et al., 2002; Wiendl, 2002; Weber et al., 2012). While the cascade of events that initiate 
leukocyte adhesion in peripheral microvessels has been well characterized (Rossi et al., 2011; 
Sallusto et al., 2012), we lack an understanding of the cues required for transendothelial 
migration (TEM) of leukocytes across the BBB in CNS. The projects described in this dissertation 
have broadened our understanding on how endothelial heterogeneity, inflammatory chemokines, 
and bioactive factors transferred by endothelial EVs guide leukocyte TEM at the ‘permissible 
sites’ along the CNS microvessels in neuroinflammation and might be applicable to peripheral 
inflammation as well. 
Venules are the portals of leukocyte entry into the CNS in neuroinflammation 
The highly-specialized CNS microvascular endothelial cells serve as the seat for Blood-Brain 
Barrier; a barricade restricting paracellular flux of solutes, and entry of circulating immune cells  
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into the tissue parenchyma (Furuse, 2010; Blasig and Haseloff, 2011; Coisne and Engelhardt, 
2011). The CNS microvascular network is comprised of arterioles, capillaries, post-capillary 
venules and venules, yet the respective contribution of each of these to the BBB is not known. In 
this regard, the brain microvascular endothelial cells (BMEC) from these different tributaries 
could exhibit structural and functional heterogeneity, which in turn might confer unique 
physiological and pathophysiological roles. Previously, using gene expression analysis of 
BMECs retrieved in situ from naïve capillaries or venules followed by immuno-laser capture 
microdissection coupled with quantitative real-time PCR analysis of 87 BBB structure and 
function related genes, we demonstrated that although the BBB properties reside in both 
segments, the capillaries are enriched in mRNAs related to solute transport, while venules 
demonstrate an increased expression of mRNAs involved in inflammation-related tasks 
(Macdonald et al., 2010). 
 However, the integrity of the BBB has been reported to be compromised in 
neuroinflammatory and neurodegenerative diseases like MS, and this observed disruption of TJs 
(Carvey et al., 2009; Coisne and Engelhardt, 2011; Grammas et al., 2011; Hawkins and Davis, 
2005; Petty and Lo, 2002) might contribute significantly to the pathology, by facilitating the 
passage of leukocyte (Garrido-Urbani et al., 2008), or by supporting leakage of serum proteins 
(Pober and Sessa, 2007) along certain microvessel subtypes or segments only. Therefore, 
knowledge of which microvascular segments are affected and consequently allow leukocytes to 
breach the BBB is critical for understanding the disease progression and the emergence of 
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treatment options. 
 In this study, using a novel microvascular contour-based 3D quantification of TJ protein 
CLN-5, a critical BBB determinant, we demonstrated a significant heterogeneity microvascular 
response along the various microvessel segments of the spinal cord during EAE, a model for MS. 
Specifically, venules displayed a significant loss of CLN-5 at intercellular junctions during EAE, 
which was accompanied by extravasation of leukocytes, loss of CLN-5 at the inter-endothelial 
locales, and compromised basement membrane integrity. In stark contrast, even the directly 
connected adjoining capillaries were completely refractory to such responses. However, the 
leakage of endogenous serum leakage, an indicator of BBB permeability was detected around all 
size microvessels during early and late EAE. Since, the capillaries in EAE fail to show CLN-5 
loss even in the chroninc EAE pahse (D24 p.i.), this observed inflammation-associated IgG 
leakage along the CNS capillaries could stem from increased transcytosis (Claudio et al., 1989; 
Proulx et al., 2012).  
 Mice with EAE typically display an asceding paralysis, progressing from the lumbar spinal 
cord towards the brain. However, if the neuroinflammatory events also propagate directionally 
isn’t clear. Therefore, it is imperative to explore the spatio-temporal sequence of events involved 
in BBB damage, e.g., barrier permeability, TJ loss and leukocyte extravasation, along the length 
of spinal cord to completely understand the progression of neuroinflammation in this model, and 
eventually in MS. 
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CCL2 guides leukocyte TEM across the endothelial and astrocyte basement membranes 
Chemokine CCL2 has been long known as a critical mediator of inflammation in the periphery 
and the CNS, by aiding the extravasation of circulating mononuclear leukocytes into the tissue 
(Leonard et al., 1991; Mantovani et al., 1993; Bennett et al., 2003; Toft-Hansen et al., 2006; 
Yadav et al., 2010). Although undetectable in the normal CNS, its expression surges orders of 
magnitude in neuroinflammatory diseases. Pioneering work by Huang et al., (2001), and Dogan 
et al., (2008), established the role of CCL2 released exclusively from CNS sources in EAE. Mice 
globally lacking CCL2 (CCL2-/-) display diminished severity and delay in onset of 
neuroinflammation in C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein35-55 
(MOG35-55). However, to date the contribution of individual CNS sources of CCL2 in the aiding the 
passage of leukocytes across the BBB in this model, mimicking MS pathology, hasn’t been 
explored. Since, endothelial cells lining the CNS microvessels and the juxtaposed astrocytes are 
two major CCL2 sources in the CNS, this study aimed at resolving their individual contributions in 
guiding leukocytes across the BBB. Getting drugs across the BBB has been a persistent 
challenge over the years (Pardridge, 2005). Therefore, resolution of the CNS CCL2 targets and 
their role in disease pathology is critical in determining if drugs would require circumventing or 
penetrating through the BBB. 
 Here, using two cell-conditional CCL2 knockout (KO) mice previously generated in our lab 
(Ge et al., 2009), lacking CCL2 gene in astrocytes (Astro KO) or endothelial cells (Endo KO) 
respectively, we were able to dissect the individual roles of CCL2 from these two major CNS 
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sources in disease progression and guiding luminal leukocytes across the BBB for the first time. 
The dual effect on EAE progression in global CCL2 KO (CCL2-/-) mice; i.e., diminished severity 
and delay in EAE onset seen by Huang et al. (2001), could be further resolved as effects 
dependent on CCL2 released either from astrocytes and endothelial cells. Specifically, reduced 
EAE severity was found in Astro KO mice and a delay in onset in Endo KO mice, reinforcing that 
CCL2 from astrocytes and endothelial cells are both critical for EAE progression, in a unique 
manner. Moreover, the lack of CCL2 in the central compartment did not affect the peripheral 
priming or activity of myelin-specific T cells, as neither of the KO mice showed deficits in T cell 
proliferation, or IL-17 and IFN-γ production, following MOG35-55 exposure in vitro, or altered 
MOG-major histocompatibility complex class II tetramer binding.  
 To substantiate these altered disease progression with the status of BBB damage and 
leukocyte extravasation in these KO mice, high-resolution 3D confocal image acquisition and 
microvessel contour based CLN-5 density analysis was performed as reported previously by our 
lab (Paul et al., 2013). We present the first evidence that endothelial-derived CCL2 may facilitate 
a ‘post-adhesion’ stages of leukocyte extravasation, as in the absence of this chemokine pool (in 
Endo KO) an apparent aggregation of leukocytes in the microvascular lumen, and a better 
preservation of junctional CLN-5 immunostaining or basement membranes compared to the 
inflamed microvessels in Astro KO was observed, corroborating the delayed disease onset seen 
in these mice. On the contrary, astrocyte-derived CCL2 may instead facilitate the passage of 
leukocytes into the parenchyma, as Astro KO mice revealed an apparent congregation of 
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leukocytes in the perivascular space. 
 In light of our results, CCL2 from either astrocytes or BMECs uniquely mediates different 
aspects of clinical EAE and the associated neuroinflammatory processes depending on the 
source. While, CCL2 from astrocytes affects severity of clinical EAE via guiding leukocytes into 
the CNS parenchyma and disrupts CLN-5 at the BBB in the process, CCL2 from BMECs affects 
disease onset, through regulating the leukocyte transendothelial migration post-adhesion. These 
results hold significant implications for the requirement for designing BBB permeable vs. 
impermeant drugs for the treatment of neuroinflammatory diseases. Along these lines, we have 
recently shown that the anti-inflammatory compound bindarit, a synthetic indazolic derivative that 
selectively inhibits the transcription of the monocyte chemoattractant subfamily of CC 
chemokines (MCP-1/CCL2, MCP-2/CCL8, and MCP-3/CCL7), can afford protections against 
EAE while inhibiting the CNS microvascular CCL2 expression (Ge et al., 2012), underscoring the 
therapeutic benefits of targeting endothelial CCL2. 
Transfer of endothelial CLN-5 to the leukocytes through EVs helps their TEM 
The presence of tight junctions (TJs) at the BBB is generally considered an impediment to 
leukocyte extravasation in the CNS. Therefore, paracellular TEM of the initial leukocytes across 
the intact BBB must therefore require the leukocytes to negotiate the endothelial TJs.  
 In this study, we provide the first report of the emergence of a sub-population of 
transmigrating leukocytes immunoreactive for TJ protein CLN-5, on their surface, in the CNS of 
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mice early during EAE, in close apposition to inflamed thoraco-lumbar spinal cord venules. Using 
high-resolution 3D confocal imaging and analysis as detailed previously (Paul et. al, 2014), the 
CLN-5+ leukocytes appeared in regions proximal to focal discontinuities in CLN-5 
immunoreactivity along the inflamed microvessels, indicative of BBB damage. The CLN-5 
staining on these abluminal leukocytes was apparently distributed all around the leukocyte 
surface in a discreetly punctate pattern. This raised several questions, e.g., if leukocytes acquire 
TJ proteins while in circulation or during the TEM process, what is the source of this CLN-5 on 
the leukocytes, and finally how is CLN-5 acquired by the leukocytes.  
 Confocal imaging and Western blotting analysis further revealed expression of CLN-5 
in leukocytes isolated from the blood of mice with EAE, consistent with a recent report (Mandel et 
al., 2012) showing the expression of TJ protein Claudin-1 and Claudin-5 in peripheral blood 
leukocytes (PBLs), predominantly in B and T lymphocytes and monocytes from MS patients. 
 Since, EVs released from cultured brain microvascular endothelial cells (BMEC) of the BBB 
have been reported to express a variety of adhesion molecules, e.g. ICAM-1 (Intercellular 
Adhesion Molecule 1), and stimulate leukocyte TEM in vitro by aiding their endothelial 
attachment, we investigated if BMEC-derived EVs have CLN-5 cargo and bind to leukocytes, 
suggestive of the delivery of CLN-5 proteins to the recipient cells.   
 Using 3D high-resolution confocal imaging and Western blot analysis, we demonstrate for 
the first time that EVs corresponding in the size to both exosomes and microvesicles obtained 
from cultured TNFα-stimulated BMEC, express CLN-5, and can bind to leukocytes. To 
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investigate if the source of CLN-5 on the transmigrating leukocytes in EAE is endothelial, we 
imaged the inflamed venules in thick thoraco-lumbar spinal cord cryosections from endothelial 
targeted, Tie-2-eGFP-CLN-5 transgenic mice. We observed labeled leukocytes in the CNS of 
these mice during early EAE, consistent with CLN-5 having been transferred from endothelial 
cells to the CNS infiltrating leukocytes. Subsequently, FACS sorted purified eGFP-CLN-5 EVs 
isolated from the plasma of Tie-2-eGFP-CLN-5 mice were shown to bind naïve leukocytes.  
 However, to date there is no direct evidence if endothelial EVs are released at the sites of 
leukocyte TEM in vivo in neuroinflammation. In this study, using serial scanning electron 
microscopy and 3D contour-based surface rendering we report for the first time that 
membrane-bound structures resembling EVs are present at the interface of endothelium and the 
marginating adherent leukocytes in vivo in inflamed microvessels from mice with EAE.  
 Having shown the transfer of CLN-5 via endothelial EVs to leukocytes, we next looked into 
the transmigration efficiency of leukocytes containing or lacking endothelial CLN-5 across an in 
vitro model of BBB, by adding eGFP-CLN-5+ or control leukocytes purified from blood of the 
Tie-2-eGFP-CLN-5 transgenic mice on BMEC monolayers. eGFP-CLN-5+ leukocytes 
consistently showed a two fold higher TEM after 2 hours and 6 hours, and a three fold increase in 
TEM after 18 hours compared to the control leukocytes.  
 Our results indicate CLN-5+ EVs released from BMEC can bind to leukocytes and thereby 
transfer CLN-5 protein, for facilitating TEM possibly through the formation of TJ protein bridges 
between these two cell types (Figure 23). However, further studies are required to validate if 
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shRNA knockdown of CLN-5 in eGFP-CLN-5+ leukocytes can reduce their transmigration and if 
TEM efficiency of leukocytes lacking endothelial CLN-5 can be rescued following incubation with 
eGFP-CLN-5 EVs isolated from the plasma of Tie-2-eGFP-CLN-5 mice with EAE.   
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Figure 23.  Interactions of endothelial CLN5+-EVs with leukocytes. EVs shed from endothelial cells could potentially transfer 
CLN-5 protein to leukocytes and foster TEM by several conceivable scenarios: (1) Binding of shed CLN-5
+
 EVs to undefined sites on 
the leukocyte surface; (2) Binding of nascent CLN-5
+
 EVs still associated with the endothelium to endogenous CLN-5 on the 
leukocyte surface; and (3) Binding of shed CLN-5
+
 EVs to endogenous CLN-5 on the leukocyte surface, resulting in temporary 
crosslinking of leukocyte to the endothelium. Binding of CLN-5
+
 EVs to endogenous CLN-5 on the leukocyte surface could potentially 
amplify leukocyte:endothelial interactions by increasing avidity of CLN-5 binding partners. Not shown are possibilities EVs might 
inject endothelial-derived CLN-5 protein and/or mRNA into the leukocyte for surface expression. Concentrated release of EVs near 
the junctional region could act in a paracrine manner to guide leukocytes to this site for TEM. 
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CHAPTER VI  
Heterogeneity of the CNS Microvascular endothelium4 
I. Introduction: To be or not be……..cellophane 
 The endothelium is recognized as a specialized epithelium lining the vasculature, the 
lymphatic vessels and the heart (Dyer and Patterson 2010). German anthropologist and 
pathologist Rudolph Virchow is credited with the earliest known description of this tissue in the 
mid-19th century, and the term endothelium (from the Greek end meaning within, and thele 
meaning nipple) was coined by the Swiss anatomist Wilhelm His soon after (to distinguish it from 
epithelium; i.e. outside the nipple).  Despite its century and half-long medical history, the 
complexity of the endothelium has only relatively recently come to light. Indeed, Virchow’s banal 
characterization of the capillary lining as “a membrane as simple as any that is ever met with in 
the body” (Laubicher et al. 2007), and Lord Florey’s no less flattering account – nearly a century 
later – of the endothelium as “a sheet of nucleated cellophane” (Florey 1966), initially branded 
the endothelium as phenotypically invariant and serving only a passive barrier function.  This 
interpretation has since changed considerably.  
 Two technical advances largely contributed to the sharp trajectory in our understanding 
about the endothelium. One, was the development of electron microscopy (EM), which provided 
                                                             
4 This work was published in Pachter, JS, Paul, D, Ge, S. Heterogeneity of the CNS Microvascular Endothelium. In: Dorovini-Zis k. 
(Ed.). The Blood-Brain Barrier in Health and Disease: Morphology, Biology and Immune Function. 2015;1:70-85. New York: CRC 
Press.  
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the earliest ability to peer into the endothelial ultrastructure – in particular, the membrane 
microdomains and junctional interfaces of individual endothelial cells (ECs) forming the 
endothelium (Bruns and Palade 1968, Simionescu et al. 1975), a tissue that is at once an organ 
within an organ (Aird 2004, Molema 2010). Two, was he initial descriptions in the 1970s of 
methods to culture ECs from umbilical vein (Jaffe et al. 1973, Gimbrone et al. 1974), protocols 
that were adapted before the decade’s end to procure and grow these cells from a multitude of 
organs and organ systems (reviewed by Balconi and Dejana 1986) – including the CNS (Panula 
et al. 1978, DeBault et al. 1979, Phillips et al. 1979).  
 These advances, along with the application of emerging immunohistological and molecular 
biological techniques, have culminated in awareness that, far from displaying a monolithic and 
inert phenotype, the endothelium exhibits substantial heterogeneity (a.k.a. endothelial diversity) 
in form, molecular composition and function (extensively reviewed by (Gerlach et al. 1985, 
Gerritsen 1987, Garlanda and Dejana 1997, Ghitescu and Robert 2002, Aird 2003,  2007a,  b,  
2010, Molema 2010). Such heterogeneity among normal vessels can be broadly classified into 
two major categories: segmental and regional. Segmental heterogeneity refers to differences in 
endothelial phenotype among the hierarchical branches of the blood vascular tree: arteries and 
veins (which comprise the macrovasculature; >100m in interior diameter), and arterioles, 
capillaries and venules (which form the microvasculature; <100m in interior diameter). The 
variety of branch sizes within the CNS microvasculature is depicted in Figure 24. By analogy, the 
lymphatic vasculature also harbors differences between lymphatic capillaries and high 
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endothelial venules (Lee et al. 2010). Regional heterogeneity alludes to the EC distinctions that 
exist in any given type of vessel segment between different organs or anatomical domains within 
a single organ/organ system (in the CNS, for example: brain vs. spinal cord; gray vs. white 
matter; or pial vs. parenchymal vessels). Superimposed on this bicameral classification is a 
microheterogeneity due to endothelial activation state, wherein adjacent ECs can manifest 
different phenotypes with regard to expression of a single or limited number of genes (Huang 
2007).  Striking examples of the breadth of both segmental and regional heterogeneity were 
revealed in the magnum opus work of Chi et al. (2003), who used DNA microarrays to determine 
the expression profile of 53 cultured ECs. These authors found that ECs from different blood 
vessels (segmental) and microvascular ECs from different tissues (regional) have distinct and 
characteristic gene expression profiles. 
 While endothelial heterogeneity has been long and widely recognized in the peripheral 
vascular beds (Vanhoutte and Miller 1985, Barbera-Guillem and Vidal-Vanaclocha 1988, Koop et 
al. 2003, Knosalla et al. 2009, Lee, Choi and Hong 2010, Stevens 2011, Molema and Aird 2012), 
until recently this issue has received comparatively little attention with regard to the central 
nervous system (CNS) (Owman and Hardebo 1988). Inasmuch as the cerebral microvascular 
endothelium is the recognized seat of the blood-brain barrier (BBB) (reviewed by Ge et al. 2005), 
endothelial heterogeneity has profound implications for understanding both homeostatic and 
pathogenic mechanisms involving the CNS vasculature. Moreover, the fact that the BBB is 
represented by biochemical, anatomical and metabolic facets (Ge et al. 2005, Macdonald et al. 
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2010), heterogeneity can be evident at one or more of these levels. The objective of this review 
is thus to specifically highlight examples of endothelial cell heterogeneity within the CNS 
microvasculature, and focus on the significance of these findings to vascular physiology, 
pathophysiology, and therapeutics. 
II. Manifestations of CNS endothelial heterogeneity at the BBB: Hiding in plain site 
 Using immune-guided laser capture microdissection (LCM) coupled to qRT-PCR 
(immuno-LCM/qRT-PCR), this laboratory profiled expression of 87 genes considered to play a 
role in BBB function and/or be enriched in isolated brain microvessels; i.e., reflecting the “BBB 
transcriptome” (Macdonald et al. 2010). This approach enabled separate global profiling of brain 
capillaries or venules, with results implying that BBB properties reside in both types of 
microvascular tributaries, though to varying degrees. Capillaries preferentially expressed some 
genes related to solute transport, while venules tended toward higher expression of a variety of 
genes involved in inflammatory-related tasks. These findings and others from a multitude of 
studies are described below, which highlight the vast accumulation of evidence of endothelial 
heterogeneity at the respective biochemical, anatomical, and metabolic levels of the BBB. 
 Biochemical: The biochemical BBB refers to the many plasma membrane transporters and 
associated enzymatic activities that regulate transcellular solute flux into and out of the CNS. 
Glycosylation patterns in the luminal and abluminal endothelial surfaces, as revealed by specific 
lectin-binding domains, may also contribute to this BBB category. Anecdotally, some of the 
earliest examples of CNS segmental endothelial heterogeneity came from EM studies evaluating 
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membrane transporters/enzyme activities and lectin binding sites. The enzymes 5’-nucleotidase, 
Mg2+-ATPase and N+-K+-ATPase were found to exhibit more intense immunostaining in arteriolar 
endothelial cells compared to both the capillary and venular endothelium (Vorbrodt et al. 1982, 
Vorbrodt 1988).  
 As regards lectins and endothelial heterogeneity, RCA binding sites were described as 
greater in intensity and regularity on the luminal face of brain capillary as compared to arteriolar 
endothelium, and being generally less robust in venules than capillaries (Vorbrodt 1988). On the 
other hand, concanavalin A binding was found to be more intense at both luminal and abluminal 
surfaces of arterioles than capillaries or venules. These findings offered a primordial hint that the 
BBB is not homogeneously distributed along the respective segments of the CNS microvascular 
tree. 
 More recently, expression of P-glycoprotein (P-gp), a member of the superfamily of 
ATP-binding cassette transporters and efflux pump for a wide range of hydrophobic amphipathic 
compounds (Sharom 2011), was reported to show significant segmental heterogeneity in brain. 
Using confocal microscopy, Virgintino et al. (2002) first called attention to the restricted 
expression of P-gp to the luminal endothelial surface of only the small microvessels of the human 
cortex, and Vogelgesang et al. (2004) followed with reporting lower expression in cerebral 
arterioles in the aged brain. Ge et al. (2005) then provided additional support for microvascular 
segregation of P-gp, by showing that its expression was concentrated in the smallest diameter 
microvessel fraction isolated from a bulk population of mouse brain microvessels by differential 
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sieving. In addition, Saubamea et al. (2012), employing thick-section (100 m) confocal 
microscopy, exquisitely resolved P-gp expression still further, highlighting strikingly 
nonhomogeneous immunofluorescent staining along the brain microvascular tree within the rat 
cortex and hippocampus. Specifically, P-gp displayed a gradient of expression, being near 
undetectable in large penetrating arterioles while being uniformly high in capillaries and venules.  
 Transferrin receptor and Glut-1 transporter, two of the most conspicuous BBB 
transporters (Orte et al. 1999), have also displayed evidence of segmental heterogeneity. Like 
P-gp, both these proteins were also observed to segregate with smaller diameter brain 
microvessels trapped on successive filters of smaller pore size (Ge et al. 2005). Cornford et al. 
(1996) further demonstrated endothelial heterogeneity of Glut-1 within the capillary compartment 
of human brain.  
 The endothelial barrier antigen (EBA), an endothelial-specific protein strongly associated 
with BBB properties in the rat (Sternberger and Sternberger 1987) but whose precise function 
remains elusive, has likewise been shown to demonstrate stark heterogeneity in situ (Saubamea 
et al. 2012).  While immunofluorescent staining of this protein was also excluded from cerebral 
arterioles, and confined to capillaries and venules like that of P-gp, it uniquely demonstrated a 
mosaic pattern – at the single cell level – in the latter vessel segments. A similar heterogeneous 
expression of EBA was described in pial microvessels (Allt and Lawrenson 1997). Thus, at least 
with regard to EBA, it appears endothelial heterogeneity may be the most extreme, with no two 
brain microvascular endothelial cells displaying the same phenotype.  
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 Expression of the sodium-dependent, glutamine transporter Snat3, a member of the 
solute carrier (SLC) family of transporters at the BBB, was recently described to be restricted to 
larger cortical microvessels, whereas a related amino acid transporter, SnaT1, was found 
distributed on smaller capillaries as well (Ruderisch et al. 2011).  
 Other examples of biochemical heterogeneity, though not immediately related to solute 
transport or BBB function, also exist along the CNS microvascular endothelium. For example, 
Saubamea et al. (2012) found that immunofluorescent staining with RECA-1, a pan 
endothelial-specific monoclonal antibody (Duijvestijn et al. 1992), yielded the opposite pattern of 
that seen with P-gp; i.e., being more intense in arterioles than venules. This at once both 
validated the P-gp findings as not due to immunostaining artifact, and provided yet another 
example of segmental endothelial heterogeneity. 
 In further evidence of such heterogeneity, this laboratory described a dramatic variance in 
expression of the blood clotting glycoprotein, von Willebrand Factor (VWF), among the different 
type brain microvascular tributaries. Specifically, immunofluorescent analysis revealed that VWF, 
which is stored within Weibel-Palade bodies (WPBs) of endothelial cells, was highly expressed in 
venules of normal brain in situ, while being nearly undetectable in contiguous capillaries 
(Macdonald et al. 2010). Microvessels isolated from brain also showed this discrepancy (Figure 
25), with venules displaying the greatest VWF immunostaining, capillaries the least, and 
arterioles an intermediate amount. This reinforces that the heterogeneous VWF staining 
previously observed in brain tissue sections was not influenced by antibody penetration, but 
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rather reflected variable VWF expression by different brain microvascular tributaries.  
Interestingly, the presence of VWF has been reported to influence BBB permeability, with VWF 
knockout (VWFKO) mice showing a significant increase compared to wild-type controls, during 
encephalitis following Bordetella pertussis toxin-induced histamine hypersensitivity (Noubade et 
al. 2008).  VWFKO mice further exhibited earlier onset and greater severity of disease, with 
heightened inflammation occurring in brain but not spinal cord.  These observations, along with 
both the discovery that certain chemokines can be sequestered in WPBs (Rondaij et al. 2006), 
and the conventional view that venules are the preferred exit of leukocyte extravasation site in 
most tissues - including the CNS (Thurston et al. 2000, Wojciechowski and Sarelius 2005, 
Owens et al. 2008, Nourshargh et al. 2010) - could suggest concentrating VWF expression within 
these particular tributaries is a means to highly focus and tightly regulate inflammation.  
 Most recently, Wang et al. (2013), reported ABO blood antigen expression was 
heterogeneous among human brain capillary endothelial cells, prompting these authors to 
speculate, “the possibility that blood-brain barrier permeability and cerebral autoregulation may 
differ over short differences.”   
 Anatomical: Perhaps the most distinguishing anatomical feature of the cerebral 
microvasculature is the high density of high resistance tight junctions (TJs) between endothelial 
cells. Since Reese and Karnovsky (1967) and Brightman and Reese (1969) identified the barrier 
to CNS penetration of exogenous horseradish peroxidase to lie at the TJs, these structures have 
been inextricably linked to the BBB phenotype. The later demonstration by Crone and Olesen 
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(1982) that frog capillaries had a transendothelial electrical resistance (TEER) of ~2000 
ohms.cm2 – nearly that found in frog skin and urinary bladder – Ussing and Windhager (1964) 
cemented TJs as the cardinal feature  of the anatomical BBB. 
 The protein make-up of TJs is complex and covers a vast original literature. Accordingly, this 
topic will not be dealt with in-depth here, and the reader is encouraged to consult recent excellent 
reviews on the subject in this volume (Chapters 1 and 2) and elsewhere (Wolburg et al. 2009, 
Coisne and Engelhardt 2011, Luissint et al. 2012). TJs are comprised of three main classes of 
transmembrane proteins: occludin, which is extensively modified at posttranscriptional and 
posttranslational levels (Cummins 2012), junctional adhesion molecules (JAMs 1, 2 and 3) 
(Bazzoni 2011), and claudins  (CLNs, of which there are now > 20 recognized isoforms in 
various endothelia and epithelia in and outside the CNS (Elkouby-Naor and Ben-Yosef 2010). 
There is general consensus that the predominant CLNs expressed at TJs in endothelial cells 
forming the BBB are CLN-3 and CLN-5 (Morita et al. 1999, Nitta et al. 2003, Wolburg et al. 2003, 
Ohtsuki et al. 2007, Schrade et al. 2012). Occludin, JAMs and claudins are linked to the 
actin-based cytoskeleton through numerous scaffolding/adaptor proteins, including zonula 
occludin proteins (ZO-1, ZO-2 and ZO-3) (Itoh et al. 1999, Wittchen et al. 1999, Bruewer et al. 
2004), which assist in regulating TJ performance and BBB phenotype through a variety of signal 
transduction cascades (Ishizaki et al. 2003, Fischer et al. 2005, Haorah et al. 2005), (Zhong et al. 
2008, Jalali et al. 2010, Morin-Brureau et al. 2011, Ma et al. 2012). 
 Early evidence that TJs were not homogeneously distributed along the CNS 
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microvasculature was gathered from painstakingly detailed freeze-fracture analysis along the 
cerebrovascular bed by Nagy et al. (1984). These authors described greater ‘complexity’ of TJ 
protein particles; i.e., the degree to which these particles comprised long, uninterrupted strands 
in freeze-fracture ‘faces,’ in brain capillaries compared to post-capillary venules. This difference 
was even more exaggerated at the level of collecting veins, which possessed TJ stands that 
were discontinuous, widely separated and free-ending. Consistent with these findings, this 
laboratory recently observed disparate expression of CLN-5 along the microvascular tree of the 
mouse spinal cord (Paul et al. 2012).  Using a novel contour-based 3D image visualization and 
quantification method, employing high-resolution confocal z-stacks from thick 
immunofluorescently stained cryosections, it was determined that the density of claudin-5 staining 
was greatest in the capillaries and smaller venules, and least in the larger venules. Specifically, a 
significant negative linear correlation was established indicating that the density of CLN-5 at 
inter-endothelial junctions varied inversely with microvessel diameter.  Allt and Lawrenson (1997) 
further described a disparity in TJ morphology within pial microvessels, noting two distinct 
junctional populations: one in which adjacent endothelial membranes appeared fused, and 
another bearing a discernible gap between apposing membranes. Interestingly, Crone and 
Olesen (1982) noted a broad distribution of TEER values among frog pial microvessels, which 
may reflect physiological correlates of heterogeneous TJ protein expression and/or function.  
 What dictates this heterogeneity in TJs and TEER values along the CNS microvasculature is 
unclear, but there is increasing evidence of the role of astrocytes in neurovascular coupling and 
 
 
136 
the induction of the BBB phenotype (Nagy and Martinez 1991, Abbott 2002, Haseloff et al. 2005, 
Wolburg, Noell, Mack, Wolburg-Buchholz and Fallier-Becker 2009, Willis 2011, Ronaldson and 
Davis 2012).  A priori, the degree of astrocyte investment onto the abluminal surface of brain 
microvessels might contribute to segmental endothelial heterogeneity in the CNS.  This 
hypothesis is lent support by recent observations of (McCaslin et al. 2011), who, using in vivo two 
photon microscopy to study astrocyte-vascular interactions in the somatosensory cortex, noted 
the highest density of astrocyte processes contacting microvessels was highest for capillaries (on 
average, 0.96 processes/1002 surface area), less in venules (0.41 processes/1002 surface 
area), and least in arterioles (0.36 processes/1002 surface area). The fact that astrocytes 
themselves are recognized to be highly functionally diverse (Bachoo et al. 2004, Hewett 2009, 
Chaboub and Deneen 2012) might further impart another layer of complexity to this issue, 
particularly as regards regional endothelial heterogeneity.   
 Lastly, beside astrocytes and endothelial cells, additional cellular elements including 
pericytes, microglia and neurons also help forge the neurovascular unit (NVU), which serves as 
the functional unit of the BBB (Bonkowski et al. 2011, Mae et al. 2011, Sa-Pereira et al. 2012). The 
perivascular distribution of these other cells, each with their own diverse phenotypes (Sims 2000, 
Choi and Kim 2008, Olah et al. 2011), could thus potentially further contribute to endothelial 
heterogeneity.  
 Metabolic: The metabolic capacity of the BBB refers to enzymes within the CNS 
microvascular endothelium that modify the biological activities of substrates on route between 
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the circulation and brain (Minn et al. 1991, Pottiez et al. 2009). Alkaline phosphatase (AP) activity, 
long considered a BBB marker (Karnushina et al. 1980), was shown to be highest in the 
pre-capillary arterioles and capillaries in brain, and depreciate in a graded manner toward the 
venules (Vorbrodt 1988). The stark segregation of AP activity in contiguous brain microvascular 
segments was later confirmed by this laboratory (Ge et al. 2005). And immuno-LCM/qRT-PCR 
analysis indicated preferential mRNA expression of gamma glutamyl transferase (gt) and 
neutral endopeptidase (NEP) by brain capillaries, while revealing a bias of glutathione S 
transferase (GSST1), angiotensin I converting enzyme (ACE) and monoamine oxidase B (MAOB) 
mRNA by venules (Macdonald et al. 2010).  
III. Functional correlates of endothelial cell heterogeneity 
 The general consensus that leukocyte extravasation in the CNS occurs preferentially at 
venules is an indictment – in functional terms – of segmental heterogeneity along the CNS 
microvascular endothelium. It further stands to reason that such endothelial heterogeneity 
should manifest itself in disparate responses of CNS microvascular tributaries in the course of 
neuroinflammatory conditions.  Indeed, this has been found to be the case.  
 Correlating with venules being the preferred exit site for leukocytes, Xu et al. (2005) reported 
that, during the ocular inflammatory condition experimental autoimmune uveoretinitis, breakdown 
of TJs and loss of CLN-1/3 and occludin at inter-endothelial contacts was focused within mouse 
retinal venules, near completely sparring capillaries. And in complete parallel to these findings, 
Paul et al. (2012) recently described the disruption of CLN-5 in mouse spinal cord as being 
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restricted to venules during the related neuroinflammatory condition experimental autoimmune 
encephalomyelitis – a recognized model for multiple sclerosis. Thus, at least with regard to the 
mouse CNS microvasculature, endothelial cells of venules not only display a lesser density of TJ 
protein than do capillaries in the normal state, but also appear more vulnerable to 
neuroinflammation-associated disruption of their TJ network.  This assessment at least partially 
resembles the remote situation regarding histamine-induced leakage in the periphery, which is a 
phenomenon restricted almost exclusively to venules (Majno et al. 1961). Whether other 
endothelial determinants of neuroinflammation – such as cytokines, chemokines, or other 
vasoactive substances and their cognate receptors, as well as adhesion molecules – 
demonstrate preferential expression by endothelial cells of CNS venules awaits detailed and 
systematic analysis. Heterogeneity in endothelial responsiveness during inflammation in 
peripheral vascular beds has recently been reviewed by (Molema 2010).  
IV: Conclusion: consequences of endothelial heterogeneity for BBB research. Since the 
mid-1970s, cultures of brain microvascular endothelial cells have provided a highly convenient 
format to peer into the operations of the BBB, and highlight its involvement in physiological and 
pathophysiological processes. This opportunity has been aided and abetted by extending the 
natural lifespan of these cells, typically by transforming them with viral, proto-oncogene products. 
To be sure, such culture systems have provided a vast amount of physiologically and clinically 
relevant information. But despite their tremendous advantages, no model has emerged that 
recapitulates the BBB with complete fidelity. While this caveat has long been rationalized as due 
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primarily to phenotypic drift, stemming from removal of these endothelial cells from their native 
environment, a closer look may reveal elements of endothelial heterogeneity at play. Moreover, 
failure to recognize this can potentially lead to erroneous conclusions about BBB function.  
 Typically, brain microvessels isolated for endothelial culture and use as BBB models are 
heterogeneous in size, and comprised of capillary, venule and arteriole fragments (Ge et al. 
2005). In fact, resulting cultures are most often – and rightly – referred to as brain microvascular 
endothelial cells (BMEC), in recognition of these cells’ precise derivation being unknown. But as 
capillaries are by far the most numerous tributaries of the microvascular network (Berne and 
Levy 1988) – they initially predominate in freshly-established microvessel cultures. This has lead, 
at times, to the assumption that BMEC cultures are strictly or mostly capillary in nature.  
 Were it the case that endothelial cells of all microvascular tributaries possess the same 
growth potential, then this assumption would necessarily hold true.  However, observations by 
DeBault et al. (1979) and Spatz et al. (1997) tell a different story.  Specifically, these groups 
noted the viability and growth of endothelial cells from brain microvascular tributaries in culture 
was vessel class- and size-dependent, with the cellular outgrowth from larger diameter vessel 
fragments being far quicker and more extensive than that from small capillaries. These 
discrepancies are consistent with the contention that during angiogenesis – the formation of new 
blood vessels from pre-existing ones in vivo – endothelial sprouts arise from venules (Thurston 
et al. 2000, Baluk et al. 2004, Adams and Alitalo 2007).  The basis for the attenuated growth of 
endothelial cells from capillary fragments in culture is not clear but may, in part, reflect a muted 
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capacity of capillary endothelial cells to produce their own growth factors.  Advancing this 
hypothesis, we observed that when purified brain capillary segments were cultured in a 
dual-chamber Transwell format – with capillaries in the top chamber, separated by a porous filter 
from a mixed population of microvessels in the bottom – endothelial growth from capillaries could 
be stimulated, though still not achieve that observed in the microvessel population (Figure 26). 
In this case, perhaps venules in the microvessel population supplied the missing requisite growth 
stimulant(s). The outcome of plating brain microvessels may well be that the BMEC cultures that 
result are largely venular derivatives – and thus, barring any special additives or modifications 
outside normal endothelial growth conditions, behave more like venules than capillaries. This 
interpretation is consistent with the relatively low TEER values (compared with the BBB in vivo) 
obtained from static BMEC cultures containing no adventitial cells of the NVU, and that such 
cultures typically highly express VWF in a homogeneous manner (like brain venules).  Simple 
BMEC cultures of this type might serve as suitable models to study neuroinflammation, but not 
so for accurately assessing BBB properties governing solute transport into and/or out of the CNS.  
Conversely, BMEC cultures of capillary derivation or somehow made to behave like capillaries, 
might more faithfully recapitulate transport of soluble ligands between the circulation and CNS, 
yet be inadequate to study inflammatory-related phenomena – especially those concerning 
leukocyte extravasation. The burgeoning examples of CNS endothelial heterogeneity would 
seem to dictate there is no ‘one-size fits all’ model. 
 What to do? Sophisticated endothelial culture paradigms that utilize human BMEC in 
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cylindrical format approximating vascular morphologies, and incorporate flow and cellular 
elements of the NVU (Cucullo et al. 2008, Cucullo et al. 2011) – all of which are likely to be 
determinants of endothelial heterogeneity – offer the best prospect of contriving models that 
display CNS vessel-specific characteristics. With mounting efforts to define endothelial ‘markers’ 
that distinguish the respective branches of the entire vascular tree (Othman-Hassan et al. 2001, 
Harvey and Oliver 2004, dela Paz and D'Amore 2009, Rivera et al. 2009, Richardson et al. 2010), 
endothelial heterogeneity of the CNS microvasculature will ultimately cease to be a problem, and 
instead provide the basis for more precise evaluation of vascular activity within the brain and 
spinal cord during health and disease.  
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Figure 24. Segmental heterogeneity along the CNS microvasculature. (a) A CNS venule from a naïve mouse detailing CLN-5 
staining (green) at intercellular junctions. The image shows microvascular tributaries (e.g. capillaries, post-capillary venules) 
emerging from a venule. The nuclei are highlighted with DRAQ5 (blue). (b) Lumbar spinal cord microvessels from a mouse inflicted 
with EAE, revealing diffuse and fragmented CLN-5 staining (yellow arrows on the zoomed-in inset) in an “inflamed” venule associated 
with increased perivascular cellularity (blue). Notably, capillaries contiguous with this venule appear to be spared this inflammatory 
response and present intact CLN-5 staining. Scale bar = 20µm. 
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Figure 25. Heterogeneity in VWF expression in isolated brain microvessels. Brightfield image shows a crude population of 
microvessel segments (Ge et al., 2005), containing representatives of all size diameter microvessel tributaries (arterioles, venules 
and capillaries). Microvessels were double immunofluorescently stained with antibodies to -smooth muscle actin (green) and VWF 
(red). -Smooth muscle actin distinguishes the muscular tunica media of arterioles (arrow). The largest diameter structure 
(arrowhead) possesses much less -smooth muscle actin staining, and most likely represents a venule (containing -smooth muscle 
actin+ pericytes). The venule stains most intensely for VWF, the arteriole intermediately so, and the small capillary segments 
apparently not at all.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
 
 
 
 
 
Figure 26. Differential BMEC growth from small- and large-sized brain microvessel segments.  A crude population of mouse 
brain microvessel segments of varying size diameter was prepared by immunomagnetic bead sorting, and then separated by 
sequential passage through filters of the following porosities, as described (Ge et al., 2005): 297 m, 70 m, 40 m and 20 m. 
Material retained on the 70 m and 20 m filters contained mixed microvessel segments (venules, arterioles and capillaries) or 
purified capillaries, respectively. The separated capillary and microvessel preparations were then each plated in the top chamber of a 
collagen IV-coated, dual-chamber Transwell filter (1.0 m pore).  Mixed microvessels were also placed in the bottom chamber of the 
capillary sample. This arrangement allowed microvessel-conditioned media to bath the capillaries. Top row, shows capillary and 
microvessel populations immediately after plating. Bottom row, shows BMEC growth from these populations after 24 hr in culture. 
Growth of BMEC is more extensive on the filters containing microvessels. 
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Figure S1. Microvascular segmentation through 3D contour surface. A 3D isosurface rendered dataset of a venule was cut using 
the Clipping Plane module on Imaris
®
. (a) Longitudinal section (L.S.) of a CNS venule from a naive mouse, detailing CLN-5 (Green) 
staining at intercellular junctions. The anterior vessel wall has been optically cut away, and a clipping plane can be seen piercing 
through the lumen and into the back/posterior vessel wall. (b) Oblique view from the side, depicting cross section (C.S.) of the same 
venule, to demonstrate the generated contour surface defines the endothelial surface boundary and excludes the hollow lumen from 
TJ quantification. (c) Clipped C.S. of a venule showing its characteristic smooth, non-puckered lumen. 
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Figure S2. CD4 staining associated with perivascular cellularity. 3D volume rendered images of z-stacks obtained from 
serial-sections of naïve and d24 EAE lumbar spinal cords used in Figure 4, stained for leukocyte marker CD4, CD31, and DRAQ5. (a) 
Parenchymal venule from naïve mouse showing intact CD31 staining along the intercellular junctions but no CD4 staining or 
perivascular cellularity (DRAQ5). (b) Parenchymal venule from d24 EAE mouse revealing CD4 staining largely coincident with 
perivascular cellularity. Severely diminished CD31 staining is also evident; confirming dense perivascular DRAQ5 staining is 
associated with inflamed vessel status. Scale bar = 15 μm. 
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Figure S3. Correlation analysis of CLN-5 density with microvascular diameter. For calculation of Pearson's correlation 
coefficient, 3 representative microvessels were analyzed from each size microvessel group (capillaries, smaller venules, and larger 
venules) sampled from spinal cords of 3 naïve mice. The density of CLN-5 at endothelial junctions displays a negative linear 
relationship with microvessel diameter. Pearson's correlation coefficient (r) = − 0.73; p < 0.05. 
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Figure S4. 2D quantification of mean pixel intensity of CLN-5 immunostaining. Representative confocal images are shown 
depicting the placement of ROIs along the intercellular junctional regions of the venular endothelium, so as to determine relative 
intensity values associated with CLN-5 immunostaining. (a) Venule from a naïve mouse; (b) Venule from a d24 EAE mouse. Insets 
highlight the dense perivascular cellularity associated with inflamed venules. (c,d) 2D quantification of CLN-5 immunostaining, 
showing significant reduction of mean pixel intensity in 3 representative venules from d24 EAE mice compared to those from naïve 
controls. The chart of mean pixel intensities reveals not only the diminished mean value associated with d24 EAE (53.13) compared to 
naïve (11.75), but also the higher variability of this measure in the diseased condition, as indicated by higher standard deviation (Std. 
Dev) and standard error (SEM). *p < 0.0005. Scale bar = 20 μm. 
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Figure S5. Endogenous serum IgG leakage from spinal cord microvessels at d6EAE. (a-c) Volume rendered z-stack of 
microvessels, showing IgG (Red), CLN-5 (Green), and nuclei/DRAQ5 (Blue). (d-f) Corresponding isosurface rendered images, 
providing enhanced spatial perspective. Leakage of IgG can be seen at this early time during disease, though this is not associated 
with any apparent disruption of CLN-5 in capillaries or venules. Scale bar = 10 μm. 
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Figure S6. Specificity of CCL2 immunostaining. Volume rendered images of z-stacks obtained from serialsections of d9 EAE 
spinal cords used in Figure 6 (left) and naïve (right) mice demonstrating specific immunoreactivity of the CCL2 antibody. No 
detectable CCL2 staining (green) was observed in naïve mice upon incubation with CCL2 antibody or in EAE mice in the absence of 
primary antibody. The endothelium is highlighted with CD31 (red), while DRAQ5 staining reveals the nuclei (blue). Scale = 20 μm. 
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Figure S7. Lack of focal CLN-5 immunostaining loss and perivascular cellularity in naïve spinal microvessels. 
Isosurface-rendered images generated from confocal z-stacks of 60 -μm thick cryosections from naïve mice showing continuity of 
CLN-5 staining (green) in naïve spinal microvessels. The lack of perivascular cellularity associated with typical inflamed microvessels 
is further highlighted with DRAQ5 staining for nuclei (blue). Scale = 20 μm. 
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Figure S8. CLN-5
+
 leukocytes along the meningeal and parenchymal thoraco-lumbar spinal cord venules in EAE. z-stack 
confocal images acquired from a thoraco-lumbar spinal cord cryosection of WT mice at 9 EAE are shown, revealing staining for TJ 
protein CLN-5 (green), endothelial CD31 (red) and nuclear DRAQ5 staining. Regions A and B are shown to highlight the 
emergence of CLN-5
+
 leukocytes along the meningeal microvessels, whereas, C underscores the TEM of CNS infiltrating CLN-5
+
 
leukocytes in parenchymal microvessels during EAE progression. 
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Figure S9. Nanoparticle Tracking Analysis (NTA) of EVs. High–resolution particle size profiling and concentration measurement 
were performed on exosomes (left) and microvesicles (right) isolated from supernatant of TNFα-stimulated cultured BMECs. 
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Alterations in Tight Junction Protein and IgG Permeability
Accompany Leukocyte Extravasation Across the Choroid Plexus
During Neuroinflammation
Bandana Shrestha, BS, Debayon Paul, MS, and Joel S. Pachter, PhD
Abstract
The choroid plexus (CP) is considered to be a point of leukocyte
entry into the CNS during normal immune surveillance and in
neuroinflammatory diseases. The structural and functional alter-
ations within the CP that support this migration are not understood.
We used quantitative, high-resolution, 3-dimensional (3-D) fluores-
cence imaging to analyze CP alterations associated with inflammatory
responses in C57/Bl6 mice after the induction of experimental auto-
immune encephalomyelitis by immunization with myelin oligoden-
drocyte glycoprotein (MOG) and complete Freund adjuvant/pertussis
toxin (MOG-CFA/PTX) or adjuvants alone (CFA-PTX). The MOG-
CFA/PTX and CFA/PTX produced similar effects, although those
caused by the former were consistently more marked. Both treat-
ments resulted in the accumulation of serum immunoglobulin G and
leukocytes in the CP stroma, consistent with elevated stromal cap-
illary permeability. They also provoked distortions and diminished
immunostaining patterns of the tight junction adaptor protein ZO-1
in the choroidal epithelium but no obvious change in the patterns of
the tight junction associated protein claudin-2. Only MOG-CFA/PTX
triggered visible extravasation of immunoglobulin G and leukocytes
across the choroidal epithelium. Our results suggest that CFA/PTX
primes the CP for neuroinflammation by inducing structural changes
that are exacerbated when there is an immune response to MOG and
reinforce the CP as a gateway for leukocytes to enter the CNS by
accessing the CSF and leptomeninges.
Key Words: BloodYbrain barrier, Brain inflammation, Choroid
plexus, Claudin-2, EAE, IgG, Leukocytes, Zonula occludens 1.
INTRODUCTION
The choroid plexus (CP) is a specialized out-pocketing
of the roofs of the third, fourth, and lateral ventricles and has
long been recognized as the site of production of cerebrospinal
fluid (CSF), within which it is suspended (1,2). The CP is a
highly compartmentalized structure that contains at its core a
tortuous capillary plexus displaying a fenestrated endotheli-
um, which is more permeable than that of capillaries forming
the bloodYbrain barrier (BBB) in the CNS parenchyma (3).
This vascular core is surrounded by a layer of choroidal epi-
thelium with a relatively high density of tight junctions (TJs)
and limited permeability, providing the CP its classification as
part of the bloodYCSF barrier (4,5). There is a confined stromal
space located between the capillaries and choroidal epithelium.
Since the pioneering work of Helen Cserr (6), the CP
has been commonly recognized for its role in generating CSF,
as most recently reviewed (7). However, a growing number of
reports have turned attention to the CP as a site through which
T cells might enter an initially uninflamed CNS in the initial
stages of neuroinflammatory diseases such as multiple scle-
rosis and the animal model of multiple sclerosis experimental
autoimmune encephalomyelitis (EAE) (8Y12). It has been sug-
gested that once encephalitogenic T cells cross the CP and enter
the CSF, they can migrate to the subarachnoid space surround-
ing the brain and spinal cord and there forge immune synapses
with resident dendritic cells. Cytokine bursts stemming from
such synapses, in turn, are thought to activate the endothelial
cell surfaces of nearby microvessels within the subarachnoid
space, thereby enabling adhesion and extravasation of leu-
kocytes circulating in the bloodstream (13Y15). Interactions
between these leukocytes and other dendritic cells in the sub-
arachnoid space would then follow, ultimately propagating an
inflammatory wave along the surface-penetrating microvessels
that enter the CNS parenchyma.
This scenario begs the question: ‘‘Are there changes
within the CP anatomy and integrity during evolving neuro-
inflammation that would allow leukocytes to navigate across
the TJs of the choroidal epithelium and enter into the CSF?’’
Currently, direct evidence of leukocyte extravasation across
the CP into the CNS ventricles, or structural arrangements of
the choroidal epithelium that might support this process, is
lacking. Therefore, we used high-resolution 3-D fluorescence
imaging to highlight aspects of CP morphologic and func-
tional changes that have not been previously resolved during
the progression of EAE.
Specifically, immunization with myelin oligodendro-
cyte glycoprotein (MOG) peptide35Y55, along with complete
Freund adjuvant (CFA) and pertussis toxin (PTX), was used
to induce EAE, and qualitative and quantitative assessments
were made at different time points for 2 TJ proteins expressed
by the CP, that is, claudin-2 (CLN-2) and zonula occludens
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1 (ZO-1) (16Y18). Claudin-2 belongs to a large family of
claudins (920 members), which are integral membrane pro-
teins that perform cell-cell bridging. Zonula occludens 1 is a
peripheral membrane scaffolding/adaptor protein that directly
or indirectly links claudins (and other integral membrane
TJ proteins) to the actin cytoskeleton (19Y21). Tight junction
protein changes were further correlated with leakage of serum
immunoglobulin G (IgG), a marker of barrier permeability
status (22), and leukocyte extravasation across the successive
CP compartments. Because administration of the adjuvants
CFA and PTX alone can significantly alter gene expres-
sion patterns in the CP (23), MOG35Y55Yimmunized mice
were compared with those receiving these adjuvants alone or
no treatment.
Our results indicate that ZO-1 and CLN-2 immunostain-
ing patterns within the CP choroidal epithelium displayed sig-
nificant, yet different, changes during the evolution of EAE, that
is, the former showed a severely altered morphology and the
latter a gradual decrease in staining intensity. Immunoglob-
ulin G was detectable at a low level in the CP stroma even in
naive animals; it was appreciably increased during disease, and
later, in acute disease, it was observed to extravasate across
the CP choroidal epithelium. A few leukocytes were also detected
in the CP stroma of naive mice. These cells showed an acute
transient accumulation early in EAE and then seemed to be
reduced to near predisease level. Correlating with this decline,
leukocytes could be seen apparently extravasating across
the CP choroidal epithelium and into the ventricles, pre-
senting direct evidence supporting the theory that the CP is
the entry site into the CNS for leukocytes in the ontogenesis
of neuroinflammation (8).
MATERIALS AND METHODS
Animals
Female C57BL/6 mice, aged 8 to 10 weeks, were obtained
from Charles River Laboratories, Inc. (Wilmington, MA) and
used in all experiments. Three animals per group were used
for each treatment and time point assessed. All animal experi-
mental procedures were performed following Animal Care and
Use Guidelines of the University of Connecticut Health Center
(Animal Welfare Assurance A3471-01) and approved under
protocol 100346-1214.
EAE Induction
Experimental autoimmune encephalomyelitis was in-
duced in mice by active immunization with MOG35Y55
peptide (MEVGWYRSPFSRVVHLYRNGK), of murine ori-
gin (W. M. Keck Biotechnology Resource Center, Yale Uni-
versity, New Haven, CT), as described (24). Briefly, on Day
0 (D0), 1 group of mice was injected subcutaneously with
300Kg of MOG peptide in CFA (DIFCO, Becton-Dickinson,
Franklin Lakes, NJ) into the right and left flanks, 100 KL per
site. These mice were also injected i.p. with 500 ng per-
tussis toxin ([PTX] List Laboratories, Campbell, CA), in
PBS, pH 7.4, on D0 and D2 after the first immunization
(referred to as the MOG-CFA/PTX group). Another group
of age-matched mice received only CFA and PTX (500 ng)
injections on D0 and a second injection of 500 ng PTX on
D2 (referred to as the CFA/PTX ‘‘control’’ group). A third
group of age-matched mice was left untreated (referred to
as ‘‘naive’’ mice) and represented ‘‘normal’’ tissue. Only
the MOG-CFA/PTX group developed EAE. Mice typically
showed development of acute clinical signs at approximately
D12, followed by ascending paralysis and chronic disease
(25). Animals were killed at D0 (naive), D6, D9, and D15 after
injection. They were monitored for clinical disease severity, and
mean clinical scores were calculated as follows: 0 = normal;
1 = tail limpness; 2 = limp tail and hind leg weakness; 3 = limp
tail and complete hind leg paralysis; 4 = limp tail, complete
hind leg and partial front leg paralysis; and 5 = death. The time
points selected for analysis, D6, D9, and D15, represent pre-
clinical (score 0), early (scores 0Y0.5), and acute stages of
EAE (scores 2Y2.5), respectively.
Tissue Preparation and Sectioning for 3-D Analysis
Mice were anesthetized by intraperitoneal injection of
ketamine (80 mg/kg) and xylazine (10 mg/kg) in PBS. Ani-
mals were then transcardially perfused (via the left ventricle)
first with heparin-PBS (10 usp/mL) to eliminate vascular blood
content and then with fixation buffer (2% paraformaldehyde
in 0.1 mol/L phosphate buffer, pH 7.4), as previously described
(24). Brains were embedded in OCT cryomatrix compound
(Thermo Fisher Scientific, Waltham, MA) before sectioning.
Twenty-micrometer-thick cryosections were obtained using
a Microm HM 505M cryostat (Mikron Instruments, Oakland,
NJ), maintained atj25-C, and deposited onto poly-l-LysineY
coated slides.
Immunostaining for 3-D Analysis
Sections were permeabilized with 0.6 % Triton X-100
in PBS for 30 minutes, and nonspecific binding was blocked
by incubation with Power block for 10 minutes in Ultrapure
(GIBCO) distilled water (22). The CP capillary endothelium was
stained with rat anti-mouse CD31 antibody (BD Pharmingen) at
1:160 dilution, followed by incubation with goat anti-rat Alexa
Fluor 555 antibody (Life Technologies, Foster City, CA) at
1:250 dilution. Choroidal epithelial cells were stained using
monoclonal pan-cytokeratin-FITC antibody (Sigma, St. Louis,
MO) at 1:160 dilution. Rabbit polyclonal antibodies to CLN-2
(Invitrogen, Billerica, MA) at 1:160 dilution, CLN-3 (Abcam,
Cambridge, MA) at 1:100 dilution, ZO-2 (Invitrogen) at 1:100,
and ZO-1 (Invitrogen) at 1:160 dilution, followed by Alexa Fluor
488 goat anti-rabbit IgG (Life Technologies) at 1:250 dilution,
were used to stain epithelial TJs. Alexa Fluor 488 goat anti-
mouse IgG Fab fragment (Life Technologies) at 1:160 dilution
was used to detect endogenous IgG within the CP. DRAQ5
(Biostatus Ltd., Leicestershire, UK) was used at 1:1000 dilution
to stain nuclei. Alexa Fluor 647 anti-mouse CD45 (BioLegend,
San Diego, CA) at 1:160 dilution was used to stain for leuko-
cytes. Sections were mounted in Mowiol (Sigma-Aldrich).
Image Acquisition and Quantitative Analysis of
TJ Proteins, IgG, and Leukocytes in the CP
Confocal z-stacks (multitrack scan) were acquired using
a Zeiss LSM 510 Meta equipped with Zeiss Fluar 40X/1.30,
63X Plan-neofluar/1.25, and 100X Plan-apochromatic/1.4 oil
immersion objective lenses. Thereafter, z-stacks were imported
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into Bitplane Imaris suite version 7.1 x64 software (Bitplane
Inc., South Windsor, CT), as previously described (22).
The CP tissues located in the lateral ventricles were eval-
uated in all experiments because complexity and develop-
mental changes of TJ proteins have been reported to show
differences among the CP locales in rats (18). Images of these
TJ proteins were first isosurface rendered to obtain a measure
of total surface area; the epithelial nuclei were represented as
spots to estimate the number of epithelial cells per image.
Total areas of TJ protein staining per epithelial cell were cal-
culated as follows:
Total TJ area=epithelial cell ¼
Total surface area of green iso surface
Number of epithelial nuclei
A slightly different method was used for relative 3-D quan-
tification of endogenous IgG that had extravasated from the
circulation into the CP. Specifically, a volumetric approach was
taken as IgG became diffusely distributed throughout the CP
by D15 of EAE. Images of extravasated IgG were isosurface
rendered, and mean voxel intensities were determined. Immu-
noglobulin G staining along the endothelial lining of the capil-
laries was specifically masked to quantify only the IgG that leaked
out of the vasculature. This was done by creating an isosurface
of the capillary staining (CD31) and assigning all the included
green (IgG) voxel intensities to zero. A mean red voxel intensity
value of the capillary isosurface was then obtained. The volume
of extravasated IgG per volume of capillaries was calculated
as follows:
Volume of IgG=Volume of capillaries ¼
Total green intensity
Total red intensity
Total green intensity ¼ Mean green intensity
 no: of green voxels
Total red intensity ¼ Mean red intensity  no: of red voxels
Leukocyte quantification was performed using the mea-
surement points module of the Imaris software suite, first
representing the CD45-positive cells as ‘‘spots’’ and then counting
the total number of spots present in the field of view. The surface
area of the capillaries was determined by creating an isosurface of
the capillary staining (CD31), and the number of leukocytes per
capillary surface area of the CP was calculated as follows:
Total number of leukocytes=capillary area ¼
Total no: of spots 102
Total surface area of the red isosurface
Laser Capture Microdissection and Quantitative
Reverse Transcription Polymerase
Chain Reaction
Immunohistochemistry-guided laser capture microdis-
section (LCM) was performed as recently described (23). In
brief, naive animals were killed by gradual CO2 inhalation.
Brains were immediately removed, snap-frozen in dry ice-
cooled 2-methylbutane (Acros, Geel, Belgium), and embedded
in cryomatrix compound (Thermo Fisher Scientific, Waltham,
MA) for cryosectioning. Coronal sections (7 Km) were cut on a
Microm HM 505 M cryostat (Mikron Instruments, Oakland,
NJ) and affixed to uncoated precleaned glass slides (Fisher
Scientific, Pittsburgh, PA). The CP stromal capillaries were
stained using a substrate combination of nitro-blue tetrazolium
chloride/5-bromo-4-chloro-3¶-indolyphosphate p-toluidine salt
(Vector Labs, Burlingame, CA) to detect the endogenous alkaline
phosphatase activity in endothelial cells. The choroidal epithelial
cells were immunostained with monoclonal pan-cytokeratin-
FITC antibody (Sigma). A PixCell IIe laser capture microscope
(Life Technologies, Foster City, CA) was used to retrieve CP
choroidal epithelial tissue from the lateral ventricles. Laser capture
microdissection samples were solubilized in Cell Lysate Buffer
(Signosis, Sunnyvale, CA) for direct reverse transcription, and
relative cDNA levels were quantified by quantitative reverse
transcription polymerase chain reaction (qRT-PCR) using an ABI
7900HT Fast Real-Time PCR System (Life Technologies Corp)
and normalized to housekeeping gene RPL-19, as described pre-
viously (26). Samples were probed for the TJ proteins CLN-1,
CLN-2, CLN-3, CLN-11, occludin, and ZO-1, and the purity of
the captured LCM material was assessed by epithelial marker
(cytokeratin-8) and endothelial cell marker (CD31) levels.
Statistical Analysis
Two CP sections from each animal and a total of 3 ani-
mals were used for each group: naive, control (CFA/PTX), and
EAE (MOG-CFA/PTX). Data from all experiments were ini-
tially assessed for normality using a Shapiro-Wilk test. Accord-
ingly, data from ZO-1, IgG, and leukocyte determinations were
subsequently analyzed by a 1-way nonparametric Kruskal-
Wallis test followed by Dunn posttest analysis; data from CLN-2
determinations were analyzed by a 1-way analysis of variance
followed by Bonferroni posttest. All statistical analyses were
performed using GraphPad Prism 5 (GraphPad, La Jolla, CA).
Results were considered significant at p e 0.05.
RESULTS
Relative Expression of Genes Encoding TJ
Proteins in the CP
The normal CP choroidal epithelium was first analyzed
by LCM to establish the relative expression of TJ components
in this tissue layer of naive mice (Fig. 1). Previous descriptions
by this laboratory have highlighted the ability of LCM to
resolve with high purity the choroidal epithelium from the
vascularized core (23). Analysis of LCM-derived choroidal
epithelial tissue by qRT-PCR revealed expression of cytokeratin
8 (K8), as well as mRNAs encoding the TJ proteins ZO-1,
CLN-1, CLN-2, CLN-3, and CLN-11, which have also been
previously identified in the CP in situ by immunocytochem-
istry as well as in cultured choroidal epithelial cells (16Y18,27).
Notably, expression of CD31, which is found in all endothelial
cells but not choroidal epithelial cells, was barely detectable,
reinforcing the high precision of the LCM process. Because
of their relatively prominent expression, immunofluorescence
studies of ZO-1 and CLN-2 were further pursued to determine
whether cytologic changes of these CP TJ components were
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correlated with functional aspects of neuroinflammation during
evolving EAE.
Distribution of TJ Proteins, IgG, and Leukocytes
Within the CP of Naive Mice
Initial studies sought to demonstrate the status of the
normal CP in naive mice (Fig. 2). With respect to ZO-1 and
CLN-2 distribution (Fig. 2A and 2B, respectively), strong immu-
nostaining for both these TJ proteins revealed a smooth con-
tour and continuous pattern, delimiting the junctions of all
choroidal epithelial cells. A scarce amount of IgG could be
detected within the CP stroma of naive mice (Fig. 2C), along
with a few leukocytes (Fig. 2D). The approaches used to per-
form relative quantification of ZO-1, CLN-2, IgG, and leuko-
cytes in the CP are illustrated in Figure 3.
Distribution of ZO-1 in the CP After
Immunization
Subsequent studies evaluated immunostaining of TJ pro-
teins and IgG at different time points in both control mice
(receiving CFA/PTX) and mice after EAE induction (receiving
MOG-CFA/PTX) (Fig. 4A). The staining pattern of ZO-1 was
altered in both groups, but the changes varied in extent. In
CFA/PTX-treated control mice, immunostaining of ZO-1 was
a bit distorted at D6, showing ridgelike irregularities in the
contour at some locales that persisted through D15. Treat-
ment with MOG-CFA/PTX to induce EAE resulted in more
drastic alterations in ZO-1 staining patterns. Similar ridgelike
irregularities were initially obvious along some choroidal epi-
thelial cells at D6, but these became more pronounced during
the disease course. By D15, the ZO-1 staining pattern was
severely crenulated throughout the choroidal epithelium, giving
a palisade appearance. To quantify these changes in TJ staining
patterns, total area of ZO-1 staining within the CP epithelium
of each image was related to the number of CP epithelial nuclei
(Fig. 4B), as shown in Figure 3. Control mice evidenced no
changes in this parameter over the time points evaluated, whereas
mice with EAE showed a stepwise elevation, with significant
changes at D9 and D15 (compared with naive). As this suggested
an increase in individual CP epithelial cell surface area during
evolving EAE, internuclei distances were also determined
as a surrogate for corresponding volume/cell size changes
FIGURE 1. Laser capture microdissection (LCM) analysis of tight junction gene expression in choroidal epithelial cells. The choroid
plexus (CP) of a naive mouse was double immunostained for LCM analysis. (A) CP tissue section before LCM retrieval. Capillaries
were stained by immunohistochemistry for CD31 using alkaline phosphatase detection and NBT/BCIP substrate (dark purple);
choroidal epithelial cells were stained by immunofluorescence using FITC-conjugated antibody to pan-cytokeratin (green). (B, C)
Laser shots showing the retrieval of choroidal epithelial cells and their deposition on the cap. (D) CP tissue section after LCM
retrieval of epithelial cells, showing capillaries left behind. (E) Collection of LCM shots of epithelial cells on the cap used for gene
expression analysis. (F) qRT-PCR analysis of LCM-derived CP epithelial tissue, indicating expression of the epithelial marker
cytokeratin 8 (K8) and several tight junction proteins. ZO-1, zonula occludens 1; cldn1, 2, 3, 11, claudin-1, -2, -3, -11.
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(see Materials and Methods, Supplemental Digital Content 1,
http://links.lww.com/NEN/A656). At D15 EAE, mean in-
ternuclei distance in CP epithelial cells was nearly 3-fold
higher than that found in naive mice, suggesting a signifi-
cant increase in CP epithelial cell volume during neuroin-
flammatory disease. Figure, Supplemental Digital Content 2,
http://links.lww.com/NEN/A657 shows an increase in CP
epithelial internuclei distance. These observations were
further supported by a significant increase in the perim-
eter of ZO-1 staining in CP epithelial cells in D15 EAE
mice compared with naive mice. Figure, Supplemental
Digital Content 3, http://links.lww.com/NEN/A658 shows
an increase in the perimeter of ZO-1 staining within the
CP epithelium.
FIGURE 2. Distribution of tight junction proteins, IgG, and leukocytes in normal choroid plexus (CP) tissue. Representative sections
of the CP of naive mice are shown. (AYC) Capillaries are immunostained for CD31 (red) in all images; isosurfaces were rendered
and nuclei of the choroidal epithelial cells are stained with DRAQ5 (blue). (A) Zonula occludens 1 (ZO-1) immunostaining (green)
and (B) claudin-2 (CLN-2) immunostaining (green) appear uniform and smooth along the interepithelial junctions, as highlighted
in the insets. (C) IgG immunostaining (green) is scant and is seen in only focal deposits apparently within the stroma (white arrow,
inset). (D) Choroidal epithelial cells were immunostained for cytokeratin (green); leukocytes were immunostained for CD45 (blue)
and isosurfaces were rendered to highlight their 3-D appearance and spatial relation to the different compartments of the CP. There
are a few leukocytes that seemingly are associated with the capillary network or in the stroma (inset).
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FIGURE 3. Three-dimensional (3-D) quantification of choroid plexus (CP) tight junction protein, IgG, and leukocytes during
evolving experimental autoimmune encephalomyelitis (EAE). (AYI) Representative sections of the CP of mice at D15 EAE are
depicted to demonstrate the approaches used for quantification of disease-associated changes in CP tight junction protein and IgG
leakage. (A, D, G) Composite 3-D data sets of confocal z-stacks. The 3-D frames are presented to display the holistic acquisition of
the data. (B, C, E, F, HYI) 2-D depictions of the images in (A), (D), and (G), respectively. The 2-D projections of 3-D images served
as the sources from which quantitative data were obtained. Isosurface rendering was performed to highlight the tortuous nature
and 3-D disposition of the respective CP compartments. Capillaries were immunostained for CD31 (red) and isosurface rendered
throughout. Zonula occludens 1 (ZO-1), an example of tight junction protein within the choroidal epithelium, was immunostained
(green) in (AYC); isosurface is rendered in (C). IgG was also shown immunostained (green) in (DYF) to demonstrate serum protein
leakage; isosurface is rendered in (F). Choroidal epithelial nuclei are stained with DRAQ5 (blue) in (AYF); leukocytes are stained for
CD45 (blue) in (GYI); DRAQ5- and CD45-positive structures were reconstructed as ‘‘spheres’’ in (C) and (I), respectively. Insets in
(C) show the total ZO-1 staining (top) and nuclei staining (bottom) used to calculate relative amount of tight junction protein/
choroidal epithelial cell. Insets in (F) show total IgG staining (top) and capillary staining (bottom) used to calculate relative amount
of leaked IgG/capillary mass. Insets in (I) show the total number of leukocytes (top) and total capillary staining (bottom) used to
calculate relative number of leukocytes/capillary surface area.
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Distribution of CLN-2 in the CP After
Immunization
The response of CLN-2 was different both qualitatively
and quantitatively from that of ZO-1 (Fig. 5A). The immu-
nostaining pattern of CLN-2 did not appear to change in
control mice receiving CFA-PTX alone, remaining relatively
linear at intercellular borders. There was, however, a slight
change in the staining intensity by D15. Likewise, the overall
CLN-2 staining pattern remained unaltered after EAE induc-
tion, although a steeper reduction in staining intensity was
FIGURE 4. Zonula occludens 1 (ZO-1) distribution in the choroid plexus (CP) during evolving experimental autoimmune en-
cephalomyelitis (EAE). (A) Representative sections of the CP were collected at the indicated time points from control complete
Freund adjuvant/pertussis (CFA/PTX) mice and from mice after EAE induction with myelin oligodendrocyte glycoprotein (MOG-
CFA/PTX). Capillaries were immunostained for CD31 (red) and isosurface rendered in all images to highlight the swelling of these
microvessels during disease. Choroidal epithelial cells were stained with DRAQ5 (blue) to identify their nuclei and immunostained
for ZO-1 (green). Inset highlights area of extensive crenulation of ZO-1 immunostaining in mice at D15 EAE. (B) 3-D quantification
and analysis of the changes in total area of ZO-1 per epithelial cell nuclei for the CFA/PTX and MOG-CFA/PTX groups. There was a
significant increase in immunostained area at D9 and D15 in the mice with EAE versus naive mice. * p G 0.05; *** p G 0.001.
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more noticeable in this group, which by D15 revealed sites
of sharp discontinuities (arrows). The ratio of total area of
CLN-2 immunostaining to number of CP epithelial cell nuclei
was calculated as for ZO-1 (Fig. 5B). This parameter did not
significantly change in control mice until D15 but was sig-
nificantly reduced earlier in mice with EAE, that is, showing
a decrease at D9 and an even greater decline at D15 of after
immunization as discontinuities became more evident.
FIGURE 5. Claudin-2 (CLN-2) distribution in the choroid plexus (CP) during evolving experimental autoimmune encephalomyelitis
(EAE). (A) Representative sections of the CP were collected at the indicated time points from control complete Freund adjuvant/
pertussis (CFA/PTX) mice and frommice after EAE induction with myelin oligodendrocyte glycoprotein (MOG-CFA/PTX). Capillaries
were immunostained for CD31 (red) and isosurface rendered in all images to highlight the swelling of these microvessels during
disease. Choroidal epithelial cells were stained with DRAQ5 (blue) to highlight their nuclei and immunostained for CLN-2 (green).
White arrows show focal disruptions in CLN-2 staining by D15 EAE. (B) 3-D quantification and analysis of the changes in total area
of CLN-2 per epithelial cell nuclei for CFA/PTX and MOG-CFA/PTX groups. There was a significant decrease in immunostaining area
corresponding to the loss in focal staining in D9 and D15 EAE versus naive mice. ** p G 0.01; *** p G 0.001. The CFA/PTX group also
showed a significant decrease in area by D15. * p G 0.05.
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Given the strongly disparate responses between ZO-1
and CLN-2, additional studies were carried out to determine
whether the different patterns of TJ protein redistribution
might be related to these proteins being of peripheral and in-
tegral membrane classes, respectively (Figure, Supplemental
Digital Content 4, http://links.lww.com/NEN/A659 shows ZO-2
and CLN-3 staining in the CP from naive and MOG-CFA/
PTX-treated mice). Zonula occludens 2, another peripheral
membrane TJ protein, demonstrated a response much like that
of ZO-1, showing a similarly crenulated pattern while appar-
ently maintaining constant intensity after MOG-CFA/PTX im-
munization. In contrast, the response of CLN-3, another integral
membrane TJ protein, paralleled that of CLN-2, exhibiting a
less intense and discontinuous pattern.
Distribution of IgG in the CP After Immunization
Increased IgG staining was seen in both control mice
and in mice after EAE induction, although to different extents
(Fig. 6A). It increased in CFA/PTX-treated control mice by
D6 and displayed greater elevation through D15. The IgG
appeared to be restricted to the CP stroma, as none could
be readily seen to infiltrate the choroidal epithelium. These
changes in IgG were even more dramatic in mice with EAE.
A visible increase in IgG immunostaining was first noted by
D6, becoming more extreme by D15. At this later time, IgG
was clearly seen permeating across the choroidal epithelium.
Because IgG staining became extremely diffuse by later stages
of EAE, relative IgG leakage within the CP was quantified
by relating its total volumetric staining to total volumetric
staining of capillaries within each image (Fig. 3). An increase in
IgG leakage was established in both control mice and those
with EAE, with a greater level (È3-fold) seen in the latter by
D15 (Fig. 6B).
Distribution of Leukocytes in the CP After
Immunization
Injection with CFA/PTX alone resulted in increased
appearance of leukocytes in the CP compared with that seen
in naive mice (Fig. 7A). However, these leukocytes appeared
to be in close association with the CP capillaries and/or
confined to the stroma. This moderate leukocyte increase
was reversed to a normal level by D9, where it remained
through D15. Immunization with MOG-CFA/PTX also re-
sulted in an apparent influx of leukocytes in the CP at D6
and D9, which reverted by D15. Notably, at D15, leukocytes
could be seen closely associated with the choroidal epitheli-
um, a few apparently caught in the act of extravasating past
the epithelial barrier. That these leukocytes were, in fact,
outside of the CP stroma was revealed by rotation of 3-D
images, wherein some extravasated leukocytes in the CSF
could be seen still tethered to the luminal surface of cho-
roidal epithelium. The Video (Supplemental Digital Content 5,
http://links.lww.com/NEN/A660) shows leukocytes attached
to the CP epithelium. It is important to emphasize here that
any leukocytes fully extravasated into the CSF are unlikely to
be represented in these images because the cells would not be
retained in the ventricles after tissue sectioning and immu-
nostaining. Quantification showed that the number of leuko-
cytes significantly increased in the CP at D6 after CFA/PTX
treatment and also did so at D6 and D9 after MOG-CFA/PTX
before returning to normal levels (Fig. 7B).
DISCUSSION
Although the appearance and developmental regulation
of TJs in the CP have been rigorously investigated for nearly
5 decades (16,18,28Y39), much less is understood of the
alterations of these junctions and their protein constituents
during neuroinflammatory disease and their relation to bloodY
CSF barrier permeability and leukocyte extravasation (40).
Hence, high-resolution 3-D imaging of the CP was performed
in this study to track and quantify such alterations and their
functional correlates (i.e. extravasation of IgG and leu-
kocytes during evolving EAE) and to distinguish MOG
immunizationYassociated changes from those caused by
adjuvants alone.
Our use of LCM/qRT-PCR to analyze the CP choroidal
epithelium selectively confirmed the relative gene expression
of major TJ proteins, particularly in MOG-sensitive C57BL/6
mice; a similar pattern was previously described in the Sprague-
Dawley rat by standard qRT-PCR of total RNA from whole
CP tissues (18). These results reinforced emerging LCM tech-
nology as a critical tool to probe gene changes in discrete
compartments of the CP (23) and focused our attention on TJ
proteins ZO-1 and CLN-2 for detailed 3-D image analysis.
Strong and smooth immunostaining of both ZO-1 and
CLN-2 was associated with all intercellular junctions of CP
epithelial cells in naive mice, as has been previously reported
in these cells from various species (16,17,27,41). However,
ZO-1 and CLN-2 showed markedly different responses to
MOG immunization or injection of adjuvants. The pattern
of ZO-1 immunostaining became moderately distorted after
CFA/PTX alone and more drastically crenulated after MOG
immunization. To the best of our knowledge, this is the first
description of such alterations in TJ staining in vivo. Recent
in vitro reports have given similar accounts of ‘‘ruffled’’ or
‘‘wavy’’ ZO-1 patterns associated with loosening of epithe-
lial TJs of cultured Caco-2 and MDCK cells after applica-
tion of nanoparticles or mechanical stretch (42,43). Together,
these observations seemingly highlight a common mani-
festation of ZO-1 redistribution that accompanies epithelial
barrier disruption. Although the basis and physiologic sig-
nificance of the peculiar alteration of ZO-1 appearance noted
here remain unknown, Samak et al (43) noted the compara-
ble disruption in Caco-2 cells to be associated with JNK-2Y,
c-SrcY, and MLCK-dependent mechanisms. Interestingly, rad-
ical ultrastructural changes in CP epithelial cells, for example,
widening of intercellular clefts, have been reported after
experimental traumatic brain injury (44), and the 2 findings
may be related to observations in the current study. The
approximately 3-fold increase in both the mean internuclei
distance and ZO-1 perimeter of CP epithelial cells during EAE
is further consistent with a significant increase in cell volume
and points toward even more alterations associated with EAE
than have been previously imagined. Interestingly, while
describing distributions of TJ proteins at the CP more than a
decade ago, Wolburg et al (16) did not note any changes in
ZO-1 distribution in EAE-afflicted mice and specifically
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commented on the difficulties of obtaining quantitative re-
sults by immunohistochemistry when using conventional con-
focal microscopy. The advantages afforded by state-of-the-art,
high-resolution, 3-D imaging may thus have uniquely enabled
us to uncover and quantify the remarkable ZO-1 responses in
the CP choroidal epithelium.
FIGURE 6. Immunoglobulin G distribution in the choroid plexus (CP) during evolving experimental autoimmune encephalomyelitis
(EAE). (A) Representative sections of the CP were collected at the indicated time points from control (CFA/PTX) mice and frommice
after EAE induction (MOG-CFA/PTX). Capillaries are immunostained for CD31 (red) and isosurface rendered in all images to
highlight the swelling of these microvessels during disease; choroidal epithelial cells are stained with DRAQ5 (blue) to highlight
their nuclei; IgG was immunostained (green). IgG can be seen extravasating across the choroidal epithelium in mice to increasing
extents across time in CFA/PTX mice and with increased severity in MOG-CFA/PTX mice (white arrows, inset). (B) 3-D quantifi-
cation and analysis of the changes in total IgG per total capillaries for CFA/PTX and MOG-CFA/PTX groups. There was a significant
increase in extravasating IgG in D15 CFA/PTX and D9 and D15 EAE mice versus IgG staining in naive mice. * p G 0.05; ** p G 0.01;
*** p G 0.001.
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FIGURE 7. Leukocyte extravasation in the choroid plexus (CP) during evolving experimental autoimmune encephalomyelitis (EAE).
Representative sections of the CP were collected at the indicated time points from control mice (CFA/PTX) and from mice after EAE
induction (MOG-CFA/PTX). Capillaries are immunostained for CD31 (red); choroidal epithelial cells are immunostained for
cytokeratin (green); leukocytes are immunostained for CD45 (blue); isosurface was rendered in all images to highlight the 3-D
appearance of these cells and their spatial relation to the different compartments of the CP. In control CP, the number of leukocytes
appears to increase at D6 but returns to near naive level by D9 and D15. The leukocytes in these mice appear to remain associated
with the capillaries or stroma. In the CP of mice with EAE, there is an increase in leukocytes at D6 and D9, which reverses to naive
level by D15. Inset highlights leukocytes that are associated with the apical surface of the choroidal epithelium, likely extravasating
into the CSF at D15 EAE. (B) 3-D quantification and analysis of the changes in total number of leukocytes per total surface area of
capillaries for CFA/PTX and MOG-CFA/PTX groups. There was a significant increase in accumulation of CD45 leukocyte immu-
nostaining in D6 control mice and in D6 and D9 EAE versus naive mice. * p G 0.05; ** p G 0.01; *** p G 0.001.
J Neuropathol Exp Neurol  Volume 73, Number 11, November 2014 Choroid Plexus Alterations in EAE
 2014 American Association of Neuropathologists, Inc. 1057
Copyright © 2014 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
By contrast to the observed effects on ZO-1, changes in
CP epithelial CLN-2 after immunization were much more subtle.
Claudin-2 showed no obvious alterations in pattern after CFA/
PTX treatment and a minimal decrease in the amount of immu-
noreactivity. A similar trend was observed after MOG im-
munization but with a sharper decrease in immunoreactivity
of CLN-2 that ultimately presented a fragmented appearance.
Wolburg et al (16) similarly observed the immunostaining
of CLN-2 to be ‘‘interrupted’’ in the CP choroidal epithelium
after EAE immunization but did not resolve whether this
was caused by MOG or adjuvant effects. Kooij et al (27) also
recently described a comparatively tempered loss of CLN-3
immunostaining in this tissue in mice immunized for EAE,
possibly suggesting that this type of response is common
among the different CLN proteins of the CP during neuro-
inflammation, as opposed to the more peculiar change in
ZO-1 pattern.
That the responses of the 2 classes of TJ proteins, ZO-1/
ZO-2 and CLN-2/CLN-3, were vastly different from each other
could reflect their respective positions and roles within the TJ
complex. Peripheral membrane ZO proteins, lying internal to
CLNs and directly connected to the actin cytoskeleton (19Y21),
might transduce the disruptive inflammatory signal to their
integral membrane CLN protein partners. Inasmuch as the epi-
thelial actin cytoskeleton can become severely disorganized
during both PTX treatment and inflammation (45,46), this could
potentially lead to retraction of ZO proteins from their mem-
brane locale and disengagement from CLNs. No longer bound
to ZO proteins, CLNs might be susceptible to rearrangement
and/or degradation (22,24). Whatever their cause, the different
effects on these 2 proteins underscore the complexity of actions
taking place at the level of the TJ in the CP choroidal epithe-
lium, and that the response of individual TJ proteins cannot
be assumed to be similar. Disparities in responsiveness among
various TJ proteins have also been reported in cultured CP cho-
roidal epithelial cells (47). In this case, CLN-2 showed reduced
protein level by Western blotting after treatment with protein
kinase C activator phorbol 12-myristate 13-acetate, whereas
levels of CLN-1, ZO-1, and occludin were spared.
In line with the characterization of the fenestrated CP
capillaries as normally ‘‘leaky’’ (48Y50), there was some evi-
dence (albeit scarce) of IgG immunostaining and a few leuko-
cytes in the CP stroma of naive mice. In contrast, while using
the same technology as used here, virtually no IgG or leuko-
cytes were detected around parenchymal CNS microvessels in
the naive situation (22,24). It would thus appear that although
CP capillaries in the healthy state are somewhat more perme-
able than the BBB, their perception as being ‘‘highly perme-
able’’ (51), and ‘‘allowing the free passage of molecules and
cells’’ (52) may merit some reconsideration. This would concur
with the description of fenestrated endothelia in airway ex-
change vessels having permeabilities to plasma proteins that
are about the same as found in continuous endothelia (53).
Choroid plexus capillaries nevertheless seemed to be-
come significantly leakier in response to CFA/PTX or MOG-
CFA/PTX, allowing for extravasation of IgG and leukocytes
into the stromal compartment. It is possible that some of the IgG
appearing in the stroma might have been derived from intra-
thecal synthesis by B cells. However, the fact that IgG levels
continually increased while leukocytes decreased in the CP
stroma at later time points argues against B cells being the
exclusive or major source of IgG observed and suggests that
a significant amount of this protein was serum derived. The
basis for this effect is unclear at this time because the pres-
ence of TJs or other less-restrictive junctional specializations
in CP capillaries has not been confirmed (51). Nevertheless,
CLN-5, occludin, and ZO-1 have been reported in this vas-
cular bed (27,35) and could possibly be consequences of
CFA/PTX or MOG-CFA/PTX immunization. We previously
found that the chemokine CCL2 is elevated within the CP cap-
illary plexus after CFA/PTX or MOG-CFA/PTX treatment
(23); this may relate to the enhanced IgG leakiness noted
here because this chemokine has been linked to downregulation
and/or redistribution of endothelial CLN-5, occludin, and ZO-1
in association with increased permeability (24,54Y58). Appear-
ance of IgG leakage across the CP choroidal epithelium was
only observed after MOG-CFA/PTX immunization and may
be caused by the more severe alterations in TJ proteins that
accompany neuroinflammation.
The observation that few leukocytes were present in the
CP stromal space in naive mice is consistent with other recent
descriptions (27,59) and may reflect a limited permeability of
normal CP capillaries to blood cellular elements. Specifically,
scant CD3-positive and CD4-positive T cells and CD68-positive
cells of myeloid lineage (dendritic cells and macrophages) have
been shown to reside in this CP compartment under normal
conditions (8,60,61). Both CFA/PTX and MOG-CFA/PTX
immunization produced a transient increase in the CP leukocyte
population. The pathway(s) by which leukocytes accumulate
in the CP stroma remains uncertain, as previous reports using
immunohistochemistry at the light and ultrastructural levels
noted expression of adhesion molecules, ICAM-1, VCAM-1,
or MAdCAM-1, on the CP choroidal epithelium but not along
the CP capillaries in SJL mice with EAE induced by immuni-
zation with CFA/PTX and myelin proteolipid protein (62,63).
We recently used LCM to detect upregulated gene expres-
sion of VCAM-1, E-selectin, P-selectin, and Smad-3 in the
CP capillary bed of C57BL/6 mice after CFA/PTX or MOG-
CFA/PTX, with Smad-3 exclusively among these showing
superinduction during MOG-CFA/PTX-induced EAE (23).
Reinforcing the relevance of these gene findings, E-selectin
and P-selectin immunoreactivity has also been described in
the CP vasculature of patients with non-neurologic disorders (8).
Previously noted examples of upregulated chemokine ex-
pression in these microvessels, for example, CCL2, CCL5, and
CCL19 (23), may thus act cooperatively with elevated adhe-
sion molecule expression to drive leukocyte extravasation across
the CP capillaries into the stroma. At present, we are unaware
of any descriptions of the CP bearing specialized postcapillary
venules, the preferred sites of exit of leukocytes from the cir-
culation (64), but are mindful of the possibility that leukocyte
extravasation from the circulation could occur at the transi-
tional regions between the CP capillary plexus and draining
venules (8).
Only MOG-CFA/PTX immunization resulted in clear
evidence of leukocyte extravasation across the CP choroidal
epithelium, which, for CCR6-bearing Th17 cells, is thought
to be mediated in significant part by epithelial expression of
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the chemokine CCL20 (12). That the CD45-positive cells
observed clinging to the apical side of the CP choroidal ep-
ithelium actually represent extravasating leukocytes is strongly
supported by the sequence of images after MOG-CFA/PTX
immunization, which showed these cells first appearing in the
CP stroma, then in association with the basolateral epithelial
surface, and finally attached to the apical epithelial surface
facing the CSF. To the best of our knowledge, the scenario
shown is the first histologic evidence of such directed transit
through the entire CP. This finding is also in accord with the
inability of CFA/PTX treatment alone to cause clinical EAE
in these mice (23) and directly supports the concept that the
rudimentary processes underlying neuroinflammatory diseases
such as multiple sclerosis and EAE originate via the trafficking
of leukocytes through CP into the CSF (8Y12). The previous
observation by Schmitt et al (60) that CFA/PTX alone resulted
in a subtle but definite increase in the number of myeloid cells
in the extraventricular CSF spaces could suggest that this
adjuvant combination promotes modest leukocyte extrava-
sation across the CP choroidal epithelium but at a level too
low to be readily detected even by high-resolution 3-D con-
focal microscopy. In this regard, histologically capturing
leukocytes in the act of extravasating across the CP choroidal
epithelium is particularly challenging because they are in effect
washed away after entering the CSF.
As with the observed IgG leakage at this site, the more
profound perturbations in TJ proteins caused specifically by
MOG-CFA/PTX immunization may enable leukocytes accu-
mulating within the CP stroma to migrate more effectively
between the choroidal epithelial cells and into the CSF, as
depicted schematically in Figure 8. Alternatively, other fac-
tors induced by MOG-CFA/PTX immunization, for example,
chemokines and/or adhesion molecules, may facilitate leuko-
cyte extravasation at this level, which, in turn, alters the integ-
rity of the CP choroidal epithelium, leading to the TJ protein
manifestations and IgG leakage observed. The fact that the CP
stroma showed apparent reduction in the leukocyte population
from D9 to D15 may further represent time needed for leuko-
cyte extravasation across the CP choroidal epithelium.
Although no absolute cause-and-effect relationship be-
tween the observed TJ alterations and IgG/leukocyte extrav-
asation can be established at this time, it is significant to point
out that neither IgG nor leukocytes were seen permeating the
CP choroidal epithelium until D15 after MOG-CFA/PTX im-
munization, whereas changes in both ZO-1 and CLN-2 were
observed earlier (D9). This time frame is thus consistent with
the noted structural changes in CP choroidal epithelial TJ
proteins having functional consequences that encourage ex-
travasation of IgG and leukocytes.
Collectively, our present results reinforce the notion that
CFA/PTX instigates a series of molecular and structural changes
associated with neuroinflammation that is augmented when
this adjuvant combination accompanies MOG immuniza-
tion. At present, it is unclear whether only one or both ad-
juvants were responsible for the observed effects, as our
objective was to specifically highlight changes in TJ protein
FIGURE 8. Schematic diagram of the choroid plexus. ‘‘Leaky’’ fenestrated capillaries [1] are surrounded by a ‘‘tight’’ layer of
epithelial cells [2], which have tight junctions [3], forming the bloodYCSF barrier (BCSFB). The stroma [4] lies in between the 2
layers. Loss of BCSFB integrity during neuroinflammation is associated with alteration of tight junctions [3], leakage of serum
protein IgG [5], and extravasation of leukocytes [6] across the BCSFB into the CSF. Leukocyte extravasation is depicted as occurring
paracellularly, that is, between choroidal epithelial cells, as it accompanies junctional disruption, although the precise mode has not
been established.
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distribution and IgG/leukocyte extravasation stemming from
MOG immunization versus collective adjuvant action. Com-
plete Freund adjuvant and PTX have each been shown sepa-
rately to disrupt TJs and increase permeability at the BBB in
other settings (65,66). However, PTX was not found to dis-
rupt barrier function in epithelial Plexus choroideusYderived
monolayer cultures (67), suggesting that CFA might be re-
sponsible for the effects noted here or that the 2 adjuvants
cooperate to alter TJs and structural integrity of the CP capil-
laries and/or choroidal epithelium in vivo in support of IgG
and leukocyte extravasation.
We previously reported that CFA/PTX alone elicited
significant changes in the expression of numerous immune
response associated genes in both CP capillary and choroidal
epithelium compartments (23), whereas MOG-CFA/PTX immu-
nization resulted in superinduction of some of these genes
as well as stimulated a novel cadre of genes in this same
functional category. In the current report, we extend these
findings to show that CFA/PTX further instigates structural
changes in the CP that may facilitate the autoimmune re-
sponse to MOG immunization. Thus, although it has been
reported that PTX, in particular, can drive CNS autoimmu-
nity via regulation of TLR4 signaling and opening up the BBB
(68,69), CFA/PTX appears to act more broadly to ‘‘raise the
floor’’ of a collective of inflammatory processes in the CP
necessary for a neuroinflammatory disease such as EAE
to develop.
Additional implications are worth noting. Attempts to
attribute gene or histologic changes seen in EAE as being a
specific autoimmune response to MOG immunization might
overlook significant contributions by CFA and/or PTX. Also,
the fact that CFA/PTX exerts prominent effects in the CP
(considered a possible gateway for leukocytes to invade the
uninflamed CNS [70Y72]) calls attention to the prospect that
other environmental toxins with activities like CFA or PTX
might target this brain structure to help trigger CNS autoim-
mune inflammation (73).
Further clarification of the modes of leukocyte traf-
ficking through the CP should enable more efficient drug
targeting to this organ and significantly broaden the prospects
for treatment of neuroinflammatory diseases (74,75).
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SUMMARY
Current therapies for multiple sclerosis (MS) are largely palliative, not curative. Mesenchymal stem cells (MSCs) harbor regenerative and
immunosuppressive functions, indicating a potential therapy for MS, yet the variability and low potency of MSCs from adult sources
hinder their therapeutic potential. MSCs derived from human embryonic stem cells (hES-MSCs) may be better suited for clinical treat-
ment of MS because of their unlimited and stable supply. Here, we show that hES-MSCs significantly reduce clinical symptoms and
prevent neuronal demyelination in amouse experimental autoimmune encephalitis (EAE) model of MS, and that the EAE disease-modi-
fying effect of hES-MSCs is significantly greater than that of human bone-marrow-derived MSCs (BM-MSCs). Our evidence also suggests
that increased IL-6 expression by BM-MSCs contributes to the reduced anti-EAE therapeutic activity of these cells. A distinct ability to
extravasate and migrate into inflamed CNS tissues may also be associated with the robust therapeutic effects of hES-MSCs on EAE.
INTRODUCTION
Multiple sclerosis (MS) is a chronic neuroinflammatory dis-
ease characterized by infiltration of peripheral immune
cells into the CNS through an impaired blood-brain barrier
(BBB) or blood-spinal cord barrier (BSCB), and loss of
myelin with accompanying scarring of axons (McFarland
and Martin, 2007). However, most current treatments for
MS only offer palliative relief without providing a cure,
andmany are also associated with adverse effects that limit
their long-term utility (Weber et al., 2012).
Transplantation of mesenchymal stem/stromal cells
(MSCs) for the treatment ofMShas emerged as an attractive
therapy due to the immunomodulatory and neuroregener-
ative properties of these cells (Auletta et al., 2012; Pittenger
et al., 1999) and their potential ability to repair the BBB
(Chao et al., 2009) with fewer side effects (Lalu et al.,
2012). MSC can home to injured tissues and exert thera-
peutic effects through the secretion of immunomodulatory
and trophic factors as well as through direct cell-cell con-
tact (Uccelli and Prockop, 2010). Importantly, allogeneic
MSCs generally do not provoke a strong host immune
response due to lack of expression of immune costimula-
tory receptors and low expression of major histocompati-
bility complex (MHC) class II antigens (Uccelli and
Prockop, 2010), raising the possibility that cells derived
from a single donor may be used to treat a large number
of patients.
Human adult-tissue-derivedMSCs have shown therapeu-
tic utility in experimental autoimmune encephalitis (EAE)
models of MS (Bai et al., 2009; Gordon et al., 2008, 2010;
Peron et al., 2012; Zhang et al., 2005) and in clinical trials
for MS patients (Connick et al., 2012; Karussis et al.,
2010; Mohyeddin Bonab et al., 2007; Yamout et al.,
2010); however, the large variability in the efficacy of
MSCs hinders their development as a standardMS therapy.
Extensive in vitro expansion of MSCs may diminish the
efficacy of these cells (Kyriakou et al., 2008), and MSCs
derived from younger cell sources (e.g., embryonic, fetal,
and umbilical cells) have higher in vitro proliferation
potential and can more readily differentiate (Barlow et al.,
2008; Giuliani et al., 2011). Thus, deriving MSCs from a
young and renewable (i.e., pluripotent) cell source, such
as human embryonic stem cells (hESCs), could (1) alleviate
the quantity and quality issues involved in the use of adult-
tissue-derived MSCs, (2) obviate the need for constant
donor recruitment, and (3) reduce the risk of pathogenicity
from the use of multiple donors.
Different groups have derived MSCs from hESCs (hES-
MSCs) with a morphology and immunophenotype similar
to those of BM-MSCs. Previously described derivation
methods involve coculturing with mouse OP9 cells and
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Figure 1. hES-MSCs Attenuate the Disease Score of MOG35-55/CFA-Immunized Mice
(A) Disease scores of MOG35-55/CFA-immunized mice treated with 10
6 hES-MSCs (CT2, H9, and MA09) or 106 parental hESCs at day 6
postimmunization. n = 5, ***p < 0.001 by Mann-Whitney. Error bar, SEM.
(B) Immunohistochemical detection of MBP (red) and CD3 for T cells (green) (a and b) and IBA1 for microglia (green) (c and d) on lumbar
spinal cord cross-sections from MOG35-55/CFA-immunized mice treated with either hES-MSC (a and c) or PBS (b and d). Scale bars, 250 mm
(a and b) and 120 mm (c and d).
(C) Relative fluorescent intensity measurements of MBP expression in digitally captured spinal cord hemi-sections. n = 4–6, **p < 0.02.
Error bar, SD. The regions shown are from the lumbar level of the spinal cord. Error bars indicate SD and the p value was determined using
two-tailed unpaired Student’s t test of the total fluorescence signal of each section.
(legend continued on next page)
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sorting, scraping, or handpicking of cells (Barberi et al.,
2005; Brown et al., 2009; Gruenloh et al., 2011; Hwang
et al., 2008; Olivier et al., 2006; Vodyanik et al., 2010),
which limits the efficiency and purity of the hES-MSCs,
as well as the ability to scale up their production. hES-
MSCs have been used in some disease models, such as
inflammatory bowel disease, lupus, and uveitis (Kimbrel
et al., 2014; Sa´nchez et al., 2011); however, no one has
shown whether hES-MSCs can be used to treat an EAE
model of MS or compared the immunosuppressive func-
tions of hES-MSCs and BM-MSCs. Here, using an improved
hemangioblast-enriching method (Lu et al., 2007), we
generated hES-MSCs from the MA09 ESC line (Kimbrel
et al., 2014) and multiple other hESC lines. We demon-
strate that these hES-MSC lines can effectively treat an
EAE model of MS and outperform multiple lines of BM-
MSCs in therapeutic activities.
RESULTS
hES-MSCs Attenuate EAE Disease in MOG35-55/CFA-
Immunized Mice when Administered either
Prophylactically or Therapeutically
In this study, we derived MSCs through a hemangioblast-
enriched, intermediate stage as described previously (Kim-
brel et al., 2014). We tested the reproducibility of this
method by generating independent MSC lines from four
different hESC lines: H9 (Thomson et al., 1998), CT2
(derived at UConn;Wang et al., 2009),MA09 (Klimanskaya
et al., 2006), and ES03-Envy (Envy, a GFP+ line derived at ES
International; Costa et al., 2005). These hES-MSC lines
expressed cell surface markers consistent with those of
adult human MSCs (Figure S1A available online) and
were capable of differentiating into osteocytes, adipocytes,
and chondrocytes (Figure S1B). We also confirmed that the
hES-MSCs were karyotypically normal for at least 12
passages (Figure S1C) and did not express telomerase
(Figure S1D).
We employed a standard EAE model of MS in which
C57BL/6 mice were immunized with an emulsion of
MOG35-55 peptide and complete Freund’s adjuvant (CFA)
to test the therapeutic utility of our hES-MSC lines. Six
days after immunization but prior to disease onset, mice
were injected with 13 106 hES-MSCs or PBS intraperitone-
ally (i.p.). hES-MSCs derived from three hESC lines (CT2,
MA09, and H9) all significantly attenuated the daily (Fig-
ure 1A), cumulative, and maximal disease scores (Fig-
ure S1E). H9 hES-MSCs also delayed the disease onset,
and MA09 hES-MSCs appeared to lower the disease inci-
dence (Figure S1E). However, mice injected with parental
hESCs (CT2)manifested high disease scores similar to those
of PBS controls (Figure 1A). To confirm the results, we
histologically analyzed microglial inflammatory activity
within the spinal cord. Immunostaining for ionized
calcium-binding adaptor molecule 1 (IBA1) revealed
inhibited development of microgliosis in MOG35-55/CFA-
immunized mice treated with hES-MSCs compared with
those treated with PBS (Figure 1B). Infiltration of CD3+
T cells into the spinal cord was decreased and the number
of interleukin-17 (IL-17)- and interferon g (IFNg)-express-
ing CD4+ Tcells in the CNS was also decreased by hES-MSC
treatment (Figures 1B, S1F, and S1G). Stronger immuno-
staining for myelin-binding protein (MBP) suggests that
demyelination was prevented in mice treated with hES-
MSCs (Figures 1B and 1C).
We also tested the effect of hES-MSC treatment on mice
that had already developed EAE (postonset). hES-MSCs
were injected on day 18 postimmunization, when all
mice had disease scores of 3. We observed a gradual decline
in disease scores from 3 down to an average score of 1.7 by
day 30 in hES-MSC-treated mice, whereas the PBS-treated
mice showed an average score of 2.8 by day 30 (Figure 1D).
Collectively, the data presented in Figure 1 show that hES-
MSCs can reproducibly decrease disease severity both
prophylactically and therapeutically in the mouse EAE
model.
Mitotically Arrested hES-MSCs Retain the EAE-
Inhibitory Effect
MSCs transplanted into animals may undergo malignant
transformation or support tumor growth formed by
host cells (Djouad et al., 2003; Wong, 2011). However,
since short-term cytokine secretion and cell-cell contact
may be sufficient to exert MSC functions (Uccelli and
Prockop, 2010), we hypothesized that mitotically arrested
MSCs may still execute a disease-modifying effect. To test
this, we irradiated hES-MSCs at 80 Gy immediately before
injecting cells into MOG35-55/CFA-immunized mice at
day 6 postimmunization. This irradiation regimen did
not significantly reduce the viability of hES-MSCs that
were replated and cultured for 48 hr in vitro (90% of
the cells were trypan-blue negative), but was sufficient
to completely attenuate cell proliferation as assessed by
(D) Disease scores of MOG35-55/CFA-immunized mice treated with 10
6 hES-MSCs 18 days postimmunization. n = 6, ***p < 0.001 by Mann-
Whitney. Error bar, SEM. At day 17 postimmunization, all mice with a disease score of 3 were pooled into a single group and then randomly
assigned to either the PBS-treatment group or the hES-MSC-treatment group. Mice that were immunized but did not show a disease score of
3 on day 17 were removed from the study.
See also Figure S1.
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bromodeoxyuridine (BrdU) incorporation during this same
time period (Figure 2A). Mice that received 23 106, but not
1 3 106, irradiated cells showed a similar reduction in EAE
disease severity asmice who received 13 106 nonirradiated
hES-MSC (Figures 2B and S2A). To determine the lifespan of
irradiated hES-MSC in vivo, we established a CT2 hESC
clone with constitutive expression of luciferase in the
hESCs and subsequent hES-MSCs (Figure S2B) by
Figure 2. Mitotically Arrested hES-MSCs Retain the EAE-Inhibitory Effect
(A) Nonirradiated or irradiated hES-MSCs (1 3 105) were cultured in vitro for 48 hr in the absence (gray line) or presence (black line) of
BrdU. The percentage of proliferating cells, as determined by flow-cytometry staining for BrdU+ cells, is indicated.
(B) Disease scores of MOG35-55/CFA-immunized mice treated at day 6 with PBS, 10
6 nonirradiated or 23 106 irradiated hES-MSCs (MA09);
n = 4, ***p < 0.001 by Mann-Whitney for comparison with the PBS control. Error bar, SEM. The table below shows a comparison of
cumulative disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease onset day.
(C) Nonirradiated (left) and irradiated (right) luciferase-expressing hES-MSCs (CT2) were tracked in MOG35-55/CFA-immunized mice by
in vivo bioluminescence imaging using the Xenogen IVIS 100 system.
See also Figure S2.
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transducing the cells with a lentiviral vector (Pomper et al.,
2009). Using these luciferase-expressing hES-MSCs, we
found that both irradiated and nonirradiated hES-MSCs
had roughly the same lifespan of at least 7 days in wild-
type mice as determined by whole-body bioluminescence
imaging (Figure 2C).
Teratoma formation is another concern for any cells
differentiated from pluripotent cells. To assess this risk,
we injected hES-MSCs into immunodeficient SCID-beige
mice at 1 3 106 cells/mouse, and found no tumor forma-
tion at the injection sites within 2 months, whereas tera-
tomas formed in mice injected with the same dose of
parental hESCs (data not shown).
hES-MSCs Have Stronger EAE-Inhibitory Effects than
BM-MSCs
Next, we compared hES-MSCs and BM-MSCs in the pro-
phylactic EAE model. We derived MSCs from six different
BM donors (four from frozen monocytes [MNCs] and two
from fresh BM) and obtained two BM-MSC lines at passage
1 from the Texas A&MMSC repository. We tested BM-MSC
lines anywhere from passage 2 to 4 and found that none of
them could consistently attenuate EAE disease scores of
MOG35-55/CFA-immunized mice, as shown in Figures 3A
(BM-MSC#1–3), 3B (BM-MSC#4), 6 (GFP-expressing BM-
MSC#5), and S3F (BM-MSC#7-8). Of note, one BM-MSC
line (BM-MSC#6, from Texas A&M) showed moderate but
significant disease-modifying effects (Figure 3C) at passage
2 relative to control PBS-treated mice (p < 0.001), but these
effects were gone at passage 4 (see Figure 5F). This is in
marked contrast to the four independent hES-MSC lines
that all showed a strong disease-inhibitory effect when
tested up to passage 5, as shown in Figures 1A (H9, CT2,
and MA09) and 6 (GFP-expressing Envy).
EAE/MS is accompanied by infiltration of reactive T cells
into the CNS (McFarland andMartin, 2007).We found that
hES-MSC-injected mice had significantly fewer CD4+ and
CD8+ T cell infiltrates in the CNS, including Th1 and
Th17 CD4+ subsets, than PBS-treated MOG35-55/CFA-
immunized mice (Figures 3D, S1F, and S1G), whereas
parental hESC line CT2-treatedmice had levels comparable
to those in controls (Figure S1F). In contrast, BM-MSC-
treated mice actually displayed significantly more CD4+
and slightly more CD8+ T cell infiltrates than PBS-treated
MOG35-55/CFA-immunized mice (Figure 3D, first two
panels). This included similar or greater Th1 numbers
and consistently greater Th17 numbers compared with
the controls (Figure 3D, last two panels). Reduced
FluoroMyelin staining of MBP in the spinal cord of both
PBS- and BM-MSC-treated mice suggests severe demyelin-
ation, whereas MBP levels were preserved in the spinal
cord of hES-MSC-treated mice (Figure 3E). The damaged re-
gions in BM-MSC-treated mice also show a high number of
DAPI-positive cells (Figure 3E), suggesting more inflamma-
tory cell infiltration. To determine whether the reduced
FluoroMyelin staining in the BM-MSC-treated mice was
due to reduced levels of myelin, loss of entire axons, or
inflammatory infiltrate blocking myelin staining, we per-
formed costaining for MBP and neurofilament (NF) on
day 32 lumbar spinal cord cross-sections. Quantification
of MBP-positive areas again revealed significantly lower
levels ofmyelination in BM-MSC-treatedmice as compared
with hES-MSC-treated ones, whereas NF staining revealed
similar numbers of axons in both groups (Figures S3A–S3E).
Considering the important role of regulatory T cells (Treg
cells detected as CD4+, Foxp3+, and CD25+) in suppressing
inflammation, we examined the ratio of Treg cells among
infiltrated CD4+ Tcells in the CNS, and found no difference
in hES-MSC-treated versus control MOG35-55/CFA-immu-
nized mice (Figure S3G). This is similar to a previous report
(Zappia et al., 2005). In vitro, both hES-MSCs and BM-
MSCs increased Treg cell proliferation in the presence of
IL-2, but there was no remarkable difference between the
two groups (Figure S3H). This suggests that enhanced Treg
cell proliferation is a common response to both hES-
MSCs and BM-MSCs, but is not necessarily a contributor
to their divergent effects in the in vivo EAE model.
Analyzing MSC Effects on T Cell Functions: hES-MSCs
Show Stronger Inhibition of Th1 Differentiation than
BM-MSCs
We next compared hES-MSCs and BM-MSCs for their
ability to inhibit T cell proliferation in vitro, using mixed
leukocyte reaction (MLR) assays. We incubated carboxy-
fluorescein succinimidyl ester (CFSE)-labeled mouse naive
T cells isolated from lymph nodes with increasing amounts
of BM-MSCs or hES-MSCs. Both types of MSCs inhibited
CD4+ and CD8+ T cell proliferation in response to a con-
stant amount of anti CD3/anti-CD28 stimulation to similar
degrees (Figure 4A). Likewise, BM-MSCs and hES-MSCs
similarly inhibited human peripheral blood mononucle-
ated cell (PBMC) proliferation induced in response to
phytohemagglutinin (PHA) over a range of PBMC/MSC
ratios (Figure 4B). Together, these data suggest that BM-
MSCs and hES-MSCs display similar inhibitory effects on
T cell proliferation in vitro.
Since MOG35-55/CFA-immunized mice treated with BM-
MSCs had more Th1 and Th17 cell infiltration in the CNS
thanmice treated with hES-MSC (Figure 3D), we examined
these T cell subtypes in vitro in the presence or absence of
hES-MSCs and BM-MSCs. Under the Th1 condition, differ-
entiation of naive CD4+ Tcells into Th1 (CD4+/IFNg+) cells
was reduced by hES-MSCs, but was unaffected or even
enhanced by different BM-MSC lines (Figure 4C, upper
panels). Interestingly, even the BM-MSC line (BM-
MSC#6) that gave a modest but significant therapeutic
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Figure 3. hES-MSCs Have a Stronger EAE-Inhibitory Effect In Vivo than BM-MSCs
(A–C) Disease scores of MOG35-55/CFA-immunized mice treated with PBS, 10
6 BM-MSCs, or 106 hES-MSCs (MA09) at day 6. n = 4–5 per group,
***p < 0.001 by Mann-Whitney for comparison with the PBS control. Error bar, SEM. The table below shows a comparison of cumulative
disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease onset day.
(D) Total numbers of CD4+, CD8+, Th1, and Th17 cells in the CNS of MOG35-55/CFA-immunized mice treated with PBS, BM-MSCs, or hES-MSCs
on day 32 postimmunization. Lymphocytes purified from the CNS were analyzed via flow cytometry for numbers of CD4+ and CD8+ cells
(left two panels) or IL-17+ and IFNg+ cells (intracellular stained) poststimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA)
and ionomycin (right two panels). n = 4, *p < 0.05, **p < 0.01. Error bar, SD; p values were determined using two-tailed unpaired Student’s
t test.
(legend continued on next page)
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response in the prophylactic EAE model could not effec-
tively reduce Th1 differentiation in this in vitro assay
(Figure 4C, upper last panel). Under the Th17 differentia-
tion condition, both hES-MSCs and BM-MSCs reduced
the differentiation of Th17 (CD4+/IL17+) cells (Figure 4C,
lower panels). However, under the same Th17-inducing
conditions, BM-MSCs, but not hES-MSCs, significantly
increased the percentage of IFNg+/IL17 (i.e., Th1) cells
(Figure 4C, lower panels). Collectively, these results show
that hES-MSCs effectively dampen differentiation of both
Th1 and Th17 in vitro, and, surprisingly, BM-MSCs
promote Th1 differentiation under a Th17-inducing
environment.
BM-MSCs Express Higher Levels of IL-6 than hES-MSC,
and IL-6 Blockage Enhances the Disease-Modifying
Effects of BM-MSCs in the EAE Model
Many factors have been reported to mediate the immuno-
modulatory and/or neuroprotective effects of MSCs
(Uccelli and Prockop, 2010). We conducted a microarray
analysis to identify differences in the expression of these
factors between BM-MSCs and hES-MSCs. The overall
expression profiles of the hES- and BM-MSC samples were
similar (data not shown); however, a small set of genes
was expressed differentially. Among these, IL6 appeared
to be much more highly expressed in BM-MSCs than in
hES-MSCs. Multiple methods, including quantitative RT-
PCR (qRT-PCR; Figure 5A), intracellular flow cytometry
(Figure 5B), and cytokine antibody arrays (Figure 5C),
confirmed this finding.
Upon IFNg stimulation, the percentage of IL-6-express-
ing hES-MSCs did not change; however, the percentage of
IL-6-expressing BM-MSC nearly doubled (Figure 5D). We
also tested MSC production of IL-6 following coculture
with stimulated PBMC/T cells, as the latter produce high
levels of IFNg and TNF-a upon stimulation. IL-6 mRNA
expression levels increased for both BM-MSCs and hES-
MSCs after coculture, yet the levels in BM-MSC were still
R10 times higher than in hES-MSCs (Figure S4A). This
large difference in IL-6 secretion was a rather unique obser-
vation because the expression levels of other secreted cyto-
kines did not differ dramatically between the two cell types
(data not shown).
Since IL-6 has been found to enhance T cell differentia-
tion (Dienz and Rincon, 2009), we sought to determine
the effects of MSC-secreted human IL-6 on mouse T cell
differentiation. First, we confirmed that human IL-6 works
just as well asmouse IL-6 at an equivalent dose for directing
mouse Th17 differentiation (Figure S4B). Next, under Th0
conditions (i.e., without any mouse cytokines), we found
that an anti-human-IL-6 neutralizing antibody with no
mouse cross-reactivity (clone MQ2-13A5) reduced the
Th1-promoting effects of BM-MSCs on mouse T cells
by 23%–50% (Figure 5E). Lastly, we observed that
MOG35-55/CFA-immunized mice treated with human BM-
MSCs plus the same anti-hIL-6 antibody showed a sig-
nificant reduction in EAE disease severity relative to the
control group (Figure 5F). This effect was specific for IL-6
produced by the BM-MSCs, as IL-6 antibody alone (no
MSCs) or BM-MSCs plus isotype control antibody failed
to reduce the EAE disease score significantly. These data
suggest that high IL-6 expression by human BM-MSCs
contributes to the inability of these cells to modulate EAE
disease severity.
Both hES-MSCs and BM-MSCs Home to the Spinal
Cord, but Only hES-MSCs Successfully Extravasate
into Inflamed Tissue
To determine whether hES- and BM-MSCs home to the
injured CNS, we used the constitutively GFP-expressing
hESC line ‘‘Envy’’ and GFP-labeled human BM-MSCs (Hof-
stetter et al., 2002) in MOG35-55/CFA-immunized mice.
Cells were injected on day 6 after immunization and spinal
cords were analyzed 8 days later (day 14 postimmuniza-
tion), a time point when disease scores for the GFP+ BM-
MSC-injected mice and PBS controls were 1.5–2.0, and
scores for the GFP+ hES-MSC were effectively 0 (Figure 6A).
Both BM-MSCs and hES-MSCs homed to the spinal cord in
mice subjected to EAE (Figure 6B), yet the vascular associa-
tion patterns of the two types of MSCwere vastly different.
At day 14, GFP+ hES-MSCs were immunolocalized in the
parenchyma adjacent to spinal cord venules, indicating
the ability of these cells to penetrate and move beyond
the vasculature to enter the parenchyma (Figure 6B, top
row). In marked contrast, GFP+ BM-MSCs appeared to
remain closely associated with the parenchymal vessels,
seemingly trapped inside the microvascular lumen and/or
confined to the perivascular space, and incapable of
breaching the bipartite complex of endothelial and paren-
chymal basement membranes (Owens et al., 2008; Paul
et al., 2014) to enter the CNS tissue (Figure 6B, second
row). This apparent retarded migration of BM-MSCs per-
sisted even at day 18, when the disease is more severe
and both tight junctions and the basement membrane
complex of the BBB have been shown to be grossly disrup-
ted (Figure 6B, third row) (Paul et al., 2013, 2014). No GFP
(E) Qualitative analysis of myelin content in spinal cord cross-sections of MOG35-55/CFA-immunized mice treated with PBS, BM-MSCs, or
hES-MSCs using FluoroMyelin staining (green) and counterstained with DAPI (blue) for infiltration of nucleated cells. Scale bar, 350 mm.
The regions shown are from the lumbar level of the spinal cord.
See also Figure S3.
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Figure 4. Effects of hES-MSCs and BM-MSCs on T Cell Functions In Vitro
(A) hES-MSCs (MA09) or hBM-MSC#7 were cocultured with 1 3 105 CFSE-labeled mouse lymphocytes stimulated with anti-CD3/CD28 at
various MSC/lymphocyte ratios. After 3 days, the proportion of proliferating CD4+ (left panel) or CD8+ (right panel) T cells was measured by
CFSE dilution using flow cytometry. The percent inhibition of T cell proliferation is relative to T lymphocytes stimulated in the absence of
MSCs. Lymphocytes from three individual mice were tested and results are average ± SD.
(B) Mitotically inactivated hES-MSCs (MA09) or BM-MSCs were incubated with CFSE-labeled human PBMC at the indicated ratios
and stimulated with 2.5 ng/ml PHA. Bars represent the average of three different BM-MSC lines and two independent hES-MSC (MA09)
clones ± SD.
(C) hES-MSCs (MA09) or BM-MSCs were incubated with mouse naive CD4+ T cells at a ratio of 1:10, followed by Th1 or Th17 differentiation
for 5 days. IFNg+ and IL-17+ CD4+ T cells were detected via intracellular flow cytometry staining after TPA/ionomycin stimulation. Data
represent four independent experiments.
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signals could be detected in control mice receiving PBS
injection alone (Figure 6B, bottom row). Movies S1 and
S2, whichweremade from confocal z-stack reconstructions
of the data sets in Figure 6B, provide a magnified 3D
perspective of hES-MSC and BM-MSC distributions, respec-
tively. Figure 6C shows a schematic detailing the regions of
spinal cord selected for analysis in Figure 6B.
DISCUSSION
In this study, we have shown that multiple hES-MSC lines
significantly attenuated disease scores in a mouse EAE
model of MS. In stark contrast, only one out of eight
independently derived human BM-MSC lines displayed a
marginal effect in the prophylactic-treatment EAE model.
Our analysis of IL-6 expression and migration of the
MSCs suggests that the superior disease-altering effects of
hES-MSCs may be related in part to the lower expression
of IL-6 and the greater ability of hES-MSCs to extravasate
the BBB/BSCB and migrate into inflamed CNS tissue rela-
tive to BM-MSCs.
In examining the effects of hES-MSCs on EAE induction,
we observed that preonset treatment of MOG35-55/CFA-
immunized mice was more effective in attenuating disease
scores than postonset treatment. This is not surprising,
since preonset treatment begins before the development
of severe demyelination, axonal damage, or inflammatory
cell infiltration. Costaining for MBP and NF in day 32
lumbar spine sections of treated animals showed that
hES-MSC treatment protected against demyelination
without affecting the number of surviving axons. These
results do not rule out the possibility that hES-MSCs may
also contribute to remyelination of axons that have already
lost their myelin. This remains to be elucidated by further
investigations examining whether and how hES-MSCs
may contribute to neural regeneration. Future studies in
the postonsetmodel will also be needed to address whether
larger doses and/or repeated injections of cells could
enhance the therapeutic effects. Of note, irradiated hES-
MSCs were also effective in reducing the EAE disease score
and had the same lifespan in vivo as their nonirradiated
counterparts. Thus, irradiation of cells may provide an
important clinical benefit by reducing concerns about the
tumorigenic potential of MSCs.
Themuted in vivo efficacy of BM-MSCs that we observed
is consistent with previous reports that showed only mild
(Gordon et al., 2008; Zhang et al., 2005) or negligible
(Payne et al., 2013) effects in the EAE mouse model. Inter-
estingly, BM-MSC#6, the BM-MSC line that caused a
modest reduction in EAE disease scores in the preonset
model at passage 2 (Figure 3C), failed to show any thera-
peutic effects when used at passage 4 during the anti-iL-6
antibody experiment (Figure 5F). On the other hand,
hES-MSCs consistently resulted in large reductions in the
disease score of MOG35-55/CFA-immunized mice when
used frompassage 2 to 5. This indicates that the therapeutic
capacity of BM-MSCs may be more vulnerable to extended
in vitro culture than that of hES-MSCs.
It has been reported that BM-MSCs derived from frozen
MNCs have less immunosuppressive effects than those
derived from fresh MNCs (Samuelsson et al., 2009). We
derived different BM-MSC lines from both frozen MNCs
and fresh (never frozen) whole BM. Both types had
similarly negligible effects in the EAE model when admin-
istered prophylactically (Figures 3A, 3B, and S3F). One BM-
MSC line (#8), derived from fresh BM, did show a modest
efficacy in the EAE model when administered postonset
(Figure S3I), but this effect was not as great as that of hES-
MSCs (Figure 1D). These data suggest that variability
among human BM-MSC lines derived from different do-
nors could influence the efficacy of these cells, whereas
hES-MSC lines consistently exhibit a greater EAE-inhibi-
tory effect than human BM-MSC lines.
In this study, we found that IL-6 was much more highly
expressed in BM-MSCs than in hES-MSCs in both the basal
and IFNg-stimulated states. Elevated IL-6 levels have been
found in blood and brain tissue fromMSpatients (Patanella
et al., 2010), and site-specific production of IL-6 in the CNS
can enhance inflammation in EAE (Quintana et al., 2009).
Mice lacking IL-6 receptor a are resistant to EAE (Leech
et al., 2013), and an IL-6-neutralizing antibody can reduce
symptoms in EAE mice (Gijbels et al., 1995). Thus, higher
levels of human IL-6 secretion by BM-MSCs relative to
hES-MSCs may contribute to functional differences in the
treatment of EAE. This idea is supported by our data
showing that blocking human IL-6 with a neutralizing
antibody partially rescues the disease-modifying effects of
BM-MSC in the EAE model (Figure 5F). It is important to
note that the anti-hIL-6 antibody in this study does not
inhibit the endogenous mouse IL-6. This suggests that
human IL-6 produced by the BM-MSCs may act in an auto-
crine or paracrine manner on the BM-MSCs themselves
and/or on surrounding cells, with the net effect of limiting
BM-MSC therapeutic activity in EAE.
Recent reports have noted that MSCs can actually
promote the differentiation of proinflammatory T cells in
certain permissive environments (Carrio´n et al., 2011;
Darlington et al., 2010). Consistently, in vivo and in
comparison with PBS controls, we observed reduced CNS
infiltration of Th1 and Th17 cells with hES-MSC treatment,
but increased CNS infiltration of Th1 and Th17 cells with
BM-MSC treatment. In vitro and in contrast to hES-MSCs,
we found that BM-MSCs skewed T cell differentiation to a
Th1 phenotype under both Th0 (nonpolarizing) and
Th17 conditions. It is possible that certain factors that are
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highly produced by human BM-MSCs, but not hES-MSCs,
can trigger Th1 differentiation, thus overriding Th17 differ-
entiation under defined in vitro conditions (Lazarevic
et al., 2011). An anti-human IL-6 antibody was able to
partially reverse the effect under Th0 conditions (Figure5E),
but not Th17 conditions (data not shown), presumably
because the presence of abundant exogenous mouse IL-6,
which was added for Th17 induction, could not be neutral-
ized by the anti-human IL-6 antibody. Together, these
results suggest that high IL-6 secretion by BM-MSCs may
impact the local cytokine milieu and augment the overall
inflammatory response, resulting in a striking difference
in Th1/Th17 CNS infiltration between hES-MSC- and
BM-MSC-treated mice.
Lastly, we observed that both GFP-labeled hES-MSCs and
BM-MSCs homed to the CNS microvasculature, but only
hES-MSCs that showed a high therapeutic potential had
the capacity to effectively extravasate and migrate into
the parenchyma. This raises the possibility that therapeutic
efficacy and MSC extravasation are somehow mechanisti-
cally linked. Such a therapeutic requirement for MSCs to
extravasate during EAE is consistent with evidence that
these cells can downregulate proinflammatory effector
functions of parenchymal microglia (Figure 1B; Lee et al.,
2012; Sheikh et al., 2011). The lack of penetration into
the CNS tissue by BM-MSCs was further remarkable in
that it persisted through late disease, a time when severe
BBB disruption has been shown to occur (Paul et al.,
2013, 2014). Since such a compromised BBB might be ex-
pected to facilitate cellular entry during EAE (Lanz et al.,
2013), this suggests that hES-MSCsmight uniquely express
specific transendothelial migratory signals or properties.
BM-MSCs, in turn, might lack one or more of the minimal
requirements for effective migration across even a structur-
ally attenuated CNS microvascular endothelium and/or
surrounding basementmembrane complex. It is significant
that in vitro culture and expansion of MSCs have both
been implicated as factors that impair homing and transen-
dothelial migration (De Becker et al., 2007; Rombouts and
Ploemacher, 2003). A priori, BM-MSCs could be more sen-
sitive to these factors than hES-MSCs, which could at least
partially explain the differences in therapeutic efficacy
observed between the twoMSC types. Determining the dy-
namic changes and differences in expression of adhesion
molecules, chemokines/chemokine receptors, and matrix
metalloproteinase between hES-MSCs and BM-MSCs
in situ will be critical for delineating the molecular require-
ments for MSC extravasation and efficacy (De Becker et al.,
2007; Teo et al., 2012). In situ gene-expression profiling of
both MSC types is currently under investigation and
should shed further light on the mechanism(s) responsible
for the unique therapeutic efficacy of hES-MSCs in EAE.
EXPERIMENTAL PROCEDURES
Culture of hESCs and Generation of hES-MSCs
hESC lineswere cultured either onMatrigel in TeSR1mediumor on
mouse embryonic fibroblasts in Dulbecco’s modified Eagle’s
medium/F12 + 20% knockout serum replacement + 10 ng/ml basic
fibroblast growth factor. hES-MSCs were generated as described
previously (Kimbrel et al., 2014). Only hES-MSCs at %5 passages
were used throughout the study. The use of hESCs in this study
was approved by the Stem Cell Research Oversight Committee of
the University of Connecticut (#2012-005).
Figure 5. BM-MSCs Express Higher Levels of IL-6 than hES-MSCs, and a Neutralizing IL-6 Antibody Reduces the Influence of BM-
MSCs on T Cells and Disease Scores
(A) qRT-PCR for IL-6 in BM-MSCs versus hES-MSCs. Bars represent the average of three independent experiments ± SD. *p < 0.05 (the
p value was determined using two-tailed unpaired Student’s t test).
(B) Intracellular flow cytometry showing the percentage of IL-6-expressing cells (black line) and isotype control (gray line) among BM-
MSC from three different donors and hES-MSCs from three hESC lines (MA09, CT2, and H9).
(C) Cytokine antibody arrays showing the level of IL-6 and IL-8 proteins in conditioned medium from hES-MSC or BM-MSC cultures.
Cytokine antibodies and controls are spotted in duplicate and labeled next to the corresponding spots. Images are representative of at
least five independent experiments.
(D) Intracellular flow cytometry showing the percentage of IL-6-expressing cells (black line) and isotype control (gray line) among hES-
MSCs or BM-MSCs treated ± 10 ng/ml IFNg for 12 hr. NC, negative control.
(E) Intracellular flow cytometry measuring the percentage of CD4+ and IFNg+ mouse T cells arising from naive T cells after coculture with
hES-MSC (MA09) or BM-MSCs from three different donors under Th0 conditions. The MSC/T cell ratio was 1:10. IgGk isotype control (upper
panels) or anti-human IL-6 neutralizing antibody (clone MQ2-13A5) was added to determine the effect of blocking IL-6 on BM-MSC-
induced production of IFNg from T cells (i.e., Th1 differentiation) (lower panels).
(F) Mean disease scores of mice immunized with MOG35-55 and treated with PBS or 1 3 10
6 human BM-MSC on day 6. Anti-human IL-6
neutralizing antibody (clone MQ2-13A5, 12.5 mg/kg/day), IgGk isotype control antibody (12.5 mg/kg/day) or PBS was administered i.v.
on days 6 and 7. ***p < 0.001 by Mann-Whitney for BM-MSC#6+anti-iL-6 versus PBS control (n = 5 per group). Error bar, SEM. The table on
the right shows a comparison of cumulative disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease
onset day.
See also Figure S4.
Stem Cell Reports j Vol. 3 j 115–130 j July 8, 2014 j ª2014 The Authors 125
Stem Cell Reports
Therapeutic Efficacy of hES-MSC in an EAE Model
(legend on next page)
126 Stem Cell Reports j Vol. 3 j 115–130 j July 8, 2014 j ª2014 The Authors
Stem Cell Reports
Therapeutic Efficacy of hES-MSC in an EAE Model
Animal Model of MS
The mouse EAE model was induced as previously described
(Stromnes and Goverman, 2006). In brief, C57BL/6mice were sub-
cutaneously injected with an emulsion of MOG35-55 peptide, CFA,
and pertussis toxin contained in the EAE induction kit fromHooke
Laboratories (Cat. No. EK-0114). BM-MSCs or hES-MSCs at 13 106
cells/mouse or PBS (a vehicle control) were i.p. injected on day 6
(for preonset) or 18 (for postonset) after the immunization. Disease
scorewasmonitored every day for up to 31 ormore days as follows:
0, no sign of disease; 1, loss of tone in the tail; 2, partial hind limb
paralysis; 3, complete hind limb paralysis; 4, front limb paralysis;
and 5, moribund (Stromnes and Goverman, 2006). For some
experiments, cumulative and maximal disease scores were also
calculated, and disease incidence and disease onset day were re-
corded. Injection and scoring were performed double-blinded in
Figure S3F. All animal studies were approved by and performed
in accordance with policies of the Institutional Animal Care and
Use Committee of the University of Connecticut Health Center.
Tracking of GFP+ MSCs in Perivascular Regions in
the CNS
Spinal cord tissue was prepared as described previously (Paul et al.,
2013). In brief, after perfusion/fixation, spinal cords were har-
vested by laminectomy and cryosectioned for immunostaining.
Anti-GFP-Alexa 488, anti-CD31 (BD Bioscience), and Alexa 555
secondary antibody (Life Technologies) were used to detect GFP+
and endothelial cells, and DRAQ5 (Biostatus) was used to visualize
the nuclei. Sections were then mounted in Mowiol and confocal
z-stacks were acquired at 1 mm increments between z slices,
following a multitrack scan, using a Zeiss LSM 510 Meta confocal
microscope. Images were analyzed with Imaris suite version 7.1
software (Bitplane). The GFP channel was isosurface rendered to
provide better spatial perspective for visualizing GFP+ cells.
Statistical Analysis
The EAE clinical disease scores for each group were graphed as the
mean ± SEM for each day of the study. Differences in EAE disease
scores between groups were analyzed using the nonparametric
Mann-Whitney unpaired U test, and individual time-point differ-
ences were analyzed using two-way ANOVA with Bonferroni’s
posttest. Percentage data for CNS-infiltrated T cells were arcsine
transformed prior to analysis. EXCEL and Prism 6.0 (GraphPad)
software was used for statistical analysis, and p < 0.05 was consid-
ered to be statistically significant (*p < 0.05, **p < 0.01, ***p <
0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and two movies and can be found
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of CCL2 in mice subjected to experimental autoimmune 
encephalomyelitis also significantly diminished the accu-
mulation of CD8+ T cells compared to wild-type animals. 
Collectively, these results highlight a novel (patho)physi-
ological role for P-glycoprotein in CD8+ T cell trafficking 
into the central nervous system during neuro-inflammation 
and illustrate CCL2 secretion as a potential link in this 
mechanism.
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Transendothelial migration · CD8+ T cells · Neuro-
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Abstract The trafficking of cytotoxic CD8+ T lympho-
cytes across the lining of the cerebral vasculature is key to 
the onset of the chronic neuro-inflammatory disorder mul-
tiple sclerosis. However, the mechanisms controlling their 
final transmigration across the brain endothelium remain 
unknown. Here, we describe that CD8+ T lymphocyte 
trafficking into the brain is dependent on the activity of 
the brain endothelial adenosine triphosphate-binding cas-
sette transporter P-glycoprotein. Silencing P-glycoprotein 
activity selectively reduced the trafficking of CD8+ T cells 
across the brain endothelium in vitro as well as in vivo. In 
response to formation of the T cell–endothelial synapse, 
P-glycoprotein was found to regulate secretion of endothe-
lial (C–C motif) ligand 2 (CCL2), a chemokine that medi-
ates CD8+ T cell migration in vitro. Notably, CCL2 levels 
were significantly enhanced in microvessels isolated from 
human multiple sclerosis lesions in comparison with non-
neurological controls. Endothelial cell-specific elimination 
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Introduction
Leukocyte migration across the endothelium of the brain 
vasculature plays a key role in the onset of the chronic 
inflammatory disorder multiple sclerosis. Upon the forma-
tion of perivascular infiltrates, clinical symptoms arise lead-
ing to severe neurological deficits. Autoreactive T lympho-
cytes play a critical role in the disease process [12], both in 
multiple sclerosis as well as its animal model experimental 
autoimmune encephalomyelitis (EAE) [15]. CD4+ T cells 
are thought to be essential for the initiation and progres-
sion of the disease, whereas CD8+ T cells, which clonally 
expand within the inflamed CNS, are believed to play a key 
role in the progression of multiple sclerosis [42].
While the molecular interactions that underlie the migra-
tion of CD4+ T cells across the brain endothelium are well-
defined, the mechanisms regulating CD8+ T cells entry into 
the central nervous system remain poorly described. In gen-
eral, the sequential steps in the diapedesis of lymphocytes 
include tethering, rolling, capture, firm adhesion and finally 
migration across the endothelial layer [38]. The continuous 
cross-talk between immune cells and brain endothelium is 
an essential element in mediating immune cell migration 
into the central nervous system parenchyma [14]. Endothe-
lial cells actively participate in this process by expressing 
adhesion molecules and producing chemokines [2, 10]. 
Upon the adhesion of lymphocytes, endothelial cells form 
ring-like membrane structures, so-called migratory cups, 
which stabilize the leukocytes onto the endothelial cell 
surface [3] and facilitate their migration. Although great 
progress has been made in the identification of the molecu-
lar interactions that mediate leukocyte transmigration [25, 
31], it is becoming increasingly clear that in order to final-
ize this process, T lymphocytes require additional activa-
tion through chemokines presented on or present within the 
endothelium [35]. However, the precise mechanism that 
underlies this signaling of the endothelium to the adhered T 
cell remains to be elucidated.
We here provide evidence that the brain endothelial 
ATP-binding cassette transporter P-glycoprotein is critical 
for the release of brain endothelial chemokines, thereby 
providing a means to control the migration of CD8+ T cells 
in particular. ATP-binding cassette transporters are highly 
expressed at the cerebral endothelium, where they actively 
remove toxic compounds from the brain at the cost of ATP 
hydrolysis [26]. Although P-glycoprotein was originally 
described as a prototypic transporter that mediates multi-
drug resistance of tumor cells [17], most recent work sug-
gests that P-glycoprotein may additionally mediate immune 
responses possibly through its capacity to mediate secretion 
of cytokines, chemokines and bioactive lipids [18–21, 39].
Here, we show that silencing of P-glycoprotein activity 
in brain endothelial cells selectively impairs the adhesion 
of CD8+ T cells to intercellular adhesion molecule-1 as 
well as their transendothelial migration through the secre-
tion of endothelial (C–C motif) ligand 2 (CCL2), a criti-
cal agent for CD8+ T cell migration. Notably, characteri-
zation of human brain microvessels freshly isolated from 
post-mortem tissue of multiple sclerosis patients revealed 
high levels of CCL2 transcripts, reinforcing a role for 
endothelial-derived CCL2 in human neuro-inflammatory 
disease. Finally, we were able to show that endothelial tar-
geted CCL2 conditional knockout mice that were subjected 
to EAE contained significantly reduced levels of infiltrated 
CD8+ T cells, highlighting the importance of secreted 
CCL2 in regulating CD8+ T lymphocytes entry into the 
brain under pathological conditions.
Materials and methods
Cell isolation and culture
The immortalized human brain endothelial cell line 
hCMEC/D3, which establishes the key features of brain 
endothelium, was cultured as described [43]. Human CD4+ 
and CD8+ T cells were purified from peripheral blood 
mononuclear cells using MACS® magnetic cell sorting kit 
(Miltenyi Biotec) according to manufacturer’s instructions. 
CD4+ and CD8+ T cell purity was >96 % as assessed by 
flow cytometry performed (FACSCalibur™) using CELL-
QuestTM software (BD Biosciences). Isolated T cells were 
cultured for 48 h before experiments. Effector T cells were 
generated by adding IL-2 (10 ng/ml) and phytohemaggluti-
nin (1 µg/ml) during 48 h.
Docking structure imaging
hCMEC/D3 cells were cultured in µSlide VI coated with 
collagen (Ibidi GmbH) to confluence. CD4+ or CD8+ T 
cells were labeled with a fluorescent membrane dye PKH26 
(Sigma-Aldrich) according to manufacturer’s instructions 
and added to the endothelial slides for 30 min. Non-adher-
ent cells were removed and slides were fixed with 4 % par-
aformaldehyde in phosphate buffered saline for 15 min and 
blocked with 5 % normal donkey serum in phosphate buff-
ered saline with 0.3 % Triton X-100 for 15 min. Cells were 
incubated with anti ICAM-1 (Santa Cruz) and anti-P-gly-
coprotein (15D3, BD Biosciences) antibodies (Electronic 
Supplementary Material 1) and relevant secondary anti-
bodies were used. After each step, the slides were washed 
three times with phosphate buffered saline. Coverslips 
were mounted with Vectashield (Vector Labs) or Mowiol 
488 reagent (Calbiochem) on microscope slides. Imaging 
was performed using a confocal laser scanning microscope 
(Leica TCS SP2).
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Silencing P-glycoprotein and qRT-PCR
Plasmids encoding specific P-glycoprotein shRNA or non-
targeting control shRNA (NTC-shRNA) were purchased 
from Sigma. Messenger RNA was isolated from hCMEC/
D3 cells using an mRNA capture kit (Roche). cDNA was 
synthesized with the Reverse Transcription System kit 
(Promega) and real-time PCR was performed as described 
previously [19]. All primer sequences are listed in Elec-
tronic Supplementary Material 2 and expression levels of 
transcripts obtained with qRT-PCR were normalized to 
GAPDH expression levels.
Flow adhesion and migration assays
NTC-shRNA or P-glycoprotein shRNA-transduced 
hCMEC/D3 cells were cultured to confluence in collagen-
coated µSlide VI flow chambers (Ibidi GmbH). Cells were 
treated with 5 ng/ml TNF-α (Preprotech) for 24 h. Cells 
were mounted onto the microscope stage using a POC-mini 
chamber system (LaCon) and connected to a perfusion 
pump. Using physiological flow conditions (flow speed 
was 500 µl/min, correlating to 0.8 dyne/cm2), 5 × 105 T 
cells/ml were perfused over the endothelial cells, followed 
by 20 min of fluid-flow. Transendothelial migration was 
characterized by the change in appearance of T cells from 
bright to dim. Migrated cells were quantified by counting 
per field-of-view. From one experiment, five fields were 
analyzed. Movies were generated using VirtualDub.
ICAM-1 binding assay
ICAM-1 binding assays were performed as described pre-
viously [4] and fluorescence was quantified using a cyto-
fluorometer (Bio-Rad). Results are expressed as the mean 
percentage of adhesion of triplicate wells.
Electron microscopy
hCMEC/D3 cells were grown to confluence on fibronec-
tin-coated Thermanox slides (Nunc) and fixed with 1 % 
paraformaldehyde overnight, then embedded in gelatine, 
infiltrated with sucrose and frozen in liquid nitrogen as 
described [36]. Ultra-thin sections (60–70 nm) were pre-
pared using a cryotome (UC6; Leica) and labeled with an 
anti-P-glycoprotein antibody (C219, Alexis) in 1 % bovine 
serum albumin (Aurion) in phosphate buffered saline 
for 1 h. Visualization was performed with Protein A gold 
10 nm (UMC). Sections were post-stained with uranyl 
acetate and uranyl oxalate. The sections were examined at 
80 keV using a Technai 12 EM (FEI Co), equipped with a 
side-mounted Megaview II camera (SIS). The specificity of 
the electron microscopy was controlled by using an isotype 
control as well as leaving out the primary antibody, which 
in both cases did not show any gold grains.
Isolation of microvessels from control or multiple sclerosis 
brains
Brain tissue (eight non-neurological controls and eight 
multiple sclerosis patients) was obtained from The Nether-
lands Brain Bank from donors with written consent. Brain 
microvessels were isolated from non-neurological patient 
tissue, normal-appearing white matter (NAWM) and mul-
tiple sclerosis lesions from post-mortem multiple sclero-
sis patients and validated by qRT-PCR as described before 
[34].
EAE induction in mice
Female mice with CCL2-deficient endothelial cells were 
developed as described previously [13] and together with 
their littermate controls (C57BL/6 background) were used 
at the age of 8–10 weeks. All mice were kept under specific 
pathogen-free conditions and used in accordance with local 
animal experimentation guidelines. EAE was induced in 
C57BL/6 mice as described previously [22].
Histology and immunohistochemistry
Brains of the killed animals were dissected, snap-frozen 
in liquid nitrogen, and stored at −80 °C. For immunohis-
tochemistry, cryosections were fixed in ice-cold acetone 
for 10 min and blocked with normal mouse serum prior to 
antibody staining. Immunofluorescence staining was per-
formed in phosphate buffered saline, supplemented with 
0.1 % bovine serum albumin as previously described [18], 
and antibodies are described in Electronic Supplementary 
Material 1. Immunofluorescent sections were enclosed in 
Vinol (Air Products) supplemented with DAPI (Invitrogen) 
and analyzed on a Leica DM6000 fluorescence microscope 
(Leica Microsystems), equipped with LAS AF (Leica) 
software.
3-D rendering of extravasating CD8+ T cells during EAE
Tissue processing was performed as described recently 
[32]. In brief, at day 16 of EAE, spinal cords were har-
vested and cryoprotected in 30 % sucrose overnight prior 
to cryomatrix embedding. Serial cryosections of 60 µm 
thickness were obtained from the thoraco-lumbar spi-
nal cord, and incubated with rabbit anti-mouse Laminin 
1 (CLPR245679; Cedarlane) antibody to highlight the 
microvascular basement membrane and with CD8β-FITC 
antibody for CD8+ T cells. DRAQ5 (DR51000; Biostatus 
Ltd.) was utilized for nuclear staining. For visualization of 
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the CD8+ T cells in inflamed venules, confocal z-stacks 
were acquired as described [32] and imported into Bitplane 
IMARIS suite version 7.1x 64 software (Bitplane Inc.) and 
a volume-rendered image was obtained in maximum-inten-
sity projection mode. Individual color channels in the vol-
ume-rendered image were subjected to iso-surface render-
ing to enhance visualization of spatial architecture around 
venules and relative localization of the CD8+ T cells.
Relative quantification of immunohistochemistry  
and 3-D rendering
Volume-rendered images were fed into ImageJ software 
(NIH) and a microvascular contour was created manually 
by cursoring out the inflamed venules of interest. Respec-
tive areas representing the microvessel segment (# of pixels 
occupied by the microvessel) and associated CD8+ T cell 
population (# of green pixels) were determined and the per-
centage vessel area occupied by CD8+ T cell aggregates 
calculated as follows: (# of green pixels)/(# of pixels occu-
pied by the microvessel) × 100. For immunohistochemis-
try, a similar approach (using ImageJ) was applied on mul-
tiple EAE lesions from 4 WT and 4 mdr1a/1b−/− animals 
by separating the green (CD4+ or CD8+ T cells) from the 
blue (CD45+ cells) channel. These images were also sub-
jected to intensity-threshold adjustment and the percentage 
of CD45+CD4+ or CD45+CD8+ cells was determined.
Statistical analysis
All data were analyzed statistically by means of analysis of 
variance (ANOVA) and Student’s t test. Statistical signifi-
cance was defined as *p < 0.05, **p < 0.01, ***p < 0.001.
Results
P-glycoprotein regulates CD8+ T cell migration across an 
in vitro model of the blood–brain barrier
To determine the potential role for P-glycoprotein in the 
transendothelial migration of CD4+ and CD8+ T cells under 
flow conditions, we generated human brain endothelial cells 
that lack P-glycoprotein activity using a lentiviral approach, 
resulting in over 80 % reduction of P-glycoprotein expres-
sion (Electronic Supplementary Material 3a) and function 
(Electronic Supplementary Material 3b) compared to non-
targeting control (NTC) shRNA-transfected cells. Silencing 
P-glycoprotein activity significantly reduced transendothe-
lial migration (Fig. 1a) and adhesion (Fig. 1b) of both T cell 
subsets across inflamed (TNF-α-stimulated) brain endothe-
lium (Fig. 1a–c). The percentage of CD8+ T cell that adhere 
to the endothelial cells and subsequently migrate was signif-
icantly impaired up to 50 % under P-glycoprotein-silenced 
conditions (Fig. 1c), whereas the migration capacity of 
CD4+ T cells after firm adhesion was independent of P-gly-
coprotein function (Fig. 1c). Upon adhesion, CD8+ T cells 
appeared immobilized on the endothelial cells (Electronic 
Supplementary Material 4), whereas CD4+ T cells still dis-
played crawling behavior followed by transmigration (Elec-
tronic Supplementary Material 5). Importantly, silencing 
P-glycoprotein did not affect the mRNA and protein expres-
sion levels of intercellular adhesion molecule-1 (Electronic 
Supplementary Material 3c, d) and vascular cell adhesion 
molecule-1 (Electronic Supplementary Material 3d, e). Col-
lectively, these results suggest that P-glycoprotein activity is 
particularly required to direct CD8+ T cell trafficking upon 
their firm adhesion to brain endothelial cells.
Fig. 1  P-glycoprotein mediates CD4+ and CD8+ T cell adhesion and 
migration under flow conditions Non-targeting control (NTC; black 
bars) or P-glycoprotein shRNA (grey bars) transfected cells were 
grown in IBIDI slides and were incubated after 2 days with TNF-α 
for 24 h. Next, freshly isolated primary human CD4+ and CD8+ T 
cells were added to visualize and quantify their migration (a) and 
adhesion (b) capacity. Moreover, the number of CD4+ and CD8+ T 
cells that started to migrate after their initial arrest on the endothe-
lial cells was quantified (c). Experiments were performed in tripli-
cate using three different human T cell donors and were presented as 
the percentage of migration/adhesion compared to NTC-transfected 
cells ± SEM. **p < 0.01, ***p < 0.001 as determined by Student’s 
t test
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mdr1a/1b−/− mice lack CD8+ T cell infiltrates 
during EAE
As reported earlier, mdr1a/b−/− mice showed signifi-
cantly reduced clinical signs of EAE [18], which coin-
cided with reduced CD45+CD3+ T cell infiltrates in EAE 
lesions. To extrapolate our in vitro results (Fig. 1) to an 
in vivo situation, we analyzed and quantified the presence 
of disease causing parenchymal CD45+CD4+ as well as 
CD8+ T cells in wild type and mdr1a/b−/− mice during 
EAE. Notably, CD45+CD8+ T cell infiltrates were almost 
completely absent from EAE lesions in mdr1a/1b−/− 
compared to their wild-type littermates, whereas the 
percentage of CD45+CD4+ T cell infiltrates was com-
parable between wild type and mdr1a/1b−/− EAE mice 
(Fig. 2a–d, quantification 2e). No changes were found in 
the percentage of circulating peripheral CD4+ T cells or 
CD8+ T cells in control (CFA: complete Freund’s adju-
vant) and EAE animals from mdr1a/1b−/− or wild-type 
mice (Fig. 2f, g) and both T cell subsets respond equally 
well to polyclonal stimuli [18], indicating that P-glycopro-
tein predominantly affects CD8+ T cell trafficking across 
brain endothelial cells in vitro but also in vivo during 
neuro-inflammation.
P-glycoprotein localizes in endothelial migratory cups 
upon T lymphocyte attachment
Binding of both effector CD4+ (Fig. 3a) and CD8+ 
(Fig. 3b) T lymphocytes to inflamed brain endothelial 
cells resulted in the recruitment of P-glycoprotein into 
the migratory cups, as indicated by the partly overlapping 
expression with an established marker intercellular adhe-
sion molecule-1. However, silencing P-glycoprotein on 
the endothelium revealed no differences in docking struc-
ture formation upon T cell attachment (Electronic Supple-
mentary Material 6), thereby excluding a potential role for 
P-glycoprotein in migratory cup formation.
Further analysis using electron microscopy revealed 
that P-glycoprotein localized at the plasma membrane 
of the endothelial cells at the contact sites of CD8+ T 
lymphocytes (Fig. 4b; quantification Fig. 4c) and CD4+ 
T lymphocytes (data not shown), whereas in control 
endothelium its plasma membrane localization is less 
predominant (Fig. 4a). Notably, P-glycoprotein expres-
sion is also observed in T cells (Fig. 4b), although P-gly-
coprotein activity is low in either CD4+ or CD8+ T lym-
phocytes compared to brain endothelial cells (Electronic 
Supplementary Material 7). Together, these results indi-
cate that P-glycoprotein becomes enriched in endothe-
lial migratory cups upon T cell attachment, where it may 
locally exert its regulatory role in CD8+ T cell transen-
dothelial migration.
P-glycoprotein regulates CD8+ T cell migration via CCL2 
secretion
To study if mediators effluxed by P-glycoprotein induce 
the migration of CD8+ T cells, we harvested supernatants 
from control or P-glycoprotein-silenced endothelial cells 
under inflammatory or control conditions, and determined 
their ability to affect CD4+ and CD8+ T cell adhesion to 
intercellular adhesion molecule-1, a key player in transen-
dothelial migration. As shown in Fig. 5a, b, conditioned 
media from TNF-α-stimulated endothelial cells signifi-
cantly induced the adhesion of both CD4+ and CD8+ T 
lymphocytes to ICAM-1 compared to conditioned media 
from untreated endothelial cells. Induced lymphocyte adhe-
sion to intercellular adhesion molecule-1 was inhibited in 
the presence of pertussis toxin (data not shown), indicating 
an important role for G-protein-coupled receptors, such as 
chemokines receptors, herein. Conditioned medium from 
TNF-α-treated endothelial cells lacking P-glycoprotein 
activity failed to induce CD8+ T cell adhesion to intercel-
lular adhesion molecule-1, whereas the induction of CD4+ 
T cell adhesion to intercellular adhesion molecule-1 was 
largely unaffected (Fig. 5a, b). These results indicate that 
P-glycoprotein is involved in the secretion of soluble fac-
tors from inflamed endothelium that selectively affect 
CD8+ T cell adhesion to intercellular adhesion molecule-1.
A potent inducer of leukocyte migration into the brain 
is the chemokine (C–C motif) ligand 2 (CCL2) [27]. Acti-
vated CD4+ and CD8+ T cells express a differential expres-
sion pattern of chemokine receptors, of which CCR2 is pre-
dominantly expressed by effector CD8+ T cells [5]. In that 
way, CD8+ T cells may more selectively respond to CCL2 
compared to CD4+ T cells. To assess whether endothelial 
P-glycoprotein is able to mediate the efflux of CCL2 by 
inflamed brain endothelial cells, we determined the pres-
ence of CCL2 in the above-described conditioned media. 
TNF-α treatment highly induced CCL2 secretion by brain 
endothelial cells, which was abrogated upon P-glycopro-
tein silencing (Fig. 5c). In contrast, expression of mRNA 
encoding for CCL2 in both endothelial cell populations 
remained unaffected, indicating that CCL2 secretion but 
not its synthesis is mediated by P-glycoprotein (Fig. 5d). 
P-glycoprotein preferentially affected the secretion of 
CCL2 by inflamed endothelium, since the secretion of the 
pro-inflammatory cytokine IL-1β was highly induced in 
the absence of P-glycoprotein (Electronic Supplementary 
Material 8). To demonstrate that CCL2 affects CD8+ T cell 
migration and to dissect the role of P-glycoprotein in this 
process, in vitro transwell migration assays were performed 
using conditioned media from inflammatory endothe-
lial cells that lack P-glycoprotein activity in the presence 
or absence of CCL2. Using this setup, we found that both 
CD4+ and CD8+ T cell migration towards the conditioned 
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Fig. 2  Lack of CD8+ T cell infiltrates in EAE lesions of 
mdr1a/1b−/− mice. Brains were isolated from EAE mice and the 
cerebellum white matter was analyzed for the infiltration of CD4+ T 
cells (green; a, b) or CD8+ T cells (green; c, d). Slides were coun-
terstained for the presence of CD45+ infiltrating cells (blue) and 
laminin positive (red) basement membranes around vessels in WT 
(a, c) or mdr1a/1b−/− (b, d) mice. Images represent representative 
tissues from four mice per group. Magnification ×200. e Quantifica-
tion of immunohistochemistry using ImageJ software on various EAE 
lesions of 4 mice per group. Data are presented as the percentage of 
CD4+ and CD8+ T cells of the total number of CD45+ infiltrates per 
EAE lesion and indicate a lack of CD8+ T cells in mdr1a/1b−/− ani-
mals compared to WT during EAE. f Peripheral blood mononuclear 
cell analysis by fluorescence-activated cell sorting revealed no differ-
ences in the number of circulating CD45+ CD4+ or g CD45+ CD8+ 
T cells in wild type (WT; black bars) or mdr1a/1b−/− (grey bars) 
mice under control (CFA complete Freund’s adjuvant) or EAE con-
ditions. Experiments were performed in triplicate using four mice 
per group in two independent experiments and were presented as the 
mean ± SEM. **p < 0.01, ***p < 0.001 as determined by Student’s 
t test
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media was significantly inhibited upon brain endothelial 
P-glycoprotein silencing (Fig. 5e). However, the addition 
of CCL2 to the conditioned media restored the migratory 
capacity of CD8+ T cells, whereas CD4+ T cell migration 
was unresponsive to CCL2 (Fig. 5e). These data collec-
tively show that expression of P-glycoprotein by TNF-α-
activated brain endothelial cells is required for release of 
chemotactic factors that stimulate migration of both CD4+ 
and CD8+ T cells. Moreover, the release of CCL2 appears 
responsible for the stimulated migration specifically of 
CD8+ T cells.
Increased expression levels of CCL2 in brain microvessels 
from multiple sclerosis patients
To determine endothelial CCL2 expression ex vivo, we 
isolated post-mortem brain microvessels from active 
demyelinating multiple sclerosis lesions, NAWM and 
non-neurological control brain tissue. Real-time PCR 
analysis revealed high endothelial purity as the expres-
sion levels of GAFP (astrocytes) and PDGFRβ (pericytes) 
were just above detection limit, whereas (brain) endothe-
lial markers like ZO-1, claudin-5 and P-glycoprotein were 
highly expressed (Fig. 5f). CCL2 mRNA gene transcripts 
were significantly higher in isolated microvessels both in 
NAWM and active multiple sclerosis lesions compared to 
transcripts in brain microvessels isolated from non-neu-
rological controls (Fig. 5g), whereas the expression levels 
of P-gp remained unaffected (Electronic Supplementary 
Material 9). These results indicate that in NAWM, inflam-
matory alterations in the brain endothelium are already 
present.
Endothelial CCL2 knockout mice display reduced CD8+ T 
cell infiltrates during EAE
To obtain proof of principle that during neuro-inflammation 
brain endothelial CCL2 drives CD8+ T cell trafficking into 
the CNS, we induced EAE in endothelial CCL2−/− mice 
[13] as well as their littermate controls. We evaluated CD8+ 
T cell influx using 3D rendering of spinal cord venules on 
day 16 of EAE (peak of the disease). As shown in Fig. 6a, b, 
high numbers of CD8+ T cells are associated with the vas-
culature of EAE animals. Vessel-associated CD8+ T cells 
in WT mice demonstrate extensive clumping with little-
to-no obvious space between cell aggregates. By contrast, 
Fig. 3  Co-localization of P-glycoprotein and ICAM-1 in endothelial 
migratory cups upon T cell attachment. hCMEC/D3 cells were stimu-
lated with TNF-α for 24 h. After that, freshly isolated primary human 
CD4+ (a) or CD8+ (b) T cells labeled with the membrane dye PKH 
(in red) were added and subsequently co-cultured with endothelial 
cells for 1 h. Next, co-cultures were fixed with paraformaldehyde and 
stained for P-glycoprotein (in green) and intercellular cell adhesion 
molecule-1 (ICAM-1 in blue), indicating a co-localization of P-gly-
coprotein with ICAM-1 in endothelial migratory cups upon CD4+ or 
CD8+ T cell attachment. Scale bar 10 µm
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infiltrating CD8+ T cells in endothelial CCL2−/− mice 
form smaller aggregates that are clearly resolvable from 
each other. It thus appears that the density of vessel-asso-
ciated CD8+ T cells is reduced in endothelial CCL2−/− 
mice with EAE, compared to WT mice at the same time-
point during disease. As shown in Fig. 6c, we observed a 
significant (p < 0.016) reduction in vessel-associated CD8+ 
T cell density in endothelial CCL2−/− mice compared to 
WT mice. These results reinforce the notion that endothelial 
CCL2 is a crucial regulator of CD8+ T cell trafficking into 
the central nervous system under pathological conditions.
Discussion
In the pathogenesis of multiple sclerosis, CD8+ T cells are 
present within brains of patients and in animals with EAE, 
where they may clonally expand and subsequently induce 
tissue damage and, in particular, axonal damage. How-
ever, the mechanism by which CD8+ T cells gain access 
to the brain remains largely unknown. Here, we describe a 
novel regulatory role for multi-drug resistance transporter 
P-glycoprotein as well as the CCL2/CCR2 axis in this pro-
cess. Our studies suggest that P-glycoprotein regulates the 
release of CCL2 by inflamed brain endothelium. In that 
way, the endothelial cells instruct adhered leukocytes, in 
particular CD8+ T lymphocytes, to migrate.
The prototypic ATP-binding cassette transporters at the 
brain vasculature are regarded as protectors of the central 
nervous system by virtue of their active efflux capacity for 
neurotoxic compounds. Our data extends the role for these 
efflux pumps, providing first-hand evidence that, under 
inflammatory conditions, a key member of this family 
(P-glycoprotein) also regulates leukocyte trafficking into 
Fig. 4  Redistribution of P-glycoprotein to endothelial plasma mem-
brane upon T cell adhesion. hCMEC/D3 cells were grown on tran-
swell polyester membrane inserts. Upon confluency, freshly isolated 
primary human CD8+ T cells were added and subsequently co-cul-
tured with endothelial cells for 1 h. Next, co-cultures were fixed and 
prepared as described in “Materials and methods”. Ultra-thin sections 
were immune gold labeled for P-glycoprotein and subsequently the 
labeled sections were analyzed by electron microscopy, indicating a 
predominant cytoplasmic localization of P-glycoprotein (as indicated 
by arrows) in endothelial cells (a; insert). Upon T cell attachment (b; 
insert), P-glycoprotein redistributes to the plasma membrane (as indi-
cated by arrows). (c) Quantification of P-glycoprotein localization 
on endothelial cells (EC) in the presence or absence of T cells. For 
this, P-glycoprotein-positive particles in 20 endothelial cells and 20 
endothelial cells that contain adhering T cells were counted by two 
independent researchers, *p < 0.05 as determined by Student’s t test. 
N nucleus
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the brain by releasing CCL2. Under neuro-inflammatory 
conditions, P-glycoprotein translocates from the cytosol 
to the plasma membrane and intra-endothelial vesicles at 
the contact site of the adhered T cell. TNF-α treatment of 
brain endothelial cells resulted in a similar P-glycoprotein 
distribution pattern (unpublished data), indicating that the 
observed effects may be regulated by downstream TNF-α 
receptor signaling events as also described for brain cap-
illaries [29]. Electron microscopy analysis further con-
firmed our observations of a membrane and vesicle-like 
Fig. 5  P-glycoprotein regulates CD8+ T cell migration via CCL2 
secretion. Supernatants from control or TNF-α-treated non-target-
ing control or P-glycoprotein shRNA-transfected cells were har-
vested and subsequently exposed to naïve CD4+ (a) and CD8+ (b) 
T cells for 30 min after which their adhesive capacity to intercellu-
lar adhesion molecule-1 was tested. Phorbol 12-myristate 13-acetate 
(PMA) was used as a positive control. Next, the presence of CCL2 
was determined in cell supernatants by enzyme-linked immunosorb-
ent assay (c) and CCL2 transcripts (d) were determined by real-time 
quantitative PCR (qRT-PCR) and presented as relative expression 
(FI fold induction) compared to GAPDH. The capacity of the above-
mentioned conditioned media to attract T cells was tested in transwell 
migration experiments (e). Conditioned media was added to the lower 
chamber in the presence or absence of exogenous CCL2 (10 ng/
ml). f Identification of endothelial purity of isolated human brain 
microvessels from non-neurological control brain tissues (n = 6) was 
performed by analyzing GFAPa (astrocytes), PDGFRβ (pericytes), 
zona-occludens-1 (ZO-1), claudin-5 and P-glycoprotein transcripts 
by qRT-PCR and presented them as relative expression compared to 
GAPDH. g CCL2 transcripts were detected by qRT-PCR on human 
brain microvessel fractions of control, normal-appearing white mat-
ter (NAWM) or multiple sclerosis (MS) lesion brain tissue (n = 6, 
respectively) and presented as relative expression (FI fold induc-
tion) compared to GAPDH. Experiments were performed in triplicate 
using three different human T cell donors (a, b, e) and were presented 
as the number of adhered T cells (a, b) or as the percentage of CD4+ 
T cell migration across NTC-transfected cells ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001 as determined by Student’s t test
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expression pattern of P-glycoprotein upon T cell attach-
ment. Recent findings show that, besides T cells being acti-
vated by chemokines presented at the endothelial surface of 
peripheral vascular beds, effector T lymphocytes also cross 
inflamed endothelial barriers by sensing intra-endothelial 
chemokines stored within vesicles localized at the contact 
site [35]. Based on our data, it may be postulated that brain 
endothelial P-glycoprotein plays a role in this process. Sub-
sequent focal release or presentation of endothelial CCL2 
may then be mediated by P-glycoprotein, providing a 
local cue for the adhered lymphocyte to initiate migration 
while maintaining low levels of CCL2 in the circulation. 
That adherent CD8+ T cells appeared most inhibited from 
migrating is consistent with P-glycoprotein/CCL2 regulat-
ing a post-adhesion event.
A controversial issue remains whether ATP-binding 
cassette transporters themselves are capable of secret-
ing chemokines directly, or are involved in the secretion 
of other more lipophilic inflammatory substrates, e.g., 
like bioactive lipids, which in turn may affect CCL2 
secretion as a secondary effect [20]. Further research 
is warranted to define the nature of the P-glycoprotein-
mediated secretome and its potential autocrine effect 
on endothelial cells (chemokine release) or its parac-
rine effect on the adhering leukocyte (e.g., leukocyte 
activation).
Fig. 6  Reduced CD8+ T cell trafficking in endothelial CCL2−/− 
mice during EAE CD8+ T cell (in green) extravasation was deter-
mined using 3-D rendering of spinal cord venules (in red) of a wild 
type (WT) or b endothelial CCL2−/− mice on day 16 of EAE. 
c Quantification of CD8+ T cell extravasation by determining the ratio 
of # of green pixels/# of pixels occupied by the microvessel (in blue), 
as an index of vessel-associated CD8+ T cell density. p < 0.0159 as 
determined by Mann–Whitney U test, n = 5 mice per group
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CCL2 is a pro-inflammatory chemokine induced dur-
ing a variety of neuro-inflammatory and neurodegenerative 
diseases [37]. The cognate receptor for CCL2 is chemokine 
(C–C motif) receptor 2 (CCR2), and the CCL2/CCR2 axis 
attracts immune cells like monocytes [28], and activated 
and memory T cells [6] to the site of inflammation. Several 
reports have indicated the relevance for CCR2 during neuro-
inflammation, as mice that lack CCR2 are resistant to the 
induction of EAE [11, 16]. Moreover, CCR2-deficient leu-
kocytes show impairments in their adhesion and migration 
capacity across microvascular endothelium in vitro [9, 23, 
44]. Our data indicate P-glycoprotein-mediated release of 
CCL2 preferentially affects CD8+ T cell migration across 
TNF-α-activated brain microvascular endothelial cells in cul-
ture. Although further research is warranted to confirm these 
findings in primary human endothelial cells, our data suggest 
that P-glycoprotein-mediated release of CCL2 may also be 
responsible for controlling trafficking of this leukocyte sub-
set into the central nervous system parenchyma under neuro-
inflammatory conditions. This may be because CCR2 is dif-
ferentially expressed among effector T cell subsets. Indeed, 
CCR2 appears to be specifically induced on activated CD8+ 
T cells, whereas CD4+ T cells express a wider range of 
chemokine receptors [5]. In addition, CCL2/CCR2 interac-
tion can also rescue CD8+ T cells from antigen/growth fac-
tor deprivation-apoptosis [7], enabling them to migrate to 
sites where antigen is available. Moreover, the generation of 
effector and central memory CD8+ T cells is abrogated in 
the absence of CCL2, as is the migration of central memory 
CD8+ T cells to inflammatory sites [41], indicating CCL2 
may influence CD8+ T cells at various levels. In multiple 
sclerosis, CD8+ T cells may clonally expand and may exert 
their lytic functions [1], such as axonal damage [30].
Brain microvessels isolated from multiple sclerosis 
patients were shown to contain high levels of CCL2. Our 
results with endothelial CCL2−/− mice underscore the sig-
nificance of these clinical findings, highlighting that vascu-
lar-derived CCL2 is a critical determinant in the multi-step 
process of leukocyte extravasation into the central nervous 
system. The finding of reduced density of vessel-associated 
CD8+ T cells in endothelial CCL2−/− mice with EAE 
could imply that the actual extent of these extravasating 
cells is diminished in the absence of an endothelial pool of 
CCL2. This interpretation is consistent with the proposed 
role of CCL2 as an ‘arrest’ chemokine, functioning at the 
luminal endothelial surface to increase the affinity and avid-
ity of leukocyte integrins and, thus, to promote to stronger 
leukocyte–endothelial interaction, thereby selectively 
inducing transendothelial migration attachment [24]. In 
this regard, it was reported that addition of anti-CCL2 anti-
body just prior to intravital microscopy, blocked leukocyte 
adhesion, but not rolling, along brain pial microvessel dur-
ing EAE [8]. Endothelial CCL2 released at the abluminal 
surface can alternatively regulate leukocyte transendothe-
lial migration as an ‘inflammatory’ chemokine to stimulate 
leukocyte chemotaxis [33], and/or serve to concentrate and 
orient leukocytes within the remodeled subendothelial and/
or perivascular space [40], while they await additional cues 
to advance further into the brain parenchyma. And a more 
recently proposed role for endothelial CCL2 is as a facilita-
tor of diapedesis to modulate migration at a ‘post-adhesion’ 
step, when contained in endothelial vesicles inaccessible to 
the circulation [35].
In conclusion, herein we show that the ATP-binding cas-
sette transporter P-glycoprotein plays a significant role in 
the selective recruitment of CD8+ T cells into the central 
nervous system during neuro-inflammation, and that this 
process may be mediated by CCL2 derived from brain 
microvascular endothelial cells. Since CD8+ T cells are 
capable of clonally expanding within multiple sclerosis 
lesions and subsequently inducing axonal damage and con-
sequent neurodegeneration, our results may provide novel 
tools to specifically hamper CD8+ T cell trafficking into 
the brain, thereby preventing severe tissue damage.
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The CCL2 synthesis inhibitor bindarit targets cells
of the neurovascular unit, and suppresses
experimental autoimmune encephalomyelitis
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Abstract
Background: Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical aspects of
neuroinflammation. Suppression of CCL2 therefore holds promise in treating neuroinflammatory disease.
Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 synthesis, could repress the
three NVU sources of CCL2 most commonly reported in neuroinflammation – astrocytes, microglia and brain
microvascular endothelial cells (BMEC) – as well as modify the clinical course of neuroinflammatory disease.
Methods: The effect of bindarit on CCL2 expression by cultured murine astrocytes, microglia and BMEC was
examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Bindarit action on mouse brain
and spinal cord in vivo was similarly investigated by qRT-PCR following LPS injection in mice. And to further gauge
the potential remedial effects of bindarit on neuroinflammatory disease, its impact on the clinical course of
experimental autoimmune encephalomyelitis (EAE) in mice was also explored.
Results: Bindarit repressed CCL2 expression by all three cultured cells, and antagonized upregulated expression of
CCL2 in both brain and spinal cord in vivo following LPS administration. Bindarit also significantly modified the
course and severity of clinical EAE, diminished the incidence and onset of disease, and evidenced signs of disease
reversal.
Conclusion: Bindarit was effective in suppressing CCL2 expression by cultured NVU cells as well as brain and spinal
cord tissue in vivo. It further modulated the course of clinical EAE in both preventative and therapeutic ways.
Collectively, these results suggest that bindarit might prove an effective treatment for neuroinflammatory disease.
Keywords: CCL2, Neuroinflammation, Blood–brain barrier, Neurovascular unit, Brain microvascular endothelial cells,
Astrocytes, Microglia
Background
The chemokine CCL2 (formerly called MCP-1) is a crit-
ical mediator of neuroinflammation in a myriad of dis-
eases states, including multiple sclerosis (MS) and its
animal model experimental autoimmune encephalomy-
elitis (EAE) [1], HIV-1 encephalitis [2], Guillain-Barré
Syndrome [3], Alzheimers disease [4], ischemia [5], neu-
rotrauma [6], epilepsy [7], neurogenic hypertension [8]
and alcoholism [9]. While its precise mechanisms of
action remain to be elaborated, among CCL2s widely
recognized effects are disruption of the bloodbrain bar-
rier (BBB) [10-12] and stimulated migration of mono-
nuclear leukocytes into the central nervous system
(CNS) [13-17].
These actions and pathogenic role, along with the fact
that constitutive expression of CCL2 in the healthy cen-
tral nervous system is severely limited [18], render CCL2
an ideal target for therapeutic intervention in neuroin-
flammatory disease [17,19,20]. Indeed, there is already
strong suggestion that pharmacological suppression of
CCL2 expression [21,22], oligomerization [23,24] or
binding to its cognate receptor, CCR2 [25,26], can
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mitigate aspects of EAE. Pharmacologic blockade of
CCL2 binding to glycosaminoglycans (GAGs) has also
been reported to antagonize an autoimmune inflamma-
tory condition of the neural retina, experimental auto-
immune uveitis [27].
While highly effective in moderating neuroinflamma-
tion experimentally, many pharmacological agents that
abrogate CCL2 expression and/or activity have neverthe-
less failed clinically. This disappointing performance in
clinical trials might stem, in part, from overly broad sup-
pression of microglia and astrocytes, a potential caveat
that could curtail beneficial action of these cells in re-
solving neuroinflammation [28,29], as well as redun-
dancy of chemokine binding sites and targets [30,31]. An
alternative approach that more selectively targets CCL2
synthesis might therefore hold therapeutic promise in
the treatment of human neuroinflammatory disease.
An attractive candidate in this regard is the well-char
acterized compound 2-((1-benzyl-indazol-3-yl) methoxy)-
2-methyl propionic acid (bindarit) [32]. A small, synthetic
indazolic derivative that preferentially inhibits transcrip-
tion of the monocyte chemoattractant subfamily of CC che-
mokines (MCP-1/CCL2, MCP-2/CCL8 and MCP-3/CCL7)
[33], bindarit has shown clinical efficacy in a broad array
of experimental inflammatory, autoimmune and vascular
disorders involving peripheral organ beds [34-38], as well
as success in recent clinical trials for diabetic nephropathy
[39] and lupus nephritis [40]. Such efficacy has been asso-
ciated with bindarits ability to interfere with monocyte
recruitment, which is also a critical feature in neuroin-
flammatory disease [13-17].
Given this clinical history of bindarit suppressing vari-
ous examples of peripheral inflammation, we investigated
its effect on expression of CCL2 in culture by the three
cell types that represent the most frequently reported
CNS sources of this chemokine during neuroinflamma-
tion: astrocytes, microglia and brain microvascular endo-
thelial cells (BMEC). These cells serve as integral
components of the neurovascular unit (NVU) [41] and,
via their expression of CCL2, can impact the BBB and
course of neuroinflammatory disease [42,43]. As a com-
plement to these culture studies, the ability of bindarit to
suppress LPS induction of CNS CCL2 expression in vivo
was well determined. And to gauge bindarits potential
clinical efficacy, its effect on EAE, a prototypical neuroin-
flammatory disease [44,45], was also examined. Results
indicate bindarit significantly suppressed CCL2 gene ex-
pression in culture, as well as blunted lipopolysaccharide
(LPS)-induced expression of CCL2 in the CNS. It also
inhibited various facets of clinical EAE, and showed signs
of promoting disease recovery. Collectively, these data
suggest that bindarit might offer promise, either alone or
in conjunction with other therapies, in the treatment of
human neuroinflammatory disease.
Methods
Reagents
All reagents and antibodies were purchased from Sigma-
Aldrich (St. Louis, MO, USA), unless specified other-
wise. Bindarit was synthesized by and obtained from
Angelini (Angelini Research Center-ACRAF, Italy).
MOG peptide35-55 was synthesized by the WM Keck
Biotechnology Resource Center at Yale University,
New Haven, CT, USA.
Preparation of bindarit
For experiments with cultured cells, a stock solution of
100 mM bindarit was prepared in dimethyl sulfoxide
(DMSO), and dilutions (50, 100, 300 and 500 μM) of the
DMSO stock were made in culture medium. For in vivo
experiments, bindarit was prepared as a suspension in
0.5% methylcellulose (MTC) at a concentration of
20 mg/ml as previously described [37].
Mice
C57BL/6 mice were obtained from the Charles River
Laboratories, Inc. (Wilmington, MA, USA). All animal
studies were performed, and CO2-mediated euthanasia
carried-out, according to the Animal Care and Guidelines
of the University of Connecticut Health Center (Animal
Welfare Assurance #A3471-01).
Isolation and culture of mouse astrocytes and microglia
Brain tissue obtained from mice at postnatal days 2 to 3
was used as the source of astrocytes and microglia. After
decapitation, brains were removed immediately and sep-
arate astrocyte and microglial cultures prepared follow-
ing a modified version of the protocol described by Ge
and Pachter [46]. Cerebral cortices were first cut into
small pieces (approximately 1 mm), and the minced tis-
sue incubated in dissecting medium (Hanks Balanced
Salt Solution, from Gibco/BRL, Rockville, MD, USA),
containing 0.5% glucose, 0.7% sucrose, 20 mM: hydro-
xyethyl piperazineethanesulfonic acid (Hepes) (pH 7.4)
with 0.03% trypsin at 37 °C for 20 to 30 minutes. The
tissue extract was then centrifuged at 1000 × g for 5 min-
utes and the resulting pellet washed and resuspended in
astrocyte culture medium (Earls Modified Eagle Medium,
from Gibco/BRL) containing 10% fetal bovine serum, 10%
horse serum, 2 mM glutamine, 20 mM D-glucose, 4 mM
sodium bicarbonate, 100 μg/ml penicillin and 100 μg/ml
streptomycin. The tissue was mildly triturated to produce
a single cell suspension, and the dissociated cells plated
onto tissue culture flasks (T-75 cm2) coated with poly-
lysine (BD Biosciences, Bedford, MA, USA). Cultures were
maintained up to 1 week in plating medium in a humidi-
fied atmosphere (5% CO2) at 37 °C. After this time, cul-
tures were shaken at 200 rpm for 2 hr at 4 °C, and
supernatants containing dislodged microglia collected.
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Supernatant material was then centrifuged at 1000× g for
5 minutes to pellet microglia. Microglia were then resus-
pended in microglia culture medium (Dulbeccos modified
Eagle Medium, from Gibco-BRL) supplemented with 10%
heat-inactivated fetal calf serum, 100 μg/ml penicillin and
100 μg/ml streptomycin) and cultured in a 24-well plate.
Following removal of microglia from the initial mixed glial
cultures, the latter were shaken for an additional 18 hr at
37 °C to remove residual neurons. The enriched astrocyte
population that remained was further depopulated of
remaining microglia by treatment with L-leucine me-
thyl ester (LME) [47]. LME was dissolved in astro-
cyte culture medium, and the solution adjusted to
pH 7.4 and filtered prior to adding to cultures to
achieve a final concentration of 50 mM. After 90
minutes of LME treatment, astrocyte-enriched cul-
tures were washed thoroughly and re-incubated with
fresh astrocyte culture medium. Cell purity was deter-
mined by immunocytochemistry using a monoclonal anti-
human glial fibrillary acid protein (GFAP) antibody, and
cultures assessed to be≥ 98% astrocytes (GFAP+).
Isolation and culture of mouse brain microvascular
endothelial cells
BMEC were isolated as previously detailed by this la-
boratory [10,48]. Primary cultures were typically grown
for approximately five days prior to sub-culturing for
experiments. At that time, purity was gauged to be ≥ 98%
BMEC, according to diI-acetylated LDL uptake [48].
BMEC also exhibited common endothelial characteris-
tics, e.g. CD31 and vWF immunostaining, plus displayed
expression of the tight junction-associated proteins ZO-1
and occluding, found enriched at the BBB.
Treatment of cultured cells
To examine effects of bindarit on basal CCL2 expres-
sion, cultured microglia and BMEC were incubated with
different concentrations of bindarit for 4 hr or exposed
to 300 μM bindarit for different time. To gauge effects
of bindarit on LPS-stimulated CCL2 expression, astro-
cytes and microglia were pretreated with 300 μM bin-
darit for 1 hr; then cells were incubated with± 100 ng/ml
LPS (Escherichia coli Serotype 026:B6) for 4 or 20 hr in
the continued presence of bindarit. After treatments, cells
were extracted for RNA purification.
Separation of brain microvessels and parenchyma
Distinct brain microvessel and parenchymal fractions
were obtained using a modification of the method to
prepare BMEC [10,48]. In brief, after removal of the
brain from the cranium, the meninges and big vessels
were discarded, and the whole brain diced into approxi-
mately 1 mm pieces. Brain tissue was then homogenized
with a 7 mL Dounce tissue grinder (Kimble/Kontes,
Vineland, NJ, USA) in PBS. The homogenate was then
transferred to a 15 ml conical tube and centrifuged at
400 × g for 15 minutes in an Eppendorf Model 5804R
centrifuge/A-4-44 rotor. The resulting pellet was resus-
pended in 18% dextran (v/v, molecular weight 60 000 to
90 000; USB Corporation, Cleveland, OH, USA) and
centrifuged at 4,500 × g for 15 minutes to pellet the
crude microvessel fraction. The dextran supernatant and
floating layer of myelinated axons were separated from
the crude microvessel pellet, then diluted 1:2 with PBS
and centrifuged at 720 × g for 10 minutes to sediment
the parenchymal fraction. Both microvessel and paren-
chymal fractions were washed twice with PBS to elimin-
ate traces of dextran. Microvessels were further washed
free of blood cells by filtering through a 40 μm cell
strainer (Becton Dickinson Labware, Franklin Lakes, IN,
USA) and eluting with PBS. Eluted microvessels were
pelleted by centrifugation at 16,000 × g in a table-top
microcentrifuge.
Treatment of animals
To determine effects of bindarit on LPS-stimulated
CCL2 expression in brain and spinal cord, C57BL/6 fe-
male mice were given intraperitoneal (i.p.) injection of
bindarit (200 mg/kg) or methylcellulose vehicle, once a
day, for 4 consecutive days. At 30 minutes following the
last bindarit injection, mice were given i.p. injection of
LPS (5 mg/kg; Escherichia coli Serotype 026:B6). Then,
4 hr after LPS injection, mice were euthanized and brain
and spinal cord dissected for CCL2 mRNA and protein
analysis.
For active induction of EAE, C57BL/6 female mice
were immunized with MOG35-55 peptide (MEVG-
WYRSPFSRVVHLYRNGK) of rat origin, by a modification
of the method previously described [49]. Briefly, on day 0
female mice 7 to 9 weeks of age were injected sub-
cutaneously with 150 μg of MOG peptide and 300 μg
of Mycobacterium tuberculosis (DIFCO, Detroit, MI, USA)
in complete Freunds adjuvant (CFA) (DIFCO) into the
right and left flank, 100 μl per site. Mice were also injected
i.p. with 200 ng pertussis toxin (List Laboratories,
Campbell CA, USA) in PBS on days 0 and 2 following the
first immunization. Animals were monitored and scored
daily for clinical disease severity according to the following
scale: 0 = normal; 1 = tail limpness; 2 = limp tail and weak-
ness of hind legs; 3 = limp tail and complete paralysis of
hind legs; 4 = limp tail, complete hind leg and partial front
leg paralysis; and 5=death. Several disease parameters
were calculated as described [49]. The mean day of onset
was calculated by averaging the time when clinical symp-
toms, that is, a clinical score≥ 1, were first observed for
two consecutive days in each mouse. The mean maximum
clinical score was calculated by averaging the highest score
for each mouse. The disease index was calculated by
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adding the daily average clinical scores in each group, div-
iding by the mean day of onset, and multiplying by 100. In
the case that an animal showed no disease, the day of
onset was arbitrarily counted as one day after the last day
of the experiment (for example, day 22). And the disease
incidence was the fraction of mice experiencing EAE.
To investigate the effects of bindarit on both the clin-
ical course of EAE and CCL2 level during disease, mice
were given daily i.p. injection of bindarit (or vehicle
MTC) at 200 mg/kg for three consecutive days, begin-
ning the day before MOG immunization (day −1), then
injections every other day till day 20. This schedule was
designed to mitigate, as much as possible, trauma asso-
ciated with daily injections at times of peak neurologic
disease and physical compromise.
RNA purification from cell cultures
Total RNA was extracted from cell cultures using the
RNeasy kit according to the manufacturers instructions.
RNA was treated with Turbo DNAse (Ambion, Austin,
TX, USA) according to the protocol provided by the
manufacturer. RNA yield and purity were determined by
spectrophotometry absorption at 260 and 280 nm.
RNA purification from CNS tissue
RNA and protein were differentially extracted from the
same mouse brain and spinal cord samples using the
AllPrep RNA/Protein kit (QIAGEN, Valencia, CA) fol-
lowing the manufacturers instructions. RNA was treated
with Turbo DNAse (Ambion, Austin, TX, USA) accord-
ing to the protocol provided by the manufacturer. RNA
yield and purity were determined by spectrophotometry
absorption at 260 and 280 nm. Protein level was deter-
mined using the Micro BCA protein assay kit (Pierce,
Rockford, IL, USA), using bovine serum albumin as a
standard.
Reverse transcription
cDNA was synthesized from the total RNA using a
SuperScript III (Invitrogen, Carlsbad, CA, USA) First-
strand synthesis system for RT-PCR with a standard
protocol. The resulting cDNA was stored at −80 °C until
used for further analysis.
CCL2 RNA determination by quantitative RT-PCR
Measurements of cDNA levels were performed by quan-
titative (q) RT-PCR using an ABI PRISM 7500 Sequence
Detection System Version 1.3, and SYBR green (AB
Applied Biosystems, Foster sity, CA, USA) fluorescence
was used to quantify relative amplicon amount. Separate
controls included a no template-control and no reverse
transcriptase-control, and standard curves were con-
structed for all primers used. Cycle time (Ct) values for all
samples were normalized to RPL-19, the housekeeping
gene encoding the 60 S ribosmal protein L19. Specifically,
relative amplicon quantification was performed using the
formula: 1þ Erefð ÞCt refð Þ= 1þ Etargetð ÞCt targetð Þñ 100%,
with ref: RPL19; target: CCL2; E: primer pair efficiency;
and Ct: threshold cycle.
For all cell culture studies and in vivo LPS studies, rela-
tive CCL2 gene expression values (after normalization to
RPL19) were expressed as percentage of control. For EAE
studies, relative CCL2 gene expression values were desig-
nated as percentage of RPL-19 expression, as control
CCL2 level (time-point 0) was undetectable. The primer
sequences used in this study were as following: for mouse
CCL2, 5- GGC TCA GCC AGATGC AGT TAA-3 (for-
ward) and 5- CCA GCC TAC TCA TTG GGA TCA −3
(reverse); for RPL-19, 5- CGC TGC GGG AAA AAG
AAG-3 (forward) and 5- CTG ATC TGC TGA CGG
GAG TTG −3 (reverse).
CCL2 protein determination
The level of CCL2 was measured with mouse JE/CCL2
commercial enzyme-linked immunoassay kit (BioSource
International Inc., Camarillo, CA) according to the man-
ufacturers instructions.
Statistical analysis
Statistical significance of differences between mean
values of bindarit-treated cultures and control cultures
was analyzed using a paired two-tailed t-test, while com-
parisons of bindarit treatment on LPS-treated mice were
performed using a two-tailed t-test for independent
samples. For analysis of bindarit effects on clinical
EAE, a chi-squared (χ2) test was used for comparisons
of disease incidence; a MannWhitney U-test was
used for comparisons of disease index; and a two-
tailed t-test for independent samples was used for
comparison of disease onset. A P-value< 0.05 was
considered significant in all cases.
Results
Bindarit differentially suppresses CCL2 expression by
cultured CNS cells
The effects of bindarit on cultured glial and BMEC were
investigated first (Figures 1, 2, 3). Figure 1 shows that
cultured microglia demonstrated both a dose and time
dependency of bindarit effect on CCL2 mRNA level.
Suppression of basal CCL2 mRNA was seen beginning
with the lowest dose of 50 μM for 4 hr, amounting to
nearly 75% reduction. Increasing the dose to 300 and
500 μM resulted in still further diminution of CCL2
mRNA to approximately 10% and 5%, respectively, of
control level. Treatment with bindarit at 300 μM for as
little as 2 hr resulted in near 60% reduction in CCL2
mRNA level, and treatment for longer times at this
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concentration resulted in suppression of CCL2 mRNA
to ≥ 90% of control level.
BMEC demonstrated a similar qualitative response
in basal CCL2 mRNA to increasing bindarit concen-
tration, but suppression was not as severe as seen
with microglia (Figure 2). Significant reduction was
not observed until 100 μM, and the maximal suppres-
sion achieved was about 20% that of control. The
time course of bindarit action on BMEC also differed.
Maximal suppression by 300 μM bindarit was
achieved at the earliest time-point of 2 hr, reaching a
level of approximately 20% of that of the control.
Longer time-points, however, appeared to result in a
lesser effect. It is important to reemphasize that, in
the normal CNS, CCL2 expression is barely detect-
able. This would suggest that both cultured microglia
and BMEC, possibly removed from a normally sup-
pressive microenvironment, are in a somewhat acti-
vated state.
This situation appears different for astrocytes. In
this case, bindarits effects on constitutive CCL2 gene
expression could not be accurately assessed, as level
of this chemokines mRNA in murine culture of these
cells is very low. Astrocyte cultures were thus stimu-
lated with LPS for different lengths of time to greatly
induce CCL2 mRNA, and the effect of bindarit on
this CCL2 induction was assayed (Figure 3A). Stimu-
lation with 100 ng/ml LPS for both 4 hr and 20 hr
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Figure 1 Bindarit effects on CCL2 mRNA in cultured microglia.
Microglia, prepared from C57BL/6 mouse brain, were incubated with
bindarit at the indicated concentrations for 4 hr (A), or exposed to
300 μM bindarit for the indicated times (B). Control cultures
received only vehicle. Relative CCL2 RNA levels were determined by
qRT-PCR, and effects of bindarit treatment reported as % change
compared to control cultures. *P< 0.05; #P< 0.01 (compared to
control at 0 concentration or 0 time of bindarit).
A
B
0
10
20
30
40
50
60
70
80
90
100
110
120
CC
L2
 m
RN
A
( %
 of
 co
nt
ro
l e
xp
re
ss
ion
)   
 
0 2 4 8 24
Time of Bindarit (300µM) treatment (hr) 
#
*
0
10
20
30
40
50
60
70
80
90
100
110
120
CC
L2
 m
RN
A
( %
 of
 co
nt
ro
l e
xp
re
ss
ion
 ) 
0 50 100 300 500
Concentration of Bindarit (µM)
*
*
*
Figure 2 Bindarit effects on CCL2 mRNA in cultured BMEC. Brain
microvascular endothelial cells (BMEC), prepared from C57BL/6
mouse brain, were incubated with bindarit at the indicated
concentrations for 4 hr (A), or exposed to 300 μM bindarit for the
indicated times (B). Control cultures received only vehicle. Relative
CCL2 RNA levels were determined by qRT-PCR, and effects of
bindarit treatment reported as % change compared to control
cultures. *P< 0.05; #P< 0.01 (compared to control at 0 concentration
or 0 time of bindarit).
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produced similar elevations in CCL2 gene expression,
and bindarit treatment at 300 μM similarly suppressed, by
40 to 60%, the induction of CCL2 mRNA at both time-
points.
In light of bindarits success at mitigating induction
of CCL2 in astrocytes, we next assayed whether it
was similarly effective in preventing induction in LPS-
stimulated microglia. Figure 3B shows that this was in
fact the case, bindarit completely suppressing the in-
duction and reducing CCL2 mRNA level to 15% of
the control (basal) value.
Bindarit blocks LPS-induced CCL2 expression in brain and
spinal cord
It was next investigated whether bindarit could suppress
LPS-induced CCL2 expression in the CNS in vivo
(Figure 4). In the normal, resting state, CNS CCL2
mRNA level is barely detectable in C57BL/6 mice
[50], but is elevated 50- to 100-fold shortly after per-
ipheral LPS injection [51]. Pretreatment with bindarit
was nevertheless able to effectively block this induc-
tion both in the brain and spinal cord, by 92% and
86%, respectively. In addition to abrogating LPS-
induction of CCL2 mRNA in the CNS, bindarit was
also effective at reducing CCL2 protein level in both
brain and spinal cord, though not to the same extent
as mRNA.
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Figure 3 Bindarit effects on LPS-stimulated CCL2 mRNA in
cultured astrocytes and microglia. Separate cultures of astrocytes
(A) and microglia (B), prepared from C57BL/6 mouse brain, were
pre-treated with 300 μM bindarit for 1 hr, then incubated
with ± 100 ng/ml lipopolysaccharide (LPS) in the continued presence
of bindarit. Astrocytes cultures were exposed to LPS for the
indicated times to stimulate CCL2 expression. Microglial cultures
were only exposed to LPS for 4 hr, as these highly express CCL2
even under basal conditions. Control cultures received only vehicle.
Relative CCL2 RNA levels were determined by qRT-PCR, and effects
of bindarit treatment reported as % change compared to control
cultures. Brackets designate comparison between the two respective
groups. *P< 0.05; #P< 0.01.
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Figure 4 Bindarit’s effects on CCL2 mRNA and protein in brain
and spinal cord following LPS. Mice received i.p. injection of
200 mg/kg bindarit (or vehicle) once a day for 4 days, followed by i.
p. injection of 5 mg/kg lipopolysaccharide (LPS) at 30 minutes after
the last bindarit treatment. At 4 hr after LPS injection, brain and
spinal cord were prepared for CCL2 mRNA (A) and protein (B)
determinations. LPS + bindarit-treated brain or spinal cord samples
were compared to corresponding samples treated with LPS + vehicle
(control). *P< 0.05; #P< 0.01.
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Bindarit therapeutically modifies clinical EAE
The ability of bindarit to modify clinical EAE was exam-
ined next. Figure 5 shows that, with a bindarit schedule
of daily injections for the first three days, and beginning
at day −1, then injections every other day till day 20,
bindarit yielded several therapeutic effects. By the criter-
ion that disease is manifest when a clinical score of at
least 1 is demonstrated for at least two consecutive days
[49], bindarit delayed onset of EAE. Specifically, control
mice developed acute disease beginning at day 8, while
bindarit-treated mice did not show evidence of clinical
disease until days 14 to 15. A second therapeutic effect
observed was reduced disease progression and severity.
Control mice showed rapid progression of EAE, pro-
ceeding towards a maximum mean clinical score of
approximately 2.1 to 2.2 by day 9. Bindarit-treated
mice evidenced slower progression, and only reached
a maximum mean clinical score of 1.5. A third therapeutic
effect was apparent reversal of disease course. After ex-
periencing rapid onset, control mice showed a plateau in
disease score typical of this monophasic MOG-induced
EAE [52,53]. However, in marked distinction, bindarit-
treated mice demonstrated a consistent downward trend
in disease score following their delayed and attenuated
peak in clinical presentation. A summary of the effects of
bindarit treatment on clinical EAE is presented in Table 1.
We next sought to examine how bindarit modifies
CCL2 expression in the brain during EAE. First, the
temporal expression of CCL2 was determined only in
MOG-immunized mice not receiving any bindarit, to
gauge the window of opportunity during which bindarit
might act. As seen in Figure 6, CCL2 RNA is barely
detectable at the time of immunization. Its expression
then accelerates beginning around day 9, is significantly
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Figure 5 Bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE). Mice were subject to EAE by active immunization
with MOG peptide, beginning on day 0, as detailed in Methods. Bindarit (or vehicle) was injected i.p. at 200 mg/kg according to the schedule
indicated, beginning at day −1 (one day before MOG immunization). Mean clinical score (A) and % incidence of EAE (B) were determined. EAE
was diagnosed when animals demonstrated a clinical score≥ 1 for two consecutive days.
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elevated by day 14, rapidly declines at day 17, and
reaches near basal level by day 21. Because bindarit has
been shown to most effectively suppress stimulated, ra-
ther than basal, CCL2 expression [33,54], bindarit effects
on CCL2 were analyzed selectively during this peak
interval. Additionally, brain tissue was resolved into
microvascular and parenchymal fractions to further
identify targeted cell types. This resolution was deemed
important, as both microvessels (BMEC) and parenchy-
mal neural cells (astrocytes and microglia) have been
reported as sources of CCL2 during EAE [55-58], though
microvessels only contribute< 1% to brain volume [59].
It was thus reasoned that parenchymal effects could
overshadow possible bindarit-induced changes in micro-
vascular CCL2 expression if only whole-brain levels were
evaluated. Figure 7 reveals that bindarit significantly
reduced peak CCL2 expression during EAE in both
microvascular and parenchymal fractions, in agreement
with what was found in our culture studies. Also, bin-
darit did not affect CCL2 expression outside the peak
window, reinforcing that its action appears restricted to
activated cells within and outside the CNS [33,54].
Discussion
Given the success of the CCL2 synthesis inhibitor bindarit
in ameliorating several animal disease models and human
clinical conditions associated with peripheral inflamma-
tory disease, initial studies were conducted to examine its
effects on elements critical to neuroinflammatory disease.
Focusing on the three main cell types responsible for
CCL2 expression during neuroinflammation, experiments
revealed bindarit significantly suppressed CCL2 in cul-
tured BMEC, microglia and astrocytes. Bindarit was
further shown to be effective in vivo in two neuroinflam-
matory paradigms: 1) it blocked LPS induction of CCL2 in
both brain and spinal cord; and 2) it therapeutically modi-
fied the course of EAE while suppressing CCL2 ex-
pression in both brain microvascular and parenchymal
compartments.
As to the effects on the seminal sources of CCL2, it
was critical to determine whether each was susceptible
to bindarit, as the specific cellular pool(s) responsible for
CCL2s pathogenic actions during neuroninflammatory
disease remain unclear [51]. While all three cell types
responded with significant reduction in CCL2 mRNA,
microglia were the most sensitive - experiencing> 90%
diminution in this chemokines expression. This high
sensitivity to bindarit holds particular significance, as
microglia are widely considered the primary immune ef-
fector cells in the CNS [60-63], and their expression of
CCL2 has been linked to monocyte recruitment into the
CNS [64,65]. As CCL2 can also direct recruitment and
proliferation of microglia [66-68], as well as activation of
these cells [68], microglial expression of CCL2 can poten-
tially support a self-sustaining cycle of neuroinflammation.
Bindarit action, however, might effectively abrogate such a
scenario.
That bindarit also suppressed CCL2 mRNA in BMEC
is noteworthy. As these cells form the first line of
defense in the BBB [69], their expression of CCL2 might
strongly influence incipient steps of neuroinflammation
[70]. Indeed, elevated CCL2 expression by BMEC has
been reported in MS [71] and EAE [55,56], as well as in
autoimmune inflammation of the peripheral nervous
system [3]. Furthermore, intravenously administered anti-
CCL2 antibody blocked heightened leukocyte adhesion to
pial venular endothelium in vivo in mice suffering acute
Table 1 Summary of bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE) parameters
Group Sick/total, number Mean day of onseta Mean max clinical score Mean disease indexb
MTC 14/14 11.42 ± 1.76 2.43 ±0.47 163.7 ± 20.53
BND 8/14 16.85 ± 2.17 1.52 ± 0.88 99.3 ± 10.21
P-value - <0.005 <0.001 <0.01
Mean presented ± SD.
aDay of onset established when clinical score ≥ for two consecutive days.
bDisease index calculated at day 21.
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Figure 6 CCL2 expression profile during experimental
autoimmune encephalomyelitis (EAE). Mice were immunized with
MOG peptide to induce EAE. At the indicated days
post-immunization, mice were sacrificed and CCL2 mRNA levels
determined in the whole brain. CCL2 expression is seen to rapidly
rise and fall between days 9 to 21, showing the highest level at day
14.
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EAE [72], as well as prevented recurring clinical episodes
in a chronic relapsing EAE model [73], possibly by antag-
onizing CCL2 at the luminal endothelial surface. Support-
ing this possibility, CCL2 harbors in its C-terminal α-helix
a binding site for GAGs typically found on the luminal
endothelial surface [74], and has been shown to bind
to the luminal surface of cultured endothelial cells
and then trigger firm adhesion followed by transmi-
gration of mononuclear leukocytes [75,76]. Binding of
CCL2 released from BMEC in culture has most re-
cently been shown to switch from the luminal to the
abluminal surface following cytokine-induced activa-
tion [77], possibly reflecting the changing roles of this
chemokine pool from first promoting leukocyte adhe-
sion to later directing extravasation into the paren-
chyma. Thus, by targeting the BMEC reservoir of
CCL2 during disease, bindarit might be able to blunt
neuroinflammation at different stages.
Bindarit action on CCL2 expression by cultured astro-
cytes had to be studied in the context of LPS stimula-
tion, as these cells exhibit barely detectable CCL2
mRNA in culture or in situ in the naïve state [50,51].
Yet despite significant induction, astrocyte CCL2 mRNA
was reduced by half or more following bindarit expos-
ure. As astrocytes constitute the most abundant glial cell
population in the CNS [78], suppression of their CCL2
production by bindarit in vivo might well exert profound
influence on pathologic events.
That bindarit could indeed act in vivo to effectively
suppress neuroinflammation was evident in both the
LPS and EAE paradigms. Injection of bindarit dramatic-
ally reduced LPS-stimulated expression of CCL2 in both
brain and spinal cord, dropping mRNA levels to near
10% of vehicle-injected control values, while cutting pro-
tein levels approximately by half. In this case, the effi-
cacy of bindarit in suppressing brain CCL2 may have
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Figure 7 Effects of bindarit on CCL2 expression in central nervous system (CNS) fractions during experimental autoimmune
encephalomyelitis (EAE). Mice were immunized with MOG peptide to induce EAE, and were injected with bindarit (or MTC vehicle) as in
Figure 5. At the indicated days post-immunization, mice were sacrificed and CCL2 mRNA levels determined in microvascular (A) and parenchymal
(B) fractions. Bindarit treated groups were compared to vehicle treated groups. *P< 0.01.
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been aided by the fact that LPS can severely disrupt the
BBB [79,80], and thereby possibly facilitate bindarit entry
into the CNS parenchyma. As CCL2 can also disrupt tight
junctions leading to elevated BBB permeability [10-12],
CCL2 generated early after LPS injection may have con-
tributed to its subsequent suppression by further enabling
bindarit CNS access.
The effects of bindarit on clinical EAE suggest that bin-
darit exerted both preventative and therapeutic actions.
Preventative action is indicated by the considerable delay
in disease onset in the bindarit-treated group, as well as
the reduced incidence and severity of disease displayed by
these mice. Possible therapeutic action is conveyed by the
steady decline in disease severity following diminished
peak clinical score. Such decline was in marked contrast
to the typical plateau in clinical score exhibited by EAE
mice given vehicle. These results are qualitatively similar
to those recently reported by Laborde et al. [81] who,
employing a regimen of twice daily oral dosage of a novel
heteroaroylphenylurea antagonist of CCL2 function, also
described delayed disease onset and resolution of EAE
symptoms. In the case of bindarit, however, clinical symp-
toms seemed to steadily remit following attenuated peak
disease, and a reduced incidence was also noted. Both
studies nevertheless highlight the prospect that selective
targeting of CCL2 activity might prevent EAE, as well as
reverse its course.
The effect of bindarit on clinical EAE was accompan-
ied by significant reduction of CCL2 mRNA in both
brain microvessel and parenchymal fractions, consistent
with bindarits mechanism of action being inhibition of
CCL2 transcription [33]. Reinforcing this point, global
knockout of the CCL2 gene has been shown to similarly
delay EAE onset, and reduce both disease incidence and
severity, effects that have been attributed to absence of
CCL2 expression within the CNS compartment [81,82].
This, along with demonstration that CCL2-deficient
mice also exhibit reduced neuroinflammatory responses
to peripheral LPS injection [83,84], underscores CCL2s
non-redundant role in neuroinflammatory disease and
accentuates its value as a therapeutic target. Results with
bindarit and EAE may further suggest that both micro-
vascular and parenchymal sources of CCL2 contribute
to pathogenesis. If this is so, it could further imply bin-
darit would not have to penetrate the BBB in order to
reach at least one of its targets, BMEC. In contrast to
the acute situation with LPS, which acts directly on the
endothelium, it is reasoned that the BBB was more in-
tact in EAE mice receiving bindarit, as mean disease
score only reached approximately 1.5. Thus, a likely
scenario is that bindarit also sufficiently crossed the
BBB to suppress the astrocyte and/or microglial re-
sponse as well. This lends promise that bindarit can
access the CNS parenchyma during the early stages of
neuroinflammatory disease, when BBB breakdown is
not yet manifested.
Conclusions
In summary, the CCL2 synthesis inhibitor bindarit,
previously shown to be highly effective in myriad ex-
perimental disease models as well as human condi-
tions having inflammatory involvement [34-40], was
observed to significantly reduce steady state and LPS-
induced CCL2 expression in cultured microglia,
BMEC and astrocytes, as well as LPS-stimulated
CCL2 mRNA and protein levels in CNS tissue in situ.
Bindarit was further effective in delaying, preventing
and attenuating clinical EAE, and evidenced signs of
possibly reversing disease course while also suppres-
sing elevation of CCL2 in brain microvascular and
parenchymal compartments. Collectively, these data
are consistent with the widely proposed critical role
for CCL2 in neuroinflammation [18-20], and suggest
bindarit, by targeting cells of the NVU [41], might
have therapeutic success in the treatment of MS and/or
other human neuroinflammatory diseases.
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Active induction of experimental autoimmune
encephalomyelitis by MOG35-55 peptide
immunization is associated with differential
responses in separate compartments of the
choroid plexus
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Abstract
Background: There is increasing awareness that, aside from producing cerebrospinal fluid, the choroid plexus (CP)
might be a key regulator of immune activity in the central nervous system (CNS) during neuroinflammation.
Specifically, the CP has recently been posited to control entry of sentinel T cells into the uninflamed CNS during
the early stages of neuroinflammatory diseases, like multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE). As the CP is compartmentalized into a stromal core containing fenestrated
capillaries devoid of typical blood–brain barrier properties, surrounded by a tight junction-expressing choroidal
epithelium, each of these compartments might mount unique responses that instigate the neuroinflammatory
process.
Methods: To discern responses of the respective CP stromal capillary and choroidal epithelial tissues during
evolving neuroinflammation, we investigated morphology and in situ expression of 93 immune-related genes
during early stages of EAE induced by immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55).
Specifically, 3-D immunofluorescent imaging was employed to gauge morphological changes, and laser capture
microdissection was coupled to an Immune Panel TaqMan Low Density Array to detail alterations in gene
expression patterns at these separate CP sites on days 9 and 15 post-immunization (p.i.). To resolve CP effects due
to autoimmunity against MOG peptide, from those due to complete Freund’s adjuvant (CFA) and pertussis toxin
(PTX) included in the immunization, analysis was performed on MOG-CFA/PTX-treated, CFA/PTX-treated, and naïve
cohorts.
Results: The CP became swollen and displayed significant molecular changes in response to MOG-CFA/PTX
immunization. Both stromal capillary and choroidal epithelial tissues mounted vigorous, yet different, changes in
expression of numerous genes over the time course analyzed - including those encoding adhesion molecules,
cytokines, chemokines, statins, interleukins, T cell activation markers, costimulatory molecules, cyclooxygenase, pro-
inflammatory transcription factors and pro-apoptotic markers. Moreover, CFA/PTX-treatment, alone, resulted in
extensive, though less robust, alterations in both CP compartments.
(Continued on next page)
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Conclusions: MOG-CFA/PTX immunization significantly affects CP morphology and stimulates distinct expression
patterns of immune-related genes in CP stromal capillary and epithelial tissues during evolving EAE. CFA/PTX
treatment, alone, causes widespread gene alterations that could prime the CP to unlock the CNS to T cell
infiltration during neuroinflammatory disease.
Keywords: Laser capture microdissection (LCM), Choroid plexus, EAE, Pertussis toxin, Neuroinflammation
Introduction
Though the choroid plexus (CP) is commonly recognized
as the production site of cerebrospinal fluid (CSF) [1-3], it
has relatively recently gained attention as a critical player
in central nervous system (CNS) inflammation [4-6]. Spe-
cifically, the CP has been suggested as the site of entry
into the uninflamed CNS of pioneer T cells searching for
their cognate antigens during immunosurveillance and in
the early stages of neuroinflammatory diseases such as
multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE) [7,8]. Current the-
ory holds that, after crossing the CP into the CSF, pioneer
T cells travel to the subarachnoid space (SAS), where
antigen-presenting cells reactivate them. In turn, reactiva-
tion is thought to set off a burst of cytokines and other
mediators that inflames meningeal and parenchymal
venules to initiate disease [9-11].
The anatomy of the CP appears well suited to orchestrat-
ing the initial steps of CNS inflammation. It projects from
the roofs of all four ventricles into the CSF, and is com-
posed of two distinct tissue layers: a highly vascularized
stroma encapsulated by a “tight” layer of epithelial cells
[12]. Unlike the parenchymal capillaries forming the re-
strictive blood–brain barrier (BBB), CP stromal capillaries
are fenestrated and contain pentilaminar junctions whose
outer leaflets are not fused [13] – properties that render the
CP capillary population highly permeable to macromole-
cules [14]. This juxtaposition of “leaky” capillaries and tight
epithelium constitutes the blood-cerebrospinal fluid barrier
(BSCFB) [15,16], an arrangement construed as enabling
blood-born leukocytes to extravasate into an uninflamed
brain during the incipient stages of MS and EAE [17,18].
Supporting this process, expression of chemokine CCL20
by choroidal epithelial cells is thought to chemotactically
draw T cells – bearing the cognate receptor CCR6 – from
the CP stroma, across the epithelium and into the CSF [8].
In situ hybridization and immuno-electron microscopy
of the CP has further revealed expression of adhesion
molecules, VCAM-1 and ICAM-1, by choroidal epithelial
cells of the healthy CP, and additionally of MAdCAM-1
by these same cells during EAE [19,20]. Also, transcrip-
tome analysis of the whole adult CP has highlighted ex-
pression of immune mediators in both healthy mice [21]
and those subject to peripheral inflammation [22], reinfor-
cing the view this organ is a critical conduit linking
immune/inflammatory activities between the periphery
and CNS. But the extremely close apposition of the differ-
ent CP layers has posed a significant challenge to studying
the depth of their respective contributions to inflamma-
tory processes. In fact, no immune function has yet been
ascribed to the CP capillary endothelium, leaving com-
pletely unresolved the factors that drive T cell emigration
into the stroma. And gene regulatory events surrounding
transmigration of T cells across the choroidal epithelium
further remain unsettled.
To elaborate the sequence of events in the CP that set
the stage for CNS inflammation during EAE induced by
active immunization with MOG35-55 peptide, we used
laser capture microdissection (LCM) coupled to qrt-
PCR-based microarray [23] to establish the time course
of expression of a panorama of immune mediators in
the separate stromal (including capillaries) and choroid
epithelial layers. Morphological changes in the CP asso-
ciated with MOG immunization were also examined by
quantitative 3-D image analysis following confocal mi-
croscopy. Results reveal substantial changes in CP gene
expression and morphology occurred in response to
vspecific aspects of the MOG immunization process.
These results could hold relevance for how combina-
tions of environmental factors trigger neuroinflamma-
tory disease.
Materials and methods
Animals
Female C57BL/6 mice, age 8–10 weeks and obtained
from Charles River Laboratories, Inc. (Wilmington,
MA), were used to minimize microvascular heterogen-
eity due to genetic variability, sex, and age [24]. Animals
were euthanized by CO2 inhalation, following Animal
Care and Use Guidelines of the University of Connecti-
cut Health Center (Animal Welfare Assurance # A3471-
01). A total of n = 3 animals/group were used for each
treatment and time-point assessed.
Induction of experimental autoimmune encephalomyelitis
(EAE)
EAE was induced in mice by active immunization with
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK),
of murine origin (W. M. Keck Biotechnology Resource
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Center, Yale University), as described [25]; following
Animal Care and Use Guidelines of the University of
Connecticut Health Center (Animal Welfare Assurance
# A3471-01). Briefly, on day 0, one group of female mice
7–9 weeks of age was injected subcutaneously with
300 μg of MOG peptide in complete Freund’s adjuvant
(CFA, DIFCO) into the right and left flank, 100 μl per
site. These mice were also injected i.p. with 500 ng per-
tussis toxin (PTX, List Laboratories, Campbell CA) in
PBS on days 0 and 2 following the first immunization
(referred to as the MOG-CFA/PTX group). The second
group of age-matched mice received CFA alone and
PTX (500 ng) injections on day 0 and a second injection
of 500 ng PTX alone on day 2 (referred to as the CFA/
PTX group). The third group of naïve age-matched fe-
male mice was left untreated. Animals were monitored
and scored daily for clinical disease severity according to
the following scale: 0 = normal; 1 = tail limpness; 2 = limp
tail and weakness of hind legs; 3 = limp tail and complete
paralysis hind legs; 4 = limp tail, complete hind leg and
partial front leg paralysis; and 5 = death. LCM tissue was
acquired at day 9 (score 0) and day 15 (score ~ 2.0) post-
immunizations.
Tissue preparation for Immuno-LCM
Brains were snap-frozen in dry ice-cooled 2-methylbu-
tane (Acros; Geel, Belgium), and stored at −80°C. Frozen
brain was embedded in cryomatrix compound (Thermo
Fisher Scientific, Waltham, MA) prior to sectioning.
Coronal sections (7 μm) were cut on a Microm HM
505 M cryostat (Mikron Instruments; Oakland, NJ) and
affixed to uncoated, pre-cleaned glass slides (Fisher Sci-
entific, Pittsburgh, PA) and stored in a slide box at −
80°C. Tissue was processed for LCM within a week of
sectioning.
Immunostaining for Immuno-LCM
Immunostaining was performed as detailed [24,26,27],
with minor modifications. Briefly, sections were fixed in
75% ethanol, on ice, for 3 min prior to staining. The CP
stromal capillaries were stained using alkaline phosphat-
ase substrate NBT (nitro-blue tetrazolium chloride)/
BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine
salt), (Vector Labs, Burlingame, CA) for 3–5 minutes in
100 Mm Tris–HCl (pH 9.5) to detect endogenous alka-
line phosphatase activity in the endothelial cells. In this
case, endothelial cells were intentionally not immunos-
tained by anti-CD31/ABC alkaline phosphatase [24,27],
as it resulted in extensive deposition of chromogenic
precipitate, which made the stromal capillaries difficult
to resolve from the choroidal epithelial layer. The chor-
oidal epithelial cells were immunostained with monoclo-
nal pan-cytokeratin-FITC antibody (Sigma) for 10
minutes (diluted 1:10 in 1X PBS+ 0.5% Tween-20).
RNAsinW RNAse inhibitor (Promega, Madison, WI) was
added to all staining reagents. Immediately after immu-
nostaining, sections were dehydrated through graded al-
cohol and xylenes as described [24].
Laser capture microdissection (LCM)
A PixCell IIe laser capture microscope (ABI, Foster
City, CA) was used to separately procure CP stromal ca-
pillary and CP choroidal epithelial tissues, as previously
described for brain parenchymal vessels [24,27,28]. We
refer specifically to CP stromal capillary tissue, instead
of pure capillary endothelium, as it was not possible to
completely resolve vascular from matrix elements (in-
cluding extravasating leukocytes) within the dense CP
stroma. Likewise, the choroidal epithelial tissue may
contain some epiplexus cells, and so is not described as
pure epithelium. Only choroid plexus material from
within the fourth ventricle and lateral recess of the
fourth ventricle was retrieved.
Tissue extraction
LCM-retrieved tissue was solubilized in Cell Lysate
BufferW (Signosis; Sunnyvale, CA) for direct reverse
transcription. Cell Lysate BufferW, pre-heated to 75°C,
was added and the resulting lysate heated at 75°C for an
additional 15 min. Samples were immediately frozen at
−80°C.
DNase treatment and cDNA synthesis
Cell Lysate BufferW extracts were treated with Turbo
DNase (Ambion; Austin, TX) according to the manufac-
turer’s instructions. Specifically, Turbo DNase buffer and
DNase were added and samples incubated at 37°C for
30 min. Next, DNAse inactivation reagent was added for
2 min at room temperature. Samples were then reverse
transcribed using the SuperScript III (Invitrogen) stand-
ard protocol with random hexamers (Roche; Indianapo-
lis, IN), and employing an extension temperature of
42°C – optimal for random hexamers – for 60 min.
Resulting cDNA was stored at −20°C until used for
analysis.
cDNA Pre-Amplification
Pre-amplification was carried for array analysis out using
TaqManW PreAmp Master Mix and a PreAmp Pool con-
taining all the primers for detection by the Mouse Im-
mune Panel TaqManW Low density Array (TLDA; Life
Technologies Corp., Foster City, CA) [23]. This panel
conatins 93 immune-related genes plus three housekeep-
ing control genes (see Additional file 1: Mouse Immune
Panel TLDA). Pre-amplification was carried out with an
initial hold at 95°C for 10 min, followed by 14 cycles at
95°C for 15 sec and 60°C for 4 min.
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qrt-PCR
Relative cDNA levels were quantified by qrt-PCR using
an ABI PRISM 7500 Sequence Detection System Version
2.3, and reported compared to housekeeping gene
GAPDH. Relative quantitation to GAPDH was per-
formed using the standard 2–δCt method of Pfaffl [29],
where δCt =Ct target threshold cycle – Ct reference
(GAPDH) threshold cycle. Expression of genes relative
to GAPDH was then represented as percent expression
of GAPDH. To assure consistency in relating gene ex-
pression patterns to a housekeeping gene, GAPDH and
two other housekeeping genes, β-actin and 18 S riboso-
mal RNA, were evaluated for constant expression across
treatments. Additionally, gene expression values for a
handful of randomly selected immune-related genes
were also determined relative to β-actin and 18 S riboso-
mal RNA (see Additional file 2: Housekeeping control
genes). Custom TaqManW primers/probes were used for
the Mouse Immune Panel TLDA. TLDA analysis was
conducted as per the manufacturer’s protocol, with
100 μl sample volumes containing a 1/32 dilution of
pre-amplified cDNA added to each port of the microflui-
dic card [23]. For qrt-PCR analysis of CD31 and Cyto-
keratin 8, ‘singleplex’ assays were used as neither of these
genes are represented in the mouse Immune Panel
TLDA.
Immunostaining for confocal microscopy
Frozen cryosections (60 μm) were fixed with 4% parafor-
maldehyde, permeabilized with 1% Triton X-100 (in
PBS) and incubated with PowerblockW for 10 min. Puri-
fied rat anti-mouse CD31 antibody (BD Pharmingen;
1:150 dilution in 10% NBS in 1X PBS + 0.5% TW-20)
was used to stain the CP capillary network followed by
incubation with goat anti-rat Alexa-555 secondary anti-
body (1:200). Pan-cytokeratin-FITC 1: 150 dilution,
(Sigma) was used to stain the CP epithelium. Next,
Alexa-647 anti-mouse CD45 antibody (1:160 dilution)
was used to stain leukocytes.
Confocal microscopy
Images were acquired on a Zeiss LSM 510 Meta laser scan-
ning confocal microscope, and optical slices (at 2-μm inter-
vals) obtained using a 40x objective. Acquired z-stacks were
background-subtracted, and 3-D isosurface rendering per-
formed using Bitplane IMARIS suite version 7.1 x 64 soft-
ware (Bitplane Inc. Saint Paul, MN). Each z-stack was
thresholded and the “filament tracker” module used to gen-
erate a 3-D traced outline of immunostained vessels in
order to determine the diameter range of the CD31-
immunostained capillary network within the choroid plexus
across different treatments.
Statistical analysis
Relative gene expression values are given as mean±
SEM. Student’s two-tailed test (Microsoft Excel 2003,
Redmond, WA) was employed to assess statistical sig-
nificance in gene expression values between MOG-CFA/
PTX and CFA/PTX samples from the CP capillary
stroma and CP epithelium groups, separately for the two
different time points assessed. Results were considered
significant at a p ≤ 0.05. Additionally, two-way ANOVA
followed by post-hoc Bonferroni analysis was performed
using GraphPad Prism 5 (GraphPad, La Jolla, CA) to de-
termine interactive effects between immunization treat-
ment and time of analysis post-immunization, and
assessed for each CP compartment.
Results
Anatomy of the CP is altered in response to MOG-
immunization
First, the anatomy of the CP was investigated using con-
focal microscopy followed by 3-D isosurface rendering.
The close apposition of stromal capillary and choroidal
epithelial layers in the CP is depicted in Figure 1. The 3-
D analysis highlights the tortuosity of the capillary
plexus. At day 15 post immunization (p.i.) with PTX and
MOG35-55 peptide in CFA to induce EAE (MOG-CFA/
PTX group), or with PTX and CFA alone (CFA/PTX
group), which does not produce disease in this para-
digm, the capillary plexus can be seen to locally ‘swell’ in
certain regions (Figure 1). Specifically, the range in
diameter of capillaries in the MOG-CFA/PTX and CFA/
PTX groups was 1.24 to 11.39 μm and 1.86 to 10.84 μm
respectively, as compared to that found in naïve (1.24 to
6.22 μm) mice. In contrast to that seen within CP capil-
laries, the morphology of the choroidal epithelial layer
remained relatively constant following immunization.
LCM enables resolution of CP stromal capillaries from the
choroidal epithelium
Studies were next carried out to confirm the ability of
LCM to resolve the stromal capillary and choroidal epi-
thelial layers. Figure 2A shows an example of the highly
selective retrieval of both tissues from naïve and EAE
brain specimens. Microscopic analysis indicates no ap-
pearance of fluorescently-stained choroidal epithelial tis-
sue in the LCM-captured capillaries and, conversely, no
alkaline phosphatase-stained capillary tissue in the
retrieved epithelial samples. Figure 2B further highlights
the purity in qrt-PCR detection of LCM tissue from the
respective CP compartments. Using equivalent amounts
of input LCM tissue (1000 laser ‘shots’) from both CP
compartments, the endothelial marker CD31 was signifi-
cantly enriched in the CP capillary tissue, while the epi-
thelial marker cytokeratin 8 was observed in CP
epithelial tissue alone. The extremely low level of CD31
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mRNA detected in CP epithelial tissue may reflect the
few monocytes and/or dendritic cells circulating through
this area in the steady-state mouse brain [29,30]. There
is thus high confidence that LCM effectively separates
CP stromal capillary from choroidal epithelial layers with
high purity.
Expression of immune-related genes by stromal CP
capillary tissue following immunization
The next series of experiments coupled LCM to TLDA
qrt-PCR arrays to further characterize expression
patterns of a panorama of 93 immune-related genes in
the separate CP compartments at different stages of the
neuroinflammatory response to immunization. Expres-
sion of these genes relative to housekeeping gene
GAPDH (GAPDH was unaffected across treatments;
Additional file 2: Housekeeping control genes), was deter-
mined in three groups of mice: MOG-CFA/PTX, CFA/
PTX and naïve at two time points: day 9 and 15 p.i.
Contrasting these three treatment groups enabled effects
of the adjuvants CFA and PTX to be distinguished from
the autoimmune response to MOG. Furthermore,
Figure 1 Morphological analysis of CP compartments following immunization. CP epithelium was stained with polyclonal antibody to pan-
cytokeratin (FITC, green), and CP stromal capillaries were immunostained with monoclonal anti-CD31 antibody (red). A CD45 antibody was used
to stain for any leukocytes present within the CP (blue). Confocal microscopy z-stack images of thick (60 μm) frozen sections of the CP were
acquired, and three dimensional rendering was performed using Imaris image analysis software. Shown are rendered images of the CP from all
three treatment conditions (MOG-CFA/PTX day 15 p.i., CFA-PTX day 15 p.i. and Naïve), revealing swelling of the stromal capillaries (arrows)
following both immunization protocols. The left side shows leukocyte and capillary staining, emphasizing the distended capillary diameters. The
right side is a composite of leukocyte, capillary, and epithelial staining. Mean capillary diameter ranges for each group were determined using the
Filament tracer module in Imaris. The choroidal epithelium appears unaltered by immunization. ‘p’ indicates brain parenchymal region. Scale:
20 μm.
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examining effects at day 9 p.i. (prior to any evidence of
clinical disease) and day 15 p.i. (after disease onset),
highlighted the progression of gene changes that may be
linked with developing pathology.
At day 9 p.i. (EAE clinical score 0), numerous gene
changes were already evident in the CP stromal capillary
tissue, despite the lack of onset of any clinical disease
signs. Specifically, both MOG-CFA/PTX- and CFA/
PTX-immunized mice showed up-regulated expression
in 49 of the genes in the panel compared to naïve ani-
mals, (Table 1), with there being no statistically signifi-
cant differences between the two immunized groups.
Some prominent inflammatory genes that were equiva-
lently elevated at this time point included: CCL2, CCL5,
CXCL10, Sele (E-selectin), Selp (P-selectin), IL1b, Stat1
and Fasl all of which were modulated more than 10 fold
higher than naïve levels. It would thus appear that, at
this early stage before clinical EAE symptoms are
present, the gene responses in the CP stromal capillary
tissue following MOG immunization may stem largely
from adjuvants CFA and/or PTX.
By day 15 p.i. (EAE clinical score 1.5-2.0), however,
the MOG-CFA/PTX-immunized group surpassed the
CFA/PTX group in up-regulation of several genes, high-
lighting what might specifically be the autoimmune re-
sponse of the CP vascular stroma. These genes included
B2m, C3, CCL19, CCL5, CD4, Gzmb, Ptgs2, Ptprc
(CD45), Smad3, Stat4, and CD40l – which were select-
ively augmented in the CP stromal capillary tissue of the
MOG-CFA/PTX group (Figure 3). The fold changes in
these genes following immunization (Figure 3, bottom)
indicate their super-stimulation by MOG-CFA/PTX
Figure 2 Immuno-LCM allows retrieval of tissue from specific CP compartments. A) Evidence of histological purity. Immunofluorescence
was performed using FITC-conjugated pan-cytokeratin antibody to highlight the CP epithelium (green), while immunohistochemistry using
alkaline phosphatase detection with NBT/BCIP as substrate was carried-out to label the endothelium of CP stromal capillaries (dark brown). LCM
was performed on a Pixcell IIe LCM unit. Images both BEFORE and AFTER LCM, as well as LCM retrieved tissue deposited on the cap, are shown
to highlight selective retrieval of CP stromal capillary (top row) and CP choroidal epithelial tissues (bottom row). B) Evidence of purity by qrt-PCR.
Levels of CD31, an endothelial marker, and Cytokeratin-8, an epithelial marker, were probed to determine the purity of the CP capillary and CP
epithelial tissues, respectively, retrieved by LCM.
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treatment. The lymphoid chemokine CCL19, expressed
by venules in brain and spinal cord in mice afflicted with
EAE [31], was elevated nearly 80-fold in the MOG-CFA/
PTX immunized mice at this time-point. And CCL5, an-
other chemokine shown to play an important role in
EAE [32], was elevated 146-fold higher than naïve levels.
Expression of Ptgs2 (COX2), suppression of which has
been associated with resistance to EAE [33,34], was near
similarly elevated – having increased 96-fold higher than
that in naïve cohorts. Slightly less elevated was Stat4, a
transcription factor whose absence has been shown to
inhibit EAE [35], which was increased > 40-fold in the
MOG immunized group. It is further noteworthy that
expression of Ptprc (CD45), the common leukocyte mar-
ker, stimulated 219-fold higher, possibly reflecting
increased leukocyte extravasation across the stromal ca-
pillaries at this later time-point. Consistent with this in-
terpretation is that message for CD40l (CD154), a
protein primarily expressed on activated T cells [36], was
detected within the CP stromal capillary tissue only fol-
lowing MOG-CFA/PTX immunization.
Notably, the CFA/PTX group indicated some dampen-
ing of immune regulation by this time, as certain genes
e.g., Smad3 and Gzmb, dropped back to levels matching
those of naïve mice, after initially displaying an elevation
at day 9. Genes that trended towards elevated expression
following MOG-CFA/PTX treatment (but with p values
slightly > 0.05) are displayed in Additional file 3: Genes
that trended towards elevated expression in MOG-CFA/
PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i, while those
that were similarly up-regulated in CP stromal capillary
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice at day 15 are listed in
Additional file 4: Genes similarly up-regulated in CP
stromal capillary tissue from both MOG-CFA/PTX- and
CFA-PTX-immunized mice at day 15 p.i. Genes that
were undetected in the CP capillary tissue in all treated
and naïve mice at both time-points were the following:
CCR4, CD19, CD3e, CSF3, Ctla4, Cyp1a2, Cyp7a1, H2-
Ea, IL12b, IL13, IL3, IL4, IL5, IL6, IL9, and Lta.
Expression of immune-related genes by CP choroidal
epithelium following immunization
Immunization also produced a change in expression of
numerous immune-related genes within the CP chor-
oidal epithelium. Moreover, these changes differed from
those observed in the capillary stroma, emphasizing the
differential immune sensitivities of the two tissues.
At day 9 p.i., the CP choroidal epithelium of only
MOG-CFA/PTX-immunized mice displayed increased ex-
pression of any immune-related genes compared to that
of naïve cohorts. Specifically, the following eight immune-
related genes were up-regulated: B2m, CCL19, CCL2,
CCR2, CD8a, CXCL10, Sele, and Selp (Figure 4A). B2m
(beta 2 microglobulin), a biomarker for certain peripheral
inflammatory conditions [37] was increased 2.2-fold in
MOG-treated versus naïve mice. The chemokine CCL2
has been demonstrated to play a critical, non-redundant
role in directing mononuclear leukocyte extravasation into
the CNS during EAE [32,38,39], and was stimulated> 24-
fold higher in the CP choroidal epithelial tissue of MOG-
CFA/PTX-treated mice compared to that in naïve cohorts.
CXCL10 and CCL19 were 28-and 14-fold higher than
naïve values, respectively. Sele (E-selectin) and Selp
(P-selectin), CCL19 and CD8a further showed pronounced
Table 1 Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTX-
immunized mice at day 9 p.i
Genes modulated similarly in stromal CP capillary of MOG-CFA/
PTX mice at day 9 p.i
Gene name Gene name
B2m{ ll15*
Bcl2l1 ll18*
C3**{ ll1b**
Ccl19{ ll7
Ccl2** Lrp2
Ccl5**{ Nfkb1*
Ccr2** Nfkb2
Cd34** Ptgs*{
Cd80 Sele**
Cd86* Selp**
Cd8a Amad3{
Col4a5 Socs2
Csf1* Stat1**
Cxcl10** Stat3
Cxcr3* Stat4{
Ece1 Stat6
Edn1 Tbx21
Fas Tfrc*
Fn1 Tgfb1
Gzmb{ Cd40
Hmox1 Fasl**
Hprt1 Vcam1
lcos Vegfa
lfng**
genes with *≥ 5 and **≥ 10 fold increase in expression in comparison to Naïve
animals.
Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP stromal capillary tissue from
immunized and naïve mice at day 9 p.i. At this early time-point, all 49
immunization-induced genes were similarly stimulated in both MOG-CFA/PTX-
and CFA-PTX-immunized mice compared to naïve animals, and only these are
listed. { denotes genes that show specific upregulation later on with disease
progression on day 15.
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stimulation specifically following MOG immunization,
being undetectable in the epithelium of both CFA/PTX and
naïve cohorts. In what appears to reflect the differential
sensitivities of the two CP tissues, CFA/PTX immunization
clearly ‘activated’ the stromal CP capillary tissue on day 9
p.i. at both the anatomical and molecular levels (Figure 1
and Table 1), but produced no detectable changes in the
CP epithelium at this time.
By day 15 p.i., genes B2m and CXCL10 displayed fur-
ther increases in expression in the CP choroidal epithe-
lium of MOG-CFA/PTX mice compared to that seen in
this cohort at day 9 (Figure 4B), showing > 19-fold and >
800-fold higher levels, respectively, compared to naïve
mice. Expression levels of yet additional genes in MOG-
treated mice also became elevated by this time; these
included Bax, Bcl2l1, C3, CD68, Gusb, H2-Eb1 and Ski
(Figure 4B). Moreover, genes CCL19, CCL2, CCR2,
CD8a, Sele and Selp, which had previously shown up-
regulation only in the MOG-CFA/PTX group at day 9,
became similarly induced in the CFA/PTX group at this
later time-point. Genes that trended towards elevated
expression following MOG-CFA/PTX treatment for
both time points (but with p values slightly >0.05) are
displayed in Additional file 5 and Additional file 6: Genes
that trended towards elevated expression in MOG-CFA/
PTX immunized CP epithelium tissue compared to CFA-
PTX-immunized mice, at day 9/15p.i., while those that
were similarly up-regulated in CP choroidal epithelial
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice for both time points are
listed in Additional file 7 and Additional file 8: Genes
similarly up-regulated in CP epithelium from both
MOG-CFA/PTX- and CFA-PTX-immunized mice at day
9/15 p.i. Those few genes that were in the CP epithelial
tissue in both immunized groups and naïve mice
included IL3, IL4, IL5, IL6, Lta.
Interaction between immunization treatment and time
In order to gain further appreciation of the extent to
which time impacted the effect of specific type
immunization on the expression patterns of immune-
related genes, two-way ANOVA was performed to
Figure 3 Genes super-induced in CP stromal capillary tissue from MOG-CFA/PTX-immunized mice at day 15 p.i. Relative mRNA expression
values were determined by immuno-LCM/TLDA in CP stromal capillary tissue from MOG-CFA/PTX-immunized, CFA-PTX-immunized, and naïve mice at
day 15 p.i. Those genes that were more stimulated; i.e., ‘super-induced’, in MOG-CFA/PTX- versus CFA-PTX-immunized mice at day 15 p.i. (compared to
naïve mice) are graphed. The bar graphs depict those specific genes showing statistically significant differences in relative expression values (p values
indicated by asterisks) between MOG-CFA/PTX and CFA/PTX experimental groups. RNA values are presented as mean percent expression relative to
GAPDH (± SEM) in log scale. * and ** represent comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p< 0.05, ** p < 0.005,
Student’s t-test, n = 3 animals/group. Fold changes in gene expression normalized to naïve animals are tabulated below the graph. Fold changes of
those genes that were up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.
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deduce interactive effects between immunization treat-
ment (e.g., MOG-CFA/PTX, CFA/PTX or naïve) and
time post-immunization. For example, the expression of
CCL19 in CP stromal capillary tissue following MOG-
CFA/PTX immunization was time-dependent (p < 0.05
for positive interaction). Two-way ANOVA was done on
all genes that displayed statistically significant modula-
tion after immunization in at least one of the CP
Figure 4 (See legend on next page.)
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compartments (as shown in Figures 3 and 4A, B) in ei-
ther of the time-points analyzed (twenty-three genes in
total). Interactive effects differed depending on the CP
compartment, further highlighting the unique responses
of the two CP tissues analyzed. Specifically, two-way
ANOVA of CP stromal capillary tissue revealed the fol-
lowing twelve genes displayed positive interaction be-
tween immunization treatment and time post-
immunization: B2m, C3, CCL19, CCL5, CD4, Gzmb,
Ptgs2, Ptprc, Stat4, CCR2, CD68, Gusb (Figure 5). CP
choroidal epithelial tissue, on the other hand, demon-
strated positive interaction for another collective of
genes: B2m, Bax, C3, CXCL10 (Figure 5).
Figure 6 qualitatively summarizes the differential
responses of the CP capillary and CP choroidal epithelial
tissues, respectively, to MOG-CFA/PTX immunization
versus CFA/PTX immunization, contrasting adjuvant
versus autoimmune effects on immune-related gene
regulation over the two time-points analyzed.
Discussion
Due to increasing awareness of the CP as fundamental
to the development of CNS inflammation [4-6],
immuno-LCM coupled to qrt-PCR array was used to
separately acquire CP stromal capillary and choroidal
epithelial tissues and assess their respective patterns of
expression in situ of a wide panorama of immune-
related genes. Gene patterns were evaluated during pre-
clinical and early clinical stages of EAE to appreciate the
switches in gene expression that accompany evolving
disease.
It is clear that the CP responds vigorously to MOG
immunization at both the anatomical and molecular
levels. Interestingly, immunization with CFA and PTX
alone produced striking effects. Swelling of the capillary
plexus occurred to nearly the same extent with injection
of just these agents, as with PTX and MOG in CFA.
PTX is an ancillary adjuvant commonly employed to
elicit EAE, as well as several other experimental auto-
immune diseases [40-44]. And while its mechanism of
action in this regard has generally been attributed to in-
creasing vascular permeability [45-47] – most notably
that of the BBB [48-51] – additional hypotheses have
been put forth [52-55]. However, to the best of our
knowledge, this is the first report to turn attention to
the CP as a possible target of PTX. It is of further inter-
est to point out that the distension of CP capillaries
noted here study bears similarity to that seen following
systemic neutralization of VEGF and TGFβ [56]. In the
latter case, CP capillary swelling was accompanied by
loss of fenestrae from endothelial cells and appearance
of multiple caveolae, transport vesicles that transcytose a
variety of cargo [57] – including chemokines [58] – and
are often associated with heightened vascular permeabil-
ity and inflammation [59,60]. Engelhardt et al. [4] had
also described ultrastructural changes of the CP during
EAE (along with CFA and PTX as adjuvants), but noted
these were mostly restricted to the CP choroidal epithe-
lium. Moreover, as comparison in this latter study was
just between healthy mice and those afflicted with EAE,
it is unclear whether the observed epithelial response
was autoimmune in nature and/or due to adjuvant
action.
Our results suggest that injection of PTX and/or CFA,
alone, might trigger an immune response in the CP ca-
pillaries that helps “set the stage” for CNS inflammation
[61]. The CP capillaries might be uniquely responsive in
this regard, as CFA/PTX treatment evoked an early re-
sponse (day 9 p.i.) in the CP stromal capillary tissue,
while the choroidal epithelium experienced neither overt
morphological nor gene expression changes at this time.
If, as speculated during MS/EAE, Th17 cells first transit
through the CP, and then travel in the CSF to reach their
cognate antigens in the SAS, then the CP capillaries
must somehow initially be rendered capable of support-
ing T cell extravasation. In the EAE paradigm used here,
PTX and/or CFA might provide the stimulus to evoke
such capability. In this regard, we noted > 10-fold in-
crease in chemokines CCL2, CCL5 and CXCL10 in the
CP stromal capillaries of both MOG-CFA/PTX- and
CFA/PTX-treated mice at day 9 p.i. Constitutive CCL2
expression within the CP stromal tissue has been
reported using in situ hybridization analysis, and shown
to be induced following peripheral tissue inflammation
[62]. The ability of CFA/PTX treatment to stimulate ex-
pression of these chemokines could potentially reflect
the actions of one or both of these adjuvants to ‘prime’
the neuroinflammatory process by activating the
(See figure on previous page.)
Figure 4 Genes super-induced in CP choroidal epithelial tissue from MOG-CFA/PTX-immunized mice at days 9 and 15 p.i. Relative
mRNA expression values of 93 immune-related genes were determined by immuno-LCM/TLDA in CP choroidal epithelial tissue from MOG-CFA/
PTX-immunized, CFA-PTX-immunized, and naïve mice at two time-points. Those genes that were more stimulated in MOG-CFA/PTX- versus CFA-
PTX-immunized mice at day 9 (Figure 4A) and day 15 p.i (Figure 4B) (compared to naïve mice) are graphed. The bar graphs depict those specific
genes showing statistically significant differences in relative expression values (p values indicated by asterisks) between MOG-CFA/PTX and CFA/
PTX experimental groups. RNA values are presented as mean percent expression relative to GAPDH (± SEM) in log scale. * and ** represent
comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p < 0.05, ** p < 0.005, Student’s t-test, n = 3 animals/group. Fold
changes in gene expression normalized to naïve animals are tabulated below the corresponding graphs. Fold changes of those genes that were
up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.
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endothelium to elicit initial auto reactive T cell extrava-
sation from the circulation into the stromal compart-
ment. This hypothesis is consistent with the recent
observation that administration of PTX to transgenic
mice over-expressing CCL2 in the CNS causes disrup-
tion of the BBB and promotes leukocyte migration into
the brain parenchyma [63].
Notwithstanding the effects of CFA/PTX treatment on
CP capillary morphology and gene expression, immu-
nization with MOG-CFA/PTX further induced the expres-
sion of additional genes – some or all of which might
specifically reflect the autoimmune response and associated
development of EAE. While perhaps necessary for disease
to develop, the CP conditions set in place by PTX and CFA
are insufficient for inducing EAE in wild-type C57BL/6
mice. For disease to occur, supernumerary induction of
some genes, and de novo induction of others must take
place. The findings by Goverman et al. and Brabb et al.
[61,64], that injection of PTX alone can “trigger” EAE in
TCR-transgenic mice specific for myelin basic protein, by
fostering T cell access to the CNS, comports with our
results and the view that PTX enables mice to reach the
disease threshold. And helping pull this trigger may be add-
itional effects of PTX on T cell behavior. Our observation
of increased mRNA for genes CD8a, CD80, CD86, Gzmb
(granzyme) and Ptprc (CD45) in the CP capillary stromal
tissue of both MOG-CFA/PTX and CFA/PTX cohorts may
reflect capture of PTX-activated CD8 T cells in transit
across the CP and into the CSF. This interpretation is con-
sistent with the recent finding by Murphey et al. [65], that
PTX stimulation of cultured spleen cells results in CD 8 T
cell activation via CD80/86 co-stimulation.
As to signals responsible for the extravasation of T cells
from the circulation into the CP stroma during MOG-
induced EAE, a combination of chemokines may fill this
role, as these immune mediators do in guiding
Figure 5 Interaction between immunization treatment and time of analysis post-immunization on expression of immune-related genes
within CP stromal capillary and choroidal epithelial compartments. Interactive effects of treatment (MOG-CFA/PTX, CFA-PTX and naïve) and
time post-immunization were determined by two-way ANOVA on the 23 immune-related genes that were super-induced following MOG-CFA/
PTX immunization in either of the two CP compartments (those genes graphed in Figures 3, 4A and B). Of these 23 genes, 13 genes in the CP
stromal capillary and 4 genes in the CP epithelial tissue exhibited significant positive interaction between treatment and time post-immunization,
and are denoted with their corresponding p values. The remaining genes that showed no significant interaction are labeled by (x). Time-
dependent changes in expression of CCL19 in stromal capillary tissue and CXCL10 in choroidal epithelial tissue are graphed as representative
examples * p< 0.05, ** p< 0.005.
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parenchymal leukocyte infiltration. In particular, CCL5
level was increased significantly in CP stromal capillary
tissue at day 15 p.i., which coincides with high CCL5 pro-
tein level reported in whole brain extract of EAE mice at a
similar time-point, and argued to mediate leukocyte ad-
herence to the CNS microvasculature [32]. And CCL19 –
a CCR7 ligand known to play a crucial role in EAE devel-
opment through IL-23 producing Th17 cells [66] – was
likewise up-regulated dramatically in the CP stromal capil-
laries of MOG immunized mice at day 15 p.i.
With specific regard to those mechanism(s) further
driving T cell migration from the CP stroma into the
CSF, recent evidence points toward expression of an-
other chemokine - CCL20 - by the CP choroidal epithe-
lium as directing CCR6+ T cells across this layer and
into ventricular fluid during MS/EAE [8]. However, as
this chemokine:cognate receptor pair was not repre-
sented on the commercial TLDA card used in these
experiments, confirmation of this pathway was not per-
formed. Aside from CCL20 providing a driving force for
T cell migration into CP epithelium, CCL2 might also
serve in this capacity, as Chodobska et al. [67] noted the
latter chemokine was rapidly stimulated in this tissue
in vivo and then released into the CSF, following trau-
matic brain injury. Indeed, the significant increase in
CCL2 we observed in the MOG-CFA/PTX CP choroidal
epithelium at day 9 p.i. might just reflect such a role for
this chemokine in EAE. The cognate receptor for CCL2,
CCR2 was also seen to be elevated in the choroidal epi-
thelium at this early time-point. Presently, it is unclear if
the high levels of CCR2 mRNA indicate activation of the
epithelium, which, in the periphery, has been shown to
express CCR2 [68,69], or the accumulation of infiltrating
CCR2+ T cells.
In what might suggest multi-level control of leukocyte
extravasation into the CSF, still other chemokines were also
significantly up-regulated by the CP during EAE – namely
CXCL10 and CCL19. As CXCL10 has been reported to be
up-regulated in the sub-ventricular zone (SVZ) during
EAE, and postulated to stimulate migration of activated T
cells into the SVZ [70], its spike in expression by CP chor-
oidal epithelial tissue at day 9 p.i. and more robust elevation
by day 15 p.i., might imply this chemokine is obligate for T
cell entry into the ventricles. In analogous manner, CCL19
was also elevated at this site at day 9 p.i. In fact, the timing
of the CP epithelial spikes in this chemokine during early
stages of EAE noted here, coincides well with that reported
by Reboldi et al. [8] for initial T cell entry into the unin-
flamed CNS through the CP. Recently, Marques et al.
[22,71] used hybridization-based microarray to assess the
global transcriptome of the whole CP following chronic
peripheral LPS stimulation. When compared to our study,
there were some common and unique findings. Among the
common findings, complement protein C3, and chemo-
kines CCL2 and CCL5 were elevated following either acute
or chronic peripheral LPS stimulation, as well as during
MOG-induced EAE (complement C3 in both CP capillary
tissue and epithelium; CCL2 in CP epithelium; and CCL5
in CP capillary tissue). And Selectin (Sele and Selp) expres-
sion was also elevated both following acute peripheral LPS
stimulation [22], and in the CP epithelium after MOG-
induced EAE. These common gene modulations may thus
reflect more generic CP inflammatory response genes.
As for unique findings, these too involved chemokines.
Marques et al. [71] reported stimulation of CCL7 and
CXCL1 in the CP following chronic LPS stimulation, while
we detected stimulation of CCL19 and CXCL10 in the CP
epithelium and CCL19 in the CP endothelium during
Figure 6 Schematic summary of the induction of immune-related genes in the choroid plexus compartments following MOG-CFA/PTX
versus CFA-PTX immunization. Depicted are qualitative ‘heat maps’ of overall modulation in immune-related gene expression patterns over
time, within the separate CP stromal capillary (left) and CP choroidal epithelial (right) tissues after the two type immunization regimens. While
CFA/PTX immunization alone induces expression of immune-related genes in both tissues, MOG-CFA/PTX immunization causes supernumerary
stimulation above this level. The differences in gene expression between the immunization regimens highlight what might reflect gene changes
specifically due to MOG-associated autoimmunity. The effects due solely to CFA/PTX immunization might reveal priming of the immune response
that is necessary for the development of EAE.
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MOG-induced EAE. A priori, up-regulation of these latter
two chemokine genes may more distinguish an EAE signa-
ture for the respective CP tissue compartments.
Of further note was our observation of a MOG-sensitive
increase in expression of B2m at day 15 p.i. in CP stromal
capillary tissue, and at both time-points in the choroidal
epithelial tissue. Aside from perhaps reinforcing a more
ubiquitous role for B2m in inflammation [37], this result
complements previous reports of increased B2m mRNA
and protein levels in both neuronal and non neuronal cell
types during EAE [72,73], a response thought to be due to
induction of synaptic plasticity by infiltrating autoreactive
immune cells. The sharp induction of complement C3,
also noted in both CP compartments of MOG-CFA/PTX
mice at the later time point (day 15 p.i), further supports
previous studies highlighting C3 deficiency inhibits devel-
opment of EAE [74].
As to the specific approach used here, i.e., LCM coupled
to TLDA, it offered extraordinary opportunity to probe, in
extensive detail, the focused immune response within the
distinct CP compartments. Earlier reports, using immuno-
histochemistry and in situ hybridization, had shown that
the respective CP stromal capillary endothelial cells and
the CP choroidal epithelial cells displayed different expres-
sion patterns of a small nucleus of adhesion molecules
during EAE [4,20]. Specifically, VCAM-1 and ICAM-1
were found to be expressed constitutively by CP choroidal
epithelial cells of healthy SJL/N mice, and then further
induced following active immunization with spinal cord
homogenate. MAdCAM-1 was only seen in these cells
after induction of EAE. However, none of these adhesion
molecules, nor E- or P-selectin, was detected in CP stro-
mal capillary endothelial cells [75].
We too noted constitutive VCAM-1 expression in the
CP choroidal epithelial tissue of healthy naïve mice. Like-
wise, VCAM-1 trended toward elevation within this CP
compartment of MOG-CFA/PTX cohorts at both days 9
and 15 p.i., though it showed no up-regulation in CFA-
PTX-immunized mice at either time-point. In further
agreement with previous observations [75], our analysis
demonstrated induction of E-selectin and P-selectin in the
CP choroidal epithelial tissue from MOG-CFA/PTX-
immunized mice at day 9. Our results nevertheless dis-
played some stark differences with earlier reports. Specif-
ically, we also noted a trend of increased VCAM-1
expression by day 15 in CP stromal capillary tissue with
MOG immunization, paralleling what has been described
in MS brain tissue [6]. And both E- and P-selectin mRNA
were also observed to be induced in CP stromal capillary
tissue of both MOG-CFA/PTX- and CFA/PTX-immu-
nized mice compared to that of naïve mice at day 9 p.i. E-
selectin increased expression in the two immunized
groups by >100-fold, while P-selectin was stimulated >10-
fold.
A priori, differences in results between these EAE
studies could result from several factors, among them
being 1) the EAE model employed (e.g., immunization of
SJL/6 mice with spinal cord homogenate versus
immunization of C57BL/6 mice with MOG35-55 peptide),
the time of analysis post-immunization (e.g, before or
after disease onset), and 3) the sensitivity of the analytic
techniques (e.g., in situ hybridization versus qrt-PCR).
As neither MAdCAM-1 nor ICAM-1 were represented
on the TLDA card used in these experiments, confirm-
ation of expression or lack thereof was not possible for
these genes.
Most recently, Liddelow et al. [76] employed LCM to
collect mouse lateral ventricular CP tissue CP for tran-
scriptome analysis of transporter gene expression during
normal development. Here, we extended this application,
utilizing LCM to resolve – for the first time – the CP ca-
pillary stromal tissue from the CP choroidal tissue, and
then separately analyzing each for their unique immune
responses to MOG immunization.
Conclusions
Induction of EAE in C57BL/6 mice by active immu-
nization with MOG35-55 peptide results in the respective
CP stromal capillary and choroidal epithelial compart-
ments each mounting vigorous, yet distinct, immune
responses, underscoring the active role of the CP in in-
stigating CNS inflammatory disease. Furthermore, our
results make clear that a significant component of the
total CP response is due to effects elicited by adjuvants
PTX and/or CFA used in the immunization protocol –
which might serve to prime the CP to support auto-
immune activity necessary for developing MS/EAE.
These results are summarized schematically in Figure 6.
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Additional file 1: Mouse Immune Panel TLDA. The card map for the
96 genes (93 immune-related genes and 3 control genes) on the
commercially available mouse Immune panel TLDA is shown, with gene
names and corresponding accession numbers.
Additional file 2: Housekeeping control genes. Ct (Threshold cycle)
values for the three housekeeping genes – GAPDH, β-Actin and 18 S
represented on the mouse Immune-panel TLDA are shown. The
housekeeping genes were almost unchanged across treatments (shown
in A and B) with < 1 cycle difference between samples. C, Six genes were
normalized to each of the three housekeeping gene and expression
patterns plotted, indicating identical patterns of expression across
housekeeping control gene used.
Additional file 3: Genes that trended towards elevated expression
in MOG-CFA/PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP stromal capillary tissue from immunized and naïve mice at
day 15 p.i. A total of 14 genes trended towards greater induction in the
MOG-CFA/PTX group compared to the CFA-PTX group; these genes are
listed with their corresponding p values. Analysis was by Student’s two-
tailed t-test.
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Additional file 4: Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTX-immunized
mice at day 15 p.i. Relative mRNA expression values of 93 immune-
related genes were determined by immuno-LCM/TLDA in CP stromal
capillary tissue from immunized and naïve mice at day 15 p.i. At this later
time-point, 25 immunization-induced genes were similarly stimulated in
both MOG-CFA/PTX- and CFA-PTX-immunized mice compared to naïve
animals, and only these are listed.
Additional file 5: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 9 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 9 p.i. A
total of 15 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.
Additional file 6: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 15 p.i. A
total of 19 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.
Additional file 7: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 9
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
and naïve mice at day 9 p.i. At this early time-point, 10 immunization-
induced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
Additional file 8: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 15
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
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induced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
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